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Background
Natural progesterone is currently unavailable for the treatment of endometrial 
hyperplasia. The first line of treatment for this condition is with the synthetic 
progestins Medroxyprogesterone Acetate (MPA) and Levonorgestrel (LNG). 
However, these hormones frequently trigger side effects which occur as a result of 
adverse gene and protein regulation. The current unavailability of natural 
progesterone is down to its poor bioavailability which is due to the low aqueous 
solubility and extensive first-pass metabolism of this compound.
Aims:
The first aim of this thesis is to compare natural progesterone with MPA and LNG in 
their regulation of a subset of genes and proteins in the endometrium whilst also 
assessing the selected proteins in biopsies from patients with endometrial hyperplasia 
before and after progestin therapy. The second aim is to study progesterone 
metabolism within the gastrointestinal tract and liver in order to direct the production 
of progesterone amorphous solid dispersions.
Methodology:
During this thesis both microbiological and pharmacological laboratory techniques 
were used. For microbiology investigations immunohistochemistry, polymerase 
chain reaction, InCell Analysis and enzyme-linked immunosorbent assay were the 
key research methods. For pharmacological research the main methods used were 
stability assays analysed by tandem mass spectrometry and high performance liquid 
chromatography, solvent emulsion evaporation, powder x-ray diffraction and 
scanning electron microscopy.
Conclusions:
Amorphous solid dispersions are an attractive option for the future production of a 
natural progesterone oral formulation with enhanced solubility. Such a formulation 
can be targeted for delivery to the distal small intestine where progesterone 
metabolism is reduced compared to other intestinal regions. This formulation would 
be of particular benefit to patients with endometrial hyperplasia as the most 
commonly used progestins to treat this disease were shown to differentially regulate 
genes and proteins in the human endometrium compared to the natural product.
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Chapter 1 Introduction
1. In troduction
1.1 The Fem ale R eproductive System
T he fem ale  rep ro d u ctiv e  system  co m p rises  tw o  m ain  parts; the o v arie s  and  the u terus 
w h ich  are connected  by  the fa llo p ian  tubes. T he  u terus then  jo in s  the v ag in a  at the 
cerv ix  w hich  opens to the  ex ternal gen italia . At b irth  the rep ro d u c tiv e  o rg an s are  all 
p resen t, though  it is no t until ad o lescen ce  that they  b eco m e fu lly  m atu re  and 
func tiona l (M orton  e t al., 2011). T h e  struc tu re  o f  the fem ale rep ro d u c tiv e  sy stem  can 
be seen  in F igure 1.1.
Fallopian Tube
Ovarian Ligament
Endometrium
Uterine,
Cavity Myometrium
Cervix
Figure 1.1: The structure of the female reproductive system. The system consists 
primarily of the two ovaries held in place by the ovarian ligaments which are 
connected to the uterus via the fallopian tubes. The uterus is made up of the 
uterine cavity and uterine wall consisting of layers including the myometrium 
and endometrium. The uterus connects to the cervix which opens into the 
vagina.
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1.1.1 The Ovaries and Fallopian Tube
T he ovaries lie in the pe lv is  and are kept in position  th ro u g h  a ttachm en t to  the pelv ic  
p erito n eu m  via tw o ligam ents com m only  know n  as the in fu n d ib u lo p elv ic  ligam ents; 
they  are also  a ttached  to  the u terus th rough  the u tero -o v arian  ligam ents. T h e  ovaries  
co n ta in  m any  fo llic les and each consist o f  an ovum  (oocy te) su rro u n d ed  by 
fo llic lu la r cells w hich  are fo rm ed during  the em b ry o n ic  stage, upon  p u b erty  the 
fo llic le  and  oocy te  beg in  to deve lop  in a p rocess ca lled  oogenesis . O n ce  d eve loped , 
the fo llic le  rup tu res, re leasin g  the oocy te from  the ovary  in the p rocess o f  ov u la tio n  
(S an ch ez  and  Sm itz, 2012). T he  oocy te leaves the ovary  and en ters the fa llo p ian  tube 
w here  fe rtilisa tio n  occurs if sperm  is present. T h e  fa llo p ian  tubes are m u scu la r tubes 
that ex ten d  from  the su p erio r co rners o f  the u terus to the edge o f  the o v arie s . T he 
in side  o f  each fa llop ian  tube is covered  in cilia  that w ork  w ith  the sm ooth  m u scle  o f  
the  tube to  carry  the o vum  to the u terus (S alad in  and M iller, 1998).
2-cell stage
8-cell stageFertilised 
egg (zygote)
4-cell stage
M orula
B lastocyst
Fertilisation
N Ovulation
Oocyte
Figure 1.2: Development of the pre-implantation blastocyst in humans. The 
oocyte begins to mature within the follicle and is released into the fallopian tube 
during ovulation. After fertilisation the fertilised egg, now called the zygote, 
undergoes a series of cell divisions until becoming the morula and then the 
blastocyst.
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If fertilisation occurs the oocyte begins to mature and undergoes cleavage as it 
travels down the fallopian tube becoming the morula. At 4 days post-fertilisation the 
morula enters the uterus where it undergoes further divisions to become the 
blastocyst (Moore et al., 2011) (Figure 1.2).
1.1.2 The Uterus
The uterus is a hollow, muscular organ which facilitates and maintains pregnancy. It 
is also the site of blastocyst implantation and home to the developing foetus for the 
whole of the gestation period. The uterus consists of three layers of tissue; the 
perimetrium, the myometrium and the endometrium. The perimetium is the 
outermost layer; it is a thin membrane that covers the uterus. The myometrium is the 
middle layer of tissue and is thick and muscular. The inner lining of the uterus, the 
endometrium, is thick and enriched with blood vessels and plays a role in protecting 
the cells of the myometrium; however the main role of the endometrium is in 
facilitating blastocyst implantation should fertilisation occur (Ramsey, 1994).
1.1.3 The Endometrium
The endometrium comprises of glandular and luminal epithelium which rests on 
blood vessel rich connective tissue called the stroma. The endometrium is described 
in terms of its layers; the stratum functionale or functional layer and stratum basalis 
or basal layer. The stratum basalis lays adjacent to the myometrium and contains 
stromal cells as well as deep glands and arteries which are retained throughout the 
menstrual cycle. The retaining of this layer is essential as it contains progenitor cells 
which serve as a regenerative source for the stratum functionale which is shed with 
each cycle (Nair and Taylor, 2010). Regeneration of the stratum functionale is 
characterised by extensive angiogenesis and an increase in estrogen and growth 
factor signalling (Maybin and Critchley, 2012). The stratum functionale makes up 
the superficial two-thirds of the endometrium and contains epithelial cells and 
glands; it also contains both densely and loosely packed stroma (Nair and Taylor, 
2010). The stratum functionale and stratum basilis are depicted in Figure 1.3.
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E n d o m etr ia lg la n c
Spiral Artery
U
Stratum
Basalis
S tratum
Functionalis
M y o m etr iu m
E n d o m e tr iu m
Figure 1.3: Layers of the endometrium. The endometrium is made up of the 
Stratum Functionalis and Stratum Basalis. The stratum basalis lays adjacent to 
the myometrium and contains stromal cells as well as deep glands and arteries 
which are retained throughout the menstrual cycle whereas the stratum 
functionalis makes up the superficial two-thirds of the endometrium and 
contains epithelial cells and glands and both densely and loosely packed stroma.
Adapted from h ttp ://q u iz le t.co m /2 1 0 4 3 5 6 9 /rep ro d u c tiv e-sv s tem -flash -card s /
If fe rtilisa tion  occurs then  m en stru a tio n  is halted  due to p ro g este ro n e  sec re tio n  by  the 
b lastocyst. P rogesterone  m ain ta ins the th ick , b lood  vessel rich  en d o m etriu m  
p ro v id in g  a perfec t env iro n m en t fo r b lasto cy st im plan ta tion . Im p lan ta tio n  occurs 
be tw een  days 20 and 24 post m en stru a tio n , the tim ing  o f  im p lan ta tio n  is crucial as it 
needs to be aligned  perfec tly  w ith  a ch an g e  in shape o f  the u n d erly in g  strom al cells 
in a p rocess is know n as d ec id u a lisa tio n  (O zturk  and D em ir, 2010). If  im p lan ta tio n  is 
successfu l the b lastocyst im plan ts deep  into the strom a and beg ins its d ev e lo p m en t 
into the foetus. In the absence o f  fe rtilisa tio n  the oocy tes d eg en era tes  and  is s loughed  
along  w ith  the ep ithelial lin ing  du ring  m en stru a tio n  and ano ther o o cy te  beg in s to
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mature within its follicle to begin another cycle. This process of cyclic shedding and 
regeneration is called the menstrual cycle.
1.2 The Menstrual Cycle
For the successful completion of the menstrual cycle each stage must be seamlessly 
controlled at a molecular level. Thus, the growth and differentiation of the human 
endometrium is regulated by the hypothalamic-pituitary axis and is under the 
coordinate control of the sex steroid hormones. There are four main hormones 
involved in controlling the menstrual cycle these are estrogen and progesterone (P4) 
produced by the ovaries and luteinising hormone (LH) and follicle stimulating 
hormone (FSH) released by the pituitary (Sherman and Korenman, 1975).
Estrogen and progesterone are both key players in the regulation of the menstrual 
cycle with estrogen dominating the proliferative phase and progesterone dominating 
the secretary phase (Sherman and Korenman, 1975). As a result, the basal level of 
circulating plasma estrogen and progesterone changes throughout the menstrual cycle 
and can vary significantly between individuals. During the proliferative phase of the 
cycle progesterone levels have been measured with a mean concentration of 0.32 (+/- 
0.25) ng/ml, this increases steadily during the luteal phase with a plateau to between 
10-20ng/ml between days 16 and 20 of the cycle (Johansson, 1969, Sherman and 
Korenman, 1975). The basal level serum estradiol also changes drastically 
throughout the menstrual cycle. In healthy volunteers, prior to the surge in LH, 
estrogen levels rise sharply constituting the proliferative phase of the cycle and fall 
abruptly between one and two days after the LH surge (Hotchkiss et al., 1971).
In the endometrium the menstrual cycle takes place in three distinct phases: the 
menstrual phase (days 0-5), the proliferative phase (days 5-14) and the secretory 
phase (days 14-28). In the human endometrium estrogen and progesterone play key 
roles in these phases; estrogen stimulates endometrial cellular proliferation during 
the proliferative phase while progesterone, in the secretary phase, exerts its 
differentiation effects upon the estrogen-primed endometrium (Sherman and 
Korenman, 1975). The ovaries also undergo cyclic changes during the menstrual 
cycle. Unlike the endometrium the ovaries undergo two distinct phases; the follicular
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p hase and the luteal phase . T h e  fo llicu la r phase  takes p lace  on days 1-14 o f  the cyc le  
and the lu teal phase takes p lace  on  days 14-28 (Johnson , 2012b). T h e  ch an g es in 
h o rm o n e  levels during  the m enstrual cycle  can be seen along  w ith  the  d iffe ren t 
en d o m etria l phases in F igu re  1.4
>* 
c  QC
rO O
C O 
>
G G
O x
Kccruled
Fo llic le I o ik k : • ;  . L .  t £ l
OJ 03
^  Pr*:>g<st<r«:*n<
Estradiol
^  lu ten is in g  Horm on*
^  Fellick S tim ulating  H orm one
1 3 5 7 9  11 1 3 1 15 17 19 21 23 25 27
2 4 6  8 10 1 2 14 16 18 20 22 24 26  28
i _______ 1__________________ Lr 't '{ " StC'ttOr\; *nD££ •
CVyoT'Sin
Days o f  t h e  M e n s t u r a l  Cycle 
Figure 1.4: Stages of the Menstrual Cycle. During menstruation the endometrial 
lining is shed and the levels estrogen begin to increase. During the proliferative 
phase of the cycle the endometrium starts to thicken in line with increasing 
levels of estrogen. The ovarian follicle also begins to mature during this phase. 
Day 14 marks ovulation whereby the primary oocyte is released from its follicle. 
Ovulation correlates with a sharp increase in leutenising and follicle-stimulating 
hormone. Following ovulation the level of estradiol declines whereas 
progesterone levels increase until the released oocyte becomes the corpus 
luteum and begins to degenerate.
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1.2.1 Menstruation
Days 1-5 of the menstrual cycle are characterised by the sloughing of the endometrial 
lining and the ovum. During this phase estrogen, primarily 17-p estradiol (E2 ), and 
progesterone are at their lowest. The menstruation phase in the endometrium also 
marks the beginning of the follicular phase in the ovaries, during this time the 
gonadotropin, FSH, is released from the pituitary gland, stimulating the maturation 
of follicles in the ovary which bare the oocyte. At this stage the oocyte has not 
reached full maturation and is referred to as the primary oocyte (Sanchez and Smitz, 
2012). The end of menstruation marks the beginning of the proliferative phase of the 
cycle.
1.2.2 The Proliferative Phase
The proliferative phase takes place on days 5-14 of the menstrual cycle. During this 
time the developing ovarian follicle produces estrogen, which promotes endometrial 
proliferation via signalling through its receptors; estrogen receptors a and p (ERa 
and ERp). Proliferation of the endometrium produces a thick endometrial lining in 
preparation for blastocyst implantation, should conception occur. The increase in 
estrogen levels also stimulates the expression of ERa, ERp and progesterone 
receptors (PRA and PRB) in all endometrial cell types to allow the receptor-based 
signalling of estrogen and progesterone (Home and Blithe, 2007). In the normal, 
fertile, endometrium the highest concentration of progesterone receptors (PRs) is 
found in epithelial cells during the late proliferative phase of the cycle and declines 
throughout the late secretory phase with the concentration of PR being greatest in the 
glandular epithelium (Nisolle et al., 1994). Although there is a lower concentration of 
PR in endometrial stroma, the receptors show only minor fluctuations during the 
menstrual cycle, with PR remaining high in the secretory phase (Ingamells et al., 
1996).
During the proliferative phase, the endometrial glands are simple and tubular and 
open out onto the surface of the endometrium, there is no crowding of glands within 
the stroma with a <50% gland to stroma ratio (Figure 1.5) (Deligdisch, 1999).
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O n day  14 o f  the cycle  the ris ing  levels o f  estrad io l reach  th e ir peak  and  stim ulate  the 
p itu ita ry  g land to re lease  the second  g o n ad o tro p in , LH . T he  surge in levels o f  LH  
cau ses  the m ature ovarian  fo llic le  to rup tu re  and  re lease  the oocy te  (now  term ed  the 
seco n d ary  oocy te) into the fa llo p ian  tube. T h e  re lease  o f  the secondary  oocy te  
trig g ers  the  beg inn ing  o f  the lu teal phase in ovaries and the sec re tary  phase in the 
en d o m etriu m  (Johnson , 2012b).
Figure 1.5: Typical biopsy of healthy proliferative endometrium 
1.2.3 The Secretory phase
T h e  secre to ry  phase  o f  the cy c le  beg ins w ith ov u la tio n . A t th is tim e the ovaries en ter 
the luteal phase o f  the cycle  and cease  to p ro d u ce  estrogen  cau sin g  the levels o f  
e s tro g en  to drop. T h e  re leased  ovum  m ak es its w ay  dow n the fa llo p ian  tube 
b eco m in g  the corpus lu teum  or ‘y e llo w  b o d y ” w h ich  p roduces p ro g este ro n e , causing  
p ro g este ro n e  levels to  rise  accord ing ly . T h is  increase  in p ro g este ro n e  causes a 
second  sm alle r peak in estrogen  du ring  the sec re to ry  p h ase  (Ingam ells et al., 1996). 
T h e  p rogeste rone increase  is a lso  the trig g er fo r the change in phase  from  the 
p ro life ra tiv e  into the secreto ry ; su itab le  fo r im p lan ta tio n  o f  the b lastocyst shou ld  
co n cep tio n  occur. T he  rising  levels in p ro g este ro n e  reg u la te  genes invo lved  in 
g ly co g en esis  (D em ers et al., 1977), p ro tein  sy n th esis  and secretion , and  cell cyc le  
reg u la tio n  (S avouret et al., 1990). T he  increase  in p ro g este ro n e  also  d o w n -reg u la tes  
its ow n recep to r (G raham  and C larke, 1997a). T h u s the exp ression  o f PR  dec lines in 
ep ith e liu m  and is undetec tab le  in g landu lar ep ith e liu m  in the late secre tary  phase. 
H ow ever, PR con ten t w ith in  the strom a p ers is ts  th ro u g h o u t the m enstrual cyc le  
(M erten s et al., 2001, L essey  et al., 1988). W ith o u t co n cep tio n  the co rp u s lu teum
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a troph ies and the levels o f  p rogeste rone  drop  trig g erin g  m enstruation . D uring  this 
stage the rise in p ro g este ro n e  levels also causes im portan t changes in the structu re  o f  
the end o m etriu m . T he  en d o m etria l g lands increase  in to rtu o sity  and  fill w ith  
g ly co g en  a llow ing  th em  to sec rete  a g ly co g en -rich  sec re tio n  w hich  is an  im portan t 
sou rce  o f  nu tritio n  fo r the fe rtilised  ovum  (D eligd isch , 1999). T h e  ab u n d an ce  o f the 
g lands also  increases w here  the endom etrium  m ay hav e  a m ore than  50%  g land  to 
s trom a ratio . D uring  th is tim e the g lands m ay exh ib it cro w d in g  bu t are o rg an ised  and 
not m ito tica lly  ac tive  (F ig u re  1.6). T he un d erly in g  strom al ce lls a lso  undergo  
structu ra l changes du ring  th is tim e in a process k now n  as dec idua lisa tion .
Figure 1.6: Typical biopsy of healthy secretory endometrium.
1.2.4 Decidualisation
D uring  the late sec re to ry  phase  o f  the m enstrual cy c le  the p ro life ra tiv e  ac tiv ity  in the 
g lan d u lar ep ith e lia  ceases and  the ep ithelial ce lls  undergo  tran sfo rm atio n  into a 
sec re to ry  state. H ow ever, ce lls  o f  the strom al co m p artm en t co n tin u e  to  p ro lifera te  
into the m id -la te  sec re tary  p hase  w hen they  undergo  d ec id u a lisa tio n , a p rocess 
w hereby  p ro g este ro n e  in stiga tes functional changes th ro u g h o u t the strom a 
(P sychoyos, 1973). D ecid u alisa tio n  can be d escribed  as the p o st-o v u la to ry  re ­
m odelling  o f  the  u terus in p rep ara tio n  for p regnancy  (G elle rsen  et al., 2007). D uring  
d ec id u a lisa tio n  d iffe ren tia tio n  and p ro lifera tion  o f  the fib ro b last-lik e  m esenchym al 
cells o f  the strom a to a dec idual cell w hich  is m o rp h o lo g ica lly  and b io ch em ica lly  
d istinc t (T ang et al., 1994, S alam onsen  et al., 2003), (F igu re  1.7). C yclic  adenosine  
m onop h o sp h ate  (cyclic  A M P , cA M P ) is a second  m essen g er th a t in itia tes 
in tracellu la r signal transduc tion  th rough cyc lic  A M P  dependen t pathw ays 
(R asm ussen , 1970) and is ab so lu te ly  param o u n t in the p rocess o f dec id u a lisa tio n
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(G elle rsen  and B rosens, 2003). If im p lan ta tion  occurs th e  u terus rem ain s in a state  o f  
dec id u a lisa tio n  and is re ferred  to  as decidua, h o w ev er, w ithou t im p lan ta tio n  the 
s truc tu re  b reak s dow n.
T he  p ro cess  b y  w hich  strom al cells dec id u a lise  is ca lled  the m esenchym al to  
ep ithelia l tran sitio n  (M E T ) (T ang  et al., 1994). D uring  the M E T  the cy to sk e le to n  is 
reo rg an ised  to  alter in te rac tio n  be tw een  ce lls and  th e ir su rro u n d in g  tissue. 
M esenchym al ce lls  are un d iffe ren tia ted  cells that are loosely  con n ected  to their 
su rro u n d in g s w hereas ep ithelia l ce lls  are ch arac te rised  b y  tigh t ju n c tio n s  and  ce ll-cell 
adhesion  m arkers (K allu ri and  W einberg , 2009). A key  p lay er in  strom al 
dec id u a lisa tio n  is dec idual p ro lac tin ; a h o rm one know n  fo r reg u la tin g  im m une and 
en d o crin e  func tions. P ro lactin  is exp ressed  in response to  p ro te in  k inase  A , w hich  is 
induced  by cyc lic  A M P. P rogesterone w orks in synergy  w ith  cy c lic  A M P  to 
u p reg u la te  dec idual p ro lac tin  gene expression  (T e lg m an n  and G elle rsen , 1998). 
T hus, h o rm o n e  sig n allin g  and in tricate  co m m u n ica tio n  betw een  h o rm o n e-b o u n d  
recep to rs and o ther p ro te ins is crucial fo r successfu l co m p le tio n  o f the m enstrual 
cycle , fo r d ec id u a lisa tio n  and fo r b lastocyst im p lan ta tion .
Mesenchymal :o Lpnhelial lransi:ion 
 >
Stromal Cell Epithelial-like Cell
Figure 1.7: Mesenchymal to epithelial transition. During decidualisation 
stromal cells undergo the mesenchymal to epithelial transition whereby they 
transform from a stromal cell to a round cell with an epithelial like phenotype.
1.2.5 Menopause
F o llow ing  the rep ro d u c tiv e  ph ase  o f  life w om en  w ill exp erien ce  m enopause . 
M enopause is defined  as the perm anen t cessation  o f  m en stru a tio n  as a resu lt o f  the 
loss o f  o v arian  fo llicu lar ac tiv ity  (U tian , 1999). A fte r m en o p au se  the en d o m etriu m  
undergoes g radual a trophy , s ta rtin g  as an inactive ph ase  w hich  ends up as a thin 
layer, o ften  rid d led  w ith cy stic  cavities lined by cubo idal o r fla t ep ithelium
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(D e lig d isch  et al., 1978)(F igure 1.8). F a ilu re  to o vu late  afte r m en o p au se  first 
dep riv es  th e  en d o m etriu m  o f  p ro g este rg en ic  stim ulation . T he estrogen ic  stim u la tio n  
m ay  co n tin u e  in som e s itua tions because  o f  the conversion  o f  and rogens secreted  by 
th e  p o stm en o p au sa l ovaries and co rtices o f  the adrenal g lands, in to  estrogens. 
O b esity , d iab etes and  m etab o lic  d iso rd ers  m ay enhance the ex tra  gonadal 
en d o g en o u s  estrogen  p ro d u c tio n  by  a ro m atisa tio n  (K irsch n er et al., 1982, F riberg  et 
al., 2007). H igh estrogen  levels, esp ec ia lly  estrad io l, are o ften  a sso c ia ted  w ith  
en d o m etria l d iseases, in p articu la r en d o m etria l h y p erp lasia  (G urp ide  et al., 1976).
Figure 1.8: Normal post-menopausal endometrium. Adapted from Khoury 2006 
(Khoury et al., 2006).
1.3 E ndom etria l Disease
E n d o m etria l d isease  re fers  to  a n u m b er o f  co n d itio n s  affec ting  the en d o m etriu m . T he 
m ost com m on  endom etria l d iso rders include endom etrio sis , p o ly cy stic  ovarian  
sy n d ro m e (P C O S ) and hyperp lasia . In m any  incidences endom etria l d isease  p resen ts 
a h e ig h ten ed  risk  o f  endom etria l cancer d ev e lo p m en t (L acey  and C hia, 2 0 0 9 , Z an e tta  
et al., 2000 , E scobedo  et al., 1991), w h ich  affects 1.6% o f  w om en  in dev e lo p ed  
coun tries (Jem al et al., 2011). E ndom etria l d isease  is o ften  linked to  a h o rm onal 
im balance , fo r ex am p le  PC O S is linked  to  h e igh tened  androgen  s ig n allin g  (E hrm ann , 
2005) and en d o m etria l h y p erp la sia  is linked  to  chron ic  estrogen  stim u la tio n  (G urp ide  
et al., 1976). PC O S is m ost co m m o n  in w o m en  aged betw een  18 and 44 (T eed e  et al., 
2010) and in som e cases can lead to  h y p erp la sia  m ak ing  PC O S the m ain  cause o f  
hy p erp lasia  in young  w om en  (B alen , 2001).
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1.3.1 Endometrial Hyperplasia
Endometrial hyperplasia is a benign condition characterised by abnormal 
proliferation of endometrial glands whereby the glands proliferate in both size and 
shape with an increased gland to stroma ratio. The importance of this disease is 
highlighted by its association with endometrial cancer (Montgomery et al., 2004). 
The risk of cancer progression is dependent on the type of endometrial hyperplasia. 
The World Health Organisation (WHO) classification of hyperplasia is based on 
glandular features (stromal architectural pattern) which are described as simple and 
complex, and the presence or absence of nuclear atypia (Skov et al., 1997). Nuclear 
atypia is described as the abnormal, often pleomorphic, appearance of cell nuclei. 
Identification of these features allows hyperplasia to be grouped into four major 
categories; the simple and complex hyperplasia without atypia and the simple and 
complex hyperplasia with atypia. Simple hyperplasia with and without atypia can be 
seen in Figure 1.9A and B.
The WHO classification system correlates the hyperplasia groups with the risk of 
progression to endometrial carcinoma. For hyperplasia without atypia there is a less 
than 5% risk of cancer progression but when atypia is present the risk increases to 
approximately 30% (Lacey et al., 2010, Gerulath and Borth, 1977). However, these 
statistics may be unreliable as the finding of nuclear atypia, which is considered the 
best indicator of malignant potential, has a wide inter-observer variation (Zaino et al., 
2006, Kendall et al., 1998).
Furthermore, the literature demonstrates that incidence of simple hyperplasia without 
atypia is highest in women age 50-54, whereas the rate of atypical hyperplasia is 
highest in women age 60-65 (Lacey et al., 2010, Rakha et al., 2012). However, 
regardless of hyperplasia type, an overwhelming body of evidence suggests that this 
disease occurs as a result of chronic estrogen stimulation unopposed by the 
counterbalancing effects of progesterone (Bergeron et al., 1999, Herrinton and 
Weiss, 1993, Smith et al., 1975).
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1.3.2 Endometrial Cancer
C ancer o f  the en d o m etriu m  can  m an ifest as on e  o f  tw o  p a th o g en e tic  types. T he  first 
type (T ype  1) is ch a rac te rised  by w ell d iffe ren tia ted  tu m o u rs , superfic ia l in vasion  o f 
the m yom etriu m , sen sitiv ity  to p ro g estin  therapy  and  a fav o u rab le  p rognosis . T he 
second endom etria l can cer type  (T ype  2) p resen ts  w ith  poorly  d iffe ren tia ted  tu m o u r 
cells, deep  m yom etria l invasion , a h igh o ccu rren ce  o f  m etasta tic  sp read , low  
sen sitiv ity  to  p rogestin  trea tm en t and  a poor p ro g n o sis  (B okhm an , 1983, S e tiaw an  et 
al., 2013).
A s w ith endom etria l h yperp lasia , type 1 endom etria l can cer is o ften  asso c ia ted  w ith  
o v er-ex p o su re  to estrogen  (W eid erp ass et al., 1999b, H errin ton  and W eiss, 1993). 
E strogen  stim u lation  causes enhanced  and lo n g -stan d in g  endom etria l p ro life ra tio n  
lead ing  to the gradual d ev e lo p m en t o f  h yperp lasia , fo llo w ed  by a typ ical h y p erp la sia  
and  even tua lly  type-1 can cer (P ersson , 2000, W h iteh ead  et al., 1981, K im  et al., 
2013a). T ype  1 tum ours and endom etria l h y p erp la sia  o ften  have p ositive  s ta in in g  for 
p rog este ro n e  recep to rs m ak ing  them  sensitive  to p ro g estin  therapy  (C arcan g iu  et al., 
1990). A  typ ical endom etria l b iopsy  can  be seen in F igu re  1.9C.
iPlk
Simple hyperplasia without 
atypia: proliferated endometrial 
glands with ireegular distribution 
and cystic dilation but widely  
separated by endometrial stroma.
Atypical hyperplasia: very 
closely packed irregular shaped 
endometrial glands seperated by 
endometrial stroma.
Endometrial cancer with stromal 
evasion: confluent glandular pattern 
in which individual glands are 
uninterrupted by stroma.
Figure 1.9: Human biopsies of endometrial hyperplasia without atypia (A), and 
with atypia (B) and type 1 endometrial cancer (C). Images adapted from Horn
(2007)
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1.4 Estrogens and Progestogens
The different roles of estrogen and progesterone in the normal and diseased 
endometrium are due to their ability to bind their receptors with high affinity and 
cause downstream regulation of target genes. Progestogens are a class of steroid 
hormones that bind to and activate the progesterone receptor (PR) with the most 
important progestogen being progesterone. Progesterone is a C-21 steroid hormone 
whereas the estrogens are a group of C-18 steroid hormones. The three main estrogen 
steroids are estrone (Ei), estradiol (E2 , 173-estradiol) and estriol (E3) with E2  being 
the most abundant estrogen during the reproductive years. There is also a fourth 
estrogen called estetrol (E4 ) which is only expressed during pregnancy.
The structures of natural estrogen and progesterone, along with androgen, were first 
determined after their isolation in the 1930s. The realisation that these steroids could 
be useful tools for disease treatment and contraception first came about after scientist 
Ludwig Haberlandt demonstrated temporary contraceptive effects in a female rabbit 
transplanted with the ovaries of a second pregnant rabbit (Muller-Jahncke, 1988). 
Soon after, it was confirmed that high levels of steroid hormones could provide 
inhibition of ovulation (Goldzieher, 1982, Perone, 1993).
Following this discovery, estrogens were employed by a number of investigators in 
an attempt to inhibit ovulation for the treatment of dysmenorrhea but it was soon 
realised that progesterone was a key player (Drill, 1977). The door to large scale 
production of progesterone was opened in the 1940s when Russell E. Marker 
discovered a method of extracting progesterone from diosgenin, a steroid sapogenin 
found in wild yam (Dioscorea villosa), through the removal of its side chain 
(Lehmann et al., 1973). This method of extraction could provide large quantities of 
progesterone at low-cost; allowing commercial availability of the drug.
Further investigation into the potential role of steroid hormones in the inhibition of 
ovulation meant attempts to develop hormone based therapies got under way. 
However, production of pharmacologically active estrogen and progesterone-based 
drugs proved difficult due to the poor bioavailability of both hormones resulting 
from their poor solubility and extensive metabolism.
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1.4.1 Estrogen (17p-Estradiol)
17P-estradiol (E2 ) has a molecular weight of 272.382 Da and an empiric formula of 
C 18H2 4O2 . The chemical structure of E2 can be seen in Figure 1.10.
HO
Figure 1.10: The Chemical Structure of 17p-estradioI. Produced using ACD 
Structure Elucidator, version 12.01 (Advanced Chemistry Development inc, 
2014)
E2 is virtually insoluble in water with an aqueous solubility of 1.51pg/mL (Shareef et 
al., 2006). After oral administration only 10% of estrogen is absorbed into the blood 
as complete estradiol with the rest being metabolised prior to absorption (Longcope 
et al., 1985).
As a result of its poor bioavailability estradiol is usually administered in the form of 
ethinyl estradiol (EE) or estradiol valerate (E2V), which are taken along with 
progestins for HRT and contraception (Nelson, 2007, Ahrendt et al., 2009, Endrikat 
et al., 2008). Synthetic estrogen is also administered alone for the treatment of HRT 
in women without a uterus or administered in combination with a progestin for 
women with a uterus. EE is produced by substituting carbon 17 of the estradiol 
molecule with an ethinyl group which serves to reduce the rate of metabolism of the 
drug in the intestinal mucosa and liver (Shoupe and Kjos, 2006). E2V on the other 
hand acts as a pro-drug; it is a synthetic ester and upon entry to the body, it is cleaved 
by esterases during intestinal absorption (Diisterberg and Nishino, 1982).
The bioavailability differs between EE and E2V. A study carried out in 2005 showed 
that the bioavailability of EE taken orally with a synthetic progestin as part of an oral
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contraception is approximately 55% (van den Heuvel et al., 2005). The reduced 
amount of EE seen is mainly due to first pass metabolism in the small intestine. EE is 
shown to be susceptible to extensive metabolism in the human jejunal mucosa, 
followed by further metabolism in the liver which leads to the breakdown of estradiol 
into inactive metabolites. Several factors, including the patients BMI and 
administering EE in combination with synthetic progestins can affect the 
bioavailability of EE (Edelman et al., 2009).
After oral administration, E2V is rapidly and completely absorbed through the small 
intestine. After and during absorption the metabolic processes that occur in the GI 
tract, intestinal mucosa and liver rapidly cleave E2V into desired metabolites; 17p- 
estradiol and valeric acid. However, extensive metabolism of the resulting free 
estradiol also occurs in these regions. As a result only -3% of an orally administered 
dose of 20mg E2V will enter the blood as unchanged E2 (Diisterberg and Nishino, 
1982).
CH1.4.2 Progesterone
O
Figure 1.11: The Chemical Structure of Progesterone. Produced using ACD 
Structure Elucidator, version 12.01 (Advanced Chemistry Development inc, 
2014)
Progesterone is also known as pregn-4-ene-3,20-dione and has a molecular weight of 
314.46 Da and an empirical formula of C21 H3 0  O2 (SIGMA-ALDRICH, 2010). The 
molecule contains two ketone and oxygenated functional groups, two methyl 
branches and four hydrocarbons, depicted in Figure 1.11. The presence of two ketone
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groups in the A-ring makes progesterone susceptible to enzymatic degradation in the 
small intestine and liver leading to poor bioavailability when delivered orally 
(Stanczyk, 2002).
A second major problem affecting the oral bioavailability of progesterone is 
solubility; poorly soluble drugs have reduced intestinal absorbance hence reducing 
their passage to the blood stream. Progesterone is hydrophobic with a reported 
aqueous solubility of 16.8ug/ml (Haskins, 1949), though recent research suggests the 
solubility of progesterone in water is almost half this amount (8.81pg/ml) 
(Yalkowsky et al., 2010). It is, however, more soluble in alcohol and sparingly 
soluble in oil, hence micronized progesterone is often delivered in oils (Hsia et al., 
2005). The low bioavailability of progesterone has been partly overcome in the form 
of micronized progesterone which contains natural progesterone with a considerably 
reduced particle size. The reduction in progesterone particle size increases its rate of 
dissolution within the intestinal fluids leading to increased intestinal absorption and 
enhanced bioavailability (Chaumeil, 1998).
In 1993 a study on healthy postmenopausal women determined that the 
bioavailability of progesterone, in its micronized form, was approximately 8 .6 % 
(Simon, 1993). The process of micronization drastically reduces the average 
diameter of particles. Micronized progesterone is absorbed rapidly with 50-60% of 
administered dose being successfully absorbed into the hepatic portal vein according 
to urinary concentrations of pregnanediol, a biologically inactive derivative of 
pregnane, formed by the reduction of progesterone (Bruno, 1999). The degradation 
of progesterone causes high levels of circulating metabolites, mainly pregnanediol, 
pregnanolone, allopregnanolone, pregnanedione, 20a-dihydroprogesterone, and 17- 
OH progesterone (de Lignieres, 1999, Ottoson et al., 1984, Andreen et al., 2005).
Despite high absorbance rates, the bioavailability of progesterone remains low. 
Several studies have been conducted to assess the bioavailability of micronized 
progesterone. Norman et al (1991) treated healthy premenopausal women with an 
oral dose of 200mg of micronized progesterone. Bioavailability varied widely 
between individuals with peak plasma levels of progesterone ranging from 8.5 to
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70.6 ng/ml 4 hours after administration. During the study orally administered 
progesterone was compared with vaginally administered progesterone and no 
significant difference in bioavailability was found between the two routes of 
administration (Norman et al., 1991). A study by Maxson and Hargrove (1985) also 
investigated the bioavailability of micronized progesterone (2 0 0 mg) administered 
orally to 9 healthy postmenopausal women. Progesterone was rapidly absorbed with 
peak plasma levels of 17.0 (+/-4.9) ng/ml being achieved at approximately 2.8 hours 
post administration and returning to normal by 24hours. These concentrations were 
equivalent to progesterone levels seen during the mid-luteal phase of the cycle. 
Interestingly the study also showed that progesterone caused no significant change in 
the levels of endogenous E2 , FSH, LH, cortisol, aldosterone, lipids or hepatic 
enzymes within the 24hour time frame (Maxson and Hargrove, 1985).
Finally, a similar study was carried out by Nahoul et al (1987) whereby 200mg of 
micronized progesterone was given orally to 6  healthy volunteers. Although this 
study showed peak plasma levels were apparent at a similar time to Maxson’s study 
(Tmax = 3.00 ± 0.44 h), they found that mean peak plasma levels were 4.70 ± 
1.15ng/ml with a range of up to 1 0 . 1 0  ng/ml, thus further demonstrating inter­
individual variability (Nahoul et al., 1987). Variation in results may also be linked to 
the different methodology used in the studies.
Due to the poor bioavailability and short half-life of micronized progesterone it has 
been limited to the treatment of certain reproductive disorders such as in HRT for the 
management of secondary amenorrhea (Levine and Watson, 2000a) and in assisted 
pregnancy as a luteal phase supplement (Friedler et al., 1999).
Despite the draw-backs with its bioavailability the development of an orally active 
natural progesterone formulation is still desirable. Research shows that the use of 
natural micronised progesterone has very few side effects and brings about benefits 
in lipid profiles and osteoporosis prevention (Goletiani et al., 2007, Sitruk-Ware et 
al., 1987, Murray, 1998).
Due to the poor bioavailability of natural P4, a great deal of research has gone into 
the development of synthetic progesterone analogues which evade the detrimental
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first pass effect. Early research in this area led to the development of the first 
commercially available oral contraceptive, Enovid, which contained the synthetic 
progestins mestranol and norethynodrel and was distributed in America and the UK 
in the 1960s (Muller-Jahncke, 1988). Like all contraceptives, Enovid worked by 
mimicking the effects of the ovarian steroids. The consequences of taking such drugs 
are primarily ovulation inhibition but changes in cervical mucus that inhibit sperm 
penetration also occur (Rivera et al., 1999).
Since the production and discontinuation of Enovid, a variety of hormone-based oral 
formulations has been made available to women nationwide. As well as 
concraception, such formulations are used in the treatment of diseases, particularly, 
endometrial hyperplasia and cancer.
1.5 Progestin Therapy for Endometrial Disease
The use of progestins for the treatment of endometrial hyperplasia and cancer serves 
to promote endometrial atrophy by inhibiting estrogenic proliferation and inhibiting 
apoptosis (Saegusa and Okayasu, 1998, Kyo et al., 2011, Amezcua et al., 2000, Syed 
and Ho, 2003). Such actions occur through the activation or repression of target 
genes. However, the synthetic progestins used in hormone therapies are often 
associated with adverse gene regulation as described later in this chapter. The use of 
man-made progestins for the treatment of endometrial disorder is often essential due 
to the poor bioavailability of the natural product (Simon et al., 1993) as described in 
section 1.4.2. At present, in the UK, natural progesterone is not prescribed for oral 
dosing. However, orally administered natural progesterone was previously prescribed 
as part of hormone replacement therapy (HRT) in order to alleviate menopausal 
symptoms. For the purpose of HRT, progesterone was used to offset the carcinogenic 
potential of estrogen. For its rare use in HRT progesterone was administered at 
200mg daily under the trade name Utrogestan (Besins and Besse, 2013). However, 
this drug was discontinued in August 2014 due to ‘low level use’ 
(The_Parmaceutical_Joumal, 2014).
Other natural, micronized, progesterone products are still prescribed in the UK, 
though these are delivered via different routes. For example, Gestone (Nordic
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Pharma Ltd) is delivered intramuscularly, Crinone (Juniper Pharmaceuticals) is 
delivered as a vaginal gel and cyclogest (L.D Collins and Co) is delivered as a 
pessary or suppository. Each of these preparations contain micronized progesterone 
and is used in assisted reproduction as a luteal phase support with cyclogest being the 
most commonly used (Kassab et al., 2008). For assisted reproduction oral micronized 
progesterone is unsuitable. After oral administration the use of natural, micronized, 
progesterone remains limited due to its susceptibility to extensive first-pass 
metabolism. As a result, oral micronized progesterone is not adequate to confer 
decidual transformation of the endometrium which is the main goal of luteal phase 
support (Bourgain et al., 1990).
The reason for using natural progesterone in assisted reproductive cycles as opposed 
to synthetic progestins is due its low incidence of systemic side effects (de Ziegler 
and Fanchin, 2000). Synthetic progestins are often associated with undesirable gene 
regulation which is preferably avoided in the delicate process of assisted pregnancy.
However, synthetic progestins are strong PR agonists and have a high affinity for the 
progesterone receptor as well as a much higher bioavailability after oral 
administration meaning small doses of progestin can be administered with maximal 
progestational activity. Thus, when it comes to the treatment of most reproductive 
disorders synthetic progestins are the choice treatment. Two of the most important 
medical applications that synthetic progestins are used for are in the treatment of 
endometrial hyperplasia and endometrial cancer.
To date, the main progestins used to treat hyperplasia are orally administered 
medroxyprogesterone acetate (MPA), or levonorgestrel (LNG) delivered through an 
inter-uterine device. Women with complex and atypical hyperplasia tend to be 
treated with hysterectomy due to the increased cancer risk whereas treatment 
guidelines generally recommend hyperplasia without atypia is treated with progestins 
(Reed et al., 2009). Progestin treatment is also given to women who wish to maintain 
fertility or are at postmenopausal age and have other co-morbidities that make them 
unsuitable for surgery.
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As well as being a commonly used progestin for hyperplasia treatment, MPA is also 
used to treat type 1 endometrial cancers. MPA is given orally at 200mg a day or 
given intramuscularly via 400mg twice-weekly injections (Kohom, 2012) but this 
form of treatment can incur severe side-effects (Bafaloukos et al., 1999, Thigpen et 
al., 1999).
1.5.1 Discovery and Implementation of Hormone Treatments
The first indication that hormones could be used for the treatment of hyperplasia and 
cancer predates the discovery of the hormones themselves; in the 1870s Thomas 
Beatson noted a link between ovaries and breasts milk and went on to discover that 
removal of the ovaries diminished milk production in the breast. He then investigated 
the role of the ovaries in breast cancer and found that their removal resulted in breast 
cancer regression, thus he had found that the stimulating effects of the ovarian 
hormones could lead to cancer of the breast (Cancer.org, 2015). However, the 
hormones themselves were not discovered nor put to use for disease treatment until 
decades later (Goldzieher, 1982, Perone, 1993).
The treatment of endometrial hyperplasia and cancer came about after Wellenbach 
and Rakoff (1953) discovered that ovariectimised hamsters developed endometrial 
hyperplasia following prolonged estrogen treatment and that the hyperplasia 
regressed when progesterone treatment followed. The two also found that 
hyperplasia development was prevented when both hormones were administered in 
combination (Wellenbach and Rakoff, 1953).
Following this discovery, the use of progesterone for both endometrial cancer and 
hyperplasia treatment was suggested (Kelley and Baker, 1961, Kistner, 1959, Kistner 
et al., 1965). However, no suitable medication was available; the poor bioavailability 
of progesterone meant that painful daily intramuscular injections would be required 
(Kohom, 2012). Thus the synthetic progestins came into play. Early studies into the 
effects of synthetic progestins on endometrial cancer showed that it was effective in 
over 30% of patients and that these patients had slow growing cancers and well- 
differentiated tumours, (Kelley and Baker, 1960) which are now referred to as typel 
tumours (Bokhman, 1983).
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Wellenbach and Rakoff s discovery not only instigated progesterone-based 
hyperplasia and cancer treatment but it also prompted investigation into the 
carcinogenic effects of estrogen in humans. Studies of women taking estrogen for 
hormone replacement therapy were carried out. The data obtained showed this 
regimen substantially increased both hyperplasia and cancer incidence (Weiderpass 
et al., 1999a, Woodruff et al., 1994). However the addition of progestins to this 
treatment prevented the hyperplasia and cancer risk (Rose, 1996), further elucidating 
the role of progestogens as inhibitors of tumorigenesis (Yang et al., 2011). This 
finding was further confirmed in the Million Women Study (Collaborators, 2005). 
Therefore, the synthetic progestins became widely used for the treatment for 
endometrial hyperplasia and progestin sensitive endometrial carcinoma.
Marketed progestin-based drugs are often described in generations. The generations 
are based on the time in which the progestin was introduced to the market with more 
recently manufactured progestins having the most desirable molecular profile.
As well as being classified in generations, progestins can also be grouped based on 
their structural derivation. Synthetic progestins can be derived from estrogen, 
progesterone or androgen and these are known as the estranges, pregnanes and 
gonanes respectively. The different structures of the progestins can lead to different 
selectivity for specific hormone receptors, namely the progesterone receptor (PR), 
androgen receptor (AR), glucocorticoid receptor (GR), mineralocorticoid receptor 
(MR) and estrogen receptor (ER) (Sitruk-Ware and Nath, 2010). The binding 
affinites of natural progesterone for these receptor are described in Table 1.1. The 
binding affinities of the two commonly used synthetic progestins, MPA and LNG, 
are also described for comparison.
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PR 100 298 323
GR 11 58 7.5
A R 3 35 58
M R 1000 3.1 17
ER 0.5 <0.02, 0 <0.02
Table 1.1: Relative binding affinities of progesterone, MPA and LNG to steroid 
hormone receptors. Relative binding affinities are expressed as a percentage of 
the total specific binding of natural progesterone. Hormone receptors described 
include Progesterone Receptor (PR), Glucocorticoid Receptor (GR), Androgen 
Receptor (AR), Mineralocorticoid Receptor (MR) and Estrogen Receptor (ER). 
Table adapted from (Africander et al., 2011).
1.5.2 Medroxyprogesterone Acetate (MPA)
T he first g eneration  p rogestin , M PA , w as deve loped  in 1954 and ad m in is te red  to 
w om en  fo r the trea tm en t o f  endom etrio sis  and recu rren t m iscarriage . It w as 
su b seq u en tly  realised  that w om en  rece iv in g  the d rug  late in p regnancy  ex p e rien ced  a 
no tab le  de lay  in fe rtility  fo llo w in g  b irth , lead ing  to the use o f  M PA  as a m eth o d  o f  
con tracep tio n . W ith in  10 years o f  its d ev e lo p m en t M P A  w as m arketed  as long  ac tin g  
in jec tab le  co n tracep tio n  under the nam e D ep o -P ro v era  and is still av a ilab le  to d ay  in 
o v er 90 coun tries w orldw ide  (R abe and R unn eb au m , 1999). In fact, d a ta  from  2010  
suggests that D ep o -p ro v era  is the m ost w idely  adm in iste red  p ro g es tin -o n ly  
co n tracep tiv es. M oreover, M P A  is the m ost com m only  used  p rogestin  fo r trea tm en t 
fo r endom etria l h y p erp la sia  and endom etria l can cer (V ereide  et al., 2006 , G u n d e rso n  
et al., 2012).
M PA  is also  know n as 17 a-h y d ro x y -6 a -m e th y lp ro g es te ro n e  aceta te  and  is a 
p ro g este ro n e-d eriv ed  ho rm o n e w ith  a h igh  affin ity  for the PR but can  a lso  b ind  to  the 
A R  and G R  w ith  a su b stan tia lly  h ig h er affin ity  than  the natural p roduct (T ab le  1.1) 
(A frican d e r et al., 2011).
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MPA has a molecular weight of 386.52Da and an empirical formula of C24H34O4. 
MPA differs from progesterone by the addition of a hydroxyl group (OH) which has 
been acetylated (COCH3) at carbon 17 and the further addition of a methyl group 
(CH3) at carbon 6  which gives the molecule relatively high progestational activity 
(Stanczyk, 2002). Although MPA, like progesterone, is a 3-oxo-4-ene steroid it has 
improved biological activity when administered orally. The structure of MPA is 
depicted in Figure 1.12.
Figure 1.12: The Chemical Structure of Medroxyprogesterone Acetate. 
Produced using ACD Structure Elucidator, version 12.01 (Advanced Chemistry 
Development inc, 2014)
Unlike progesterone, the solubility of MPA presents less of an issue when attempting 
to deliver the drug orally. The solubility of MPA is 1 mg/ml in water according to 
national toxicology program (1992); the increased solubility thus increases the drugs 
bioavailability when administered orally.
However, akin to the natural product, MPA has been shown to undergo extensive 
metabolism in the liver by reduction at the free oxygen molecule in A-ring, as well as 
hydroxylation and conjugation (Stanczyk, 2002) and yet is still active after oral 
dosing (Thigpen et al., 1999). There are no official figures on the oral bioavailability 
of MPA but it is estimated to be 15% which is still an improvement on progesterone 
even in its micronized form (Pannuti et al., 1982, Adlercreutz et al., 1983a, Fotherby,
CH3
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1996). The reason for the slightly improved bioavailability of MPA may be down to 
a degree of first pass metabolism evasion through steric hindrance due to the acetate 
group on carbon 17 of the MPA molecule, (Stanczyk, 2003). However, the increased 
affinity of MPA for the progesterone receptor means that even though only a small 
percentage of the administered drug reaches systemic circulation it is sufficient to 
cause an endometrial reaction.
After intramuscular administration MPA is often well tolerated, however, a common 
subset of side-effects has been reported amongst users including amenorrhea and 
weight gain. Such side effects are commonly flagged up by users of synthetic 
progestins thus suggesting a requirement for developing an oral formulation 
containing natural progesterone with improved bioavailability.
1.5.3 Levonorgestrel (LNG)
LNG is a second generation synthetic progestin derived from nortestosterone and is 
widely used for the treatment of endometrial hyperplasia as well as in a variety of 
contraceptives including the LNG intra uterine device (Mirena Coil) and the 
combined oral contraceptive, Microgynon which is the most commonly prescribed 
combined oral contraceptive in the UK (NHS, 2010). LNG is also administered 
orally as a daily, progestin-only, contraceptive pill or in high doses as an emergency, 
post-coital contraception. It is one of the most commonly used and studied synthetic 
progestin in the UK and the most widely used emergency contraceptive (Brunton LL, 
2006, Langston, 2010, Glasier et al.). The molecular weight of LNG is 312.4Da, its 
empirical formula is C2 1 H2 8O2 and its aqueous solubility is approximately 2.5pg/mL 
(DrugBank, 2010). LNG is derived from and structurally similar to testosterone but 
with the addition of an ethynyl group (H O C ) to significantly reduce androgenic 
activity (Stanczyk, 2002). The chemical structure of LNG is shown in figure 1.13.
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,CH
HOH,C
Figure 1.13: The Chemical Structure of Levonorgestrel. Produced using ACD 
Structure Elucidator, version 12.01 (Advanced Chemistry Development inc, 
2014)
Unlike progesterone, the oral bioavailability of LNG is considered to be very high. 
This information is based on several studies similarly concluding that LNG is almost 
completely absorbed after oral administration (Hiimpel et al., 1978, Grimmer et al., 
1986, Back et al., 1987). The main reason for the high bioavailability of LNG is that 
it evades hepatic first pass metabolism and is rapidly and completely absorbed in the 
digestive tract (Hiimpel et al., 1978). However, LNG has been shown to undergo 
extensive reduction at the a,P-unsaturated ketone in ring A and hydroxylation at 
carbons 2 and 16 with its metabolites circulating predominantly as sulphates 
(Stanczyk and Roy, 1990).
The general acceptance that LNG is rapidly absorbed and has high bioavailability is 
based on studies that quantified serum levels of circulating LNG following treatment. 
Initial studies in this area were carried out in the 1970s and 1980s (Back et al., 1981, 
Hiimpel et al., 1978, Goebelsmann et al., 1986). Humpel et al (1978) were the first to 
report that LNG is rapidly and completely absorbed and not subject to first pass 
metabolism (Humpel M et al., 1978). Following this, Back et al assessed the 
bioavailability of LNG in women taking 150pg and 250pg doses of the hormone 
combined with 30jig of ethinyl estradiol. The study reported that after the 150pg 
dose the bioavailability of LNG is 89% and 99% after the 250pg dose (Back et al., 
1981). The final study looked at the bioavailability of LNG and ethinyl estradiol
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given orally and intravenously in 24 healthy women. The study found that LNG had 
complete bioavailability after oral administration (Goebelsmann et al., 1986).
Although LNG has a very high bioavailability, the acting percentage of LNG found 
in the endometrium is low. A study conducted by Devoto et al looked at LNG used 
in emergency contraception, they concluded that the endometrial concentration of 
orally delivered LNG lies between 15 and 50 nmol/mg. They noted that the 
endometrial concentration of LNG is lower when administered orally rather than 
vaginally yet blood plasma concentrations are higher after oral administration 
(Croxatto et al., 2001). Although the endometrial concentration of progesterone is 
low compared to the administered dose, it is still an effective treatment due to the 
high binding affinity of LNG for the PR. After oral administration approximatedly 
45% of LNG and its metabolites are excreted in the urine and about 32% are excreted 
in faeces, mostly as glucuronide conjugates (DrugBank, 2010).
1.6 Natural vs Synthetic Progestins
The use of natural progesterone is, of course, limited by its poor bioavailability. 
However the development of micronized progesterone products has allowed the 
effects of orally delivered natural progesterone to be assessed. The physical and 
emotional side effects of progesterone compared with MPA were analysed in a study 
carried out in 2002. The study concluded that neither treatment affected mood but 
that MPA caused increased bleeding and breast tenderness whereas no physical 
complaints were noted in users taking natural progesterone (Cummings and 
Brizendine, 2002). Natural progesterone is also said to increase quality of life 
relating to physiological, somatic, and vasomotor effects compared with MPA 
(Fitzpatrick et al., 2000).
Furthermore, natural progesterone does not influence lipid profiles and does not 
cause significant changes in high density lipoprotein cholesterol whereas MPA and 
LNG cause a significant decrease (Bruno, 1999). LNG is also known to cause side 
effects with the biggest complaint being abnormal menstrual bleeding (Damey et al., 
1992, Berenson and Wiemann, 1993). Other side effects of LNG include weight
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gain, headaches, acne and mastalgia (breast tenderness) (Berenson and Wiemann, 
1993).
Patients receiving MPA to treat endometrial hyperplasia or carcinoma can experience 
more severe side effects; Bafaloukos et al described side effects such as weight-gain, 
hypertension and thrombophlebitis in women receiving MPA (Bafaloukos 
(Bafaloukos et al., 1999). Thigpen et al also listed thrombophlebitis as a side effect 
in women receiving MPA and also described the occurrence of pulmomary emboli in 
1% of volunteers (Thigpen et al., 1999).
As described, during HRT, progestins are often administered in combination with 
estrogen to protect the endometrium against hyperplasia development. However, the 
protective effect of progestins seen in the endometrium is not replicated in the breast 
progestins can be seen to increase breast cancer risk. Yet this is not the case with 
micronized progesterone, Gompel (2012) showed that micronized progesterone does 
not heighten proliferation in breast tissue when compared to MPA (Gompel, 2012).
The physical and biological side effects of natural progesterone and its synthetic 
counterparts are down to their roles at the molecular level. Progesterone and its 
derivatives bind to and signal via hormone receptors; they bind these receptors with 
different affinities and differentially regulate associated target genes (Table 1.1). The 
predominant receptor involved in progesterone signalling is the progesterone 
receptor.
1.6.1 Progesterone Receptor
Both the effects of natural progesterone and synthetic progestins are mediated 
through binding the PR. The PR is a member of the family of ligand-activated 
nuclear transcription regulators. Members of this family are highly conserved 
between species and are characterised by organisation into specific functional 
domains (Scarpin.K, 2009).
Humans express three PR isoforms, PR-A (94 kDa), PR-B (116 kDa) and PR-C (60 
kDa), these are encoded on the same gene on chromosome 11 at q22-23. The PR-B 
isoform only differs from the PR-A in that it encodes an additional 164 amino acids
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in its N-terminal region (Graham and Clarke, 1997a). Both isoforms are transcribed 
from a single gene by alternate initiation of transcription from two distinct promoters 
(Gronemeyer, 1991). The more recently discovered PR-C isoform has a different 
conformation from the two larger isoforms, this affects the hormone-binding region 
of the receptor. Although unable to bind hormones, PR-C remains important as it is 
capable of binding to and inhibiting PR-B (Wei et al., 1997, Lange, 2008).
Both PR-A and PR-B isoforms contain three functioning domains, the N-domain, the 
DNA-binding domain (DBD) and the C-terminal ligand binding domain (LBD).
The structurally significant N-terminus contains transcription activation domains 
which are essential for transmitting a transcription activating response to receptor- 
bound DNA and for the binding of co-activators. The N-terminus of the PR-B 
isoform contains two transcription activation domains, AF-1 and AF-3, whereas the 
PR-A isoform contains only AF-1, allowing the binding of different coactivators to 
PR-A and PR-B (Giangrande et al., 2000), and causing the activation capability of 
PR-B to be stronger than that of PR-A (Sartorius et al., 1994) Also within the N- 
terminus is a PXXP region which enables ligand-bound PR to activate the mitogen 
activated protein kinase (MAPK) pathway, an important pathway involved in a 
diverse array of functions including proliferation and differentiation 
(Boonyaratanakomkit et al., 2001).
In the PR-A N-terminus lies an inhibitory domain (ID) which, when activated, blocks 
PR-As transcriptional ability but permits the receptor to suppress other steroid 
receptors such as PR-B and ER. The ID only becomes functional when PR binds to 
its hormone (Hovland et al., 1998).
Both PRA and PRB contain a DBD. The DBD contains a dimerization domain and a 
nuclear localisation sequence which is used to target the protein to the cell nucleus. 
Both receptor types also contain a LBD. Asides from its role in binding the receptor 
to its ligand, the LBD also contains determinants that allow the receptor to dimerise 
and bind heat shock proteins which are key proteins involved in stabilising the 
unliganed PR. Further to this, within the DBD there is a transcription activation 
domain (AF-2) and determinants for a nuclear localisation sequence (Leonhardt et
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al., 2003b). A  full anno tation  o f  the p rogeste rone  recep to rs  can be seen  in F igure  
1.14.
In m ost h um an  tissues P R -A  and PR -B  are ex p ressed  at equal ra tios, h o w ev er, in the 
en d o m etriu m , a decrease  in P R -A  can  be seen d u rin g  the secreto ry  ph ase  o f  the 
m enstrual cyc le  (S carp in .K , 2009) and m ore d rastic  ch an g es o ccu r du rin g  p reg n an cy  
(T ay lo r et al., 2009). In m ost tissues P R -B s are s tro n g er tran sac tiv a ters  than  P R -A s 
and the  recep to rs regu la te  bo th  overlapp ing  and d is tin c t genes (R icher et al., 2002). 
H ow ever, P R -A  can  act as a d om inan t rep resso r o f  PR -B  a llow ing  P R s to  s ilen ce  or 
induce p ro g este ro n e  ac tion  (T ung  et al., 1993). It is u n c lea r w he ther the sig n a llin g  o f  
natu ral p ro g este ro n e  th rough  the d iffe ren t PR iso fo rm s is m im icked  by the syn thetic  
p rogestin s. F o r exam ple , S choonen  and co -w o rk ers  show ed  that the syn thetic  
p ro g estin s, L N G  and gestodene , d isp layed  d iffe ren t b in d in g  affin ities fo r P R -A  and 
PR -B  (S ch o o n en  et al., 1998).
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Figure 1.14: Human PR-A and PR-B Protein Structures. Figure adapted from 
Leonhardt 2003. Domains include N-domain, DNA Binding Domain (DBD), hinge (h), 
and Ligand Binding Domain (LBD). Boxed Numbers describe the following: 1-Site of 
MAPK phosphorylation activity, 2-Site of PR post-translational activity 
(sumoylation), 3-Hsp: region for binding of heat shock protien in absence of 
ligand, 4-Dimerisation domain (DI), 5-Region of co-regulator binding, 6 - 
Activation function 1 (AF-1), 7-AF-2, 8-AF-3, 9-Inhibitory Domain (ID).
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1.6.2 Progesterone Receptor Mechanisms of Action
Prior to ligand binding, the PR exists in the cytoplasm in an inactive state due to its 
association with chaperone proteins. Progesterone or progestins diffuses into the cell 
and binds to cytoplasmic PR at the ligand binding domain. Ligand binding causes a 
conformational change in the PR and allows it to dissociate from its chaperone 
proteins which include heat shock proteins and other protein substrates (e.g P23, 
P59) (Li and O'Malley, 2003). Two active, ligand-bound PRs homodimerize at the 
dimerization domains and are subsequently targeted to the nucleus through nuclear 
localisation sequences found in both the DNA binding domain and the ligand binding 
domain (Figure 1.15) (Tsai and O'Malley, 1994, Li and O'Malley, 2003). Once in the 
nucleus the PR dimers can initiate transcription to up or down-regulate target genes. 
Transcription initiation can occur through the direct binding of PR to progesterone 
response elements (PREs) in the DNA sequence or through the recruitment of protein 
co-regulators. Co-regulators such as members of the steroid receptor coactivator 
(SRC) family can bind the PR at AFs 1 and 2 (Figure 1.14) to form a stable complex 
and cause gene activation or repression.
The PR may be subject to a number of post-translational modifications including 
phosphorylation, SUMOylation, acetylation and ubiquitination (Diep et al., 2015). 
For example, the ligand-bound PR is phosphorylated at serine 294 by MAPK and 
respectively marked for ubiquitin mediated degradation (Lange et al., 2000, Qiu et 
al., 2003).
1.7 Regulation of Target Genes and Proteins
Ligand dependent gene regulation through the PR can cause up or down-regulation 
of many genes and their resulting proteins in the human endometrium. The 
expression level of the PR itself has been widely reported to be down-regulated in 
the presence of progesterone through a negative feed-back process (Graham and 
Clarke, 1997a, Tibbetts et al., 1998). The presence of PR in the normal endometrium 
is well documented (Ehrlich et al., 1981, Mylonas et al., 2004), however in the 
hyperplastic endometrium, the expression of PR is often different and gene 
regulation is affected as a result of changes in the number, abundance and type of
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progesterone receptors and the abnormal levels of endogenous hormones (Nyholm et 
al., 1992).
The presence of PR in the endometrium and its regulation by progesterone or 
synthetic progestins is of great importance. Previous studies have demonstrated that 
the histological response to therapy with progestins is mediated by PRs and the 
intensity of the response correlates with receptor levels (Holinka et al., 1984, 
Deligdisch et al., 1978). Thus, patients with a high receptor level tend to receive 
progestin therapy. However, the initial success of such therapy is often short lived as 
the progestin treatment serves to down-regulate its own receptor which eventually 
leads to a reduction in the therapeutic response (Janne et al., 1979). Therefore it is 
vital to assess the levels of PR in cellular research and patient therapy to establish the 
efficacy of treatments and studies.
As well as regulating itself, ligand binding to the PR also regulates a vast array of 
gene targets. Indeed, the altered expression of some PR targets has been associated 
with endometrial hyperplasia (Mutter et al., 2000, Gallos et al., 2013) yet, the 
presence and stage of this condition has not been predicted by any clinical or 
biological markers. Genes involved in cell secretion, adhesion, apoptosis and 
proliferation are often adversely regulated in such conditions and may help to 
distinguish hyper-proliferation with malignant potential from benign hyperplasia 
(Moreno-Bueno et al., 2003). As endometrial hyperplasia is often treated with 
synthetic progestin therapy it is of keen interest to establish if any potential markers 
are adversely regulated by the synthetic hormones with which they are treated. Genes 
of particular interest include those that are already associated with endometrial 
cancer as well as novel gene targets. The targets chosen for this study are described 
below.
1.7.1 Regulation of PR
The first gene of interest is the PR itself, which is regulated by ligand binding through 
a negative feedback loop in endometrial epithelium (Graham and Clarke, 1997a, 
Tibbetts et al., 1998). However, studies in macaque endometrial stroma, show PR is 
not down-regulated by P4  in this tissue (Brenner and Slayden, 2012). In contrast, E2
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causes an induction in the expression of stromal and epithelial PR. The induction of 
PR by E2  has been shown in the endometrial epithelial cancer cell line, Ishikawa 
(Hata and Kuramoto, 1992, Jamil et al., 1991). In this particular cell line, PR has been 
shown to be down-regulated by P4  after E2  priming (Lessey et al., 1996). Like P4 , 
MPA has also been reported to down-regulated PR (Tseng and Zhu, 1997), however, 
contradictory findings exist on the regulation of PR by LNG. Critchley (1998) 
demonstrated a significant reduction in PRA and B in women with an LNG 
intrauterine device (Critchley et al., 1998) and Vereide (2006) showed a marked 
reduction in PRA and PRB expression in endometrial hyperplasia following LNG 
treatment (Vereide (Vereide et al., 2006)2006). In contrast, a study by Meng (2010) 
compared biopsy samples from healthy fertile women receiving either oral or vaginal 
LNG and found orally delivered LNG significantly reduces PR-A and PR-B in 
glandular epithelial cells, but not in luminal epithelial or stromal cells, whereas 
vaginal delivery did not affect the expression of either PR (Meng et al., 2010).
The available data on P4 and progestin regulation of the PR is conflicting (Critchley 
et al., 1998);(Vereide et al., 2006, Meng et al., 2010) but the majority of the data 
suggests a down-regulation of PR after progesterone based treatment. To date no 
direct comparison has been made between the effects of P4 and synthetic progestins 
on the endometrium.
1.7.2 Forkhead box O protein 1
The second gene of interest is forkhead box O protein 1 (FOXOl). FOXOl is a 
member of the FOXO subfamily of Forkhead/winged helix transcription factors and 
is known to be regulated through ligand-bound PR in endometrial epithelial and 
stromal cells (Ward et al., 2008, Labied et al., 2006) through direct signalling 
mechanism (Kyo et al., 2011). Proteins of the FOXO family are characterised by a 
distinct forkhead domain with a butterfly-like appearance and regulate diverse 
cellular functions, such as differentiation, metabolism and proliferation (Accili and 
Arden, 2004). However, FOXOl proteins have been shown to induce the expression 
of genes encoding proteins involved in cell cycle inhibition and apoptosis in response
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to growth factors, hormones and environmental cues (Labied et al., 2006, Kyo et al.,
2011 ).
In the normal endometrium, FOXOl is mainly associated with the process of 
decidualisation (Christian et al., 2002, Gellersen and Brosens, 2003), however, 
FOXOl is a known tumour suppressor (Myatt et al., 2010) and a marked loss of the 
FOXOl protein expression is associated with endometrial cancer (Goto et al., 2008). 
Yet the level of FOXOl protein expression in endometrial hyperplasia has never 
been investigated.
Up-regulation of FOXOl by progesterone and the synthetic progestins through the 
PRB in cancerous endometrium and normal endometrial stroma is well documented 
(Kyo et al., 2011, Wang et al., 2009, Labied et al., 2006, Ward et al., 2008). As well 
as regulating FOXOl expression, the PR also cooperates directly with this 
transcription factor to regulate genes such as those that encode cell cycle inhibitors 
(Brosens and Lam, 2013).
Overall, FOXOl serves as an excellent positive control for progesterone/progestin 
mediated endometrial target gene regulation and may also serve as a possible marker 
for endometrial hyperplasia.
1.7.3 Amphiregulin
The third gene of interest is amphiregulin (AREG) which is regulated by agonist- 
bound PR-A (Conneely and Jericevic, 2002, Mulac-Jericevic et al., 2000). Human 
AREG is an 84-amino acid glycoprotein discovered and characterized in the late 
1980s (Shoyab et al., 1988). It is a member of the epidermal growth factor (EGF) 
family of proteins and can interact with EGF receptor to promote normal growth in 
epithelial cells. Although AREG does not contain a PRE site, AREG is proven to 
have an AP-1 (Aguiari et al., 2012)and SP1 (Lamber et al., 2010) sites which PR 
homodimers can bind to and regulate transcription.
AREG is expressed at varying levels in the normal endometrium throughout the 
menstrual cycle (Gui et al., 2008b)(Gui et al., 2008b)(Gui et al., 2008b)(Gui et al., 
2008b)(Gui et al., 2008)(Gui et al., 2008)(Gui et al., 2008)(Gui et al., 2008)(Gui et
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al., 2008)(Gui et al., 2008). During the secretary phase, levels of AREG are more 
than 30 times higher than in the proliferative phase which is down to its up- 
regulation by progesterone. The AREG protein is located in the cytoplasm and 
predominantly expressed in the epithelial layer of the endometrium (Gui, Zhang JR 
et al. 2008). An up-regulation of AREG by 2-fold or more has been documented in 
endometrial cancer (Moreno-Bueno et al., 2003, Ejskjaer et al., 2007) yet its role in 
endometrial hyperplasia has not been thoroughly investigated. Hence, the level of 
AREG expression in endometrial hyperplasia warrants further research.
1.7.4 Lactoferrin
Lactoferrin (LF), also known as lactotransferrin, is an epithelial secretory 
glycoprotein and is a member of the transferrin family of proteins. LF has a 
molecular mass of 80kDa and has non-haem iron-binding properties. It was first 
discovered in milk and later found in surface mucosa epithelium as well as many 
biological secretion including tears, semen and saliva. This protein also displays 
antibacterial, antimicrobial and antifungal activity (Sanchez et al., 1992, Adlerova et 
al., 2008).
LF is expressed in the human, monkey and mouse endometrium at varying levels 
throughout the menstrual cycle (Teng et al., 2002, Newbold et al., 1992) and has 
been shown to be regulated by both estrogen and progesterone. LF is directly up- 
regulated by estrogen through an estrogen response element in the LF promotor 
(Zhang and Teng, 2000) and is down-regulated by progesterone (Walmer et al., 
1992, Kurita et al., 2000), though whether this regulation is direct or requires a 
coregulator is unknown. Moreover elevation in LF expression has been directly 
correlated with a peak in endometrial proliferation. A small degree of investigation 
has gone into the changes in LF within endometrial hyperplasia with no changes 
being reported with the exception of one individual case within a small sample 
population (n=10) where LF was seen to be elevated (Walmer et al., 1995). LF is 
frequently overexpressed in PR-negative endometrial carcinomas (Moreno-Bueno et 
al., 2003, Walmer et al., 1995) and further research into its potential role in 
hyperplasia may be valid. Furthermore LF is specifically regulated through the PR-B
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which may elaborate on the different roles of the individual PR types in hyperplasia 
progression.
1.7.5 Gene Regulated in Breast Cancer 1 (GREB1)
As discussed the regulation of genes by the different progestins used in the treatment 
of hyperplasia is important. Therefore, as well as looking at potential markers of 
hyperplasia progression, a further subset of genes will also be assessed to observe 
any differences in gene regulation by the synthetic compounds.
The first gene to be looked at will be the gene regulated in breast cancer 1 (GREB1). 
The GREB1 gene codes for the GREB1 protein which is a single-pass membrane 
protein that has been suggested to play an important role in hormone responsive 
tissue and cancer (Ghosh et al., 2000). GREB1 is present in the human endometrium 
at both RNA and protein level. The GREB1 gene is an early response gene in the 
estrogen receptor-regulated pathway (Pellegrini et al., 2012). Not only is Grebl a 
direct target of estrogen but it is also an androgen target and contains a progesterone 
response element in its promoter (Rae et al., 2006). Furthermore GREB1 expression 
has been shown to be induced by estrogen in endometrial epithelial cells (Gori et al., 
2011). Therefore, GREB1 will be used as a positive control for estrogen treatment 
and its potential novel regulation by progesterone and the synthetic progestins will 
also be investigated.
1.7.6 Prolactin
Prolactin (PRL) is a highly conserved polypeptide hormone present in all vertebrates 
examined. It is synthesized in, and secreted from, specialized cells of the anterior 
pituitary gland called lactotrophs (Freeman et al., 2000). This multifaceted hormone 
has more roles than any other hormone secreted by the pituitary with more than 300 
functions described and carries out its actions through binding the prolactin receptor 
(Bole-Feysot et al., 1998). Although the role of PRL is predominantly associated 
with milk production it also plays an important role in endometrial decidualisation 
and is temporally expressed in the endometrium at the window of implantation 
(Jones et al., 1998). PRL expression has been shown to be regulated through the PR
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in differentiating human endometrial stromal cells. However, progestins are very 
weak inducers of PRL and require more than 8  days of stimulation before enhancing 
PRL expression, yet, the role of progestins in PRL regulation is important in 
amplifying the decidual response. The ability of progestins to synergistically enhance 
cAMP-induced PRL expression has been demonstrated in several studies (Gellersen 
et al., 1994, Telgmann et al., 1997, Brosens et al., 1996, Brar et al., 1997, Tang and 
Gurpide, 1993). As PRL is a well-established marker of stromal decidualisation, its 
expression in this process after exposure to different progestins will be examined.
1.7.7 Insulin-like Growth Factor 1
The final gene target of interest is insulin-like growth Factor 1 (IGF-1). IGF-1 is a 70 
amino acid, single chain polypeptide (Rinderknecht and Humbel, 1978) and is the 
only gene described herein that is not regulated by estrogen or progesterone (Weihua 
et al., 2002, Ace and Okulicz, 1995). However, IGF is upregulated by androgens via 
signalling through the androgen receptor (Zhu and Kyprianou, 2008). It is therefore 
possible for synthetic progestins, capable of binding the AR, to upregulate this gene 
and such differences will be assessed during this thesis.
The regulation of the described PR target genes is depicted in Figure 1.15.
Differences in gene regulation' between progesterone and synthetic progestins 
coupled with the increased prevalence of side effects after progestin consumption 
highlights the benefits of delivering a the natural compound over its artificial 
counterparts. However, the difficulty in delivering natural progesterone has meant no 
such drug has been made available for long term oral delivery.
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Figure 1.15: Gene Regulation by Ligand-bound Progesterone and Estrogen 
Receptors. Progesterone (P4, black) and Estrogen (E2 , Green) bind to their 
receptors and enter the nucleus where they activate or repress target genes by 
either directly binding to response elements in the DNA (ERE, PRE) or 
recruiting co-regulators such as AP-1 and SP-1.
1.8 The Gastrointestinal Tract and Liver
T o u n d erstan d  the underly ing  m echan ism s invo lved  in the  po o r oral b io av ailab ility  o f  
p ro g este ro n e  it is im portan t to first understand  the p h y sio lo g y  o f  the gastro in testinal 
(G I) trac t and  m o reover the p ro b lem s asso c ia ted  w ith  p ro g este ro n e  abso rp tio n  
th rough , and m etabo lism  w ith in  th is o rgan system . O n ce  absorbed  th rough  the 
in testina l w all p rogeste rone trave ls th rough  the h ep a tic  po rta l vein  to the liver w here  
it un d erg o es fu rther m etabo lism  and can en te r the  en terohepatic  c ircu la tion  
(S y m o n d s et al., 1994) T hus the ro les o f  the GI trac t, the liver and en tero h ep atic  
c ircu la tio n  w ill be d iscussed  herein.
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1.8.1 The GI Tract
The components of the GI tract consist of the oral cavity, oesophagus, stomach and 
small and large intestines (Figure 1.16). The histology and physiology of each region 
varies depending on their particular functions (Lee and Yang, 2001). Consumed 
items enter the oral cavity and are passed into the oesophagus as a bolus where they 
are moved toward the stomach through peristalsis. Entry of the bolus into the 
stomach is governed by the cardiac orifice; it is then processed into chyme before 
exiting the stomach through the pyloric region into the duodenum. Stomach juices 
are highly acidic consisting of mainly hydrochloric acid, mucus and several enzymes 
(Johnson, 2012b). The chime produced in the stomach is also highly acidic (pH 3.5) 
and needs to be neutralised upon entry to the small intestine. The duodenum 
represents the first 25cm of the small intestine and receives the opening to the bile 
and pancreatic duct. Bile is highly alkaline and serves to neutralise the acidic chyme 
from the stomach causing the pH to rise to approximately pH 6  (Fallingborg, 1999). 
Bile is also involved in emulsifying fats and aiding digestion. The entry of pancreatic 
juices into the duodenum provides enzymes such as peptidases and lipases to further 
aid in the digestion of food. The main role of the duodenum is thus in the breakdown 
of food but the presence of enzymes in the duodenal mucosa and fluid also have a 
major influence on the metabolism of many drugs (Lee and Yang, 2001).
Upon exiting the duodenum semi-digested food enters the jejunum; which is 
approximately 2.5m long. The jejunum is the major site of food and drug absorption 
able to absorb small nutrient particles that have been enzymatically broken down in 
the duodenum. After absorbtion nutrients and drug enter the enterohepatic circulation 
and are delivered to the liver through the hepatic portal vein for further metabolism 
(Johnson, 2012a).
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Figure 1.16: Anatomy of the Gastrointestinal tract. Adapted from
http://wwH.nvasi.com/anatomv-of-gastrointestinal-tract/
E n tero h ep atic  c ircu la tio n  is the p rocess by  w hich  b ile , b ilirub in , and o th er substances 
includ ing  m any  d rugs leave the sm all in testine  and are transported  to the liv er v ia  the 
hepa tic  portal vein , from  here  they  are re tu rned  to  the duod en u m  th rough  the b ile  
duct and can  rep ea t the cy c le  again  (F igure 1.17). It has been  su g g ested  that 
p ro g este ro n e  is ab le  to  u n d erg o  en th ero h ep atic  c ircu la tio n  w hich  can  cau se  a second  
peak  in b lood  p lasm a levels o f  th is d rug  (S y m o n d s et al., 1994). E n te ro h ep a tic  
c ircu la tio n  is im portan t to  co n sid er w hen  ad m in is te rin g  d rugs as som e d rugs w hich  
are not co n sid ered  tox ic can  accu m u la te  at h igh  levels in the liv er beco m in g  
ex trem ely  h ep a to to x ic  (Z im m erm an , 1999).
T he  rem ain in g  je ju n a l co n ten ts  en te r the final and  longest reg io n  o f  the sm all 
in testine; the ileum  w hich  lies b e tw een  the je ju n u m  and large in testine . T h is  is the 
longest reg io n  o f  the sm all in testine ; reach ing  up to  4m  in length  in som e adults. T h e  
m ain  ro le  o f  the ileum  is in the ab so rp tio n  o f  v itam in  B and b ile  salts as w ell as any  
sm all und igested  p ro d u c ts  no t abso rbed  in the je ju n u m . T h e  pH  o f  the sm all in testine  
g rad u ally  rises from  pH 6 in the d u o d en u m  to abou t pH  7 .4  in the term inal ileum  
(F allingborg , 1999). A fte r passin g  th ro u g h  the ileum  any unab so rb ed  con ten t en ters
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the large  in testine ; the ileum  is separated  from  the large in testine  b y  the ileocaecal 
sph incter.
T h e  large  in testine is ap p ro x im a te ly  1.5m  long and  consists  o f  the caecum , co lo n  and 
rectum . T he  large in testine has fo u r m ajo r func tions; sto rage and  e lim in a tio n  o f 
faeces, m etab o lism  o f p ro te ins, abso rp tion  o f  w a te r and  e lec tro ly tes and p ro d u c tio n  
o f  ce rta in  v itam ins such  as v itam ins K and  B (Johnson , 2012a).
DRUG
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Tissues
Figure 1.17: Schematic Diagram of Enterohepatic Circulation. Drugs 
administered orally are absorbed through the GI tract and transported to the 
liver via the hepatic portal vein before entering body tissues. From the liver 
some drugs are returned to the GI tract through the bile duct and can repeat 
the cycle again
1.8.2 The Liver
T he liver is the largest in ternal o rgan  in h um ans and rests in the abdom en  b e lo w  the 
d iaphragm . T he m ain  function  o f  the liver is to  p rov ide  m etabo lic  con tro l w hich  
re sponds to the ch ang ing  needs o f  the body. T o  achieve this p recise  m etab o lic  
con tro l, the liver p roduces p ro te ins and enzym es at a spec ific  and  ch an g in g  ra te  
th ro u g h  regu la tion  o f  gene tran sc rip tio n  (L eB ou ton , 1993). T h e  liver also  h as  a w ide
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variety of functions outside of protein synthesis including detoxification, glycogen 
storage, decomposition of erythrocytes, and producing chemicals involved in 
digestion such as bile. This series of liver functions are carried out by the liver cells, 
the hepatocytes. The most important function of the liver in terms of this project is its 
major role in steroid hormone metabolism (Cameron, 1957). The liver contains a 
number of enzymes capable of metabolising steroid hormones, in particular enzymes 
of the cytochrome P450 (CYP) pathway (Ogu and Maxa, 2000) and aldo-keto 
reductases (AKRs) (Jez and Penning, 2001). The main route of steroid hormone 
degradation by such enzymes is through reduction at the ketone structure in ring A 
(Yates et al., 1958) followed by glucuronide conjugation (Rao and Taylor, 1965).
1.9 Progesterone Metabolism
The significance of liver metabolism on the oral bioavailability of drugs, including 
hormones, is widely recognised (Obach, 2001, Kuhnz and Gieschen, 1998). This first 
pass effect has been shown to have a huge impact on the bioavailability of key 
hormones used in contraception and hormone therapies. Natural progesterone 
undergoes extensive metabolism in the liver, predominantly by cytochrome P450 
(CYP) enzymes (Yamazaki and Shimada. 1997) but also by reductases and 
hydroxysteroid dehydrogenases and has a low oral bioavailability (<10%) (Stanczyk, 
2002).
A great deal of research has shown that the liver is responsible for a large percentage 
of progesterone first pass metabolism; many studies have observed the extent of 
progesterone metabolism by CYP enzymes in the liver (Yamazaki and Shimada, 
1997, Williams et al., 2004, Nebert and Russell, 2002, Szklarz and Halpert, 1997b)
Nicotinamide adenine dinucleotide phosphate (NADPH) is a cofactor required for 
several anabolic reactions. In particular it acts as a source of electrons for redox 
reactions of several enzymes implicated in progesterone metabolism including CYPs 
and aldo-keto reductases (AKRs) (Lemley and Wilson, 2010). Such enzymes utilise 
NADPH by reducing hydrogen atoms to water through the addition of an oxygen 
molecule; this reaction is dependent on a supply of electrons which are derived from 
NADPH (Nelson, 2005).
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The role of CYPs and AKRs in the reduction and oxidation of progesterone is well 
established (Penning et al., 2000, Yamazaki and Shimada, 1997, Williams et ah, 
2004, Swart et al., 1993a, Szklarz and Halpert, 1997b, Nebert and Russell, 2002). 
Moreover, a high rate of NADPH dependent progesterone metabolism in liver 
homogenates of common laboratory animals has been described (Rao and Taylor, 
1965, Cooke and Vallance, 1965).
Even though the hepatic metabolism of progesterone is well characterised there is 
very little information on progesterone metabolism in the intestine. The only data 
that appears to be available is in early studies by Nienstedt and colleges (Nienstedt et 
al., 1980). These authors reported the metabolism of progesterone in ileum and 
colonic tissue samples of two adult male subjects and pooled intestinal homogenates 
of 13 human foetuses. The same group also published an earlier paper describing the 
metabolism of progesterone in the intestine of mongrel dogs, they suggested that the 
main routes of progesterone metabolism in the intestine was through reduction at 
keto groups or the a-ring double bond and through the addition of new functional 
groups to the molecule (Nienstedt and Hartiala, 1969, Harri et al., 1969).
Interest in the metabolising capabilities of the small intestinal mucosa has been 
increasing since the realisation that it is likely to be the most significant site of drug 
biotransformation outside of the liver, which is due to the presence of metabolising 
enzymes such as CYPs and AKRs (Barski et al., 2008, Thelen and Dressman, 2009). 
The levels of CYP and AKR enzymes have been shown to vary along the intestinal 
tract and are both generally higher in the proximal regions of the small intestine. 
Moreover the expression of different subtypes of these enzymes differs between 
regions of the small and large intestine (Barski et al., 2008, Thelen and Dressman, 
2009, Mitschke et al., 2008). The reduction in enzymatic activity in the distal small 
intestine and colon may improve drug stability in these regions; for instance the HIV 
inhibitor UC-781 has been shown to be significantly more stable in the colon and 
ileum compared to the duodenum and jejunum (Van den Mooter et al., 1998).
The mucosa of the human small intestine has been found to contain CYP enzymes 
known to metabolise progesterone, namely CYP3A and CYP2C (Thom et al., 2005,
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Paine et al., 2006, Zhang et al., 1999). However in the rat intestine different CYPs 
have been identified; CYPs 1A1, 2B1, and 3A1 can all be detected and CYP 2C6 and 
2C11 can also be found at low levels (Zhang et al., 1996, Kaminsky and Fasco, 
1992). Of these, CYP2B1 and CYP2C11 are known catalysers of progesterone 
(Borlakoglu et al., 1993, Kitareewan and Walz, 1994). Further down the intestinal 
tract the expression levels of CYP enzymes change in type and abundance with but 
all are expressed at a reduced level compared to the proximal intestine (Thelen and 
Dressman, 2009). Enzymes of the AKR 1C family have all been shown to be 
involved in the oxidation of progesterone, these can be found at varying levels in the 
rat small intestine with the exception of AKR1C4 which is found almost exclusively 
in the liver (Penning et al., 2000). Other members of the AKR1C family of enzymes 
are also highly expressed in the human liver but can also be found throughout the 
human gastrointestinal tract with the highest levels detectable in the duodenum 
(Palackal et al., 2002).
Differences between rat and human cytochromes have also been observed in the 
liver, for instance the progesterone metabolising CYPs, CYPs 3A4, 2C9 and 2C19, 
are all present in the human liver yet these homologs are not found in the rat liver 
(Martignoni et al., 2006). Furthermore the metabolising enzymes present in the liver 
differ from those found in the intestine of the same individual in both type and 
abundance (Martignoni et al., 2006, Chhabra et al., 1974).
Interspecies differences in the metabolising capabilities of drugs can often make 
animal models poor surrogates for humans; for instance the bioavailability of several 
progestins have been shown to differ significantly between human and animal 
models (Diisterberg et al., 1981), and many more such discrepancies have been 
described (Musther et al., 2014). It is therefore important to compare differences 
between human and animal models as such differences could have considerable 
implications on human risk.
Although liver metabolism clearly has a large impact on the oral bioavailability of 
progesterone, the role of large intestinal bacteria and enzymes on the stability and 
overall bioavailability of drugs is often ignored. Progesterone, mainly as metabolites,
45
C hapter 1 Introduction
has been recovered from the faeces and urine of primates after oral administration 
with over 40% of the total drug recovered reportedly being found in faeces (Wasser 
et al., 1994, Ziegler et al., 1989). This suggests that the ileo-colonic region of the GI 
tract may play a role in progesterone transformation. Contents of the large intestine 
consist of several enzymes and many different to those found in the liver. These 
enzymes are secreted by the large amount of bacterial species present in the colon 
(10n -1012 cfu/mL) leading to different mechanisms of drug metabolism in the colon 
compared to the liver (Jung and Kim, 2010, Sousa et al., 2008a). The available 
information on progesterone, stability to colonic bacterial metabolism is insufficient. 
In fact the available studies provide no quantitative information regarding the 
stability of progesterone to colonic bacteria but only highlight the metabolites formed 
as a result of metabolism. Furthermore these studies were all carried out before 1980.
The limited information on progesterone stability in intestinal tissues and fluids 
makes it difficult to understand what proportion of metabolism is owed to the liver 
and what is owed to the intestines. In order for a natural progesterone drug to be 
produced understanding such concepts is vital as the metabolic capabilities of the 
intestine could have a huge impact on oral bioavailability.
1.10 Progesterone transporters
Like metabolising enzymes, membrane transporters can also be major determinants 
of the pharmacokinetic profiles of drugs. It is now considered more as a rule, than an 
exception, that a given pharmacological agent will interact with a membrane 
transporter at some point after oral administration. Although progesterone is a highly 
lipophilic molecule, able to diffuse through cells across a concentrations gradient, 
transporters are still likely to affect progesterone uptake. For example, the uptake of 
progesterone by adrenal cells might be at least partially accounted for by a specific 
carrier-mediated transport mechanism generated by sodium ions and an 
electrochemical mechanism (Ogihara et al., 2004). Furthermore, a number of specific 
transporters have been implicated in progesterone transport. ATP-binding cassette 
(ABC) transporter 2 is able to transport a number of steroids including progesterone 
(Vasiliou et al., 2009) and intracerebral progesterone concentrations have been
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shown to be influenced by MDRl-type P-gp function; however, the effects are only 
small (Uhr et al., 2002). Although detailed investigation into the role of transporters 
in progesterone metabolism will not be investigated during the course of this project, 
the possibility of progesterone active transportation should be taken into 
consideration when investigating the rate of progesterone metabolism.
1.11 Overcoming Poor Bioavailability
When it comes to enhancing the bioavailability of lipophilic drugs, improving their 
solubility is of great importance. When administered orally, drugs will only fully 
permeate the intestinal wall if they have good solubility in the surrounding medium 
and drugs with these properties tend to have better oral bioavailability (Savjani et al.,
2012).
Solubility can be defined as the maximum amount of a substance/solute that can be 
fully dissolved in a solvent to form a homogenous solution (Gong et al., 2007). This 
process involves the active breakdown of chemical bonds in the solute and the 
separation of molecules in the solvent to create space for the dissolving substance 
(Figure 1.18) (Gong et al., 2007). Thus the chemical structure of the solute affects its 
ability to dissolve within the given solvent and vice versa. The energy required to 
breakdown bonds within the solute comes from the formation of new bonds between 
the solute and solvent. When taking the example of hydrophilic and lipophilic drugs 
in water, the hydrophilic compound would readily form bonds with the water 
molecules which would, in turn, release energy to breakdown the drug framework 
causing the drug to dissolve. However, lipophilic drugs do not readily form bonds 
with the water molecules and thus no energy is produced to break down the drug 
lattice (Silberberg, 2009).
Another factor affecting intestinal permeability is dissolution. Dissolution is a kinetic 
process quantified by the rate at which the solute dissolves in the solvent. Drug 
particle size can strongly influence the rate of dissolution whereby small particles 
dissolve more readily as they have an increased surface area to volume ratio (Jinno et 
al., 2006). Micronization of this progesterone can significantly enhance the rate of 
dissolution. Indeed, micronized progesterone with a particle size of <25pm has been
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shown to improve progesterone oral bioavailability (Hargrove et al., 1989, Salin- 
Drouin, 2000, Levine and Watson, 2000b). However, micronized progesterone is 
only administered in high doses for the short-term treatment of certain reproductive 
disorders and has significant intra- and inter-patient variability (Levine and Watson, 
2000b). Other patents have also been written for natural progesterone with improved 
bioavailability and all contain progesterone in its micronized form (Besins and 
Besse, 2013, Maxson et al., 1990, Chandler et al., 1997, Liu et al., 2010a), yet none 
are mainstream, commercially available, products (Liu et al., 2010a). Thus, there still 
exists a need for a progesterone composition that has a higher oral bioavailability and 
reduced inter-patient and intra-patient variability than the currently available 
products. It is also important that the formulation does not contain unsuitable 
components which could lead to adverse reactions after consumption. One method 
for producing such a formulation is with solid dispersions.
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Figure 1.18 The Solution Formation Process.
1.11.1 Solid Dispersions
A rev iew  paper by  D h iren d ra  et a l (2009) defined  so lid  d isp ers io n s as “ a g ro u p  o f 
so lid  p roduc ts  co nsisting  o f  at least tw o d iffe ren t com ponen ts, g en e ra lly  a 
hy d ro p h ilic  m atrix  and a h y d ro p h o b ic  drug. T he m atrix  can be e ith er c ry s ta llin e  o r 
am orphous. T he drug  can  be d ispersed  m olecu larly , in am o rp h o u s partic les  (c lu sters) 
or in cry sta llin e  p a rtic le s '’ (D h iren d ra  et al., 2009).
Solid  d isp ers io n s w ere first p roposed  in 1961 by  S ek iguch i and O bi; they  d escribed  
the m elting  o f  su lfa th iazo le  and urea fo llow ed  by  rap id  cooling . T he resu ltin g  
eu tec tic  m ix tu re  d isp layed  faste r d isso lu tion  and im p ro v ed  b io av ailab ility  com pared
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to  co n v en tio n a l fo rm u la tio n s (S ek iguch i and O bi, 1961). S ince th is d isco v ery , a great 
deal o f  research  has led  to  im provem en ts and  enh an cem en ts o f  th is  type o f  
fo rm u la tio n . T h e  nex t d eve lopm en t in so lid  d isp ers io n  p roduc tion  con ta in ed  
m o lecu la rly  d ispersed  p artic les  in a ca rrie r system  as o p p o sed  to eu tec tic  m ix tu res. 
T h ese  system s dem o n stra ted  fa s te r d isso lu tion  and im proved  b io av a ilab ility  (K an ig , 
1964).
T h e  nex t step  in solid  d isp ersio n  deve lopm en t cam e in the shape o f  am o rp h o u s so lid  
d isp ers io n s (A S D s) w hich  im prove d isso lu tion  as they  are  less th erm o d y n am ica lly  
s tab le  (C h iou  and R iegelm an , 1969). W ith  A S D s the ch o sen  com p o u n d  is d ispersed  
m o lecu la rly  in an irregu lar fo rm  in an am orphous carrier. T h e  term  am o rp h o u s refers 
to  a ty p ica lly  c rysta lline  so lid  in a n o n -c ry sta llin e  state  (F igure  1.19).
T he  m ain  advan tages o f  using  A S D s have been  described  by V asconcelos (2 0 0 7 ) and 
can be sum m arised  in a few  m ain  poin ts. F irstly , the p repara tion  o f  A S D s leads to a 
red u ctio n  in partic le  size w hich  resu lts in increased  surface  area im prov ing  
d isso lu tio n  and therefo re  increased  b ioavailab ility . S econd ly , the w ettab ility  o f  the 
partic les is im proved  m ean ing  the su rface tension  o f  su rro u n d in g  flu ids is reduced  
a llow ing  the partic les to  becom e ‘w e t’, causing  them  to d isso lve  m ore rap id ly . A nd 
finally , A S D s tend  to have a h ig h er apparen t so lu b ility  than  cry sta llin e  solid  
d isp ers io n s as they  co n ta in  the drug  in a supersa tu ra ted  sta te  due to the  fo rced  
so lu b ilisa tio n  in the ca rrie r (V asco n ce lo s  et al., 2007).
Crystalline
Amorphous
Figure 1.19: The Atomic Structure of Crystalline and Amorphous Solids.
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1.11.2 Progesterone Amorphous Solid Dispersions
Saffoon et al (2011) discussed suitable candidate drugs for improved solubility with 
solid dispersions. They reported that poorly water-soluble drugs with high 
permeability are the best options as dissolution is the rate limiting step to intestinal 
absorption (Saffoon et al., 2011). Progesterone, therefore, appears to be an ideal 
candidate.
There are several methods which could be utilised to produce progesterone ASDs 
and each has its advantages and disadvantages. The most commonly used methods 
include hot-melt extrusion, spray-drying and emulsion solvent evaporation and these 
are discussed herein. Hot-melt extrusion is an anhydrous process whereby a drug and 
polymer are melted and forced through an orifice to form fine particles in a fast and 
continuous manner (Breitenbach, 2002, Chokshi and Zia, 2010). However, hot-melt 
extrusion requires high temperatures which may inactivate sensitive products and the 
machinery is often expensive and difficult to maintain (Madana and Madanb, 2012). 
The spray drying technique is very different from hot-melt extrusion. It involves 
dissolving a drug and polymer in a solvent then spraying this solution into a stream 
of heated air to rapidly evaporate the solvent. Spray drying possesses many 
advantages which make it an attractive option for industrial applications; the precise 
control of production parameters results in good reproducibility and particle size can 
be reduced to as little as lpM  (Vasconcelos et al., 2007). The draw-backs of the 
spray-drying technique include the cost at lab scale and the use of high temperatures 
which, once again, may inactivate sensitive products (Nandiyanto and Okuyama, 
2011).
The final method to be discussed is emulsion solvent evaporation. During this 
technique the polymer and drug are both dissolved in a solvent which is added to a 
liquid with which the solution is immiscible. A surfactant is also added to the 
mixture. The mixture is stirred continuously until the solvent is removed by 
evaporation, which usually takes several hours. Eventually, a suspension of 
amorphous microparticles containing the drug and polymer is formed and can be 
separated from the solution by filtration (Watts et al., 1989). The key advantages to
51
C hapter 1 Introduction
using the emulsion solvent evaporation method is its simplicity and low cost making 
it a useful technique for assessing new drug candidates for ASDs. However, 
conductivity to industrial scale-up is difficult and solvent residues may be an issue if 
evaporation is not fully complete (Freitas et al., 2005) Watts (Watts et al., 1989). 
Nonetheless, emulsion solvent evaporation is a good option for early investigation 
into the production of progesterone ASDs.
As well as considering the method for progesterone ASD production, it is also 
important to consider the type of polymer to be used. Polymers play two main roles; 
first of all, they stabilise against crystallisation. ASDs are thermodynamically 
unstable and can recrystallize within a pharmaceutically relevant time-scale (Lee et 
al., 2014); such occurrences would negate any solubility advantages. Secondly, 
polymers can enhance dissolution by preventing crystallisation of the supersaturated 
solution produced as a result of the dissolved ASD.
The mode by which polymers prevent crystallization has been ascribed to various 
mechanisms including interactions between the drug and polymer (Khougaz and 
Clas, 2000), an increase in activation energy for nucleation (Van den Mooter et al., 
2001) and a glass-transition (Tg)-dependent mobility reduction (Kumavat et al., 
2013). Tg refers to the temperature region at which the polymer transitions from a 
hard, glassy material to a soft, rubbery material (Gibbs and DiMarzio, 1958). When 
the drug and carrier form a homogenous mixture the solid dispersion is in one 
amorphous phase. The high Tg of the polymer causes an increase in the Tg of the 
drug, thus reducing the drugs mobility. This type of reduced mobility is often 
referred to as anti-plasticisation (Kumavat et al., 2013).
There are a variety of polymers available for the production of ASDs including 
synthetic polymers and natural derivatives. Examples of synthetic polymers are 
povidone, polyethyleneglycol and polymethacrylates. Natural product based 
polymers are primarily composed of cellulose derivatives including ethylcellulose, 
hydroxypropylcellulose and hydroxypropyl methylcellulose (hypromellose, HPMC) 
or starch derivatives such as cyclodextrins (Leuner and Dressman, 2000).
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One example of a well-known synthetic polymer is Eudragit, a polymethacrylate. 
Eudragit is commonly used for the production of amorphous solid dispersions 
(Nollenberger et al., 2009). Eudragit is trademark of Rohm GmbH & Co. KG. 
Darmstadt in Germany and was first marketed in the 1950s. It is prepared by the 
polymerization of acrylic and methacrylic acids or their esters (Nikam V .K 2011). 
An example of a naturally derived polymer is the cellulosic enteric coating agent, 
HPMC acetate succinate (HPMCAS) which is an esterified derivative of 
hypermellose, a semi-synthetic, inert polymer. HPMCAS has been shown to be an 
attractive candidate for use as a carrier in solid dispersions (Tanno et al., 2004). 
There are a variety of Eudragit and HPMCAS polymers avialble on the market which 
differ by their dissolution profiles. Eudragit S for example is already in use for the 
targeted delivery of mesalazine to the colon for the treatment of ulcerative colitis and 
is marketed as Asacol®.
1.12 Thesis Aims
The aim of this thesis is to first investigate the differences in target gene and protein 
regulation between natural progesterone and the synthetic progestins, MPA and LNG 
which are commonly used in the treatment of hyperplasia. These differences will be 
assessed through a series of in vitro stimulation experiments on endometrial 
epithelial and stromal cell lines to observe changes at the RNA and protein level. 
Furthermore, biopsies will be taken from patients receiving synthetic progestin 
treatment before and during therapy to assess the effects of the two named progestins 
on protein targets in an in vivo situation. Moreover, several of the targets will be 
assessed for their potential role as markers of hyperplasia presence and progression.
To probe the reasons behind the poor biavailability of natural progeserone the 
stability of progesterone throughout the GI tract will be established using tissues and 
fluids from rat and human intestine and liver, the results of this data will be used to 
determine an area of the intestine where progesterone is most stable with a view to 
developing an oral formulation targeted to this region.
The production of a natural progesterone targeted delivery system will be attained 
through the use of amorphous solid dispersions (ASD). Once produced, the
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efficiency of the progesterone loaded ASDs will be characterised through a series of 
experiments to determine particle topology, dissolution profiles and chemical 
stability. The progesterone amorphous powder will then be subjected to the same 
series of in vitro experiments as the synthetic progestins to establish whether 
progesterone ASDs differs from progesterone at the molecular level.
In summary the aims of this thesis are: a) to investigate the effect of natural and 
synthetic progestins on the regulation of PR targets in endometrium using in vitro 
models and patient samples, b) to better understand the stability of progesterone in 
the GI tract and liver and c) to produce a natural progesterone formulation for 
targeted oral delivery with improved bioavailability.
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2. Materials and Methods
During this chapter materials and methods are grouped into the chapters within 
which they are used.
2.1 Materials and Methods Used in Chapter 3
2.1.1 Immunohistochemistry Analysis of key Progestin Target Proteins
2.1.1.1 Clinical Data and Patient Demographics
Sixty patients were enrolled in this study. Patient recruitment and consent was 
carried out at Gynaecology clinics in Singleton, Neath Port Talbot and Bridgend 
Hospitals, ABMUHB. Ethical approval was obtained from the South Wales Research 
Ethics Committee. Formal written consent was obtained from all patients. The 
patients were pre or postmenopausal. The study groups contained patients with 
hyperplasia without atypia (20 patients) or with atypia (20 patients). Study groups 
were matched by age and BMI with the control group (20 patients) (Table 2.1). The 
endometrial samples were obtained either by Pipelle endometrial sampling in clinic, 
or by Dilatation and Curettage for patients undergoing Hysteroscopy assessment 
under general anaesthetic. The groups were established after the histological 
examination, which was routinely performed for all patients as part of their care. 
From 18 patients in the non-atypia group, samples were investigated for the 
expression of biomarkers pre and post endogenous hormone treatment with the 
synthetic progestin, Medroxyprogesterone Acetate (MPA) 20mg/day for 3 months. 
The histology of all these samples reverted back to atrophic endometrium after MPA 
treatment.
Controls Hyperplasia Hyperplasia w ith atypia
AGE 50 ± 9.76 51±12.56 53±10.6
BMI 28 ± 6.75 27± 4.78 28± 2.3
Table 2.1: Age and BMI of Patients from Control, Hyperplasia and Hyperplasia 
with Atypia Groups. Values are given as mean ± standard deviation
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2.1.1.2 Immunohistochemistry Analysis of Patient Samples from Control and 
Study Groups
Immunohistochemistry (IHC) is a method used to demonstrate the presence and 
location of proteins within tissue sections. For IHC analysis, control and study 
samples were fixed in 10% buffered formaldehyde for 24hours at the time of 
endometrial biopsy. The fixed samples were embedded in paraffin and cut into 
sections between 3 and 4 pM in thickness. Sections were removed of paraffin 
(dewaxed) with xylene, incubated through a series of methanol grades and fixed onto 
Superfrost slides for staining. Routine Haematoxylin and Eosin staining was 
performed on each slide and the sections examined for morphometric dating of the 
endometrial biopsy according to Noyes criteria modified by Accosta and Lessey 
(Acosta et al., 2000).
For the detection of proteins using specific antibodies, barcode labels for each 
antibody were printed and attached to the slides; the Ventana machine (Ventana 
Biotek Solutions, Tucson, AZ, USA) at Singleton Hospital is able to recognise the 
barcode and was used for the IHC experiment. First, slides were heated in citrate 
buffer CC1 (Ventana) on a benchmark XT processor to 100°C for lhour for antigen 
retrieval. Next, the slides were incubated with lOOpL of primary antibody (Table 
2.2). The length of time and the temperature used for this incubation was optimal for 
the specific antibody used.
Antibody nam e Catalogue num ber Species
FKHR (FOXOl) (H128) Sc-11350 Rabbit
Progesterone Receptor Novo-Castra NCL-PGR Mouse
Amphlregulin (H155) Santa Cruz SC25436 Rabbit
Lactoferrin (B97) Santa Cruz Sc-53498 Mouse
Table 2.2: Antibody Name, Manufacturer/ Catalogue Number and Species of 
origin used for Immunohistochemical Analysis
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Positive immunostaining was detected using Ventana I View DAB detection kit 
(Ventana Biotek Solutions Tucson AZ). Staining was visualised by detection of the 
interaction between Avidin-Biotin peroxidase complex solution and the secondary 
biotinated antibody.
Finally, slides were counter-stained with lOOpL Haematoxylin stain for 1 minute at 
room temperature, incubated in xylene for 5 minutes then left to air-dry and mounted 
in DPX to be examined by light microscopy.
2.1.1.3 Scoring of IHC slides
Fixed slides were visualised under Zeiss light microscope at 40x objective. The 
presence of proteins within the samples was detected by evidence of brown staining. 
Each slide was scored by three independent observers for both intensity and 
distribution of proteins in glandular and luminal epithelium and also in Stroma. The 
cellular location of the staining was also noted (nuclear or cytoplasmic). Each scorer 
used an immunohistochemical scoring system previously described by Lai et al, 
2005 (Lai et al., 2005). Positive red-brown stain was scored for intensity and 
distribution of staining (H-score). Intensity was scored from 0 to 4 where 0 reflects 
the absence of a stain and 4 is very strong staining. Distribution of stain throughout 
the tissue section was scored as follows: 0 - absent, 1 -  less than 30%, 2 -  30-60%, 3 
-  more than 60% and 4 -  100%. Positive and negative controls were also scored; 
positive control was from human colon and negative control was endometrial tissue 
without primary antibody. Scoring of controls allowed for more accurate scoring of 
tissue samples. The observers were blinded to the patients’ diagnosis and 
demographics prior to scoring the slides.
2.1.1.4 Statistical Analysis of IHC Scores
Data distribution was assessed for normality using the Kolmogorov-Smimoff test. 
Non-normally distributed data were then analysed with the non-parametric Kruskal 
Wallis test, followed by a Mann-Whitney U test applied post hoc to determine 
statistical significance. All IHC data was deemed non-normal and analysed using this 
method. Statistical analyses were performed using SPSS version 10.0 (SPSS,
58
Chapter 2 M ateria ls  and M ethods
Chicago IL). A P value of less than 0.05 was considered statistically significant and 
was expressed by one star (*), a P value of >0.01 was expressed by two stars (**) 
and a P value of >less than 0.001 was considered highly significant and expressed by 
three stars (***).
2.1.2 Cell Culture
2.1.2.1 Introduction to Endometrial Cell Lines
Two endometrial cell lines were utilised during this study; one representing the 
epithelial compartment of the endometrium and one representing the stromal 
compartment. A brief background on the cell lines is given.
The well-differentiated endometrial adenocarcinoma cell line, Ishikawa, was isolated 
from a 39 year old female of Asian ethnicity in 1982. The presence of estrogen, 
progesterone and androgen receptors have been documented in in vitro culture cells 
from this cell line (Lessey et al., 1996, Lovely et al., 2000, Nishida et al., 1985). 
Furthermore, the fact that cell growth can be maintained in an estrogen-free medium 
shows a lack of estrogen dependency (Nishida et al., 1985). Extensive research has 
been carried out on this cell line and estrogen and progesterone receptors have been 
shown to be regulated in a similar manner to the normal endometrial epithelium 
(Lessey et al., 1996), thus making this cell line adequate for the experiments carried 
out in this study.
The second cell line to be used was the human endometrial stromal cell (HESC) cell 
line. HESCs were cultured from a woman of reproductive age; the cells were 
obtained during a hysterectomy for a benign condition. The cells were immortalised 
using human telomerase reverse transcription (hTERT); hTERT was used to add 
TTAGGG repeats to telomeres to compensate for their shortening. The HESC cell 
line contains no chromosomal, structural or numerical abnormalities and is shown to 
display similar outcomes to primary, unpassaged, stromal cells after treatment with 
ovarian hormones. HESCs are karyotypically, morphologically and phenotypically 
comparable to primary parent cells and are a credible cell line for work in this project
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(Krikun et al., 2004). Both the Ishikawa and HESC cell lines were purchased from 
the European Collection of Cell Cultures.
2.1.2.2 Culture of Cell lines
The cell lines described each have adherent properties and were cultured in plastic 
culture vessels (Falcon T25, 75, 125) in Dulbecco’s Modified Eagle Medium: 
Nutrient Mix F-12 (DMEM/F-12) supplemented with 10% foetal bovine serum 
(FBS), 1.5mM glutamine, ImM sodium bicarbonate, ImM sodium pyruvate and 1% 
pen-strep. The cells were maintained at 37°C in a 5% CO2 humidified incubator. 
Cells were sub-cultured according to guidelines set by distributor; Ishikawa cells 
were split at subcultivation ratio of 1:5 at 70-80% sub-confluency and HESC cells 
were split at a subcultivation ratio of 1:3 at 70-80% sub-confluency.
In order to sub-culture cells, cells were first washed in calcium and magnesium free 
phosphate buffered saline (PBS) (Gibco) in order to maintain pH, osmotic balance 
and to promote cell detachment. The PBS wash serves to promote detachment as it 
removes DMEM/F12 residue from the cells. The supplemented DMEM/F12 contains 
calcium, magnesium and bovine pancreatic trypsin inhibitor which block the anti- 
adherent action of trypsin (Borjigin and Nathans, 1993). Following the wash step, 
cells were detached from the culture vessel by incubation with 0.25% trypsin ImM 
Ethylenediaminetetraacetic acid (EDTA) (pH 8 ) in Hanks’ Balanced Salt Solution 
(HBSS) containing phenol red and excluding CaCI2 , MgCh and MgSC>4 (Gibco 
Invitrogen Cat No: 25200-056). The cells were incubated in the trypsin solution for 
no more than 5 minutes at 37°C. To confirm cell detachment, cells were observed 
using an inverted light microscope (Zeiss). On confirmation of detachment lOmL of 
supplemented DMEM/F12 media was added to the suspension to neutralise the 
trypsin and prevent further tryptic activity which could damage the cells. The 
suspended cells were transferred to a sterile 15mL centrifuge tube and spun at 1200 
rotations per minute (RPM) for 5minutes in an Eppendorf 5810 centrifuge. The 
excess media was decanted and the resultant cell pellet was re-suspended by physical 
disruption and immersed with lOmL of supplemented DMEM/F12 media. The 
desired ratio of cells was taken from the suspension and incubated in a T75 flask in
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fresh media at 37°C in a limited 5% CO2 atmosphere. All materials in this section 
were sourced from Gibco Invitrogen unless otherwise stated.
2.1.2.3 Plating Cell Lines for RNA, Western Blot and InCell Analysis
In preparation for in vitro incubation with steroid hormones, Ishikawa and HESC cell 
lines were plated into either 6  or 12 well plates. For RNA, Western Blot and InCell 
analysis cells were handled as described in Section 2.1.2.2. However, when re­
suspended in lOmL of supplemented media, cells were counted using TC10 
automated cell counter (biorad). To count cells, 50pl of cell suspension was diluted 
in 1 : 1  with trypan blue; trypan blue can enter the nucleus of dead cells allowing these 
cells to be excluded from the cell count. 1 0 pl of the cell suspention with trypan blue 
was pipetted onto a dual chamber counting slide (Biorad) and placed in the cell 
counter; the cell counter then automatically estimated the amount of cells per mL 
excluding cells with trypan blue in the nucleus. Cells were counted 3 times using this 
method and an average cell count was taken. The amount of cells was then adjusted 
appropriately by adding supplemented DMEM/F12 media. For western blot and 
RNA analysis 1 x 105 Ishikawa cells were added to 6  well plates (well volume 
9.6cm2) (CellStar Cat no. 657160). For HESCs 2 x 105 cells were added to 6 -well 
plates. The use of an increased concentration is necessary for HESC cells as the 
growth rate of these cells is reduced in comparison to the Ishikawa cell line. For 
InCell Analysis lxlO 4 Ishikawa cells or 2xl0 4  HESC cells were counted and seeded 
into a 24-well plate (CellStar Cat no. 662160). After seeding, cells were placed in a 
5% CO2 atmosphere at 37°C for 24h. At this time cells were approximately 70% 
confluent.
After the 24h incubation cells were rinsed in PBS. Following this, cell media was 
replaced with DMEM F I2 media supplemented with 10% dextran-coated, charcoal 
treated FBS (Gibco), 1.5mM glutamine, ImM sodium bicarbonate, ImM sodium 
pyruvate and 1 % pen-strep (stripped media) and incubated for a further 24h.
After the second incubation period, media was replaced with fresh stripped media 
and treatment preparations were added to the cells for 48h.
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Ishikawa and HESC cells to be harvested for PCR or InCell analysis were treated 
with MPA, P4  or Levonorgestrel (LNG). Ishikawa cells were also treated with 17p- 
estradiol (E2 ) alone or combined with each of the progestogens (MPA, P4 or LNG) 
while HESC cells were treated with 8 -Bromodadenosine 3’, 5’ Cyclic 
Monophosphate (cyclic AMP, cAMP) alone or combination with progestegens.
2.1.2.4 Preparation of Cell Treatment
E2 was prepared by adding 0.00272g of powdered E2 (Cat: E8875 >98% Sigma 
Aldrich) to 1ml of absolute ethanol (100%) (Fisher Scientific) to give a concentration 
of lOmM. This was then serial diluted 1:10 until a lOOpM stock was reached. lpL  of 
the lOOpM stock was added to each lmL of cell media to give a lOOnM treatment 
concentration.
P4 , MPA and LNG were prepared as follows: 0.00314g of Progesterone (PO130-25g) 
or 0.00386g of MPA (Cat: M1629, SIGMA) or 0.00312g of LNG (Cat: N2260, 
SIGMA) were added to 1ml of absolute ethanol (100%) (Fisher Scientific) to give a 
concentration of lOmM. This was then diluted 1:10 to give a ImM stock. lpL  of 
stock was diluted in lmL of media to give a treatment concentration of lpM  of 
hormone.
For the preparation of cyclic AMP 1.16mL of distilled water was added directly to 
25mg of cyclic AMP powder (Cat number B7880 25MG) to give a stock 
concentration of 50mM. This was diluted 1:100 into cell media to give a final 
concentration of 0.5mM.
2.1.3 Western Blot Analysis
Ishikawa or HESC cells were grown to confluency in a six-well plate as described in 
Section 2.1.2.3. Cells were then scraped directly into 250pl of extraction buffer 
consisting of 0.05M Tris (pH7), 8 M Urea, 1% sodium dodecyl sulphate (SDS) and 
0.01% phenylmethanesulfonylfluoride (PMSF) in distilled water. The samples were 
then ready for immediate protein quantification using the Bradford assay.
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2.1.3.1 Protein quantification by Bradford Assay for Western Blot Analysis
Prior to Western Blot analysis protein was quantified with the Bradford assay using 
Bradford Reagent from Sigma (B6916) and following manufacturer’s guidelines; a 
brief description of the procedure is given. Due to the large amount of urea in the 
samples, samples were diluted 1 : 1 0  in water in order to be compatible with the 
Bradford Reagent. lOOpl of diluted sample was then added to 3mL of Bradford 
Reagent in 15mL centrifuge tube (fisher scientific) and vortexed gently for thorough 
mixing. The samples were incubated for 10-15minutes and lmL of sample was 
transferred to 1.5mL cuvettes (fisher scientific). The absorbance was measured using 
the nanodrop 2000c (Thermo scientific) at an absorbance of X595nm. A standard 
curve was generated using known concentrations of bovine serum albumin (BSA) in 
diluted extraction buffer to give concentrations between 0 and 0.25mg/ml protein.
The concentration of protein in the samples was then calculated using the straight 
line equation (Y=mX+c) from the BSA standards and inputting the values obtained 
for the protein within this equation. The quantified protein was adjusted to lOpg for 
analysis by Western Blot.
2.1.3.2 Protein Separation by Gel Electrophoresis
Separation of proteins was achieved through sodium doecyl sulphate polyacrylamide 
gel electrophoresis (SDS PAGE). A 7.5% polyacrylamide gel was prepared for SDS- 
PAGE using the components listed in Table 2.3. The resolving gel was made first 
and pipetted into a 1.5mm space between two glass plates (biorad); 2-propanol 
(Sigma Cat no. 109827) was pipetted on top of the gel to create a flat surface for the 
application of the stacking gel. 2 -propanol was removed using distilled water 
(millipore) and blotting paper (Whattman). Once the resolving gel had set the 
stacking gel was added and a 1.5mm comb containing 10 wells was rested in the 
solution until it set.
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Reagent Stacking Gel (4%) Resolving Gel (7.5%)
MilliQ Distilled W ater (Millipore) 3mL 7.25mL
30% Acrylamide solution (Bio- 
Rad, UK)
650pL 3.75mL
1.5M Tris (pH 8.8) - 3.75mL
1.0M Tris (pH 6.8) 1.25mL -
10% SDS (Fisher Scientific) 50pL 150pL
TEMED (SIGMA) 5pL 15pL
10% APS (SIGMA) 25 pL 75pL
Table 2.3 Reagents required for the production of Stacking and Resolving Gels 
for Gel Electrophoresis.
To prepare the protein samples for gel electrophoresis, the samples in extraction 
buffer were added in a 1:1 ratio to 2x laemmli buffer (Sigma Cat no. 53401-1VL). 
Laemmli buffer contains glycerol and bromophenol blue. Glycerol causes the 
samples to sink to the bottom of the well and bromophenol blue is a tracking dye 
which migrates through the gel first and provides a good indication of how far the 
proteins have travelled. The laemmli buffer also contains SDS detergent which fully 
denatures the protein and removes all higher order structures as well as causing the 
protein to become uniformly negatively charged allowing it to migrate towards the 
positive electrode during the electrophoresis process. A colour-stained molecular 
weight marker (Sigma) was also diluted in laemmli buffer at the same ratio allowing 
it to travel at the same rate as the samples.
After the addition of laemmli buffer, samples were incubated at 95°C for 5 minutes 
in a T100 thermal icycler (Biorad) to denature the proteins and lOpg of protein was 
loaded into the required wells. 5pl of protein ladder (Biorad) was also added to the 
first well. Samples were run on a 7.5% SDS-polyacrylamide gel for 80minutes at 
120volts in 1% SDS electrophoresis buffer (pH 8.3). 1% SDS buffer was produced 
by adding 15.lg  Tris Base, 72g Glycine and 5g SDS to 1L of distilled water, this was 
then pH tested and diluted 1:5 in water before use.
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2.1.3.3 Protein Transfer to Membrane
Separated proteins were transferred to polyvinylidene (PVDF) membrane with 
0.2mM pores and a protein binding capacity of 150-160 mg/cm2 (Bio-Rad). The 
membrane was cut to a similar size to the electrophoresis gel, activated for 15s in 
absolute ethanol (fisher scientific), transferred to distilled water (millipore) for 5mins 
then allowed to equilibrate in transfer buffer (Table 2.4) for lOminutes. The activated 
membrane was loaded into a biorad cassette against the SDS gel enveloped in filter 
paper and sponges as depicted in Figure 2.5.
Cathode
Gel holder
Rlter paper ----------------------------------
Yzzzzzzzzzzzzm
PVDF membrane A -----------------------------------
Filter paper ----------------------------------
Gel holder
Anode
Figure 2.1: Layout of Components for Protein Transfer from Electrophoresis 
Gel to PVDF membrane.
The transfer was carried out in Transfer buffer and subsequent wash steps carried out 
in lx  Tris Buffered Saline with tw e e n  (TBS tw een_Ethylenediam inetetraacetic acid) 
(Table 2.4). The transfer was carried out for 60minutes at lOOvolts and the 
appearance of the molecular weight marker on the transfer paper was used to confirm 
the transfer of proteins.
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R eagen t N am e C om p on en t Q uantity
Transfer Buffer Tris-Base 3.63g
Glycine 16.8g
M ethanol 300mL
dH20 1200mL
5xTBS buffer Tris 12.lg
Sodium  Chloride 40g
dH20 1000ml
lxTBS T w een 5xTBS buffer lOOmL
dH20 400m L
Tween20 0.5mL
Table 2.4: Buffer Reagents, Components and Quantities use in Western Blot 
Analysis.
2.1.3.4 Protein Detection
Following transfer, the membrane was removed from the cassette and submerged in 
2mL of blocking buffer containing 5% BSA in lxTBS tween (Table 2.4) for 1 hour 
on a see-saw rocker (Stuart Ltd) at 20osc/min. The membrane was washed 5 times 
for 5minutes each time in lxTBS tween then submerged in primary antibody in 
blocking buffer overnight at 4°C on a rocking table at 40osc/min. The antibodies and 
concentrations used are described in Table 2.5. Following incubation the membrane 
was washed again 5times for 5minutes each time in lxTBS tween. It was then 
incubated in secondary antibody (Ant-rabbit IgG-HRP, Table 2.5) for lhour at room 
temperature on rocker at 20osc/min. A final 5 washes were carried out before the 
membrane was incubated for 3 minutes at room temperature in Biorad enhanced 
chemiluminescence (ECL) stain. The secondary antibody used in the procedure is 
coupled to a horseradish peroxidise (HRP) label, the ECL stain contains the substrate 
luminol which is oxidized by HRP to produce light. The light emitted from this 
reaction produces a protein band, the band was visualised using a chemidoc™ MP 
imaging system (Biorad).
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A ntibody nam e M anufacturer Species Final conc. (pg/mL)
GAPDH (FL335) Santa Cruz sc-25778, Rabbit 1
PR (H-10) Santa Cruz sc-7208 Rabbit 2
ERa (HC-20) Santa Cruz sc-542 Rabbit 2
ERp Pierce Ltd PA1-311 Rabbit 2
AR Santa Cruz N-20 Rabbit 2
Ant-rabbit IgG- 
HRP
GE Healthcare, NA934V Donkey 1
Table 2.5 Antibody Name, Manufacturer, Species of origin and Concentration 
used for Western Blot Reactions
2.1.3.5 Western Blot Data Analysis
Fluorescent bands were analysed using Quantity One Imaging softoware (Biorad). 
The volume rectangle tool was used to draw around bands and background and
r\
quantify the band density by calculating signal intensity/area mm . The housekeeping 
protein, GAPDH, was also run against all samples and quantified in the same way. 
The density of GAPDH was used as a reference to normalise the concentration of 
protein. The volumes were then plotted on a graph in Microsoft excel.
2.1.4 Real Time Polymerase Chain Reaction (RT-PCR)
2.1.4.1 Isolation and Quantification of Ribonucleic Acid
The RNeasy kit from quiagen was used for the Isolation of ribonucleic acid (RNA); 
all components discussed were supplied by the kit unless otherwise stated and the 
full manufacturers protocol, ‘total RNA isolation from animal tissues’ can be found 
in Appendix A. In short, after 48 hours of treatment, 350pl of RLT buffer was added 
to the confluent monolayer of cells. Cells were scraped using cell scrapers (greiner 
bio-one) and the cell lysate was pipetted directly into qia-shredders for 
homogenisation. The homogenised lysate was combined with ethanol and transferred 
to RNeasy spin columns which bind RNA strands more than 200 base pairs in length.
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To eradicate any unwanted genomic DNA bound to the spin columns, DNAse 1 
digest kit (quiagen) was used in combination with the RNeasy kit by adding DNAse 
to RDD buffer in a 1:7 ratio. The solution was added directly to the spin column 
membrane and incubated for 15 minutes.
Finally RNA was eluted in 30pl of RNase free water. The spin column was 
centrifuged between each step as described, all centrifugation steps were carried out 
in eppendorf centrifuge 5424. The eluted RNA was quantified using the nanodrop 
2 0 0 0 c (thermo sceientific) spectrophotometer and the reading taken in pg/pl of 
RNA.
2.1.4.2 cDNA Synthesis with Reverse Transcription (RT) Enzyme
RNA was converted to cDNA using the Applied Biosystems high capacity reverse 
transcription kit. First RNA was adjusted to a final concentration of lOOug/mL in a 
total volume of 12pL of RNAse free water in microfuge tubes. 2pL of this solution 
was isolated and added to a further 38pL of RNAse free water and kept for PCR 
untranscribed negative control. The remaining 10pL was added to components from 
the reverse transcription kit in the following concentrations; 2pL of lOx RT-buffer, 
0.8pL of 25x dNTP mix (lOOmM), 2pL of lOx RT-random primers, lpL  of 
Multiscribe Reverse Transcriptase and 3.2pL of Nuclease-free water to give a total 
volume of 20pL. The components were mixed gently by pippetting up and down and 
centrifuged briefly to collect residual liquid to the bottom of the tube and to eliminate 
any air bubbles.
The samples were subsequently placed in a T100 Thermal Cycler (Biorad) and 
heated to 25°C for 10 minutes, 37°C for 2hours and 85°C for 5minutes, the cycle 
was then held at 4°C until the samples were collected from the machine. The long 
incubation at 37°C allows for cDNA synthesis and the short incubation at 85°C is 
required for the inactivation of the reverse transcriptase enzyme. cDNA was stored at 
-20°C until used in the RT-PCR reaction. Furthermore, cDNA was diluted in 
nuclease free water (Ambion) in ratios of 1:5 1:10, 1:100 and 1:1000 (cDNA: water). 
The 1:10 dilution served as the working template for RT-PCR and the remainder of 
the dilutions were used to produce a standard curve.
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2.1.4.3 Primers used in Quantitative Real-Time PCR
Quantitative real-time PCR (qRT-PCR) was used to amplify cDNA against specific 
primer pairs. The primers used are described in table 2.6.
Each primer set was designed using beacon designer software and ordered through 
Sigma Aldrich. Primers were designed to span a region of 75-150bp and were 
ordered with a synthesis scale of 0.025pmol and purification desalt. Primers were 
ordered dry in a powder constitution and diluted to a lOOpM stock upon arrival. For 
use in the qRT-PCR reaction primers were converted to 4pM by diluting in distilled 
water.
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G ene Primer Primer Sequence (F)
Am plicon  
Length (bp)
Ta (*>C)
GAPDH
Sense GTCCACTGGCGTCTTCAC
145 54.7
Antisense CTTGAGGCTGTTGTCATACTTC
PR
Sense CTGCACTCGGCCTCAACGGG
119 66.2
Antisense TGTGGGCTCTGGSCTGGCTTC
FOXOl
Sense TCCTACGCCGACCTCATCAC
93 63.0
Antisense CACGCTCTTGACCATCCACT
AREG
Sense TGGACCTCAATGACACCTACTC
150 53.5
Antisense AGGACGGTT CACTACTAGAAGG
LF
Sense GCTACTTCACRGCCATCC
128 48.7
Antisense ACTCCACTGGTTACACTTG
PRL
Sense CCACTACAT CCATAACCT CT
140 60.0
Antisense GGGCTTGCTCCTTGTCTTC
GREB1
Sense ATCAGCTGCTCGACTTGCTG
134 62.0
Antisense TGAGCTCCGGTCCTGACAGAT
IGF1
Sense CTT CAGTT CGTGTGTGGAG
75 55.0
Antisense CGCCCTCCGACTGCT
Table 2.6: qRT-PCR primer pairs for mRNA expression levels
2.1.4.4 Quantitative Real-Time Polymerase Chain Reaction
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) was used to amplify 
cDNA against specific primers (described previously) in order to obtain an amplicon 
of 75-150bps in length. All results were normalised against an internal reference 
gene (GAPDH) and primers were also run against RNA template negative control. 
For the PCR reaction 2.5pl of cDNA (diluted 1:10 in nuclease free water), 2.5pl of 
forward and reverse primer premix (4pM) and 5pl of ssofast evagreen supermix 
(Biorad, 172-5203) were pipetted, in triplicate, into a clear 96-well plate (Biorad). 
The plate was sealed with Biorad PCR microseal plate sealers then vortexed briefly 
and centrifuged for 1 minute at 1000 rpm to collect residual liquid. Dilutions of 1:5, 
1 : 1 0 0  and 1 : 1 0 0 0  of the untreated control sample were also added to the plate in
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ord er to g en e ra te  a standard  curve. T h e  p la te  w as hea ted  and coo led  using  a C F X 96  
PC R  therm al C ycler (B iorad). P la tes w ere hea ted  to 98°C  fo r 2m inu tes, then 
underw en t 40  cycles o f  h ea tin g  and co o lin g  as fo llow s; the p late  w as h ea ted  to 98°C  
for 2 seconds to denatu re  the D N A  then  coo led  for 5 seconds to  the annealing  
tem p era tu re  o f  the p rim er pa ir b e in g  u tilised , the p late  w as th en  h ea ted  to  72°C  for 
lO seconds fo r e lo n g atio n  and the cycle  w as repeated  (F igure 2.2). F o llo w in g  the 
P C R  reac tion  a m elt cu rve w as gen era ted  by  h o ld ing  the p late  at, at least, 1°C below  
the p rim er annealing  tem pera tu re  fo r 10 seconds then  stead ily  ra isin g  the tem p era tu re  
in increm en ts o f  0.2°C  until a tem p era tu re  o f  95°C  w as reached  (F igure  2.2).
D ata  ob ta in ed  from  the PC R  and H igh R eso lu tion  M elt analysis w as au to m atica lly  
saved  to B ioR ad  C FX  m anager 3 .0 , fu rth e r ana lysis  o f  the data  w as carried  out on  an 
excel sp readsheet.
 2 j 3-----------1-
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2:00
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Figure 2.2: Typical qRT-PCR protocol layout. The current example is based on 
PR primers.
2.1.4.5 qRT-PCR Data Output (CFX manager)
T he PC R  reaction  m ix consists  o f  p rim er, sam ple and S ybr green. S ybr g reen  is a 
cyan ine dye that b inds d o u b le -s tran d ed  D N A  and em its  green  light at ?t520nm  upon 
binding. D u rin g  the elongation  step  the light em itted  increases as the dye b inds m ore 
D N A , thus the light em itted  is p ro p o rtio n a l to  the am ount o f  D N A  am plified  by  the 
prim ers. T he am ount o f  light em itted  is recorded  in re la tiv e  fluorescen t un its (R F U ) 
and is p lo tted  against the n u m b er o f  cyc les on a logarithm ic scale. F rom  th is data  a 
quan tifica tion  cyc le  (C q) v alue  is de term ined  as a cycle  n u m b er at w hich
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flu o rescen ce  h as  in creased  above b ack g ro u n d  (Jo rdan  and K urtz , 2 010). T h e  po in t at 
w hich  signal is no  lo n g er b ack g ro u n d  is de term ined  by the p rog ram  (S ee  F ig u re  2.4). 
F luo rescence  d e tec ted  b e lo w  the b ackground  level is from  n o n -sp ec ific  signal from  
ineffic ien t b in d in g  o f  sy b r green . T he possib ility  o f  it being  from  p rim er d im ers, 
incorrect an n ea lin g  o r co n tam in a tio n  is ru led  out by the p ro d u c tio n  o f  a m elt curve. 
M elt curves w ere  g en e ra ted  du ring  each  run and the p re sen ce  o f  o n ly  one peak 
confirm s the ab sen ce  o f  p o ssib le  con tam inan ts. A n exam ple  o f  a ty p ica l m elt curve 
can  be seen  in F ig u re  2.3.
Melt Peak
600
500
200
100
Temperature, Celsius
Figure 2.3: Melt curve from a typical Quantitative PCR reaction. The example 
shows a melt curve generated with PR primers against Ishikawa cDNA.
2.1.4.6 Generation of a standard curve
In o rder to  e ffec tiv e ly  ana lyse  P C R  data and check the e ffic ien cy  o f  p rim ers, 
standard  cu rv es w ere  generated . T he  contro l sam ple fo r each  rep lic a te  o f  each 
experim en t w as serial d ilu ted  as p rev io u sly  described  (1 :10 , 1:100 and  1:1000 
cD N A : w ater), 2 .5 p ls  o f  these  d ilu tio n s  w as added  to 2.5ju 1 o f  rev erse  and  fo rw ard  
p rim er p rem ix  and 5 p l o f  syb r green . T he sam ples w ere run w ith  th e  P C R  reaction  
and cT  values w ere gen era ted  and p lo tted  against the logarithm  o f  the inpu t am ount 
o f standard . A n ex am p le  o f  the standard  cu rve generated  fo r G A P D H  on Ish ikaw a 
cells can be seen  in F ig u re  2.4.
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Figure 2.4: Typical qRT-PCR amplification plot. The example shows a standard 
curve generated with GAPDH primers against Ishikawa cDNA. Red Arrow 
indicates point at which signal overtakes background noise.
A new  standard  cu rve  w as p roduced  on each  PCR  run. E ach  standard  cu rve w as 
ch eck ed  fo r v a lid ity  w ith the slope fa lling  betw een  -3.3 and -3 .8 , s tandard  curves that 
varied  g rea tly  from  these values w ere d iscarded  and new  standard  cu rves w ere 
generated . T h e  slope o f  the standard  curve is a good ind icato r o f  the effic ien cy  o f  the 
PC R . a slope o f  -3 .322  is a 100%  effic ien t but due to  ex p erim en ta l lim ita tio n s th is is 
ra re ly  p o ss ib le  and a slope w ith  an R “ value o f  be tw een  0 .95 and 1.00 is accep tab le . 
F igure  2 .4  sh o w s an ex am p le  o f  a standard  cu rve ob ta in ed  from  the re feren ce  gene 
G A P D H .
y  = - 3 .6 4 3 6 x + 1 5 .1 7 4  
R2 =  0 . 9 9 8
 r ----- r - - -  - 1 --------------------- 1------------------ 1-------------- O - l
- 3 .5  -3  - 2 .5  -2  - 1 .5  -1  - 0 .5  0
Log S ta r t in g  Q u a n t i t y  
♦  GAPDH  Linear (GAPDH)
Figure 2.5: Typical Standard curve obtained from reference gene GAPDH.
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2.1.4.7 qRT-PCR Data Analyses using Microsoft Excel
The triplicate cT values generated by the biorad (CFX manager 3) were copy-pasted 
to Microsoft excel. An average of the three values was calculated and one value was 
excluded where necessary. Next the standard curve was generated and data from the 
linear equation was used in calculating the log of the starting quantity. The log of the 
starting quantity was calculated using the following equation:
Where Y is the log of the starting quantity, X is the average cT, Z is the slope of the 
standard curve and M is the curve intercept on the Y axis. To calculate the actual 
starting quantity the log of the starting quantity was calculated to the power of 1 0  
using the excel function Power (10,Y). The starting quantity was then normalised to 
the constitutively expressed genes, GAPDH, by dividing the starting quantity of the 
sample by the starting quantity of the reference gene.
All experiments were run in triplicate and subject to statistical analyses was based on 
the three repeats. Normalised starting quantity of hormone-treated samples was 
compared to control and to each other using two-tailed students T-Test in excel. As 
with all experiments, a P value of less than 0.05 was considered statistically 
significant and was expressed by one star (*), a P value of >0.01 was expressed by 
two stars (**) and a P value of >less than 0.001 was considered highly significant 
and expressed by three stars (***).
2.1.5 High Content Screening using InCell technology
Cells were cultured as previously described (Section 2.1.2.2). After 48h of incubation 
with hormone treatments Ishikawa or HESC cell monolayers were washed with PBS 
5 times for 5 minutes each time and fixed with paraformaldehyde (4% w/v) for 10 
minutes at 4°C. For the remainder of the procedure three 5-minute PBS washes 
followed each incubation step unless otherwise stated. Following fixation, cells were 
permaeblised by incubating with Triton X-100 (0.01%v/v) for 5 minutes at 25°C. 
Cells were incubated in blocking buffer (5% goat serum and 1% BSA in PBS) for 2
74
Chapter 2 M ateria ls  and M ethods
hours at 25°C. Next, cells were incubated at 4°C overnight with primary antibody. 
The primary antibodies used and the concentrations used for incubation are described 
in Table 2.5. PBS containing 1% BSA and 0.01% Tween20 was used for all washes 
from this point onwards. For fluorescent detection of the primary antibodies, an 
incubation of 1 hour with a secondary anti-body conjugated to a fluorescent label 
was required. The corresponding secondary antibodies used against each protein can 
also be seen in Table 2.7. The cell nuclei in all preparations were counter stained 
with a NucBlue™ (Life Technologies #R37605) 4’, 6-diamidino-2-phenylindole 
(DAPI) preparation (2 pl/ml PBS for 30-60s at 25°C). Following the final washes 
cell were imaged in excess PBS.
Antibody nam e
Santa Cruz Catalogue 
num ber
Species
Final conc. 
(pg/mL)
FOXOl (FKHR) (H-128) SC-11350 Rabbit 1
PR (H-190) SC-7208 Rabbit 2
Amphiregulin (H-155) SC-25436 Rabbit 1
Lactoferrrin (B97) SC-53489 Mouse 4
GREB1 (N-13) SC-138794 Rabbit 1
Anti-Rabbit IGG Texas Red SC-2780 Goat 1
Anti-M ouse IGG Texas Red SC-2781 Goat 1
Table 2.7 Antibody Name, Manufacturer, Species of origin and Concentration 
used for InCell Analysis
2.1.5.1 Image Acquisition
High content screening of all proteins using immuno-fluoresce was undertaken using 
the InCell Analyzer 2000 (GE Healthcare). Image data was recorded in two emission 
spectra channels; DAPI nuclear staining (Channel 1 X 470 nm for 0.1s) and Texas 
Red protein staining (Channel 2 X nm for up to 5s). The nuclear stain was a 
requirement to separate individual cells in subsequent analysis. Five low
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magnification images (lOx objective) were obtained for control and treated samples. 
Four images were obtained per well and each image contained approximately 500 
cells giving a total of 2000 cells imaged per well. All experiments were carried out in 
triplicate.
The InCell analyser acquisition software allows for a random distribution of fields 
across the well surface and regions of the centre or edge of the well may be excluded 
from field selection. The regions close to the well boundary were excluded from field 
selection as they were not representative of other areas of the well. The exposure 
time for each channel was kept constant across all experiments; therefore changes in 
fluorescence were directly attributable to protein expression levels. The output file is 
termed XDCE, which is a folder containing compiled images from all channels and 
all fields of view screened.
2.1.5.2 High Content Screening Image Analysis
XDCE files were analysed using InCell workstation software suite (GE Healthcare 
Analysis) to quantify protein immuno-fluorescence. The protocol used on InCell 
workstation was able to detect individual cells as the high contrast between DAPI 
stain and background facilitated efficient nuclear identification. To analyse 
fluorescent stain across the whole cell, a lOpM collar was drawn around the nucleus 
representative of the cytoplasmic region (Figure 2.6). The protein fluorescence was 
then determined for the cell nucleus based solely on the area overlying the DAPI 
stain whereas whole cell intensity was calculated based on the area covering the 
whole cell, inclusive of the area overlying the nucleus. The intensity was calculated 
by the software on a cell by cell basis and assigned a value for protein expression 
given in arbitrary units. The intensity of fluorescence was normalised against a 
negative control which involved subtracting the cell intensity of a no-antibody 
negative control from the experimental value to account for any background staining 
meaning the remaining signal was due to specific protein-bound primary antibody. 
All analysis was subject to three independent repeats and data was transferred to 
Spotfire Decision Tree for further analysis.
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Cell im ag es  a q u i r e d f r o m  InCell a n a l y s e r  2000.  A. DAPI c h a n n e l  (Nucleus) .  B. Texas Red C h an n e l  ( P ro te in  Stain)
F lo u res c en t  In tens i ty  d e t e r m in e d  us ing  InCell W orks ta t ion .  C. DAPI c h a n n e l  (Nucleus) .  D. Texas Red C h a n n e l  (P ro te in  Stain)
Figure 2.6: Nuclear and Cellular Identification using InCell Analyser 
Workstation. Nuclear staining was identified by the high-contrast intensity 
between DAPI stain and background as determined by the software whereas 
cellular intensity was identified by the application of a 1 0 pm collar around the 
nuclear circumference.
2.1.5.3 InCell Data Analysis in Spotfire DecisionSite and Microsoft Excel
A fter runn ing  InC ell W o rk sta tio n  analysis on a cell-cell basis, data  w as com piled  
using S potfire  D ecisionS ite  ana ly tics so ftw are  (T ibco), w hich  is ab le to con d en se  the 
vast am ounts o f  data from  the W o rk sta tio n  output.
D ata ob ta ined  in S po tfire  w as then  transferred  to excel in o rder to  graph  data 
effic ien tly  and carry  out s ta tistica l analysis. T he w ell values w ere  tested  for 
s ign ificance using  a tw o -ta iled  S tu d e n t’s T -test conducted  on average values. T reated  
sam ples w ere com pared  aga inst the un trea ted  con tro ls  w here P  v a lu es  o f  <0 .05 , 
<0.01 and <0.001 w ere considered  sta tis tica lly  sign ifican t and deno ted  w ith  a *, ** 
and *** respectively .
2.1.6 Prolactin  Enzym e-linked im m unosorbent assay (ELISA)
A fter incubation  and trea tm en t o f  H E S C s for R N A  ex trac tion  as d esc rib ed  (S ection  
2 .1 .2 .2), cell supernatan t w as co llec ted  and stored  at -20°C  in 1.5m L ep p e n d o rf tubes 
until u tilised  in an en zy m e-lin k ed  im m unosorben t assay  (E L ISA ). T h e  am oun t o f
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secreted prolactin was determined using commercially available ELISA kit (R&D 
systems, cat no.DY682) following the manufacturers standard protocol. All 
antibodies described were provided in the kit.
Prolactin monoclonal capture antibody was incubated overnight in a 96-well ELISA 
microplate (greiner) at a concentration of 0.8pg/ml. The long incubation allowed the 
antibody to bind to the plate. The plate was next incubated with blocking buffer, 
consisting of BSA (1% w/v) in PBS, to block all unbound sites on the plate and 
prevent false positive results. The plate was then ready to perform the assay.
To quantify the amount of secreted prolactin, known concentrations of prolactin were 
used to generate a 7-point standard curve. A standard was provided with the ELISA 
kit, containing 150ng/ml of recombinant human prolactin. The standard was serial 
diluted to concentrations of 1000, 500, 250, 125, 62.5, 31.25 and 15.63pg/ml for use 
in the assay. Reagent diluent without standard was prepared to account for 
background and subtracted from each reading.
Samples or standards were incubated in the ELISA plate for 2hours allowing 
prolactin protein to bind the capture antibody, after the incubation excess supernatant 
was decanted and the plate was washed 3 times in a wash buffer consisting of 0.05% 
Tween® 20 in PBS to remove any unbound protein.
Next biotinylated secondary antibody containing goat anti-human Prolactin was 
added to each well for 2 hours to bind adhered prolactin protein. Next, after 3 
washes, Streptavadin-horseradish peroxidase (HRP) was added to the plate for 20 
minutes out of direct sunlight. Streptavadin binds to biotin in the secondary antibody 
while the conjugated HRP provides enzyme activity for the detection of prolactin. 
After washing away excess streptavidin HRP, a substrate solution was added to the 
plate. The substrate contained hydrogen peroxide and Tetramethylbenzidine which 
reacted with HRP to caus a blue colour to develop in proportion to the amount of 
prolactin present in the sample or standard. Sulphuric acid (1M) was then added 
directly to the plate to stop this reaction; the addition of sulphuric acid also causes 
the solution to turn yellow. The optical density of each well was then determined 
immediately using a microplate reader set to 450 nm. The standards were used to
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prepare a standard curve and all optical densities from unknown samples were 
compared to this.
2.1.7 Cell Imaging and Image J
HESC cells were imaged with Zeiss light microscope using Zeiss imaging system. 
Still images were taken of live cells at 20x magnification in 6  well plates at 48hours 
after treatments.
Images were then subjected to image J analysis which quantifies cell roundness 
based on the equation:
R = 4 * pi * A /P A2
Where R is roundness, A is area in pixels and P is Perimeter
This equation generates a value from 0-1 where 1 is a perfect circle. Image analysis 
was carried out on three independent repeats and displayed as a bar graph showing 
the average of 3 repeats. The data was then subject to students t-test to establish 
significance where P values of <0.05, <0.01 and <0.001 were considered statistically 
significant and denoted with a *, ** and *** respectively.
2.2 Materials and Methods Used within Chapter 4
2.2.1 Stability of Progesterone in Tissue Homogenates
The stability of progesterone was assessed in homogenates of the human and rat liver 
and pooled intestinal mucosa and in the rat proximal and distal small intestinal 
mucosa and colonic mucosa. Stability assays were carried out in the presence and 
absence of the co-factor NADPH. The stability of progesterone was also assessed in 
human liver and intestinal cytosol in the presence and absence of several enzyme 
inhibitors.
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2.2.1.1 Preparation of Stock and Working Solutions for Homogenate Stability 
Assay
Fresh lOmM stock solution of progesterone or midazolam positive control (Abeam 
Biochemicals) was prepared in Dimethyl Sulphoxide (DMSO). The lOmM stock 
solutions were then further diluted in DMSO to give a final working solution of 
0.4mM. Fresh stock solution of NADPH was prepared by adding NADPH 
tetrasodium salt (Roche Applied Science) to PBS to a final concentration of lOOmM. 
Stock solutions were prepared fresh before each experiment.
2.2.1.2 Preparation of Liver and Intestinal Homogenates
Pooled samples of human and rat intestinal homogenates and rat liver homogenates 
were purchased from biopredic international and arrived pre-prepared in a pH 7.4 
buffer containing lOOmM Tris-HCl, lmM EDTA and 250mM Sucrose. Rat Intestinal 
and liver homogenates were obtained from a pool of 3 male Sprague Dawley rats. 
The rats from which intestinal homogenates were produced weighed between 250 
and 260 grams and the rats from which liver homogenates were produced weighed 
between 190 and 230g and were from 6 -8 weeks old. The human intestine 
homogenate was obtained from a 75 year old deceased male with peritonitis. Human 
livers were obtained from the UK human tissue bank and contained pooled samples 
from 9male and 3 female donors (donor details can be seen in Appendix B). Liver 
homogenates were prepared by removing any excess fat and weighing 50g from each 
liver sample. The samples were then suspended in ice cold SET buffer (50 mM Tris- 
HCl and 50 mM EDTA in distilled water adjusted to pH7.4) at a final volume of 
approximately 2.5 times the weight of the liver. The liver was minced and poured 
into a pre-cooled bead-milling homogenisation vessel (Precellys) and homogenised 
at 11,000 rpm. Any unhomogenised tissue was discarded and the total weight of 
homogenised tissue was determined. The samples from individual sections of rat 
intestine approximating duodenum, jejunum and ileum were obtained from 6  male 
Sprague Dawley rats between 6-10weeks old, the rats weighed between 200-270g. 
After sacrifice by lethal injection the intestines were immediately excised and placed 
in oxygenated KREBs buffer (1.26 M NaCl, 25 mM KC1, 250 mM NaHCQ3, 12 mM
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NatkPO^ 1 2  mM MgCL and 25 mM CaC^). The intestines were washed in KREBs 
buffer to remove any part-digested food contents. The muscle layer of the intestinal 
wall was removed by scraping away with a scalpel and the remaining mucosa was 
weighed then added to 2.5 times its weight in KREBs buffer. The homogenate was 
minced then homogenised in a Precellys bead-milling homogeniser. Any 
unhomogenised tissue was discarded and the total weight of homogenised tissue was 
determined.
The protein concentration for liver and pooled intestinal samples was determined 
using the method described by Lowry et al (1951) with BSA as a standard. The 
Lowry assay is based on 2 steps which lead to colour development; the first is a 
reaction between protein and copper and the second is the reduction of a folin 
reagent by the copper treated protein. The absorbance of the colorimetric change 
within the BSA standards and the samples was measured at 540nm on a 
SPECTRAFluor Plus (TECAN) spectrophotometer. The protein concentration was 
adjusted to 5mg/ml for these homogenates by diluting in phosphate buffer (pH7.4). 
Phosphate buffer (PB) was produced by dissolving 7.1g of Na2HP04 anhydrous in 
500ml of distilled water, this solution was warmed to 37°C and the pH was adjusted 
to 7.4 using the a solution containing 6 .8 g KH2P04 anhydrous in 500ml of distilled 
water.
The protein concentration of rat duodenum, jejunum and ileum samples was 
determined using the detergent compatible (DC) protein assay kit (Biorad) with BSA 
standards. This assay is based on the Lowry method and uses copper and folin to 
develop colour. Briefly, 5 pi of sample or standard, 25pl alkaline copper tartrate and 
200pl of dilute folin reagent were pipetted into a 96-well microplate. The solution 
was incubated at room temperature for 15 minutes and the absorbance was measured 
at 750nm on SPECTRAFluor Plus (TECAN) spectrophotometer.
2.2.1.3 Homogenate Stability Assay
Homogenates of the human and rat liver and pooled intestine or PB control were 
incubated in wells of a 1ml deepwell RNAse/DNAse 96 well plate (fisher) for 5 
minutes in thermomixer comfort (eppendorf) until reaching a temperature of 37°C.
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Progesterone or midazolam stock solution was diluted into the homogenate to give a 
final concentration of lpM. A final concentration of ljiM of progesterone was also 
added to the PB control.
After the short incubation of up to 5 minutes, either a final concentration of ImM 
NADPH stock solution or PB was added to the mixtures to start the reaction and 
samples were taken immediately and diluted 1:3 in ice cold Acetonitrile (t-0). The 
samples were then continuously incubated at 37°C with shaking (700rpm) and further 
samples were taken at 5, 10, 20, 30, 60 and 120minutes, these were also immediately 
added to ice-cold Acetonitrile upon sampling to stop any enzymatic reaction. The 
samples were centrifuged in Heraeus Multifuge centrifuge (thermo scientific) for 30 
minutes at 3000rpm to pellet the homogenates.
After centrifugation supernatant was removed and added diluted 1:1 with water, a 
final concentration of 0.2pM of Metoprolol (Sigma Aldrich, UK) was included in 
this solution as an internal standard for LC-MS/MS.
2.2.2 Stability of Progesterone in Human Liver and Intestinal Cytosol
2.2.2.1 Preparation of Human Liver and Intestinal cytosol
Human liver and intestinal cytosol were purchased from In Vitro technologies and 
stored at -80°C until use. Human liver cytosol came prepared in O.lmM EDTA in 
phosphate buffer with a protein concentration was 24.1 mg/ml. Details of the donors 
were not made available. Human intestinal cytosol came with a predetermined 
protein concentration of 11.7mg/ml. The cytosol consisted of a pooled sample 
obtained from 3 male and 3 female donors (donor details can be seen in Appendix 
C). The protein concentration was adjusted to 0.5mg/ml for both intestinal and liver 
cytosol by diluting the preparation in phosphate buffer with O.lmM EDTA (From 
here on this buffer will be referred to as PB).
2.2.2.2 Cytosol Stability Assay
The stability of progesterone was assessed in liver and intestinal cytosol in the 
presence or absence of specific enzyme inhibitors and NADPH cofactor.
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Progesterone was also incubated in phosphate buffer (PB) alone as a control. The 
stability of two as positive control substrates, pthalazine and dolasetron, were also 
assessed.
Human liver cytosol, human intestinal cytosol or PB control (with O.lmM EDTA) 
were pre-incubated in wells of a 1ml deepwell RNAse/DNAse 96 well plate for 10 
minutes in thermomixer comfort (eppendorf) until reaching a temperature of 37°C. 
The enzyme inhibitors listed in Table 2.8 were prepared in PB with 0.2% DMSO and 
added to the cytosol or PB at the final concentrations also seen in Table 2.8. The 
resulting mixtures were then incubated for a further 5 minutes. Next, a final 
concentration of lOOpM NADPH or PB was added to the mixtures. Finally 
progesterone or control substrates (pthalazine or dolasetron) were added to the 
mixture at a final concentration of lpM  and mixed by pipetting to initiate the 
reaction. The final concentrations of each component in the mixture were: lOOpM 
NADPH, 50-100pM enzyme inhibitor and lpM  of substrate in cytosol containing 
0.5mg/ml protein.
Upon initiation a 50pl sample was immediately taken followed by sample removal at 
10, 20, 30, 60 and 120 minutes. Enzymatic reaction was terminated by immediately 
diluting the samples in 100 pL of acetonitrile. Samples were centrifuged for 30 
minutes at 4°C and 2500 rpm. Supernatant was removed and diluted in a 1:1 ratio 
with milli-Q water. Metoprolol internal standard was added to this solution at a final 
concentration of 0.2pM.
83
Chapter 2 M aterials and M ethods
Inhibitor Name
Molecular 
Weight (kDa)
Enzyme Inhibited
Final Concentration 
(pM)
Epalrestat 319.40 AKR, particularly AKR1B1 lOOpM
Finasteride 372.54 AKR, particularly AKR1D1 lOOpM
Diazepam 284.74 AKR1C lOOpM
AKR cocktail
Epalrestat 319.40 lOOpM
Finasteride 372.54 AKR lOOpM
Diazapam 284.74 lOOpM
Hydralazine 196.64 A ldehyde oxidase 50 pM
M enadione 172.18
A ldehyde Oxidase, 
cytochrom e P450 reductase
100 pM
Chlorpromazine 355.33 Aldehyde Oxidase 100 pM
Aliopurinol 136.11 Xanthine Oxidase 100 pM
AKR1C cocktail
Flufenamic Acid 281.23 AKR1C lOOpM
Diazapam 284.74 lOOpM
Table 2.8: Enzyme Inhibitors incubated with progesterone in human liver or 
intestinal cytosol.
2.2.2.3 Sample Analysis by Liquid Chromatography Tandem Mass 
Spectrometry
All samples obtained from the homogenate and cytosol stability assays were 
analysed by liquid chromatography with tandem mass spectrometry (LC MS/MS). 
The LC MS/MS system used for all homogenate analyses consisted of an Acquity 
Binary Solvent Manager (BSM), Acquity 4-position heated column manager, 2777 
Ultra high pressure autosampler and a Xevo-TQ MS Triple Quadrupole mass
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spectrometer (Water Ltd, Herts, UK). The analysis was performed using a solvent 
system and gradient (parameters can be seen in Table 2.9). Mobile phase A consisted 
of lOmM ammonium formate +0.1% v/v formic acid in water and mobile phase B 
contained acetonitrile only. The column used was Aquity HSS T3 (1.8um) 
2.1x50mm (Water Ltd, Herts, UK). The samples were run at 70°C with an injection
Time
(min)
Flow Rate 
(uL/min)
%  M obile  
Phase A
%  M obile 
Phase B
Gradient
Profile
0.00 600 100 0 6
0.05 600 100 0 6
1.00 600 5 95 5
1.40 600 100 0 11
1.80 600 100 0 6
volume of 8 pl. Mass Spectrometry specifications can be seen in Table 2.10.
Table 2.9: LC parameters for the analysis of progesterone in homogenate and 
cytosol stability assays.
Ionisation Positive
Source Temp 600°C
Needle Current 500|iA
Aquistion
Multiple Reaction 
Monitoring (MRM)
Collision Gas High Purity Nitrogen
Table 2.10 Mass Spectrometry Parameters for analysis of progesterone in 
homogenate and cytosol stability assays.
2.2.2.4 Stability Assay Data Analysis
After LC-MS MS analysis peak area of substrates was determined using Labsys 
(Setaram) through auto-integration. The stability of progesterone and control 
substrates to all homogenates was assessed by taking the average peak area of three
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repeats. The percentage degradation was assessed by taking the concentration of drug 
at the first time point as 100%. Rate constants (k) were determined by fitting the 
percent drug remaining vs. incubation time curves to a first-order kinetic model by 
least squares minimization. Half-life (ti/2 ) was determined by plotting the peak area 
against time for each drug and plotting the point at which half the drug had degraded.
2.2.3 Solubility of Progesterone in Relevant Solutions
In order to assess the stability of progesterone in intestinal fluids it was first 
important to ensure that progesterone was fully dissolved in these solutions. The 
main component of the intestinal fluids is Phosphate Buffered Saline (PBS). PBS 
was prepared according to the British Pharmacopeia by adding 1 gram of KH2PO4 , 2 
grams of K2 HPO4  and 7.5 grams of NaCl into 1 L of distilled water and stirring until 
completely dissolved. The pH of the obtained buffer was adjusted to 6.80 with 
diluted NaOH. The solubility of progesterone was determined in this solution alone 
and in combination with solubility enhancers in order to obtain a maximal 
concentration of fully dissolved progesterone for sufficient analysis of progesterone 
depletion in intestinal fluids. The solubility of progesterone was determined in 
triplicate in the PBS solutions described in Table 2.11.
Solution Com ponents
1 PBS (99%), DMSO (1%)
2 PBS (99%), Etoh (1%)
3 PBS (98%), DMSO (1%), Tween80 (1%)
4 PBS 98%, Etoh (1%), Tween80 (1%)
5 PBS (99%), DMSO (1%) Cremophor(l%)
6 PBS 98%, Etoh(l%), Cremophor(l%)
Table 2.11: Components of 6 Solutions in which Progesterone Solubility was 
Determined.
To assess the solubility of progesterone in these solutions the ‘shake flask’ method 
was used. To assess the solubility of progesterone in Solutions 1 and 2 (Table 2.10), 
65pM of progesterone was first dissolved in the solvent in triplicate and added to
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PBS with the final concentration of solvent being 1% in each solution. The solutions 
were then tightly closed in vials and placed in a heated shaking block 
(BamsteadStem RS900) at 37°C and 300rpm. The solutions were left to shake for 2 
hours then a lOOpl sample was carefully removed, filtered through a 0.2pm filter 
(VWR international) and analysed by HPLC (Agilent 1100 series). To calculate the 
solubility of progesterone standards containing known amounts of progesterone in 
80:20 methanol: water were again used to obtain a linear equation. This equation was 
then used to determine the solubility.
The solubility of progesterone in Solutions 3-6 (Table 2.10) was determined by 
dissolving progesterone first in the solvent and then further diluting this solution in a 
ratio of 1:4 in 25% Tween80 or 25% Cremophor in water. This solution was then 
added to PBS at a ratio of 1:19. The final concentration of solvent was 1% and the 
final concentration of Tween80 or Cremophor was 1% in all solutions. The final 
concentration of progesterone in these samples was 65pM (0.02mg/ml). The 
solutions were again incubated in a heated shaking block and at 2 hours, lOOpl of 
solution was removed and filtered through a 0.2pm filter (VWR international). The 
samples were then analysed by HPLC and the solubility calculated as previously 
described. Separate standard curves were used for each experiment (R2>0.98).
For the solubility experiments the following isocratic HPLC parameters were 
maintained: The column used was Phase Seperations 250 x 4.6mm licrosphere 
column with 5uM particle size, the detector wavelength was 242 nm, the flow rate 
used lml/min and the mobile phase consisted of 80:20 methanol water. The 
thermostat temperature was maintained at 26°C. The injection volume used for the all 
solubility experiments was lOpl with one exception. The injection volume was 
increased to lOOpl for experiments containing PBS 2 as the concentration of 
progesterone was too low to detect with a smaller injection volume.
As the aqueous solubility of MPA and LNG is higher than that of progesterone, the 
solubility of these compounds was not assessed in the relevant fluids.
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2.2.4 Stability of Progesterone in Simulated Intestinal Fluid
2.2.4.1 Preparation of Drug Stock Solution for Simulated Intestinal Fluid 
Studies
Drug stock solutions were prepared on the day of the experiment. Stock solutions of 
progesterone, MPA and LNG were prepared in DMSO (50%), tween80 (12.5%) and 
water (37.5%), at a concentration of 1.3 mM. On dilution with the human simulated 
intestinal or colonic fluid, the concentrations of tween 80 (Sigma Aldrich) and 
DMSO was 1% w/w as to minimize any potential effects on colonic enzymes. All 
three drugs were shown to be stable for at least 24 hours in the stock solution.
2.2.4.2 Preparation of Simulated Small Intestinal Fluid
Simulated intestinal fluid was prepared according to USP specifications (Test 
Solutions, United States Pharmacopeia 35, NF 30, 2012). 0.68 g of monobasic 
potassium phosphate was dissolved in 75 ml water, then 7.7 ml of 0.2 N NaOH was 
added to adjust the pH to 6 .8 . To this lg of pancreatin (Sigma Aldrich) was added 
and shaken gently until dissolved and the volume adjusted to 1 0 0 ml with water. 
Pancreatin was added after adjusting the pH of the solution to 6 . 8  to avoid 
precipitation of the enzyme.
2.2.4.3 Stability Testing in Human Simulated Small Intestinal Fluids
Simulated intestinal fluid was prepared as described. The drug stock solution at a 
concentration of 1.3 mM was added to simulated human colonic fluid or PBS control 
to achieve a final concentration of 65 pM and mixed on a horizontal shaker at 100 
rpm (VXR basic Vibrax®, Leicestershire, UK). Samples were withdrawn at 0, 2, 6  
and 24 hours and a final sample was taken at 24 hours and added to ice-cold 
acetonitrile as a stop reagent to inactivate the degrading enzymes and precipitate the 
interfering proteins during analysis. The samples were centrifuged at 10,000 rpm for 
10 minutes and the supernatant was collected and stored at 4°C until analysed by 
UV-HPLC
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2.2.4.4 Preparation of Basal Medium and Phosphate Buffer Saline
A Basal medium was first prepared to support anaerobic bacterial growth in the 
faecal slurry, by dissolving Peptone water and yeast extract (3g) (Oxoid Limited) in
1.3 L of distilled water was and autoclaving at 125 °C for 20 minutes. In a 200 ml 
volumetric flask, sodium chloride (O.lg) (Fisher Chemical), dipotassium hydrogen 
orthophosphate (0.06g) (Fisher Chemical), of magnesium sulphate heptahydrate 
(0.015g) and calcium chloride hexahydrate (0.0lg) (VWR) were weighed and 
dissolved in distilled water (ca. 150mL) under stirring. Following that, tween 80 
(3mL) was added to the solution and was stirred until completely dissolved. L- 
cysteine and bile salts (0.75g) (Sigma Life Sciences) were added and stirred until 
completely dissolved. To this solution, vitamin K (15 pL), haemin (0.0075g, in two 
drops of 1 N sodium hydroxide) and 0.025% resazurin (6 mL) in deionised water 
solution were added under stirring. Sodium bicarbonate (3g)(Sigma Aldrich) was 
added at the end and the final volume was made up to 2 0 0  ml with distilled water. 
The flask was stoppered during stirring to avoid dissolution of oxygen. The resulting 
solution was filtered (0.45pm, Millex GP syringe-driven filter units, Millipore, 
Ireland) into the peptone water and yeast extract solution. This step was performed 
aseptically in a Laminar Flow Cabinet. The bottle was kept tightly closed and at 
room temperature until used.
Phosphate buffer saline was prepared according to British Pharmacopoeia 
specifications by adding potassium dihydrogen orthophosphate (0.014M), 
dipotassium hydrogen orthophosphate trihydrate (0.017M) and sodium chloride 
(0.256M) in distilled water (2L) and stirring until dissolved. The pH was adjusted to 
6 . 8  using 0.1N HC1 or IN NaOH solutions.
2.2.4.5 Preparation of Human Simulated Colonic Fluid
Two healthy male volunteers were given a plastic receptacle into which the samples 
were provided. The receptacle containing freshly voided human faeces was placed 
into an anaerobic workstation (Electrotek 500TG workstation, Electrotek, UK) 
maintained at 37°C and 70% relative humidity. The faecal material was weighed and 
diluted with PBS pH 6 . 8  to obtain 20% (w/w) slurry (60g of faecal material was
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diluted with 240g of PBS 6.80) by homogenization using an Ultra Turrax (IKA T18 
Basic) homogenizer at a speed of 18,000 rpm until no large solid agglomerates were 
observed. The homogenized faecal slurry was sieved through 350pm nylon mesh 
(Sefar NitexTM, Heiden, Switzerland) to remove any unhomogenised fibrous 
material. The basal medium prepared was then added to the sieved homogenized 
faecal slurry to achieve a 1 : 1  dilution (300g of the sieved homogenized faecal slurry 
was diluted with 300g of basal medium). Hence, the final concentration of faecal 
material in the slurry used for stability studies was 1 0 % (w/w).
2.2.4.6 Stability Testing in Human Simulated Colonic Fluids
The stability of all drugs in simulated human colonic fluid was carried out in an 
anaerobic workstation maintained at 37°C and 70% relative humidity. Control 
studies were carried out in PBS pH 6 . 8  in the absence of colonic bacteria. The drug 
stock solution at a concentration of 1.3mM was added to simulated human colonic 
fluid to achieve a final concentration of 65 pM and mixed on a horizontal shaker at 
lOOrpm (VXR basic Vibrax®, Leicestershire, UK). Samples were withdrawn at 0, 10, 
20, 30, 60, 120, 240 and 360 minutes and a final sample was taken at 24 hours and 
added to ice-cold acetonitrile as stop reagent to inactivate the degrading enzymes and 
precipitate the interfering proteins during analysis. The samples were centrifuged at 
10,000 rpm for 10 minutes and the supernatant was collected and stored at 4°C until 
analysed by UV-HPLC.
2.2.4.7 Simulated Intestinal Fluid Sample Analysis by UV-HPLC
All UV-HPLC analysis were performed using Hewlett Packard 1100 series HPLC 
Value System with G1312A binary pump, G1315A diode array detector and G1313A 
Autosampler. The equipment was connected to and subsequently analysed on Dell 
Dimension Dim 300 PC with Chemstation for LC 3D systems software (Agilent).
The HPLC method described by Maliwal et al was used to analyse progesterone, and 
adapted for MPA and LNG. The hormones were eluted isocratically using a mobile 
phase consisting of 80:20 methanol and water, the column used was Phase 
Separations 250 x 4.6 mm licrosphere column,5pM particle size, at 40°C and the UV
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detector wavelength was set at 242 nm with a flow rate of lml/min. lOOjil of sample 
was injected for each run (Maliwal et al., 2009). The samples were allowed to run for 
60 minutes to reduce run-over. The retention time for progesterone, MPA and LNG 
was 8 .6 minutes, 6 . 8  minutes and 7 minutes respectively.
2.2.4.8 Simulated Intestinal Fluid UV-HPLC Data Analysis
The stability of the three drugs was assessed by taking the average peak area of three 
repeats. The percentage degradation was assessed by taking the concentration of drug 
at the first time point as 100%. Rate constants (k) were determined by fitting the 
percent drug remaining vs. incubation time curves to a first-order kinetic model by 
least squares minimization. Half-life (ti/2 ) was determined by plotting the peak area 
against time for each drug and plotting the point at which half the drug had degraded.
2.3 Materials and M ethods Used within Chapter 5 
2.3.1 Preparation and Characterisation of Progesterone Amorphous Solid 
Dispersions
2.3.1.1 Production of Progesterone Amorphous Solid Dispersions
Two polymer types were utilised for the production of progesterone microparticles; 
Eudragit and HPMCAS. Eudragit L I00 is an anionic copolymer of methacrylic acid 
and methyl methacrylate with pH dissolution threshold of pH 6.0 and was used in the 
initial production of progesterone loaded microparticles. HPMCAS HF, MF and LF 
are cellulosic enteric coating agents with dissolution thresholds of pH6 .8 , 6  and 5.5 
respectively.
Progesterone loaded microparticles were produced using the emulsion solvent 
evapouration method. This method involves a preparation containing two immiscible 
liquids where one liquid (the internal phase) is dispersed in the other (the external 
phase) (O'Donnell and McGinity, 1997). Figure 2.7 shows the steps involved in the 
preparation of microparticles using this method.
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Progesterone loaded Eudragit LI00 microparticles were prepared using the oil-in-oil 
emulsion solvent evaporation method based on previous work by Kendall (2006, 
2009) whereas microparticles with HPMCAS as a polymer were prepared using the 
oil-in-water emulsion solvent evaporation method. The emulsion solvent evaporation 
process comprises of two mass transfer processes i) the diffusion of the solvent from 
inner phase droplets to the external phase and ii) The solvent evaporation from the 
external phase to the environment.
For the preparation of progesterone microparticles with Eudragit L100, 300mg of 
progesterone and 2.7g of Eudragit L100 were dissolved in 30ml of absolute ethanol 
(the internal phase). The internal phase was slowly added to liquid paraffin (165ml), 
containing 1 % (w/w) sorbitan sesquioleate as a dispersing agent, under stirring at 
lOOOrpm. The stirring speed was obtained using Heidolph RZR1 mechanical 
overhead stirrer (Heidolph Instruments, Schwabach, Germany). The solution was left 
to stir overnight at room temperature allowing the solvent to fully evaporate and the 
microparticles to form. The solidified microparticles were separated from solution 
and washed 3 times with 50mL of w-hexane (95%) via vaccum filtration through a 
pyrex sintered glass filter (pore size 4; 5-15pm). This method is subject to patent 
number US 20130101646 A1 (Basit et al., 2013) and available to use within this 
study through collaborative work with Kuecept LtD who are licenced to use this 
method.
For the preparation of progesterone microparticles with HPMCAS polymers, 200mg 
of progesterone and 1.8g of HPMCAS were dissolved in 30ml of ethyl acetate: 
dichloromethane (1:1 v/v). The resulting clear solution was emulsified into 200ml 
deionised water containing 1 % (w/w) polyvinyl alcohol as a dispersing agent, under 
stirring at lOOOrpm. The stirring speed was obtained using Heidolph RZR1 
mechanical overhead stirrer. The solution was left to stir overnight at room 
temperature allowing the solvent to fully evapourate and microparticles to form. The 
solidified microparticle were separated from solution and washed 3 times with 50mL 
of deionised water through vaccum filtration using a pyrex sintered glass filter (pore 
size 4; 5-15pm). Post filtration, the sample was stored under desiccation prior to 
further use.
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A b C D
Figure 2.7: Emulsion Solvent Evaporation. A) The drug and polymer are both 
dissolved in the solvent and then added gradually to the immiscible phase 
containing a surfactant under propeller stirring. B) The solvent is then 
removed by a long period of evaporation at room temperature under continuous 
propeller stirring (solvent evaporation). C) Eventually a suspension of 
microparticles containing the drug and polymer forms within the external phase 
and D) are removed from solution through filtration, washed 3 times with an 
appropriate solution and allowed to dry.
2.3.1.2 Microparticle Morphology and Size Estimate
M icro p artic le  m o rp h o lo g y  and ap p ro x im ate  size w ere de term ined  using  scann ing  
e lec tron  m icro sco p y  (S E M ). M icropartic les w ere  fastened  on SE M  adhesion  pads 
and coated  w ith  go ld  using  a gold  sp u tte r m odu le  in a h igh  vacuum  ev ap o ra to r 
(E m itech , K 550). A P h ilip s/F E I X L 30  T M P  SE M  w as used  to observe  the sam ples at 
5kV  to p ro v id e  d e ta ils  o f  the su rface ch arac te ris tic s  as w ell as the m orpho logy  o f  the 
m icropartic les. Im ages w ere o b ta ined  lOOx, 500x , lOOOx, 2500x and 5000x 
m agn ifica tion . Im ages ob ta ined  at 500x m ag n ifica tio n  w ere used to  estim ate  
m icro p artic le  size.
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2.3.1.3 Powder X-ray Diffraction
Powder X-ray diffraction (PXRD) is a technique often used in the pharmaceutical 
industry to assess the physical form of samples; particularly crystal structure and 
atomic spacing. X-rays are electromagnetic radiation that can be measured in 
wavelengths. If an X-ray beam impacts on a crystal, the beam will be scattered in all 
directions by the atoms within the crystal. Although some beams will be disguised by 
destructive interference others will be made visible through constructive interference 
causing the X-ray scattering to be concentrated into a few sharp diffraction peaks 
which are then measured in wavelengths. However if the X-ray hits a non-crystalline 
(amorphous) structure the X-ray scattering is spread throughout reciprocal space and 
therefore not detected as peaks (Guinier, 1994). Therefore PXRD was used to assess 
the crystallinity/amorphicity of natural progesterone powder and progesterone in 
solid dispersions.
The X-ray diffractometer is composed of three major parts: an X-ray tube, a sample 
holder and a diffracted x-ray detector where electromagnetic radiation is applied to 
the sample. The sample and the detector are rotated and the intensity of the reflected 
x-ray beam is measured by the detector. A filter slit focuses the X-ray beam and the 
intensity peak of the diffracted X-ray is recorded. The angle of diffraction (the theta 
angle) is measured in degrees (°). For practical reasons the diffractometer measures 
an angle two times the theta angle, this is referred to as 2 theta.
A Bruker D8  scanning X-ray diffractometer was used for the analysis of 
progesterone and progesterone amorphous solid dispersions. The samples were 
placed in a 9mm silicon wafer and gently smoothed and compressed with a Perspex 
block. Samples were scanned on a 2-theta scale ranging from from 2° to 40° at 0.039 
°/sec. The peak was calculated using Diffrac.Suite data analysis software (Bruker).
2.3.1.4 Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) is a relatively fast technique that requires 
only limited amount of sample and can provide high levels of sensitivity. DSC is the 
measurement of changes in a uniform heat flow rate passed to a sample and a
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reference sample whilst they are subjected to a controlled temperature program 
(Hohne et al., 2003). As the temperature of the samples changes the differences of 
heat flow between them is recorded and can be visualised on a thermogram. 
Crystalline materials have a melting endotherm, ie. a temperature at which the lattice 
of the structure breaks down, which can be visualised as sharp dip in heat flow on the 
thermogram. Amorphous materials on the other hand have a reduced melting point 
due to the absence of a structured lattice. As a result, this technique can be used to 
distinguish between amorphous and crystalline materials. A DSC Q1000 V9 
differential scanning calorimeter (TA instruments) was used for the analysis of 
progesterone and progesterone ASDs. Reference and samples were accurately 
weighed to weights between 3 and 5mg and placed in hermetic aluminium pans. An 
isothermal period of 100°C was applied to the samples for 5 minutes to eliminate any 
residual content on the pan. The samples were then cooled and scanned from 40°C to 
150°C at rate of 20°C/min. Data was subsequently analysed on TA Instruments 
Universal Thermal Analysis Sofware (version 4.5a).
2.3.1.5 Drug Encapsulation Efficiency in Microparticles
Progesterone microparticles were prepared with a 1:9 drug to polymer ratio. To 
assess the actual concentration of progesterone within the microparticles, 50mg of 
microparticles were dissolved in 50ml of 100% methanol to give a final 
concentration of 1 mg/ml of microparticles and therefore a final concentration of 
0.1 mg/ml progesterone. The efficiency of the microparticle loading was determined 
by running samples on HPLC. The HPLC system parameters are described in Section 
2.2.3.8 . All samples were eluted isocratically using a mobile phase consisting of 
0.1% Trifluoroacetic acid (TFA) in 50:50 acetonitrile and water. The column used 
was Zorbax 150 x 4.6 mm with 3.5pM particle size at 25°C and the UV detector 
wavelength was set at 242 nm with a flow rate of lml/min. lOpl of sample was 
injected for each run. The samples were allowed to run for 20 minutes. Standards of 
known concentrations were used to produce a standard curve and the straight line 
equation was used against peak area to quantify drug present in the sample. The 
method was validated for system suitability and linearity.
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System suitability was evaluated by replicate (n= 6 ) injection of the same standard 
solution containing progesterone at a concentration of 1 mg/ml. The retention time, 
peak area and tailing were consistently replicable between repeats indicating system 
suitability. Linearity was tested in the concentration range of 0.1mg/ml-2mg/ml.
Furthermore, progesterone standards (1 mg/ml) were injected intermittently
t l ithroughout the procedure (every 6  injection) and in triplicate at the beginning and 
end of each HPLC analysis and and no change was observed in retention time, peak 
area or tailing.
2.3.2 In Vitro drug release profiles of progesterone-loaded HPMCAS 
microparticles
Dissolution of HPMCAS HF and MF coated progesterone ASDs was carried out 
using the shake flask method with manual pH switch. An important requirement 
when carrying out a dissolution test is to ensure the procedure is carried out in sink 
conditions whereby the amount of medium should be sufficient enough to dissolve 
the expected amount of drug released. To ensure the experiment was under sink 
conditions the amount of sample added was 1 0 % that of the solubility in the media 
used. The dissolution medium used for this experiment was fed-state simulated 
gastric fluid (FeSSGF). FeSSGF was prepared according to manufacturer guidelines 
(Biorelevant). To produce 500mL of FeSSGF, lg of NaCl was dissolved in 450mL 
of distilled water and the pH was adjusted to 1. 6  with HC1. The volume was made up 
to 500mL with distilled water. Next 0.03g of SIF Powder Original was added to 250 
mL of this buffer and stirred until completely dissolved; the volume was then made 
up to 500mL using the same buffer.
The solubility of progesterone in FeSSGF was calculated as described in Section 
2.3.4. The encapsulation efficiency of the progesterone ASDs was taken into account 
when carrying out dissolution to further ensure sink conditions and accurately 
measure the amount of progesterone being added to the dissolution buffer.
To determine the dissolution of progesterone ASDs in relevant media, 4mL of 
FeSSGF (pH 1.6) was warmed to 37°C in a heated shaking block (Bamstead Stem
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RS900) with a shaking rate of lOOrpm. Predetermined amounts of accurately 
weighed progesterone ASDs were added to the mixture and a 500pL sample was 
taken and filtered through a 0.2pm filter. A further 500pL sample was taken at 
2hours. After taking the second sample the dissolution media was manually adjusted 
to pH 6.5 for HPMCAS MF ASDs or pH7 for HPMCAS HF ASDs with a 4N NaOH 
solution and the volume of liquid was brought to 4mL with the addition of FeSSIF 
buffer. Following pH switch 500pL samples were taken immediately and another 
sample was taken after 2 hours. Dissolution media without ASDs was also sampled 
at the same time-points and taken as a blank sample. All experiments were carried 
out in triplicate and analysed by HPLC.
2.3.2.1 Drug Release Data Analysis
To determine the dissolution rate of progesterone ASDs, the quantity of progesterone 
in the samples was determined by HPLC. HPLC analysis was performed using the 
system described in Section 2.2.3.8 . All samples were eluted isocratically using a 
mobile phase consisting of 0.1% TFA in 50:50 acetonitrile and water. The column 
used was Zorbax 150 x 4.6 mm with 3.5pM particle size at 25°C and the UV 
detector wavelength was set at 242 nm with a flow rate of lml/min. 100pi of sample 
was injected for each run. The samples were allowed to run for 20 minutes. The 
retention time for progesterone was 7minutes. Peak area determined using 
Chemstation (Agilent) auto-integration software. Peak area for each sample was 
subsequently entered into an excel spreadsheet and the concentration of progesterone 
in each sample was determined based on progesterone standards of known 
concentration. The removal of 500pl samples and the increase in media volume were 
taken into account during the analysis.
2.3.3 CACO-2 Cell Culture and Assay
2.3.3.1 Introduction to the CACO-2 cell line
In 1975 Fogh et al established a collection of cell lines from gastrointestinal tumors 
in order to carry out work on cancer mechanisms (Fogh and Trempe, 1975). In 1983 
attention was turned to such cell lines as models for differentiated intestinal cells due
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to their specific intestinal properties. It was then discovered that most of the cell lines 
established could be induced to partially differentiate after treatment with certain 
biological factors. However, one of the cell lines, the CACO-2 cell line, showed 
spontaneous differentiation after long-standing culture. Studies carried out on these 
cells showed that upon differentiation they express the same biochemical and 
morphological characteristics as enterocytes of the small intestine including 
transporter proteins, efflux proteins, and Phase II conjugation enzymes (Pinto et al., 
1983). As a result of its intestinal properties CACO-2 cells serve as a model of 
paracellular movement of compounds across the monolayer.
To assess the permeability of compounds using the CACO-2 model cell line, 
monolayers are cultured on a semi-permeable membranes inserted into wells of 
multi-well culture plates. Test compounds are then added to either the apical or 
basolateral sides of the monolayer and their permeability assessed (Breemen and Li, 
2005).
2.3.3.2 Routine Subculture of Caco-2 Cells
CACO-2 cells were grown until passage 59 in a 175cm cell culture flask (Falcon). 
Cells were cultured in Dulbecco’s modified eagle medium (DMEM; +L-glut., +D- 
glucose, +Na pyr.) containing foetal bovine serum (10%) L-glutamine (2mM) non- 
essential amino acids (1%) v/v, penicillin (50units/mL) and streptomycin (50pg/mL).
All sub-culture techniques were carried out aseptically in a lamina flow hood.
For the sub-culture of CACO-2 cells, cells were grown to between 70 and 100% 
confluent. PBS, Trypsin/EDTA and growth medium were warmed to 37°C using a 
beaded water bath (Thermoscientific). Cell media was removed from the flask and 
cells were washed two times in lOmL warm PBS. Cells were incubated at 37°C in 
2ml of trypsin EDTA in a shaking incubator (Stuart Scientific). After 5-7 minutes 
>90% of the cells detached and were diluted in lOmL of warmed media to stop the 
action of Trypsin/EDTA on the cells. The cell suspension was transferred to a 15ml 
sterile centrifuge tube and pelleted by centrifugation for 4 minutes at 800rpm. 
Supernatant was decanted and the resulting cell pellet was re-suspended in fresh
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m edia  and  d e-ag g reg ated  by  asp ira tion . C A C O -2  cells w ere split at a su b cu ltiv a tio n  
ra tio  o f  1:5 into 15ml o f  fresh  m ed ia  in a s te rile  cell cu ltu re  flask.
2.3.3.3 Seeding 12-well inserts with CACO-2 cells
In o rder to  seed C A C O -2  ce lls in to  a 12-w ell transw ell plate, the  ce lls  w ere  su b ­
cu ltu red  until reach in g  p assag e  n u m b er 59 and g row n until >90%  co n flu en t in a T - 
175 flask . C ells w ere  su b -cu ltu red  as d esc rib ed  until a cell pelle t w as ob ta ined . A t 
th is po in t cells w ere re -su sp en d ed  in 10ml o f  cu ltu re  m edium  and  d e -ag g reg a ted  by  
asp ira tion . Im m ed iate ly  afte r asp ira tio n  ce lls  w ere coun ted  w ith  a h aem o cy to m e te r 
using  the fo llow ing  p rocedure :
•  50 p l o f  cell su sp en sio n  w as added  to  5 0p l o f  0 .4%  trypan  so lu tio n  in PB S. 
T rypan  b lue  w as used  to  d e te rm in e  cell v iab ility ; n o n -v iab le  ce lls  take-up  
T rypan  blue and  b eco m e dark  b lue  in co lou r w hereas b lue  dye is seen  only  
around the edge o f  v iab le  cells.
•  A cover slip  w as secured  to  the h aem o cy to m ete r and 10pL o f  ce ll/try p an  
b lue  so lu tion  w as p ip e tted  d irec tly  into one o f  the co u n tin g  ch am b ers. T he 
p repara tion  w as ob serv ed  m icro sco p ica lly  at lOx ob jective . A c lick  co u n te r 
w as used to coun t ce lls in each  o f  5 squares o f  the h aem o cy to m e te r as 
dep ic ted  in F ig u re  2.8. T o  avo id  coun ting  the sam e ce lls  tw ice, ce lls  that 
w ere po sitio n ed  o v er the b o tto m  and righ t bo rd er w ere not cou n ted . T he 
num b er o f  v iab le  ce lls w as recorded .
TO
5
i
Figure 2.8: Haemocytometer grid. When counting CACO-2 cells using the 
haemocytometer the finer grid lines shown in square 5 were ignored. Cells in 
the main squares numbered 1 to 5 were counted and the average taken.
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After determining the number of viable cells per square of the haemocytometer the 
following equation was used to calculate the number of cells per mL:
Number o f cells p er  mL =  average cell count x 104 x dilution fac tor
Based on the calculation cells were diluted appropriately to a final concentration of 
2xl0 5 cells/mL. 500pl of the cell dilution was then added to the apical chambers of 
the CACO-2 transwell. The transwell inserts used for this procedure were of 12mm 
in diameter with a 0.4pM pore size polycarbonate membrane in a 12-well culture 
plate. The following procedure was used when plating the CACO-2 transwell:
• Prior to seeding, the semi-permeable insert membranes were pre-wetted with 
culture medium for approximately 30min at 37°C by aseptically adding 
1.5mL of warmed growth media into the basolateral plate wells and adding 
500|iL of warmed media to the transwell insert. Transepithelial electrical 
resistance (TEER) measurements were taken before and after incubation 
using Evom Epithelial Voltohmmeter.
• Following the incubation step, media was removed from the transwell inserts 
and replaced with 500pL of diluted cell suspension to give a final 
concentration of 1 x 1 0 5cells per transwell.
• The lid was replaced and the assembly was placed in a 37°C, 5% CO2 
incubator. TEER measurements were taken again after lhour of incubation 
and cells were replaced in the incubator.
2.3.3.4 Replacing Media in 12-well Cell Inserts and Feeder Plates
Replacement of CACO-2 cell media was carried out every two to three days for 28 
days; at this time the cells were used for the permeability experiment. To replace the 
growth media, the media was first removed from the basolateral compartment of the 
transwell membrane then carefully removed from the apical compartment using a 
vacuum suction pipette. 500pL of fresh media was added to the apical side of the 
membrane followed by 1.5mL of fresh media to the baso-lateral side. Cells were 
placed in a 37°C, 5% CO2 incubator for 1 hour and TEER measurements were 
recorded in triplicate.
100
Chapter 2 M ateria ls  and M ethods
2.3.3.5 Preparation of Assay Solutions
The CACO-2permeability assay was carried out in HBSS (GIBCO) supplemented 
with 1% DMSO, 1%HEPES (GIBCO), 1%FBS and 0.1% Vitamin E (pH 6 .8 ). 
Progesterone and progesterone ASDs were added directly to this media to give a 
final concentration of 5pg/ml (16pM) of progesterone. The concentration of 
progesterone in the ASDs was calculated prior to the experiment in order to ensure 
equal concentrations of progesterone were added to wells containing the natural drug 
and ASD.
2.3.3.6 CACO-2 Permeability Assay
Before carrying out the CACO-2 permeability assay TEER measurements were taken 
and recorded in triplicate.
The culture media was removed from both the apical and basolateral side of the 
transwell plate and replaced three times with Hanks Balanced Salt Solution 
substituted with 1% N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 
1% FBS and 0.1% vitamin E. Cells were incubated in the supplemented HBSS 
solution for 30 minutes at 37°C. After incubation the TEER measures were taken 
again in triplicated and recorded. The HBSS was removed from the donor 
compartment and replaced with the pre-prepared progesterone and progesterone- 
loaded HPMC-AS solutions. lOOpL of sample was taken immediately from the 
basolateral compartment of each well and
Samples (100 pL) were taken from the basolateral compartment at regular time 
intervals over a 1 2 0  minute period and replaced with the same volume of fresh 
buffer. At the end of the experiment, 100 pL was also taken from the upper 
compartment. All experiments were conducted in triplicate at pH 6.0, 37 °C, 5% 
C02 and 95% relative humidity.
All samples were diluted with acetonitrile immediately after removal to obtain a 
sample-to-acetonitrile volume ratio of 1:4 and then analysed for progesterone content 
using HPLC.
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2.3.3.7 Sample analysis by HPLC
HPLC analysis was performed using the system described in Section 2.2.3.8 . All 
samples were eluted isocratically using a mobile phase consisting of 80% Methanol 
and 20% distilled water. The column used was Zorbax 150 x 4.6 mm with 3.5pM 
particle size at 40°C and the UV detector wavelength was set at 242 nm with a flow 
rate of lml/min. lOOpl of sample was injected for each run. The samples were 
allowed to run for 20 minutes. The retention time for progesterone was 7minutes. 
Peak area was determined using Chemstation (Agilent) auto-integration software. 
Peak area for each sample was subsequently entered into an excel spreadsheet and 
the concentration of progesterone in each sample was determined based on 
progesterone standards of known concentration. The removal of lOOpl of sample and 
was taken into account during the analysis.
System suitability was evaluated by replicate (n= 6 ) injection of the same standard 
solution containing progesterone at a concentration of 5pg/ml. The retention time, 
peak area and tailing were consistently replicable between repeats indicating system 
suitability. Linearity was tested in the concentration range of l-10pg/ml.
Furthermore, progesterone standards (5pg/ml) were injected intermittently 
throughout the procedure (every 6 th injection) and in triplicate at the beginning and 
end of each HPLC analysis and and no change was observed in retention time, peak 
area or tailing.
2.3.3.8 CACO-2 Data analysis
Data was analysed based on percent disappearance/ appearance of progesterone in 
the apical and basolateral compartments of the transwell. This was calculated by 
running samples of known concentrations of progesterone to obtain a standard curve. 
From this, the concentration of progesterone was determined in the apical and 
basolateral compartments and presented as percent of the initial treatment 
concentration.
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The apparent permeability coefficient (Papp) was also calculated. Papp was calculated 
using the following equation:
1
P n rm  =  ----  X-------
m  dt ACo
where (dQ/dt) is the permeability rate, A is the diffusion area of the monolayer and 
Co is the initial concentration of progesterone in the apical compartment (Sadeghi et 
al., 2008).
2.3.4 Solubility of Progesterone and Progesterone loaded HPMCAS 
microparticles
The shake flask method (Baka et al., 2008) was used to determine the solubility of 
progesterone versus progesterone ASDs in simulated fasted and fed intestinal fluids 
(FaSSIF and FeSSIF). Both fluids were prepared according to manufacturer 
guidelines (Biorelevant). To produce 500mL of FeSSIF, 2.02g of NaOH pellets, 
4.325g of glacial acetic acid and 5.937g of NaCl were dissolved in 450mL of 
distilled water. The pH was adjusted to 5 with IN HC1 and the volume was made up 
to 500mL with distilled water. Next 5.600g of SIF Powder Original (Biorelevant) 
was added to 250 mL of this buffer and stirred on a magnetic stirrer until completely 
dissolved. This volume was made up to 500ml with buffer and used within 48hours 
of production. FaSSIF was produced in the similar manner to FeSSIF. To produce 
500mL of FaSSIF, 0.2lOg of NaOH pellets, 1.719 g of NaH2 P 0 4  Anhydrous, and 
3.093g of NaCl were dissolved in 450mL of distilled water. The pH was adjusted to
6.5 with IN HC1 and the volume was made up to 500mL with distilled water. Next, 
1.120g of SIF Powder Original (Biorelevant) was added to 250 mL of this buffer and 
stirred on a magnetic stirrer until completely dissolved. This volume was made up to 
500ml with buffer and allowed to stand at room temperature for 2hours until the 
colour became opalescent. The solution was used within 48 hours of production.
The solubility of progesterone was determined by adding saturated amounts of drug 
to the relevant solution in 3 separate screw-top vials (VWR). The vials were tightly
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closed and placed in a heated shaking block (BamsteadStem RS900) at 37°C and 
300rpm. The solutions were left to shake for 24 hours and lOOpl of supernatant was 
carefully withdrawn at 2 and 24h, filtered through a 0.2um filter (VWR international) 
and analysed by HPLC. Solution without API was taken as a blank.
To calculate solubility, standards containing known amounts of progesterone in 
80:20 methanol: water were used to obtain a linear equation. This equation was used 
to determine the solubility of progesterone in both buffers. Solubility was determined 
as pg/mL based on the average of 3 repeats using the same HPLC method described 
in Section 2.2.3.8 .
2.3.5 Gene and Protein Analysis of Progesterone Targets
The regulation of progesterone target genes and proteins was compared between 
natural progesterone and the progesterone ASD in Ishikawa and HESC cell lines. 
The methods used for this comparison were qRT-PCR, InCell Analysis, Protein 
ELISA and cell image analysis using image j. These methods are described in detail 
in Section 2.1 with the only difference being the preparation of hormone treatments.
To produce stock concentrations of P4  ASD, the encapsulation efficiency was taken 
into account. A stock solution of lmM of P4 ASD was then prepared in DMSO. For 
comparison of unformulated P4 and P4 ASD, fresh stock of P4 was prepared in a final 
concentration of lmM in DMSO as opposed to ethanol which was used in earlier 
studies. Both DMSO and ethanol were shown not to effect gene expression at the 
given concentrations.
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3. Gene and Protein Regulation by Progesterone and Synthetic Progestins 
in the Human Endometrium
3.1 Introduction
Natural progesterone has poor bioavailability limiting its medicinal use. In fact in the 
UK, natural progesterone is only prescribed for luteal support in IVF protocols and is 
delivered vaginally in this circumstance (Kassab et al., 2008). Synthetic progestins 
are man-made versions of progesterone with progestogenic effects similar to that of 
the natural compound but have a vastly improved oral bioavailability. As a result, 
progestins are commonly used in contraception and hormone replacement therapy 
and also used for the treatment of endometrial hyperplasia and cancer. Endometrial 
hyperplasia is a condition characterised by a benign proliferation of endometrial 
glands and can be seen to have simple or complex glandular features with or without 
the presence of nuclear atypia (Montgomery et al., 2004). Synthetic progestins are 
routinely administered for the treatment of this condition and serve to antagonise 
estrogen driven growth, slowing disease progression (Gunderson et al., 2012, Kim et 
al., 2013a). There are two main progestins used to treat endometrial hyperplasia, 
these are medroxyprogesterone acetate (MPA) and levonorgestrel (LNG) (Vereide et 
al., 2006, Zaino et al., 2014, Kim et al., 2013b). MPA is progesterone-derived 
hormone that is given orally at 20mg/day for hyperplasia treatment. LNG on the 
other hand is derived from, and structurally similar to, testosterone. It is used for the 
treatment of endometrial hyperplasia and cancer either alone (Orbo et al., 2014, Pal, 
2012) or in combination with MPA (Kim et al., 2013b, Kim et al., 2012) and is 
typically delivered via an intrauterine device.
However, the use of these progestins is associated with the occurrence of side- 
effects. Minor side-effects are common and include abnormal menstrual bleeding and 
breast tenderness (Cummings and Brizendine, 2002, Berenson and Wiemann, 1993); 
though more serious side-effects have been reported in hyperplasia patients 
(Bafaloukos et al., 1999, Thigpen et al., 1999). Side-effects are most often attributed 
to adverse progestin signalling within the target tissue; the main receptor through 
which progestin signalling occurs is the progesterone receptor (PR), however,
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synthetic progestins may bind and activate other hormone receptor with high affinity 
(Sitruk-Ware and Nath, 2010). Furthermore, the regulation of targets through the PR 
itself may also differ. Alterations in signalling patterns can possibly lead to the 
differential regulation of target genes and their resulting proteins including targets 
that are linked to cancer; indeed increased incidence of breast and endometrial cancer 
have been linked to hormone exposure (Fournier et al., 2005, Stanford et al., 1995, 
Seeger et al., 2003, Kelley et al., 1976, Kaaks et al., 2002). Thus, the aim of this 
chapter is to establish whether progesterone target genes and proteins are adversely 
regulated by MPA and LNG compared to the natural compound.
To help determine this, a number of target genes and proteins were selected and their 
control compared between the progestogens. The expression of four main targets of 
interest will first be assessed in healthy and hyperplastic endometrium in order to see 
if they are adversely regulated in this condition. Following this, target expression 
will be assessed before and after progestin (MPA) therapy to determine whether their 
expression is restored. The targets to be analysed are PR, Forkhead Box O Protein 1 
(FOXOl), Amphiregulin (AREG) and Lactoferrin (LF) which are described in 
Section 1.7.
As natural progesterone is not currently prescribed to patients with endometrial 
hyperplasia it is impossible to compare gene regulation between natural and synthetic 
progestogens in vivo in patients with this condition. However, it is possible to make a 
direct comparison of natural progesterone with MPA and LNG in well-established 
endometrial cell lines. Therefore, gene and protein regulation by progesterone, MPA 
and LNG, will be assessed in two model cell lines representing the endometrial 
epithelium (Ishikawa) and stroma (HESC).
These cell lines will be treated with natural progesterone, MPA and LNG in order to 
determine how each progestogen regulates specifically selected target genes and 
proteins (listed in Table 3.1). As the available cell lines are not hyperplastic in origin, 
to make a direct comparison of protein regulation between the cell lines and the 
patient biopsies may be misleading. Nonetheless, if the regulation of the targets by 
MPA in the cell lines is in line with that seen in vivo it may be a good indication that
107
Chapter 3 Gene and Protein Regulation by Progesterone and Synthetic Progestins in the
Hum an Endom etrium
any differential gene alteration by natural progesterone seen in the cell lines may also 
occur in patients.
As well as directly regulating target genes, progesterone also works in synergy with 
the second messenger cyclic AMP. Cyclic AMP and progesterone are involved in the 
regulation of genes associated with a phenotypic change in the endometrial stroma 
known as decidualisation (Gellersen and Brosens, 2003) (Section 1.2.4). Therefore, 
in addition to assessing progestogen target regulation, the role of natural and 
synthetic progesterone in stromal decidualisation will also be compared.
Furthermore, as endometrial hyperplasia is most often caused by an excess of 
estrogen, particularly estradiol (Ziel and Finkle, 1975, MacDonald et al., 1976), and 
many progestin therapies are administered in combination with synthetic estradiol 
(Bono et al., 2014), progesterone and progestin signalling will also be studied in the 
presence of this hormone.
For the purpose of this study, target regulation by the progestogens will be assessed 
in the epithelial carcinoma cell line, Ishikawa, in the presence or absence of estradiol 
and in the stromal cell line, HESC, in the presence or absence of cyclic AMP. The 
specific target genes and proteins to be analysed are listed in Table 3.1 along with a 
summary of their regulation through relevant hormone receptors.
A direct comparison of the effects of MPA, LNG and progesterone on a specific 
subset of progesterone-sensitive genes and proteins has yet to be carried out in 
human endometrial cells making much of this work novel.
In sum, the main aim of this chapter is to determine if synthetic progestins 
differentially regulate a number of specifically selected target genes compared to the 
natural compound. This will be determined in vivo endometrial hyperplasia patients 
and in vivo in endometrial cell lines.
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Target
Location within 
the
Endometrium
Regulation through Ligand-bound Receptors
PR ER AR
FOXOl
Epithelium and 
Strom a
1s (Ward, 
Hoekstra e t al. 
2008)
'T' (Schuur, Loktev 
e t al. 2001)
4, (Huang, 
M uddim an e t al.
2004)
PR
Epithelium and 
S trom a
vf (Mote, 
Balleine et al. 
1999)
1s (Aronica 
and
Katzenellenbogen
1991)
Unknown
AREG Epithelium
1s (Mulac- 
Jericevic, Mullinax 
e t al. 2000)
1s (Gielen, 
H a n e k am p e ta l .  
2006)
'T' (Sehgal, Bailev 
e ta l .  1994)
GREB1
Epithelium and 
S trom a
Unknown
T* (Pellegrini, 
Gori e t  al. 2012)
1s (Rae, Johnson 
et al. 2006)
LF
Epithelium and 
S trom a
vf (Kurita, Lee et 
al. 2000)
1s (Kelver, Kaul 
et al. 1996)
- (Yu and Chen 
1993)
PRL Strom a
/h* (Brosens, 
Havashi e t  al. 
1999)
'h (DeVito, 
Avakian e t al. 
1992)
- (Nevalainen, 
Valve e t al. 1997)
IGF1 Unnknown
(Ace and 
Okulicz 1995)
(Ace and 
Okulicz 1995)
'T (Weihua, 
E km ane ta l .  
2002)
Table 3.1: Regulation of target genes through ligand bound PR, ER and AR. 
t  indicates upregulation, j  indicates downregulation, - indicates no change.
*Weakly induced but enhances cAMP-induction
3.2 M ateria ls and  M ethods
M ateria ls  and  m eth o d s used  w ith in  th is ch ap te r are d esc ribed  in detail in Section  2.1. 
B riefly , IH C  w as used  for p ro te in  d e tec tio n  in slides p roduced  from  patien t b iopsies. 
W estern  B lot and P C R  w ere used to  assess the basal p ro te in  and gene levels o f  PR , 
A R  and ER  w ith in  the Ish ikaw a and  H E S C  cell lines. PC R  w as also used to 
determ in e  reg u la tio n  o f  PR, A R E G , F O X O l, LF, and IGF1 by p ro g este ro n e  and the 
syn thetic  p ro g estin s  in the Ish ikaw a cell line. PC R  w as fu rther used  to assess the
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regulation of PR, FOXOl, LF, GREB1 and PRL in the HESC cell line. All primers 
used in these reactions are detailed in Table 2.6. Furthermore, InCELL analysis was 
used to determine regulation of target proteins by progesterone and the progestins in 
both cell lines. Antibodies used for InCELL analysis can be seen in Table 2.7. 
Images of HESC cells were obtained using a light microscope and cell roundness 
was determined using imageJ to establish the extent of cellular decidualisation. 
Decidualisation was further confirmed by the detection of secreted prolactin using 
ELISA.
3.3 Results and Discussion
3.3.1 Expression of Progestogen-Regulated Proteins in Endometrial Biopsies of 
the Healthy and Hyperplastic Endometrium.
In order to determine differences in protein regulation by natural and synthetic 
progestins in endometrial hyperplasia, a number of proteins (PR, FOXOl, AREG 
and LF) were selected. These were chosen due to their potential adverse expression 
in this disease in order to see if their expression was restored after synthetic progestin 
treatment in an equivalent manner to natural progesterone. Thus, during the first 
section of this chapter, the expression of the chosen targets was determined in the 
normal human endometrium (control) and hyperplastic endometrium without atypia 
(H) and with atypia (HA). Moreover, there is currently no single gene or protein 
marker available to assess the presence or stage of this condition. Therefore, these 
targets will also be assessed as potential biomarkers for this condition.
To determine protein level, immunohistochemistry (IHC) was used and the intensity 
and distribution of staining was calculated using H-score (min 0, max 4) (Section 
2 . 1 .1).
3.3.1.1 Differential Expression of PR in Endometrium of Women with 
Hyperplasia Comparing to Controls
The first protein to be investigated was PR. The presence of PR is essential if 
progesterone regulated targets are to be analysed; the hormonal milieu of the 
endometrium and its potential response to the action of progestins is represented by
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PR concentration. Therefore, the expression of PR was determined in glands and 
stroma of hyperplastic endometrial samples with and without atypia, and controls. 
The intensity and distribution of staining was calculated using H-score (min 0, max 
4) (Section 2.1.1) and the total score was compared between the groups (Figure 3.1).
PR expression in the glands at nuclear and cytosol level was significantly different 
between study and control groups. At nuclear level, there was a higher concentration 
of PR in the H (p<0.05) and HA (p<0.05) groups compared to controls. A similar 
pattern was also observed at cytosol level, again with higher expression of PR in the 
H (p=0.001) and HA (p>0.01) groups compared to controls (Figure 3.1). 
Contradictory to this study, PR has been shown to decrease from control to 
hyperplasia to atypical hyperplasia in glandular nucleus (Pieczynska et al., 2011). 
Yet the presence of PR in patients with hyperplasia is well documented in both 
nucleus and cytoplasm (Vereide et al., 2006, Ehrlich et al., 1981, Wildemeersch et 
al., 2007, Bozdogan et al., 2002). However, estrogen is a known inducer of PR (Hata 
1992 and Jamil 1991) and hyperplasia patients are known to have an increase serum 
estradiol levels (Baskin et al., 2002, Mutter et al., 2007) so it is not wholly surprising 
that such an induction in PR was observed. A study by Nunobiki et al also reported 
high levels of PR in patients with simple hyperplasia, though his findings showed a 
stepwise decrease with disease progression (Nunobiki et al., 2003).
In the stroma, the expression of PR was significantly lower in the HA group 
comparing to control at nuclear (p=0.04) and cytosol level (p=0.02). However, there 
was no significant difference in PR expression between the H group and control 
(Figure 3.1). A reduction in cytosolic and nuclear PR in the HA group compared to 
the H group was also apparent but not statistically significant. The overall reduction 
of PR in HA group compared to both H and control is in line with the literature. 
Research carried out by Snijders et al (1992) described a loss of stromal PR 
expression in atypical hyperplasia compared to hyperplasia without atypia (Snijders 
et al., 1992) and a loss in stromal PR expression has been well correlated with 
endometrial hyperplasia disease progression (Ehrlich et al., 1981, Bozdogan et al.,
2002). The presence of stromal PR is important in women who go on to receive 
progestin therapy, as progesterone-induced paracrine signaling can affect
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endom etria l ep ith e liu m  m ean ing  loss o f  PR in th is tissue can affect su rround ing  
endom etria l co m p artm en ts (K u rita  et al., 2000).
A lth o u g h  changes in PR  level w ere seen  w ith  d isease  p resence , these w ere not in  line 
w ith  p rev ious find ings, m ak ing  PR  a p o o r m arker fo r the p resence  and p ro g ressio n  o f  
endom etria l h yperp lasia . H ow ever, the h igh  level o f  PR expression  in  these tissu es  
su ggests  that p rog este ro n e  th e rap y  w ould  be a su itab le  trea tm en t op tion  fo r these  
p a tien ts , and g iven  the adverse  reg u la tio n  seen  w ith  the syn thetic  p rogestin s, a 
natu ra l p rog este ro n e  trea tm en t m ay be a b e tte r op tion  fo r these  patien ts.
Endometrial expression of PR
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Figure 3.1: Expression of PR in endometrial samples from normal human 
endometrium (Control), hyperplasia without atypia (H) and hyperplasia with 
atypia (HA). Staining was assessed in the nuclear (Nuc) and cytosolic 
compartments (Cyt) using the H-score system with 3 independent scorers. 
Statistical analysis was performed using a Mann Whitney test. *p^0.05, 
**p<;0.01. Corresponding IHC images can be seen in Appendix D. (n=20)
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3.3.1.2 Differential Expression of FOXOl in Endometrium of Women with 
Hyperplasia Comparing to Controls
FOXOl is a transcription factor involved in cell cycle regulation and differentiation 
in the endometrium (Takano et al., 2007) and is known to be up-regulated by ligand 
bound PR (Ward et al., 2008, Labied et al., 2006). At present there is no available 
data on the level of FOXOl in patients with endometrial hyperplasia. As FOXOl is 
widely reported to be down-regulated in endometrial cancer (Goto et al., 2008, Myatt 
et al., 2010, Lam et al., 2012), it was of interest to see if the levels of this protein 
were affected in endometrial hyperplasia, particularly in cells with atypia as these are 
often cancer precursors. The expression of FOXOl in the control and study groups 
was assessed at glandular and stromal levels in the nucleus and cytosol of 
endometrial cells (Figure 3.2).
Expression of FOXOl in endometrial glands at nuclear and cytosol level was 
significantly different between study and control groups. A lower nuclear expression 
of FOXOl was observed in the HA (p>0.001) and H (p>0.001) groups compared to 
controls. At cytosol level a similar pattern was observed, with lower expression of 
FOXOl in the HA (p=0.003) and H (p=0.02) groups compared to controls (Figure
3.2).
In the stroma, the expression of FOXOl was significantly lower in the HA group 
comparing to control at nuclear (p<0.01) and cytosol level (p<0.05). However no 
significant differences in FOXOl expression were observed in the stroma between 
the H group and control or between the H and HA groups (Figure 3.2).
Although no previous research has been published on the levels of FOXOl in 
endometrial hyperplasia, a loss of FOXOl has been reported in endometrial cancer in 
several studies (Goto et al., 2008, Myatt et al., 2010, Lam et al., 2012). FOXOl is 
involved in cell fate decisions and acts as a tumor suppressor (Greer and Brunet, 
2005), so it is not surprising that FOXOl is lost in HA patients where cells are 
abnormal and at a higher risk of developing into a cancerous tumor. There does 
appear to be an increasing reduction in FOXOl protein expression in endometrial 
glands as disease progresses with a marked reduction in FOXOl in both glands and
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strom a from  the h y p erp la sia  w ith a typ ia  group. T h ese  data th ere fo re  suggests that 
loss o f  g lan d u lar F O X O l m ay  be ind icative  o f  h y p erp la sia  p resence  w hereas loss o f 
bo th  g lad u lar and  strom al F O X O l m ay  be ind icative  o f  atypical hyperp lasia  
suggesting  F O X O l cou ld  be a po ten tial b io log ical m ark er fo r both p resence and 
p rog ression  o f  th is d isease .
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Figure 3.2: Expression of FOXOl in endometrial samples from normal human 
endometrium (Control), hyperplasia without atypia (H) and hyperplasia with 
atypia (HA). Staining was assessed in the nuclear (Nuc) and cytosolic 
compartments (Cyt) using the H-score system with 3 independent scorers. 
Statistical analysis was performed using a Mann Whitney test. *p^0.05, 
**p^0.01. Corresponding IHC images can be seen in Appendix E. (n=20)
3.3.1.3 Differential Expression of AREG in Endometrium of Women with 
Hyperplasia Comparing to Controls
A R E G  is a gene reg u la ted  by lig an d -b o u n d  PR and is ex p ressed  at vary ing  levels in 
the en d o m etriu m  th ro u g h o u t the m enstrua l cyc le  (G ui et al., 2008a). A n assessm en t
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of the endometrial expression of AREG in the control and hyperplasia study groups 
was performed to investigate the expression of this PR target as a potential marker 
for endometrial hyperplasia presence and stage (Figure 3.3). In both glands and 
stroma there was a significant decrease in nuclear expression of the AREG protein in 
both study groups compared to control (Figure 3.3). This decrease was not paralleled 
in cytosol with the exception of the HA stroma where cytosolic AREG was 
significantly reduced compared to control (P<0.05).
The AREG protein is known to interact with epithelial growth factor (EGF) and 
transforming growth factor alpha (TGFa) receptors to promote proliferation of 
normal epithelial cells (Plowman et al., 1990) and has been shown to be up-regulated 
in endometrial cancer cells (Ejskjaer et al., 2007). It is thus surprising that such a 
significant reduction was observed. However, a high degree of functional 
redundancy compensation within the family of EGF receptor (EGFR) ligands has 
been reported (Schneider and Wolf, 2009) meaning it is possible that high levels of 
other EGFR ligands such as EGF and TGFa may be compensating for a loss of 
AREG. Indeed Nikura et al documented the presence of TGFa in hyperplasia 
patients, with highest levels in atypical hyperplasia (Niikura et al., 1996). 
Interestingly, in the same study, AREG was reported to be completely absent in all 
endometrial samples, including healthy, hyperplastic and cancerous endometrium 
(Niikura et al., 1996). Furthermore, endometrial hyperplasia is associated with 
reduced progesterone signaling (Herrinton and Weiss, 1993) and progesterone 
withdrawal is known to impact on many genes (Catalano et al., 2007, Critchley et al.,
2003), therefore the loss of AREG may be a direct result of progesterone absence. 
Though the ability of estrogen to up-regulate this protein raises further questions into 
why a reduction was witnessed.
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Figure 3.3: Expression of Amphiregulin in endometrial samples from normal 
human endometrium (Control), hyperplasia without atypia (H) and hyperplasia 
with atypia (HA). Staining was assessed in the nuclear (Nuc) and cytosolic 
compartments (Cyt) using the H-score system with 3 independent scorers. 
Statistical analysis was performed using a Mann Whitney test. *p^0.05, 
**p^0.01. Corresponding IHC images can be seen in Appendix F. (n=20)
3.3.1.4 Differential Expression of Lactoferrin in Endometrium of Women with 
Hyperplasia Comparing to Controls
LF is a m ajo r estro g en -in d u c ib le  sec re to ry  p ro tein  w ith  an eleva tion  in its ex p ressio n  
co rre la tin g  d irec tly  w ith a peak in p ro life ra tio n  o f  endom etria l ep ith e lia  (K e lv er et 
al., 1996). T he  co rre la tio n  betw een  L F  and  endom etria l p ro life ra tion  p ro m p ted  us to 
investigate  its ex p ressio n  in h y p erp la sia  g iven  the p ro life ra tive  n a tu re  o f  th is 
cond ition . LF ex p ressio n  in the en d o m etria l g lands at nu clea r and cy to so l level w as 
s ig n ifican tly  d iffe ren t betw een  stu d y  and con tro l groups. A t n u c lea r level, a
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sig n ifican tly  lo w er ex p ressio n  o f  L F  w as ob serv ed  in the en d o m etriu m  o f  H A  
(p< 0 .05 ) and  H (p = 0 .0 1 ) patien ts co m p ared  to  con tro ls . T he dow n reg u la tio n  w as 
su rp ris in g  as en h an ced  estrogen  s ignaling  is asso c ia ted  w ith  the h y p erp la s tic  
en d o m etriu m . D esp ite  b e ing  sign ifican t, the dow n  reg u la tio n  w as m in im al and not 
seen  in o th er loca tions. A t cy toso lic  level the ex p ressio n  o f  L F  in the  H A  and  H 
groups w as no t s ta tis tica lly  d iffe ren t in the g lands w hen  co m p ared  to co n tro ls  (F igu re  
3 .4). In the  strom a, the L F  ex p ressio n  w as not s ta tis tica lly  s ig n ifican tly  d iffe ren t 
be tw een  the study  g ro u p s and con tro l in e ither the n u clea r o r the  cy to so lic  
co m p artm en ts . T h ere  w as also  no statistica l d iffe ren ce  in L F  ex p ressio n  w h ilst 
co m p arin g  study  g roups in both  ep ith e lia  and strom a (F igu re  3 .8). A k in  to th is 
find ing , W a lm er e t a l (1 9 9 5 ) rep o rted  no a lte ra tion  in LF ex p ressio n  in w o m en  w ith  
en d o m etria l h y p e rp la s ia  although  th e  au thors h ig h lig h ted  one excep tion  w here  a 
patien t w ith  a typ ica l h y p erp la s ia  p resen ted  w ith e leva ted  L F  (W alm er et al., 1995).
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Figure 3.4. Expression of Lactoferrin in endometrial samples from normal 
human endometrium (Control), hyperplasia without atypia (H) and hyperplasia 
with atypia (HA). Staining was assessed in the nuclear (Nuc) and cytosolic
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compartments (Cyt) using the H-score system with 3 independent scorers. 
Statistical analysis was performed using a Mann Whitney test. *p<!0.05, 
**p^0.01. Corresponding IHC images can be seen in Appendix G. (n=20)
3.3.1.5 Summary of Section 3.3.1
The overall findings of this section can be summarised into three main points. 1. The 
data obtained confirmed that the target proteins are adversely expressed in 
endometrial hyperplasia suggesting they are clinically relevant proteins. 2. That PR is 
present at high levels in endometrial hyperplasia suggesting this condition is 
susceptible to progestin treatment. 3. PR, FOXOl, AREG and LF could be used as 
potential biomarkers of endometrial hyperplasia since their expression is altered 
compared to healthy patients. Therefore these targets are good candidates for 
investigation of progestins regulation through PR activity in vivo.
3.3.2 Expression of Progestogen-Regulated Proteins in Hyperplastic 
Endometrial Biopsies Pre and Post MPA treatment
Having determined the adverse expression of PR, FOXOl, AREG and LF in 
endometrial hyperplasia, it was next interesting to see if their expression was restored 
with progestin therapy. Therefore, the levels of these proteins were determined pre 
and post MPA treatment. The patients recruited for this part of the study were 
diagnosed with hyperplasia without nuclear atypia. Patients with atypical hyperplasia 
did not receive progestin therapy as they underwent hysterectomy for the 
management of their pathological condition.
3.3.2.1 The Expression of FOXOl in Women with Hyperplasia Pre and Post 
Treatment with MPA in Vivo
As detailed in Chapter 1 (Section 1.7.2), in vitro treatment models have revealed that 
progestins directly induce FOXOl via transcriptional activation to inhibit the growth 
of cancer and pre-cancerous endometrial epithelial cells (Ward et al., 2008, Labied et 
al., 2006), demonstrating FOXOl as a target of MPA treatment. The pre and post 
MPA treatment samples from patients with hyperplasia without atypia were
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investigated  for the exp ression  o f  th is tran sc rip tio n  fac to r and the resu lts  can be seen 
in F igure  3.5.
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Figure 3.5. Expression of FOXOl in endometrium of patients with hyperplasia 
without atypia before and after treatment with MPA (20mg/day) for 3 months. 
Staining was assessed in the nuclear and cytosolic compartments using the 11- 
score system with 3 independent scorers. Statistical analysis was performed 
using a Mann Whitney test. *p^0.05, **p^0.01. Corresponding IHC images can 
be seen in Appendix H. (n=18)
A n increased  expression  o f  F O X O l w as observ ed  afte r p rogestin  trea tm en t in the 
nu cleu s o f  g landu lar ce lls (p= 0 .001) and in the cy to p lasm  o f  strom al ce lls (p> 0 .05). 
M P A  trea tm en t failed  to sig n ifican tly  m od u la te  F O X O l expression  in the cy toso l o f  
the g lands o r in the nucleus o f  strom al ce lls a lthough  the  overall trend  ind icated  a rise  
in F O X O l p ro te in  post M P A  trea tm en t (F igu re  3 .5). T h is  study  has p rev io u sly  
show n that F O X O l is d o w n -reg u la ted  in endom etria l hyperp lasia  patien ts  (F igu re
3.2). H ow ever, M PA  trea tm en t ap p ears to have  resto red  the exp ression  o f  th is 
p ro tein . T his in fo rm ation  is in line w ith  p rev ious find ings that F O X O l is a p rogestin  
targe t in vivo  and suggests that M P A  causes an induction  o f this p ro tein ; it also  
ind icates that these  patien ts have re sp o n d ed  to  p rogestin  trea tm ent. H ow ever, it
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remains unknown whether the changes seen in FOXOl would be the same had 
natural progesterone been administered instead of MPA.
3.3.2.2 The Expression of PR in Women with Hyperplasia Pre and Post 
Treatment with MPA in Vivo
Samples from 18 patients in the hyperplasia without atypia group were investigated 
for the expression of PR before and after treatment with MPA 20 mg/day for 3 
months. PR has been previously reported to be down-regulated after progestin 
treatment due to a negative feedback loop (Graham and Clarke, 1997b). In line with 
the literature, progestin treatment induced a significant decrease in PR expression in 
the nucleus (p>0.05) and cytosol (p>0.05) of endometrial glandular and stromal cells 
post treatment (Figure 3.6). A study by Vereide et al (2006) revealed a significant 
down-regulation of PR in endometrial cells after progestin therapy. The group 
reported a reduction in PR after treatment with two progestins, LNG and MPA with a 
pronounced reduction in the LNG group and a more reserved reduction in the MPA 
group (Vereide et al., 2006). The extent of PR down-regulation post MPA treatment 
was similar between the previously published research and the data obtained within 
this study.
In contrast to epithelial cells, no significant changes were observed in stromal 
expression of PR in the nucleus or the cytosol between pre and post treatment groups 
(Figure 3.6). The maintenance of PR in endometrial stromal cells is not surprising as 
stroma retains PR in the progesterone-dominated phase of the menstural cycle 
suggesting this tissue is less sensitive to inhibitory effects of progesterone (Mote et 
al., 1999). Although there were no significant changes in stromal PR levels post­
treatment, the mean PR H-score tended to be reduced in these samples, a similar 
trend was also reported by Vereide and co-workers whereby there was an overall 
decrease in stromal PR following MPA treatment (Vereide et al., 2006). The 
observed reduction in PR is likely to influence the long-term efficacy of the progestin 
treatment as a loss of receptor negates the actions of the progestins.
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Figure 3.6: Expression of PR in endometrium of patients with hyperplasia 
without atypia before and after treatment with MPA (20mg/day) for 3 months. 
Staining was assessed in the nuclear and cytosolic compartments using the H- 
score system with 3 independent scorers. Statistical analysis was performed 
using a Mann Whitney test. *p^0.05, **p^0.01. Corresponding IHC images can 
be seen in Appendix I. (n=18)
O verall, in vivo, M P A  serv es  to  d o w n -reg u la te  the PR  in endom etria l ep ith e liu m  but 
does no t a lte r PR ex p ress io n  in S trom a.
3.3.2.3 The Expression of AREG in Women with Hyperplasia Pre and Post 
Treatment with MPA in Vivo
T he pre and  post M P A  trea tm en t sam ples from  h y p erp la sia  w ithou t a ty p ia  patien ts  
w ere in v estig a ted  fo r the  ex p ressio n  o f  A R E G  (F igure 3 .7). P rev ious research  has 
show n that M P A  is ab le  to  u p reg u la te  A R E G  (S m id -K o o p m an  et al., 2003), and that 
p ro g estin -in d u ced  u p -reg u la tio n  occurs th rough  ligand bound  P R -A  (D as et al., 1995, 
M u lac-Je ricev ic  et al., 2000). Indeed  a s ign ifican tly  h ig h er ex p ressio n  o f A R E G  
(p=0 .02 ) w as o b serv ed  in the  s trom a at n uclea r level afte r trea tm en t w ith this 
p rogestin . H o w ev er, in  the g lan d u la r ce lls  at n uclear and cy toso l levels as w ell as in 
the strom al ce lls  at cy toso l levels th e  exp ression  o f  A R E G  w as not sign ifican tly
(. ompaiison of PR Endoinetiial Expression 
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d iffe ren t befo re  and  afte r M PA  trea tm en t (F igure  3.7). W h eth er natu ra l p ro g es te ro n e  
w ould  evoke an eq u iv a len t resp o n se  rem ains to  be determ ined .
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Figure 3.7. Expression of AREG in endometrium of patients with hyperplasia 
without atypia before and after treatment with MPA (20mg/day) for 3 months. 
Staining was assessed in the nuclear and cytosolic compartments using the H- 
score system with 3 independent scorers. Statistical analysis was performed 
using a Mann Whitney test. *p<;0.05, **p^0.01. Corresponding IHC images can 
be seen in Appendix J. (n=18)
3.3.2.4 The Expression of LF in Women with Hyperplasia Pre and Post 
Treatment with MPA in Vivo
L F is know n  to be inh ib ited  th rough  ligand-bound  PRB in ep ithelia l and  strom al 
cells. P re and  p o st M PA  trea tm en t sam ples from  h y p erp la sia  p a tien ts  w ere  
investigated  fo r the  ex p ressio n  o f  L F  (F igu re  3.8). A sta tis tica lly  sig n ifican tly  h ig h er 
ex p ressio n  o f  L F  w as o bserved  in the g lands at n u clea r (p= 0 .04 ) and  cy toso l 
(p= 0 .04 ) level a fte r trea tm en t w ith  p rogestin . T he up -reg u la tio n  o f  LF a fte r M PA  
trea tm en t w as unexpected . Im m un o h isto ch em ica l ana lysis o f LF in hea lth y  p rim ate  
en d o m etriu m  su ggests  L F  is d o w n -reg u la ted  by  p rogestin  in vivo  (T eng  et al., 2002).
122
Chapter 3 Gene and Protein Regulation by Progesterone and Synthetic Progestins in the
Human Endometrium
Y et in the case  o f  h y p erp la stic  en d o m etria l g lands; th ere  w as a s ig n ifican t increase  
w h ich  m ay  suggest adverse  gene reg u la tio n  by M P A  that d iffers from  the natu ra l 
d rug. O n the o th e r hand , in the strom al cells at n u c lea r and cy toso l level, the 
en d o m etria l ex p ressio n  o f  L F  did not change s ign ifican tly  afte r M P A  trea tm en t 
(F ig u re  3.8).
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Figure 3.8: Expression of LF in endometrium of patients with hyperplasia 
without atypia before and after treatment with MPA (20mg/day) for 3 months. 
Staining was assessed in the nuclear and cytosolic compartments using the H- 
score system with 3 independent scorers. Statistical analysis was performed 
using a Mann Whitney test. *p<0.05, **p^0.01. Corresponding IHC images can 
be seen in Appendix K. (n=18)
3.3.2.5 Summary of Section 3.3.2
T he data  p resen ted  w ith in  this sec tion  show s the reg u la tio n  o f F O X O l, PR , A R E G  
and L F  by  M P A  in vivo. It w as n o t po ssib le  to determ in e  the reg u la tio n  o f  these  
p ro te ins by  L N G  as b iopsies w ere  not ava ilab le  from  w om en rece iv in g  th is 
trea tm en t. It w as also  not possib le  to assess the reg u la tio n  o f  these p ro te in s  by  
p ro g este ro n e  as th is natu ral p roduct is not p rescribed  to w om en for the trea tm en t o f
123
Chapter 3 Gene and Protein Regulation by Progesterone and Synthetic Progestins in the
Human Endometrium
h y p erp la sia . T o  sum m arise  the find ings ob ta in ed  w ith in  th is section , a tab le  w as 
p ro d u ced  show ing  the reg u la tio n  o f the fou r p ro te ins b y  M PA  (T ab le  3.2).
Protein Glands StromaNuc Cyt Nuc Cyt
FOXOl T - - T
PR i 1 - -
AREG - T -
LF T t - -
Tables 3.2: Changes in the expression of target proteins after MPA treatment in 
vivo. Green indicates an increase in protein expression, blue indicates a decrease 
and pink indicates no change.
3.3.3 PR, ER and AR are expressed in human endometrial epithelial and 
stromal cell lines
A s it w as not p o ssib le  to com pare  the reg u la tio n  o f  targe ts by  natu ra l and syn thetic  
p ro g estin s  in vivo, w ork  to  assess d iffe ren ces  in gene reg u la tio n  by natu ra l and 
syn thetic  p ro g estin s w as assessed  in vitro  in tw o endom etria l cell lines; Ish ikaw a 
ce lls and  H um an  E ndom etria l S trom al C ells (H E S C s). Ish ikaw a ce lls w ere used  as a 
m odel cell line fo r h u m an  endom etria l ep ith e liu m  and H E S C s w ere  used  as a m odel 
strom al cell line.
In  o rd e r to  assess the ac tions o f  P4 M P A  and L N G  in these cell lines, it w as first 
im portan t to es tab lish  w h e th er the cell lines ex p ressed  the m ain  recep to r th rough  
w hich  these  h o rm o n es signal; the p ro g este ro n e  recep to r (PR ). A s estrogen  w as used 
in co m b in a tio n  w ith  the p rogestin s to trea t Ish ikaw a cells it w as also im portan t to 
assess the p resence  o f  the estrogen  recep to r (E R ) in this cell line. F urther to this, 
s id e-e ffec ts  assoc ia ted  w ith syn thetic  p ro g estin  are o ften  attribu ted  to  their ab ility  to 
b ind to and signal v ia  the androgen  recep to r (A R ) (B en tel et al., 1999, K loosterboer 
et al., 1988. B urton  et al., 2003, P h illip s et al., 1990). T herefo re , the p resence o f  AR 
w as also  quan tified  in both  cell lines.
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The human endometrium naturally expresses PR, ER and AR and these levels have 
been shown to fluctuate throughout the menstrual cycle (Ingamells et al., 1996, 
Lessey et al., 1988, Mertens et al., 2001). Furthermore, different isoforms of these 
receptors are also expressed at precise ratios. The PR has two main isoforms, PR-A 
and PR-B. PR-B is the larger of the two isoforms with a molecular weight of 
116kDa, PR-A contains the same amino acid structure as PR-B but is truncated at the 
N-termins resulting in a smaller protein with a molecular weight of 99kDa 
(Giangrande and McDonnell, 1998). Both isoforms are seen at different ratios 
throughout the menstrual cycle with both appearing at similar levels in proliferative 
phase and PR-A appearing to be the most dominant in the secretory phase (Mangal et 
al., 1997, Mote et al., 1999).
There are also two dominant ER isoforms, ERa and ERp, which have again been 
shown to be regulated at an intricate balance throughout the monthly cycle (Mylonas 
et al., 2004, Lecce et al., 2001). The smaller ER isoform, ERp, has a molecular 
weight of 52-54kDa and ERa has a molecular weight of 6 6 kDa, splice variants of 
both isoforms also exist (Wang et al., 2005, Peng et al., 2003).
The molecular weight of the full length AR-B is llOkDa. The AR-A isoform has a 
truncated N-terminus leading to its lower molecular weight of 87kDa (Lubahn et al., 
1988).
The basal expression of PR, ER and AR RNA was quantified within the Ishikawa 
and HESC cell lines through RT-PCR. The whole PR-A RNA sequence lies within 
the coding region of the longer PR-B isoform and the primers used for this analysis 
lay within the coding region of PR-A thus causing both isoforms to be amplified 
during the single PCR reaction. The same scenario occurs for AR, whereby the 
primers used amplify both isoforms of the protein. Thus, the normalised starting 
quantity of PR and AR seen in Figure 3.9 is the total RNA inclusive of all isoforms. 
Separate sets of primers were used to analyse ERa and p. The results indicate the 
presence of the hormone receptors at RNA level, though only very low levels of ER 
were detected in HESCs.
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Receptor Receptor
Figure 3.9: mRNA expression levels of nuclear receptors in the Ishikawa (A) 
and HESC (B) cell lines.
RNA was extracted was extracted from Ishikawa and HESC cells using the 
Quiagen RNeasy kit, the RNA was then converted to cDNA, and amplified using 
PCR. The average starting quantity of the target mRNA was calculated by 
obtaining the cycle number at which the gene was first amplified and plotting 
this number within a standard curve. The results were normalised against 
reference gene GAPDH. E rror bars represent standard deviation from the 
mean of 3 repeats.
T o assess w hether the R N A  detec ted  fo r the ho rm o n e recep to r is transla ted  in to  
pro te in , the levels o f  PR , ER  and A R  pro te in  in the Ish ikaw a and H E SC  cell lines 
w as determ ined  by  im m u n o b lo t analysis. D ue to the d iffe ren t m o lecu lar w eigh t o f  
the ind iv idual iso fo rm s found  w ith in  PR , A R  and ER, they could  be v isu a lised  
sep ara te ly  on the im m u n o b lo t m em brane.
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Figure 3.10: Protein immunoblot images showing PR-A and B (A), ERa (B), 
ERp (C) and AR-A and B (D) protein expression in Ishikawa and HESC cell 
lines. Graphs show quantified band density of receptor levels in the Ishikawa 
(E) and HESC (F) cell lines.
Ishikawa and HESC cells were grown to confluencey in triplicate in a 6-well 
plate. Cells were scraped in extraction buffer (Section 2.1.3) for protein 
extraction. Immunoblots were separated by SDS-PAGE then immunoblotted
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against GAPDH (sc-25778, Santa Cruz) PR (H10: sc-7208, Santa Cruz), ERa 
(HC-20 sc-542 Santa Cruz), ERp (PA1-311 Pierce Ltd) and AR (N-20, Santa 
Cruz) antibodies.
Band density was determined using Quantity One software (Bio-Rad). The 
Band Density of GAPDH samples were also quantified and used to normalise 
the data. Band density of PR-A, PR-B, ERa, ERp, AR-A and AR-B are shown.
Protein blot analysis of receptor expression in the Ishikawa cell line revealed that 
these cells express each of the protein receptors analysed at varying levels with AR- 
B being the most highly expressed (Figure 3.10 E). The expression of AR has been 
previously shown in the Ishikawa ceil line (Lovely et al., 2000) and this was 
confirmed in this study with the expression of AR-B being far higher than AR-A.
The expression of PR in Ishikawa cells has also been confirmed in previous work 
(Hata and Kuramoto, 1992). This study revealed that the level of PR-B expression is 
greater than the levels of PR-A, although the levels of PR-A were lower, protein was 
still detectable (Figure 3.10 A and E). ERa and ERp were also detected in the 
Ishikawa cell line which is in line with previous findings (Nishida et al., 1985).
In the HESC cell line the expression of AR-A was greater than AR-B but both were 
expressed at high levels (Figure 3.10 D and F). Both PR-A and B were also 
detectable in this cell line with the expression of PR-B being greater than PR-A 
(Figure 3.10 A and F). However, ER expression was very poor. The ERP could be 
detected at low levels but no ERa could be detected at all (Figure 3.10 B, C and F).
The expression of the relevant hormone receptors in the Ishikawa cell line suggests 
their sensitivity to gene alterations after hormone exposure. The absence of ERa and 
low expression of ERp in the HESC cell line should not influence the results as the 
combined estrogen treatment will not be applied to these cells. However, the high 
expression of PR and AR protein subtypes will allow differences in signalling 
patterns to be seen.
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3.3.4 MPA, LNG and P4  differentially regulate target gene expression in 
endometrial epithelial cells.
Given the expression of PR and ER has been determined in the Ishikawa cell line, 
these cells were used as a model for the human endometrium. Confluent cell 
monolayers were cultured in the presence of P4 , MPA or LNG either alone or in 
combination with E2 in order to compare their target regulation. Thereafter, PR 
signalling pathways were assessed through the PR targets described in Table 3.1.
For this investigation, cells were treated with lpM  of progestogen for 48 hours. The 
treatment time of 48 hours was chosen as FOXOl, the positive control for this study, 
is known to be affected by progestin treatment at this time-point in both endometrial 
epithelial and stromal cells (Kyo et al., 2011, Labied et al., 2006, Zoumpoulidou et 
al., 2004). Likewise, lpM  of progestin has been shown to be a sufficient 
concentration to obtain a progestogenic response in the endometrium in vitro (Labied 
et al., 2006, Zoumpoulidou et al., 2004, Smid-Koopman et al., 2003)
3.3.4.1 FOXOl is significantly up-regulated by MPA, P4  and LNG in the 
Ishikawa cell line.
The first target to be analysed was FOXOL FOXOl was utilised as a positive control 
for the action of P4 , MPA and LNG in Ishikawa cells. Indeed progesterone-induced 
FOXOl up-regulation has been well characterised, and is shown to occur specifically 
through the PRB (Kyo et al., 2011, Wang et al., 2009, Ward et al., 2008). 
Furthermore, this up-regulation has been demonstrated in the Ishikawa cell line after 
progesterone and progestin treatment (Kyo et al., 2011, Ward et al., 2008), thus 
making FOXOl an ideal target for confirming the sensitivity of the current cell line 
to progestin treatment.
Moreover, a direct comparison between the regulation of FOXOl by MPA, LNG and 
P4 has yet to be made. Therefore, as well as using FOXOl as a positive control, the 
differences in regulation of FOXOl between the progestogens will also be assessed.
Figure 3.11 B shows that MPA, P4 and LNG each significantly up-regulated FOXOl 
gene expression in the Ishikawa cell line compared to untreated control. P4
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significantly up-regulated FOXOl gene expression by 1.6 fold (P<0.05) while MPA 
caused a 1.4 (P<0.05) fold increase, although the induction was modest, the up- 
regulation was consistent between repeats and deemed significant by students T-test. 
LNG caused a 1.75 fold induction of the FOXOl gene which was greater than that of 
MPA and P4 ; however there was no significant difference in the regulation of 
FOXOl gene between the progestogens.
The modest but significant increase in FOXOl RNA after progestin treatment was 
sufficiently translated to protein (Figure 3.11 C). Figure 3.11 A (Control) shows 
basal FOXOl protein expression in Ishikawa cells and the intensity of the red stain 
can be seen to increase after treatment with MPA, P4 and LNG (Figure 3.11 A) 
suggesting the amount of protein present has increased. This observation was 
confirmed by the quantitative analysis of the stain intensity which showed that MPA, 
P4 and LNG significantly up-regulated the FOXOl protein (Figure 3.11 C). These 
results are in concurrence with the findings observed in vivo in patients diagnosed 
with hyperplasia and treated with MPA (Fig 3.5).
Furthermore, FOXOl is a transcription factor that shuttles in and out of the nucleus 
and control samples from this study show that FOXOl is predominantly expressed in 
the nucleus in Ishikawa cells (Figure 3.11 A, Control). In line with previous findings 
(Ward et al., 2008), treatment with progestins up-regulated both cytoplasmic and 
nuclear FOXOl protein at the same level with the difference between nuclear and 
cellular intensity remaining the same pre and post hormone treatment (Figure 3.1 ID).
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Figure 3.11: FOXOl gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h with lpM  of hormone. A) Fluorescent 
images showing formaldehyde fixed cells with DAPI-stained cell nucleus (blue), 
Texas-Red stained FOXOl protein (red) and fused DAPI/Texas Red image at 
lOx optical zoom. B) RT-PCR data showing basal transcript level of FOXOl 
normalised to GAPDH. C) Cell intensity data obtained from InCell Analyser 
Workstation based on an average of 3 repeats observing at least 3 fields of view 
within each repeat. Data is represented as fold. D) Nuclear minus Cell Intensity. 
Cell intensity accounts for the average intensity of the whole cell whereas 
nuclear intensity accounts for the intensity found above the DAPI stain only. 
The difference between these concentrations is plotted. A negative control 
containing Ishikawa cells incubated with secondary antibody only can be seen in 
Figure A; InCell Analyser Data is normalised to background based on this 
negative. E rror bars represent standard deviation from the mean of 3 repeats. 
Data was analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, 
***P<0.001). All data presented in this section was subjected to the same 
analysis.
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Like progesterone, E2  is capable of up-regulating FOXOl through binding its 
receptor (Lengyel et al., 2007, Schuur et al., 2001). When Ishikawa cells were treated 
with E2 alone there was an average 2-fold increase of FOXOl RNA, however, this 
was not significant due to noticeable deviations from the mean (Figure 3.12B). Yet, 
when E2 was delivered in combination with P4 or MPA, FOXOl gene expression was 
significantly up-regulated (1.8 and 1.4 fold respectively). Despite a 1.5 fold increase 
in FOXOl RNA after E2 plus LNG treatment, this was not significant.
After incubation with MPA combined with E2 there was no change seen in the 
expression of FOXOl protein in the Ishikawa cells compared with untreated control 
(Figure 3.12C). This was contrary to the 1.5 fold increase seen in treatment with 
MPA alone (Figure 3.11C). On the other hand, when cells were treated with E2  in 
combination with LNG there was a significant 1.5 fold increase in FOXOl protein 
(Figure 3.12C). P4 + E2  treatment also caused a significant up-regulation in FOXOl 
protein at the same level as when cells were treated with P4 alone (both 1.5 fold) 
(Figure 3.11C and 3.12C). Overall, progestogen treatment alone caused a significant 
increase in FOXOl RNA and protein which was reduced with the addition E2 , 
particularly when E2 was added to MPA, where protein induction was diminished 
(Figure 3.12C). This result implies that patients treated with MPA may need to be 
monitored for estrogen levels since estrogen may affect the action of this progestin. 
In fact a group of patients recruited for this study were treated with MPA and did not 
respond to treatment but due to their management and care it was not feasible to 
obtain endometrial biopsies.
Moreover, previous work has shown that ligand bound ER is able to interact directly 
with members of the FOXO family of proteins (Schuur et al., 2001) and agonist- 
bound ER can lead to the inactivation of FOXOl (Lengyel et al., 2007) which may 
have led to the observed decrease in FOXOl after E2  treatment.
After E2 treatment, the red protein stain can be seen over a broad range compared to 
control where it appears compact and nuclear localised (Figure 3.12A). To assess 
whether this was indeed the case the intensity of protein stain (Texas Red) was 
calculated in the region above the DAPI-stained nucleus only as well as over the
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whole cell as described in Section 2.1.5. The cellular intensity was then subtracted 
from the nuclear intensity. Figure 3.12D shows that there is little difference between 
nuclear and cytosolic FOXOl protein with E2 treatment confirming FOXOl 
displacement. This data correlates with previous findings that show E2  causes 
downstream phosphorylation of FOXOl leading to its movement out of the nucleus 
(Lengyel et al., 2007). As expected, after the combined treatment of Ishikawa cells 
with the progestogens and E2 there was an increase in nuclear positioning compared 
to E2 alone (Figure 3.12D). However, it can be seen that, after P4  + E2 treatment, the 
location of the FOXOl protein was not significantly different to the control cells 
(Figure 3.12D). After treatment with E2 and progestins there was a significant 
difference in nuclear location. Existing research shows that androgens negatively 
regulate FOXOl (Huang et al., 2004) and that ligand-bound AR can inactivate the 
FOXOl protein (Li et al., 2003), thus, the ability of MPA and LNG to bind and 
activate the AR may have influenced the current data.
133
Chapter 3 Gene and Protein Regulation by Progesterone and Synthetic Progestins in the
Human Endometrium
A B
C o n t r o l
E2 M P A + E 2  P + E 2 L N G + E 2
E 2 lO O n M
M P A  l u M  
+  E ,  lO O n M
E2 M P A + E 2  P 4 + E 2  L+E2P 4 l u M  + 
E ,  lO O n M
LN G  l u M  
+ E2 lO O n M
F O X O l E2 M P A + E 2  P 4 + E 2  L N G + E 2
Figure 3.12: FOXOl gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. MPA, P4 and LNG treatment 
concentration was lpM  whereas E 2 treatment concentration was lOOnM A) 
Fluorescent images showing formaldehyde fixed cells with D API-stained cell 
nucleus (blue), Texas-Red stained FOXOl protein (red) and fused DAPI/Texas 
Red image at lOx optical zoom. B) RT-PCR data showing basal transcript level 
of FOXOl normalised to GAPDH. C) Cell intensity data obtained from InCell 
Analyser Workstation based on an average of 3 repeats observing at least 3 
fields of view within each repeat. Data is represented as fold. D) Nuclear 
Intensity minus Cell Intensity. Cell intensity accounts for the average intensity 
of the whole cell whereas nuclear intensity accounts for the intensity found 
above the DAPI stain only. The difference between these concentrations is 
plotted. A negative control containing Ishikawa cells incubated with secondary 
antibody only can be seen in Figure A; InCell Analyser Data is normalised to 
background based on this negative. E rror bars represent standard deviation 
from the mean of 3 repeats. Data was analysed using a two-tailed students T-
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Test (*P<0.05, **P<0.01, ***P<0.001). All data presented in this section was 
subjected to the same analysis.
The overall findings relating to FOXOl as a positive control are indicative that genes 
in the Ishikawa cell line can be influenced by progestogens, therefore suggesting the 
cell line is sufficient for the analysis of the remaining target genes. Moreover no 
differences were observed between the progestogens in the regulation of the FOXOl 
gene in the presence or absence of E2 .
3.3.4.2 Progesterone Receptor is differentially regulated by P 4 ,  MPA and LNG 
in the Ishikawa cell line.
The second target to be analysed is the Progesterone Receptor (PR). The PR itself is 
regulated by its own ligand, and potential differential regulation of this receptor by 
synthetic or natural ligands has not previously been investigated. As the presence of 
PR in the Ishikawa cell line has already been confirmed, this section will focus on the 
regulation of PR by the progestogens. The PR contains estrogen and progesterone 
response elements within its promoter region and can therefore be regulated through 
ligand-activated PR and ER (Petz and Nardulli, 2000, Vegeto et al., 1993). 
Progesterone has been widely reported to down-regulate the PR (Graham and Clarke, 
1997b) whereas estrogen has been reported to up-regulate the PR (Hata and 
Kuramoto, 1992, Jamil et al., 1991). MPA and LNG have also been shown to down- 
regulate PR in several studies (Hanifi-Moghaddam et al., 2006, Critchley et al., 1998, 
Vereide et al., 2006) with one exception that suggested LNG does not alter PR levels 
(Meng et al., 2010).
Furthermore, work carried out on the Ishikawa cell line has shown that PR is down- 
regulated by progesterone after being primed with estradiol (Lessey et al., 1996). The 
down-regulation of PR by MPA has also been shown in another epithelial cell line 
(Hanifi-Moghaddam et al., 2006) though with a vastly reduced treatment 
concentration (InM) compared to this study (lpM). Although there is currently no 
data available on the effect of LNG on the PR in endometrial cell lines, data from 
patient samples suggest that LNG also down-regulates PR in glandular epithelia 
(Critchley et al., 1998, Vereide et al., 2006) though there is conflicting information in
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luminal epithelia whereby some have reported an increase in PR and others have 
reported no change (Critchley et al., 1998, Vereide et al., 2006, Meng et al., 2010). 
The effects of the progestogens on PR in the Ishikawa cell line were assessed to 
determine whether they differentially regulate this receptor.
Figure 3.13B shows that, contrary to previous publications, P4  and LNG significantly 
up-regulated PR gene expression in the Ishikawa cell line. MPA alone, however, did 
not change the level of PR RNA compared to the control. The increase in PR gene 
expression after treatment with P4  was further confirmed at protein level whereby an 
obvious increase in protein intensity can be seen after P4 ttreatment in Figure 3.13A. 
Upon quantifying this up-regulation, it was found that PR expression was more than 
8  fold of that seen in control cells (Figure 3.13C). On the other hand, MPA caused no 
change in PR protein expression compared to control (Figure 3.13C), this is different 
from in vivo data where a significant decrease in PR was observed after MPA 
treatment (Figure 3.6).
Although LNG caused a marginal increase in PR protein (1.3 fold), this was by no 
means significant (Figure 3.13C). Moreover the up-regulation of the PR protein by 
P4  was significantly different to both LNG and MPA (P>0.05). The evident up- 
regulation of PR by P4 is contradictory to previous findings, however, previous work 
utilised different hormone concentrations and incubation times as well as priming 
cells with E2 treatment which must have had an influence on the downstream target 
regulation (Lessey et al., 1996, Hanifi-Moghaddam et al., 2006).
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Figure 3.13: PR gene and protein expression in the Ishikawa cell line following 
hormone treatment for 48h. Each treatment was at a final concentration of 
lpM . A) Fluorescent images showing formaldehyde fixed cells with DAPI- 
stained cell nucleus (blue), Texas-Red stained PR protein (red) and fused 
DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data showing basal 
transcript level of PR normalised to GAPDH. C) Cell intensity data obtained 
from InCell Analyser Workstation based on an average of 3 repeats observing 
at least 3 fields of view within each repeat. Data is represented as fold. D) 
Nuclear minus Cell Intensity. Cell intensity accounts for the average intensity of 
the whole cell whereas nuclear intensity accounts for the intensity found above 
the DAPI stain only. The difference between these concentrations is plotted. A 
negative control containing Ishikawa cells incubated with secondary antibody 
only can be seen in Figure A; InCell Analyser Data is normalised to background 
based on this negative. E rror bars represent standard deviation from the mean 
of 3 repeats. Data was analysed using a two-tailed students T-Test (*P<0.05, 
**P<0.01, ***P<0.001). All data presented in this section was subjected to the 
same analysis.
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It is well documented that estrogen causes an increase in PR (Hata and Kuramoto, 
1992, Jamil et al., 1991) and this was confirmed at RNA level in the Ishikawa cell 
line (Figure 3.14B). To establish whether this effect was translated to protein, the 
InCELL analyser was again used to quantify PR protein level before and after 
treatment with E2 alone and E2 combined with the progestogens (Figure 3.14).
E2 alone caused a significant up-regulation of PR RNA and further increased the 
levels of PR when applied to the cells in combination with MPA or P4 . In particular, 
there was a noticeable increase in the average starting quantity of PR RNA after 
treatment with MPA combined with E2 (6.5 fold). Despite the large average increase, 
the induction was not statistically significant (P=0.061). However, in the presence of 
E2 , up-regulation of PR by LNG was very similar as in its absence (2.3 fold in both) 
(Figure 3.14B).
At protein level, treatment with E2 also caused a marked increase in PR both alone 
and in combination with the progestogens (Figure 3.14C). The increase caused by 
each of the combined treatments was confirmed to be significant by student t-test 
but, although the overall fold increase was greater (2.5 fold), the increase was not 
significant with E2 treatment alone (P=0.054). Furthermore, in the combined 
treatments, no significant difference was observed between treatment groups.
Interestingly, the combination of P4  and E2 caused a lesser increase in PR expression 
than treatment with P4  alone, although both were significant (P>0.05).
Similarly to the FOXOl protein, PR protein appears to be localised to the nucleus, 
particularly after progestogen treatment both alone (Figure 3.14D) and in 
combination with E2 (Figures 3.14D). When PR binds to its ligand it is translocated 
to the nucleus where it regulates target genes and proteins (Leonhardt et al., 2003a), 
therefore the increase in nuclear PR after progestogen treatment falls in line with 
expectation.
LNG and MPA altered PR level in a significantly different manner to P4 in Ishikawa 
cells. The differential regulation of PR by the progestogens may be detrimental in an 
in vivo situation.
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Figure 3.14: PR gene and protein expression in the Ishikawa cell line following 
hormone treatment for 48h. MPA, P4 and LNG treatment concentration was 
lpM  whereas E2 treatment concentration was lOOnM A) Fluorescent images 
showing formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas- 
Red stained PR protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of PR normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser Workstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. D) Nuclear minus Cell Intensity. Cell 
intensity accounts for the average intensity of the whole cell whereas nuclear 
intensity accounts for the intensity found above the DAPI stain only. The 
difference between these concentrations is plotted. A negative control containing 
Ishikawa cells incubated with secondary antibody only can be seen in Figure A; 
InCell Analyser Data is normalised to background based on this negative. E rro r 
bars represent standard deviation from the mean of 3 repeats. Data was 
analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). 
All data presented in this section was subjected to the same analysis.
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3.3.4.3 Amphiregulin gene and protein expression is not altered after 
progestogen treatment in the Ishikawa cell line.
The third target to be assessed is amphiregulin (AREG). The regulation of AREG by 
P4  was first described in mouse uterine epithelium whereby a rise in AREG 
correlates with rising P4 and is blocked by a PR antagonist (Das et al., 1995). A rise 
in AREG in the human endometrium has also been shown to increase with rising P4 
(Gui et al., 2008a). This up-regulation has been reported to be mediated specifically 
through the PR-A isoform (Conneely and Jericevic, 2002, Mulac-Jericevic et al., 
2000), though this finding is controversial (Smid (Smid-Koopman et al., 2003). If 
AREG is indeed regulated through the PR-A isoform its regulation may be affected 
by the low level of PR-A expressed in the Ishikawa cell line (Figure 3.10A) which is 
likely to influence P4 regulation of AREG expression. Furthermore, AREG is 
stimulated by androgen in prostate (Sehgal et al., 1994) suggesting potential for 
MPA and LNG to further influence AREG expression through binding the AR.
Despite the reported up-regulation of AREG by P4 , after 48 hours of incubation with 
the progestogens there was no significant change in the expression of AREG RNA in 
the Ishikawa cell line. However, LNG up-regulated AREG 1.5 fold but with 
noticeable deviation from the mean rendering the result insignificant (Figure 3.15B). 
A similar result was seen at protein level, whereby there was some up-regulation 
after MPA and LNG treatment (1.4 fold) but this was not significant (Figure 3.15A 
and C). The absence of a significant increase of MPA has been reported once 
previously; study by Geilen and colleges (2006) found that AREG was not 
significantly up-regulated by MPA in the endometrium though there appeared to be 
an average overall increase in the protein (Gielen et al., 2006). Although there was 
no statistically significant change in AREG expression, an interesting trend was 
observed whereby MPA and LNG treatment up-regulated AREG at both RNA and 
protein level (Figure 3.15B and D). A non-significant increase in nuclear AREG was 
also observed in the glandular epithelium post MPA treatment in endometrial 
hyperplasia samples (Figure 3.7), suggesting that the synthetic progestins may 
weakly regulate this protein.
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Figure 3.15: AREG gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. All treatment concentrations were lpM . 
A) Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained AREG protein (red) and fused DAPI/Texas 
Red image at lOx optical zoom. B) RT-PCR data showing basal transcript level 
of AREG normalised to GAPDH. C) Cell intensity data obtained from InCell 
Analyser Workstation based on an average of 3 repeats observing at least 3 
fields of view within each repeat. Data is represented as fold. A negative control 
containing Ishikawa cells incubated with secondary antibody only can be seen in 
Figure A; InCell Analyser Data is normalised to background based on this 
negative. E rror bars represent standard deviation from the mean of 3 repeats. 
Data was analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, 
***P<0.001). All data presented in this section was subjected to the same 
analysis.
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Estrogen has also been previously shown to up-regulate AREG gene expression, this 
has been shown in breast tissue (Martinez-Lacaci et al., 1995, LaMarca and Rosen, 
2007) and in endometrium (Gielen 2005, Gielen 2006). Within this study, the 
expression of AREG was up-regulated by E2 by 1.5 fold at both RNA protein level 
but was only deemed statistically significant at RNA level (P<0.05) (Figure 3.16). A 
similar observation was also made after treatment with E2 in combination with each 
of the progestogens though the apparent up-regulation was not statistically 
significant (Figure 3.16). In sum, LNG, MPA and P4 +/- E2 similarly regulate AREG 
at both RNA and protein level in the Ishikawa cell line after 48 hours of treatment.
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Figure 3.16: AREG gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. MPA, P4 and LNG treatment 
concentrations were lpM  whereas E 2 treatment concentration was lOOnM A) 
Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained AREG protein (red) and fused DAPI/Texas 
Red image at lOx optical zoom. B) RT-PCR data showing basal transcript level 
of AREG normalised to GAPDH. C) Cell intensity data obtained from InCell 
Analyser Workstation based on an average of 3 repeats observing at least 3 
fields of view within each repeat. Data is represented as fold. A negative control 
containing Ishikawa cells incubated with secondary antibody only can be seen in 
Figure A; InCell Analyser Data is normalised to background based on this 
negative. E rro r bars represent standard deviation from the mean of 3 repeats. 
Data was analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, 
***P<0.001). All data presented in this section was subjected to the same 
analysis.
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3.3.4.4 Lactoferrin is significantly down-regulated in the Ishikawa cell line after 
treatment with P 4 ,  MPA and LNG.
LF is expressed in the human and mouse endometrium at varying levels throughout 
the menstrual cycle (Masson et al., 1968, Newbold et al., 1992). During the mouse 
estrous cycle levels of LF increase during the estrogen dominated phase and decrease 
during the progesterone dominated phase suggesting its down-regulation by 
progesterone in this species (Newbold et al., 1992, McMaster et al., 1992). 
Moreover, in both human epithelial and human stromal cells LF is suppressed by 
progesterone and this occurs specifically through the PRB (Tibbetts et al., 1998, 
Kurita et al., 2000, Conneely and Jericevic, 2002). On the other hand, LF is up- 
regulated by estrogen (Zhang and Teng, 2000, Kelver et al., 1996) and is not altered 
through androgen signalling (Yu and Chen, 1993) therefore the synthetic progestins 
cannot adversely regulate LF through binding the AR.
In line with the literature, data from Ishikawa cells showed that LF was significantly 
down-regulated after treatment with each of the progestogens at the RNA level 
(Figure 3.17 B). However, the extent of LF inhibition differed with the different 
progestogen treatments. After treatment with P4, LF was reduced to less than 0.2 fold 
of that found in the untreated control, however, after treatment with LNG or MPA, 
LF was only reduced to approximately 0.6 fold of the control. The difference in LF 
inhibition between MPA and P4 treatment was statistically significant. Moreover, the 
regulation of LF by MPA in the Ishikawa cell line was the opposite of that observed 
in vivo, whereby LF was upregulated in glandular epithelium in vivo and down- 
regulated in this cell line.
The significant LF down-regulation by the progestogens appears to have been 
translated to protein. However, the extent of LF down-regulation was similar 
between all the treatments with each treatment similarly causing a decrease of 
between 0.7 and 0.8 fold, this can be seen in Figure 3.17 C and can be visualised in 
Figures 3.17 A.
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Figure 3.17: LF gene and protein expression in the Ishikawa cell line following 
hormone treatment for 48h. All treatment concentrations were lpM . A) 
Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained LF protein (red) and fused DAPI/Texas Red 
image at lOx optical zoom. B) RT-PCR data showing basal transcript level of 
LF normalised to GAPDH. C) Cell intensity data obtained from InCell Analyser 
Workstation based on an average of 3 repeats observing at least 3 fields of view 
within each repeat. Data is represented as fold. A negative control containing 
Ishikawa cells incubated with secondary antibody only can be seen in Figure A; 
InCell Analyser Data is normalised to background based on this negative. E rror 
bars represent standard deviation from the mean of 3 repeats. Data was 
analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All 
data presented in this section was subjected to the same analysis.
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The combined treatment of E2  and P4 hampered the down-regulation of LF, causing 
an overall reduction of 0.75 fold (Figure 3.18) compared to the striking 0.2 fold 
decrease seen with P4 treatment alone. On the other hand, the addition of E2 to LNG 
and MPA treatment caused little change. The combination of E2 and LNG or MPA 
caused 0.6 and 0.5 fold decrease in LF RNA respectively; however, the decrease was 
not significant after LNG treatment. Conversely, MPA plus E2 treatment caused a 
significant down-regulation in LF RNA (Figure 3.18B).
When treated with E2 alone, the expression of LF protein in Ishikawa cells did not 
change (Figure 3.18C). However the addition of E2 to LNG and P4 abolished the 
significance of the down-regulation although it did not have an influence on the 
overall fold decrease (Figure 3.18C). On the other hand, LF protein expression 
remained significantly less than control in Ishikawa cells after treatment with E2 plus 
MPA (Figure 3.18C).
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Figure 3.18: LF gene and protein expression in the Ishikawa cell line following 
hormone treatment for 48h. MPA, P4 and LNG treatment concentrations were 
lpM  whereas E 2 treatment concentration was lOOnM A) Fluorescent images 
showing formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas- 
Red stained LF protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of LF normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser Workstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. A negative control containing Ishikawa cells 
incubated with secondary antibody only can be seen in Figure A; InCell 
Analyser Data is normalised to background based on this negative. E rror bars 
represent standard deviation from the mean of 3 repeats. Data was analysed 
using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data 
presented in this section was subjected to the same analysis.
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3.3.4.5 GREB1 is induced by progestogenic as well as estrogenic signalling in the 
Ishikawa cell line.
The next target to be assessed was GREB1. As described in Section 1.7.5, the 
GREB1 gene is an early response gene in the estrogen receptor-regulated pathway 
(Pellegrini et al., 2012) and is a direct target of estrogen (Ghosh et al., 2000) GREB1 
is also an androgen target and contains a progesterone response element in its 
promoter (Rae et al., 2006).
Although the presence of a progesterone response element suggests that GREB1 may 
be influenced by PR binding, the regulation of GREB 1 by progesterone has not been 
reported until now. The present study shows that P4, LNG and MPA significantly up- 
regulate GREB1 gene expression in the Ishikawa cell line (Figure 3.19B). Moreover, 
GREB1 was up-regulated significantly more by P4 than MPA (P<0.01) and the 
average increase in GREB1 RNA was far greater after treatment with LNG (2.8 fold) 
compared to P4 (2.2 fold) and MPA (1.5 fold).
The significant changes seen in GREB 1 RNA were not seen at protein level using the 
InCell analyser (Figure 3.19B). Despite the lack of statistical significance, up- 
regulation at protein level was still apparent which could potentially be confirmed 
with further repeats or the use of a more sensitive antibody.
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Figure 3.19: GREB1 gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. All treatment concentrations were lpM . 
A) Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained GREB1 protein (red) and fused DAPI/Texas 
Red image at lOx optical zoom. B) RT-PCR data showing basal transcript level 
of GREB1 normalised to GAPDH. C) Cell intensity data obtained from InCell 
Analyser Workstation based on an average of 3 repeats observing at least 3 
fields of view within each repeat. Data is represented as fold. A negative control 
containing Ishikawa cells incubated with secondary antibody only can be seen in 
Figure A; InCell Analyser Data is normalised to background based on this 
negative. E rror bars represent standard deviation from the mean of 3 repeats. 
Data was analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, 
***P<0.00I). All data presented in this section was subjected to the same 
analysis.
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It is worth noting that one study by Pellegrini et al (2012) investigated GREB1 
expression in women suffering with endometriosis and looked at patients taking or 
not taking contraception in their control group. Although there is limited information 
available, Pellegrini reported that there is no difference in GREB1 levels in the 
human endometrium within the control group suggesting that the intake of progestins 
does not influence GREB1 expression in vivo (Pellegrini et al., 2012). This data 
however, does not elaborate on the type of progestin taken or the duration of use.
GREB1 expression is known to be induced by estrogen in the Ishikawa cell line 
(Naciff et al., 2009, Gori et al., 2011) and was therefore used as a positive control for 
the estrogen responsiveness of the Ishikawa cell line. After E2 treatment, GREB1 
RNA was indeed significantly up-regulated. A 3.2-fold induction was observed at 
RNA level (P>0.05) (Figure 3.20B) and 2.8 fold induction observed at protein level 
(P>0.01) (Figure 3.20C). GREB1 protein expression also increased after combined 
E2 and progestogen treatment but not significantly (Figure 3.20C).
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Figure 3.20: GREB1 gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. MPA, P4 and LNG treatment 
concentrations were lpM  whereas E 2 treatment concentration was lOOnM A) 
Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained GREB1 protein (red) and fused DAPI/Texas 
Red image at lOx optical zoom. B) RT-PCR data showing basal transcript level 
of GREB1 normalised to GAPDH. C) Cell intensity data obtained from InCell 
Analyser Workstation based on an average of 3 repeats observing at least 3 
fields of view within each repeat. Data is represented as fold. A negative control 
containing Ishikawa cells incubated with secondary antibody only can be seen in 
Figure A; InCell Analyser Data is normalised to background based on this 
negative. E rror bars represent standard deviation from the mean of 3 repeats. 
Data was analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, 
***P<0.001). All data presented in this section was subjected to the same 
analysis.
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3.3.4.6 IGF1 gene expression is enhanced in the presence of MPA and LNG but 
not in the presence of P 4 .
The final gene to be assessed was insulin-like growth factor 1 (IGF1). IGF1 is not 
regulated by estrogen or progesterone (Weihua et al., 2002, Ace and Okulicz, 1995) 
but is enhanced by ligand-activated androgen receptor (Zhu and Kyprianou, 2008). It 
is thus possible that MPA and LNG are able to regulate this gene through binding the 
AR. Indeed the results showed that IGF1 was significantly up-regulated by LNG and 
MPA but not affected by P4  (Figure 3.21). MPA binds the AR with more than twice 
the affinity of progesterone and LNG binds with more than 3 times the affinity 
(Africander et al., 2011) which has inevitably affected the differences seen in the 
regulation IGF by these hormones. Furthermore there was a significant different 
between P4  and both MPA and LNG (P<0.05).
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Figure 3.21: Normalised starting quantity of IGF1 RNA in Ishikawa cells after 
48h of treatment with 1pm of P4, MPA or LNG. RNA was extracted was 
extracted from Ishikawa cells using the Quiagen RNeasy kit, the RNA was then 
converted to cDNA, and amplified using PCR. The average starting quantity of 
the target mRNA was calculated by obtaining the cycle number at which the 
gene was first amplified and plotting this number within a standard curve. The 
results were normalised against reference gene GAPDH. Error bars represent 
standard deviation from the mean of 3 repeats. Data was analysed statistically
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using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All PCR 
data presented in this section was subjected to the same analysis.
3.3.4.7 Summary of Section 3.3.4
Gene
Regulation by Progestogens in 
Ishikawa
M PA P4 LNG
FO X O l 1.5* 1.5* 1.7*
PR 1 4*** 2.3*
AREG 1.4 1 1.7
LF 0.06** 0.02*** 0.06*
GREB 1 1.5* 2.2*** 3*
IGF1 1.8* 0.9 2.5*
B
Protein
R egulation  by P rogestogen s in 
Ishikawa
M PA P4 LN G
FO X O l 1.5* 1.5**
8**
2*
PR 1 1
AR EG 1.4 1 1.4
LF 0.7* 0.7* 0.8*
GREB1 2.5 2 1.5
C
Gene
Regulation by Progestogens in the presence of E2 in 
Ishikawa cells
E2 MPA P4 LNG
FO XO l 1.70 1.50* 1.60* 1.75
PR 5.50* 6.52 4.68* 2.32*
AREG 1.61* 1.31 1.81 1.27
LF 1.30 0.49** 0.82 0.65
GREB1 5.53* 3.06*** 4.52*** 3.61**
D
Protein
Regulation by Progestogens in the presence of E2 in 
Ishikawa Cells
E2 MPA P4 LNG
FO XO l 1.23 1.31* 1.57* 1.45
PR 2.53 2.27* 1.54* 3.47*
AREG 1.41 0.82 1.46 1.16
LF 0.72 0.63 0.68 0.62*
GREB1 1.91** 1.26 1.59 1.77
Tables 3.3 A-D: Tables summarise the regulation of target genes (A) and 
proteins (B) by progestogen treatment alone and in combination with estradiol 
(C and D) in Ishikawa cells. Green indicates an increase in protein expression, 
blue indicates a decrease and pink indicates no change.
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The data presented within this study highlighted some differences in gene and 
protein regulation in Ishikawa cells by P4 , MPA and LNG. To help visualise these 
differences, tables summarising the effect of each progestogen at gene (Table 3.3A 
and B) and protein level (Table 3.3C and D) were produced.
The regulation of PR, FOXOl, AREG and LF by MPA was not always in line with 
in vivo data. This may be owed to the fact that Ishikawa cells are cancerous in origin 
and the molecular pathology of endometrial cancer is different to endometrial 
hyperplasia, particularly without atypia (Matias-Guiu et al., 2001). This suggests that 
Ishikawa cells may be a poor model for determining differential gene regulation by 
natural and synthetic progestins in vivo in hyperplasia patients. Nonetheless, the data 
still shows that synthetic progestins are capable of adversely regulating a number of 
genes and proteins.
3.3.5 MPA, LNG and P4 differentially regulate target gene and protein 
expression in human endometrial stromal cells (HESCs).
As with the Ishikawa cell line, the regulation of a number of genes and proteins by 
P4, MPA and LNG was assessed in the HESC cell line. As described in Section 2.1.2, 
the HESC cell line is shown to display similar outcomes to primary, unpassaged, 
stromal cells after treatment with ovarian hormones. Furthermore, a high expression 
of PR and AR was determined in the HESC cell line (Figure 3.10). Although the 
levels of ER were low, this should not limit outcomes as estradiol treatments were 
not used with the HESC cell line. Therefore, during this section HESCs were used to 
assess genetic and morphological changes induced by P4, compared to MPA and 
LNG.
3.3.5.1 FOXOl is up-regulated by progestogen combined with cyclic AMP in the 
Stroma but is not significantly up-regulated by progestogen alone.
Several studies have been carried out to identify the role of FOXOl in endometrial 
stroma. Collectively, these studies have shown that FOXOl is involved in regulating 
the expression of decidual marker genes and is markedly induced upon 
decidualisation both in vivo and in vitro (Christian et al., 2002, Gellersen and
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Brosens, 2003, Labied et al., 2006, Gellersen et al., 2007). FOXOl binds to target 
genes as part o f a complex o f transcription factors in response to cyclic AMP and 
progesterone dependant signalling (Gellersen et al., 2007, Christian et al., 2002). 
Prolactin is a prominent marker of decidualisation and is an example of a FOXOl 
target gene regulated in this way (Christian et al., 2002, Kim et al., 2003). The 
addition of cyclic AMP to cultured human endometrial stromal cells has been shown 
to cause an up-regulation of FOXOl RNA and protein which is enhanced by the 
addition of a progestogen. The added progestogen not only enhances the expression 
of FOXOl in differentiating stromal cells but simultaneously induces cytoplasmic 
retention and inactivation of the FOXOl protein and withdrawal of progestin causes 
rapid nuclear re-accumulation (Labied et al., 2006). Interestingly treatment with 
progestin alone does not appear to enhance FOXOl expression in stromal cells 
(Labied et al., 2006). In addition to this, androgens have been shown down-regulate 
FOXOl in prostate (Huang et al., 2004) which may suggest that MPA and LNG can 
influence FOXOl to some extent through binding to the androgen receptor.
As previously shown by Labied et al (2006), treatment with progestin or 
progesterone alone did not induce FOXOl RNA expression in HESC cells (Figure 
3.22B). This was also the case at protein level, though interestingly the level of 
FOXOl protein did increase after treatment with MPA and although this was not 
significant, a similar pattern can be seen at RNA level (Figure 3.22C) which may 
suggest MPA is having some effect on the FOXOl protein unlike the other 
progestogens. In line with this observation, a significant increase in cytosolic 
FOXOl in the endometrial stroma of hyperplasia patients was observed after MPA 
treatment (Figure 3.5).
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Figure 3.22: FOXOl gene and protein expression in the HESC cell line 
following hormone treatment for 48h with lpM  of hormone. A) Fluorescent 
images showing formaldehyde fixed cells with DAPI-stained cell nucleus (blue), 
Texas-Red stained FOXOl protein (red) and fused DAPI/Texas Red image at 
lOx optical zoom. B) RT-PCR data showing basal transcript level of FOXOl 
normalised to GAPDH. C) Cell intensity data obtained from InCell Analyser 
Workstation based on an average of 3 repeats observing at least 3 fields of view 
within each repeat. Data is represented as fold. D) Cell and Nuclear Intensity. 
Cell intensity accounts for the average intensity of the whole cell whereas 
nuclear intensity accounts for the intensity found above the DAPI stain only. 
A negative control containing Ishikawa cells incubated with secondary antibody 
only can be seen in Figure A; InCell Analyser Data is normalised to background 
based on this negative. Error bars represent standard deviation from the mean 
of 3 repeats. Data was analysed using a two-tailed students T-Test (*P<0.05, 
**P<0.01, ***P<0.001). All data presented in this section was subjected to the 
same analysis.
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The addition of cyclic AMP to MPA, P4  or LNG caused a marked induction of the 
FOXOl gene (Figure 3.23B). Cyclic AMP alone caused a 6  fold increase in FOXOl 
RNA which was enhanced to 11.4 fold when combined with MPA. The combined 
treatment of cyclic AMP with P4  or LNG also caused a significant up-regulation of 
the FOXOl gene ( 6  and 4.9 fold respectively) however the increase was at a similar 
level to that seen with cyclic AMP alone making it is difficult to certify the influence 
of these hormones on FOXOl induction. Again in line with RNA data, treatment of 
HESC cells with cyclic AMP caused a marked increase in the level of FOXOl 
protein. Treatment with cyclic AMP alone caused a significant induction of FOXOl 
protein (P<0.01), and this was again enhanced by the addition of MPA and LNG. 
However, the combination of cyclic AMP and P4  did not cause a greater increase 
than with cyclic AMP alone. Although the fold increase did not change with the 
addition of P4 , its addition clearly had a similar effect on the protein to the other 
progestins (Figure 3.22B and C). Figure 3.23A shows FOXOl protein (red) in 
Ishikawa cells, after treatment with cyclic AMP alone it appears that the level of 
protein is greater in the nucleus compared to the rest of the cell. Figures 3.23A also 
shows Ishikawa cells after treatment with cyclic AMP plus P4 , MPA and LNG. The 
level of protein in these images not only appears to increase but also appears 
homogenous throughout the cell rather than localised to the nucleus. To confirm this 
observation the whole cell intensity was subtracted from the nuclear intensity and 
difference was plotted (Figure 3.23D). There was indeed a significantly larger 
difference between nuclear and cytosolic FOXOl in cells treated with cyclic AMP 
alone compared to control and this difference was decreased by the presence of the 
progestogens which is in line with findings by Labied (2006).
Based on the images shown in Figure 3.23A, it is tempting to speculate that HESC 
cells become rounder after cyclic AMP plus progestogen treatment due to the process 
of decidualisation. However, it was not possible to quantify cell roundness in the 
absence of a membrane stain using this technique, nonetheless, this observation was 
confirmed under light microscope in Section 3.3.6.
157
Chapter 3 Gene and Protein Regulation by Progesterone and Synthetic Progestins in the
Human Endometrium
C o n t r o l
c A M P  5 y M
M P A  l u M  +  
c A M P  5 u M
P .  l u M  +  
c A M P  5 u M
L N G  l u M  + 
cAMP 5uM
0 . 5
o  2.5
u  0 . 5
e  1200
C 8 0 0
=  4 0 0
F O X O l
Figure 3.23: FOXOl gene and protein expression in the HESC cell line 
following hormone treatment for 48h with lpM  of progestin and/or 5pM cyclic 
AMP. A) Fluorescent images showing formaldehyde fixed cells with DAPI- 
stained cell nucleus (blue), Texas-Red stained FOXOl protein (red) and fused 
DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data showing basal 
transcript level of FOXOl normalised to GAPDH. C) Cell intensity data 
obtained from InCell Analyser Workstation based on an average of 3 repeats 
observing at least 3 fields of view within each repeat. Data is represented as fold. 
D) Cell and Nuclear Intensity. Cell intensity accounts for the average intensity 
of the whole cell whereas nuclear intensity accounts for the intensity found 
above the DAPI stain only. A negative control containing Ishikawa cells 
incubated with secondary antibody only can be seen in Figure A. InCell 
Analyser Data is normalised to background based on this negative. E rror bars 
represent standard deviation from the mean of 3 repeats. Data was analysed 
using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data 
presented in this section was subjected to the same analysis.
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In summary there was no statistically significant difference in the regulation of 
FOXOl by the progestogens in HESCs whereby FOXOl was not altered by 
progestogen alone and was significantly induced by progestin combined with cyclic 
AMP.
33.5.2 PR is upregulated after progestogen treatment in Human endometrial 
stromal cells.
In the literature progestogens have been shown to down-regulate the PR in 
endometrial eptihelium (Hanifi-Moghaddam et al., 2006, Critchley et al., 1998, 
Vereide et al., 2006). However, an increase in PR expression between 2 and 10 fold 
has been reported in MPA and P4 -treated stromal cells (Tseng and Zhu, 1997). Data 
obtained within this study confirmed that PR RNA is significantly induced by P4  by 
more than 1.5 fold (P>0.05) after 48hours of incubation (Figure 3.24B), however this 
was not seen with the protein analysis (Figure 3.24C). MPA treatment also had no 
effect on PR RNA or protein levels in HESC cells (Figure 3.24B and C). 
Furthermore, data obtained within this study from patients taking MPA in vivo is in 
concurrence with these observations, showing no change in stromal PR expression 
after MPA treatment (Figure 3.6). The PR induction by MPA found in the 1998 
study by Critchley took at least 2-3 days therefore a longer incubation time may be 
necessary to replicate this result (Critchley et al., 1998).
Unlike MPA, LNG caused a small but significant increase in PR RNA in HESC cells 
after 48 hours (Figure 3.24B) but again this was not significant at protein level 
(Figure 3.24C). No study has been previously carried out to investigate the effects of 
LNG on PR in cultured stromal cells, although the use of an LNG inter-uterine 
device has been shown to cause no change in stromal PR levels (Critchley et al., 
1998). Changes seen during in vivo work may be affected by paracrine signalling 
between epithelial and stromal compartments of the endometrium (Kurita et al., 
1998) as well as the presence of other hormones.
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Figure 3.24: PR gene and protein expression in the HESC cell line following 
hormone treatment for 48h with lpM  of progestin. A) Fluorescent images 
showing formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas- 
Red stained PR protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of PR normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser Workstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. I)) Cell and Nuclear Intensity. Cell intensity 
accounts for the average intensity of the whole cell whereas nuclear intensity 
accounts for the intensity found above the DAPI stain only. A negative control 
containing Ishikawa cells incubated with secondary antibody only can be seen in 
Figure A. InCell Analyser Data is normalised to background based on this 
negative. E rror bars represent standard deviation from the mean of 3 repeats. 
Data was analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, 
***P<0.001). All data presented in this section was subjected to the same 
analysis.
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As well as progesterone, work has been carried out to determine the regulation of PR 
by cyclic AMP. Cyclic AMP is able to stimulate PR expression without the 
requirement of a ligand (Rowan et al., 2000, Aronica and Katzenellenbogen, 1991). 
Although a marginal induction of PR was seen after cyclic AMP treatment alone, the 
addition of progesterone was required to cause a significant increase of 1.9 fold 
(Figure 3.25B) at the RNA level. Although the addition of MPA or LNG to cyclic 
AMP treatment did not lead to significant changes in PR RNA levels, a slight up- 
regulation was observed which was sufficient to cause changes at protein level 
whereby all cyclic AMP incubations, both alone and in combination with a 
progestogen, caused a small but significant increase in PR protein (Figure 3.25C). 
Synergistic action of ligand-bound PR and cyclic AMP is vital for decidualisation and 
pregnancy establishment as well as to drive decidualisation in IVF patients with luteal 
defects. Thus any differential gene regulation by the progestins through this pathway 
could have major consequences in vivo in particular for IVF patients who are 
sometimes administered with synthetic progestins (Chakravarty et al., 2005, Kuang et 
al., 2015). However, no differences between progestogen treatments with cyclic AMP 
were observed in the regulation of PR.
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Figure 3.25: PR gene and protein expression in the HESC cell line following 
hormone treatment for 48h with lpM  of progestin and/or 5pM cyclic AMP. A) 
Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained PR protein (red) and fused DAPI/Texas Red 
image at lOx optical zoom. B) RT-PCR data showing basal transcript level of 
PR normalised to GAPDH. C) Cell intensity data obtained from InCell Analyser 
Workstation based on an average of 3 repeats observing at least 3 fields of view 
within each repeat. Data is represented as fold. D) Cell and Nuclear Intensity. 
Cell intensity accounts for the average intensity of the whole cell whereas 
nuclear intensity accounts for the intensity found above the DAPI stain only. A 
negative control containing Ishikawa cells incubated with secondary antibody 
only can be seen in Figure A. InCell Analyser Data is normalised to background 
based on this negative. E rror bars represent standard deviation from the mean 
of 3 repeats. Data was analysed using a two-tailed students T-Test (*P<0.05, 
**P<0.01, ***P<0.001). All data presented in this section was subjected to the 
same analysis.
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3.3.5.3 Lactoferrin is down-regulated by progestogens in HESC cells and this is 
further amplified by the addition of cyclic AMP.
The amount of data available on the regulation of LF in human endometrial stroma is 
limited. However, the current literature suggests that LF is regulated in a similar 
manner as in the endometrial epithelium whereby it is inhibited by progesterone 
through the PRB in both tissue types (Kurita et al., 2000). The regulation of LF by 
cyclic AMP has yet to be reported. The data obtained within this study suggests that 
lpM  of P4  or LNG sufficiently inhibits LF gene expression (Figure 3.26B) whereas 
MPA does not alter the expression of LF RNA in HESC cells. Data obtained from 
the InCell Analyser also showed that the LF is significantly down-regulated by 
progesterone at the protein level (Figure 3.26C, P>0.01). MPA and LNG also caused 
a slight reduction in LF protein but this was not significant. These results are very 
similar to those observed in stromal PR in hyperplasia patients (Figure 3.6).
The addition of cyclic AMP to progestogen treatment enhanced the progestin- 
induced down-regulation of LF RNA and protein causing LF RNA to decrease by 
more than half with each progestin/cyclic AMP combination (Figure 3.27B). 
Furthermore, combined MPA/Cyclic AMP treatment caused a significant down- 
regulation of the LF gene (P<0.01) and protein (P<0.05) (3.26B and C) whereas 
MPA treatment alone had no effect (3.26B and C). Cyclic AMP alone did not alter 
LF gene expression implicating synergistic action between cyclic AMP and the 
progestogens (Figure 3.27).
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Figure 3.26: LF gene and protein expression in the HESC cell line following 
hormone treatment for 48h with lpM  of progestin. A) Fluorescent images 
showing formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas- 
Red stained LF protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of LF normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser Workstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. A negative control containing Ishikawa cells 
incubated with secondary antibody only can be seen in Figure A. InCell 
Analyser Data is normalised to background based on this negative. E rror bars 
represent standard deviation from the mean of 3 repeats. Data was analysed 
using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data 
presented in this section was subjected to the same analysis.
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Figure 3.27: LF gene and protein expression in the HESC cell line following 
hormone treatment for 48h with lpM  of progestin and/or 5pM cyclic AMP. A) 
Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained LF protein (red) and fused DAPI/Texas Red 
image at lOx optical zoom. B) RT-PCR data showing basal transcript level of 
LF normalised to GAPDH. C) Cell intensity data obtained from InCell Analyser 
Workstation based on an average of 3 repeats observing at least 3 fields of view 
within each repeat. Data is represented as fold. A negative control containing 
Ishikawa cells incubated with secondary antibody only can be seen in Figure A. 
InCell Analyser Data is normalised to background based on this negative. E rror 
bars represent standard deviation from the mean of 3 repeats. Data was 
analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). 
All data presented in this section was subjected to the same analysis.
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3.3.5.4 GREB1 is not regulated by P 4 , MPA or LNG alone but is significantly 
up-regulated by cyclic AMP both alone and in combination with the 
progestogens.
G R E B 1, a gene o f  unkn o w n  fun c tio n , has been  show n  to  be up -regu la ted  by estrogen  
in b reast and en d o m etriu m  (P elleg rin i et al., 2012 , G h o sh  et al., 2000) and w as thus 
used  as a positive  contro l fo r estrogen  reg u la tio n  ea rlie r in th is study. D uring  this 
investigation  it w as d e te rm in ed  that, as w ell as estro g en , p ro g este ro n e  is a lso  ab le to 
s ign ifican tly  u p -reg u la te  G R EB 1 gene ex p ressio n  in en d o m etria l ep ithelium . T h ere  is 
cu rren tly  no data on  the effec ts  o f  p ro g este ro n e  on the  G R EB 1 gene in endom etria l 
s trom al cells, h o w ev er due to  the substan tial changes seen  in the Ish ikaw a cell line 
a fte r p rogestin  trea tm en t it w as dec ided  to assess changes in G R EB 1 R N A  and 
p ro te in  after p rogestogen  trea tm en t in endom etria l strom al cells.
H ow ever, afte r 48 hours o f  trea tm en t w ith P 4, M P A  o r L N G  no changes w ere 
observed  in G R EB  1 R N A  or p ro te in  betw een  con tro l and trea ted  sam ples in H E SC  
cells (S ee F igure 3.28 fo r g raph ical data. F or im ages see A ppend ix  L).
C M PA P4 LNG c MPA P4 LNG
Figure 3.28: GREB1 gene and protein expression in the HESC cell line 
following hormone treatment for 48h with lpM  of progestin. A) RT-PCR data 
showing basal transcript level of GREB1 normalised to GAPDH. B) Cell 
intensity data obtained from InCell Analyser Workstation based on an average 
of 3 repeats observing at least 3 fields of view within each repeat. Data is 
represented as fold. InCell Analyser Data is normalised to background based on 
negative control. E rror bars represent standard deviation from the mean of 3 
repeats. Data was analysed using a two-tailed students T-Test (*P<0.05,
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**P<0.01, ***P<0.001). All data presented in this section was subjected to the 
same analysis.
When treatments were combined with cyclic AMP, however, there was a substantial 
increase in GREB 1 gene expression. Cyclic AMP alone induced a more than 5 fold 
increase in GREB 1 RNA. The observed increase was also visible after treatment with 
cyclic AMP combined with MPA, P4 and LNG but only significant with P4. (Figure 
3.29B). Interestingly, the fold induction of GREB1 RNA was higher in HESC cells 
after treatment with cyclic AMP alone compared to the combined treatment of cyclic 
AMP and the progestogens suggesting progestogens may be hampering cyclic AMP 
in terms of this target. After cyclic AMP treatment, GREB 1 protein was significantly 
up-regulated by 1.5 fold (P>0.01), a similar up-regulation could be observed after 
treatment with cyclic AMP plus each of the progestogens whereby they all caused a 
significant increase of between 1.4 and 1.5 fold (P>0.05) (Figure 3.25C). The 
changes seen in GREB 1 RNA and protein after cyclic AMP treatment in endometrial 
cells suggest a potential role for GREB 1 in processes such as stromal decidualisation. 
However, as there was no significant differences between cyclic AMP treatment 
alone and in combination with the progestins, it is possible that the observed changes 
were as a result of cyclic AMP alone. Based on the data obtained within this study, 
the role of GREB 1 in the endometrium certainly warrants more investigation.
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Figure 3.29: GREB1 gene and protein expression in the HESC cell line 
following hormone treatment for 48h with lpM  of progestin and/or 5pM cyclic 
AMP. A) Fluorescent images showing formaldehyde fixed cells with DAPI- 
stained cell nucleus (blue), Texas-Red stained GREB1 protein (red) and fused 
DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data showing basal 
transcript level of GREB1 normalised to GAPDH. C) Cell intensity data 
obtained from InCell Analyser W orkstation based on an average of 3 repeats 
observing at least 3 fields of view within each repeat. Data is represented as fold. 
A negative control containing Ishikawa cells incubated with secondary antibody 
only can be seen in Figure A. InCell Analyser Data is normalised to background 
based on this negative. E rror bars represent standard deviation from the mean 
of 3 repeats. Data was analysed using a two-tailed students T-Test (*P<0.05, 
**P<0.01, ***P<0.001). All data presented in this section was subjected to the 
same analysis.
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3.3.5.6 Prolactin is induced by LNG, MPA and P4  when in combination with 
cyclic AMP and is also induced by LNG alone.
Prolactin (PRL) is a multifaceted gene regulated through the PR in differentiating 
human endometrial stromal cells. Progestogens alone are very weak inducers of the 
PRL gene, yet, the role of progestogens in PRL regulation is important as they 
synergistically enhance cAMP-induced PRL expression (Gellersen et al., 1994, 
Telgmann et al., 1997, Brosens et al., 1996, Brar et al., 1997, Tang and Gurpide, 
1993). In line with the literature, after incubating HESC cells with P4 or MPA for 48 
hours, no significant change in PRL gene expression was observed (Figure 3.26). 
After incubation with LNG on the other hand, there was a significant, 3.8 fold, up- 
regulation of the PRL gene which was also significantly different to its regulation by 
P4 (P=0.011). The regulation of PRL by LNG in endometrial stromal cells has not 
been reported previously.
After incubating HESCs with P4, MPA or LNG combined with cyclic AMP, there 
was an obvious induction in PRL gene expression. Cyclic AMP alone induced an 
caused PRL starting quantity to rise from 0.01 to >200,000, this rose further to 
>1350,000 with the addition of MPA. Treatment with cyclic AMP and LNG or P4 
both increased PRL starting quantity to more than 100,000, which was less than the 
increase seen with cyclic AMP alone (Figure 3.30). The difference in PRL starting 
quantity after treatment with MPA plus cyclic AMP and P4 plus cyclic AMP was 
also significant, highlighting some potential differences in the effects of this 
synthetic progestin on genes involved in stromal differentiation.
It is worth noting that the likely reason for such substantial increases is due to the 
low levels of PRL found at basal levels in HESCs, thus a 10 cycle increase can lead 
to vast numbers when calculating starting quantity.
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Figure 3.30: The effects of P4, MPA and LNG on PRL gene expression in HESC 
cells in the absence (A) and presence (B) of cyclic AMP
T he transcrip tion  o f  the PR L  gene leads to the syn thesis o f  the P R L  pro te in  w hich  is 
secreted  into su rround ing  flu ids (R ong  H uang et al., 1987). T he  am ount o f  secreted  
p ro lac tin  in the cu ltu re  m edia su rround ing  H E SC  ce lls du rin g  trea tm en t was 
there fo re  assessed . A fte r 48 hours o f  incubation  w ith P 4 the levels o f  secre ted  PR L 
rem ained  unchanged  from  H E SC  cells. H ow ever, in the p resence  o f  M P A  and LN G , 
P R L  secretion  w as u p -regu lated . D esp ite  no change in P R L  gene ex p ressio n  in 
H E S C s after M PA  trea tm en t, M P A  sign ifican tly  increased  the secreted  P R L  pro te in  
by 4 .2  fo ld  (P >0.05). In line w ith  the R N A  data , L N G  increased  P R L  p ro te in  by 
m ore than  20 fold , though  this w as not sign ifican t (F igu re  3 .31).
A fte r incubating  H E S C s w ith P4, M P A  or L N G  com bined  w ith  cyc lic  A M P , there 
w as an obv ious induction  in secreted  P R L  pro te in  w hich  co rre la ted  w ell w ith  data 
ob ta ined  at R N A  level. C yclic  A M P  alone induced  P R L  p ro te in  37 fo ld , this rose to 
73 fold w ith  the ad d itio n  o f M PA . A s w ith R N A , trea tm en t w ith  cyc lic  A M P 
com bined  w ith P4 o r L N G  increased  P R L  gene ex p ressio n  but by the sam e o r less 
than  the increase seen  w ith  cyclic  A M P  alone (F ig u re  3.31).
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Figure 3.31: Secreted PRL levels in response to MPA, P4 and LNG in the 
presence (A) or absence (B) of cyclic AMP.
The ELISA technique was conducted to measure hormone-stimulated levels of 
secreted PRL in HESCs. Values are given as average and standard deviation. 
Student’s t-test was used to test significance. Significant changes are represented 
by * (*, P<0.05 **, P<0.01).
T he d iffe rences ob serv ed  in the regu la tion  o f  the PR L  gene and p ro te in  by P 4 and 
M P A  m ay be due to ind irec t s ig n a llin g  by M PA  or p o ten tia lly  due to  the d iffe ren ce  in 
affin ity  fo r the PR by  these  ho rm ones. Such d iffe rences hav e  not been  researched  
p rev io u sly  but m ay have p ro found  effec ts  on strom al cell p h en o ty p e  in vivo  as w ell as 
w ith in  th is study.
3.3.5.7 The HESC cell line decidualises after treatment with cyclic AMP and 
combined treatment of cyclic AMP and each of the progestogens but not with 
the progestogens alone.
T he increase in P R L  ex p ressio n  is ind icative  o f  strom al d ec id u a lisa tio n , th ere fo re  the 
ex ten t o f  dec idua lisa tion  w as v isu a lised  using  light m icro sco p y  and fu rth e r con firm ed  
by ca lcu la tin g  the level o f  ce llu lar roundness using  Im age J , w here a value o f  1 
rep resen ts  a perfect c irc le  and th is v alue  decreases w ith a red u ctio n  in c ircu larity .
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HESCs were imaged after 48 hours of incubation with P4 , LNG and MPA in the 
presence or absence of cyclic AMP or with cyclic AMP alone. Figure 3.32A shows 
untreated HESCs as a control, in this image cells appear to be elongated and flowing. 
ImageJ analysis gave a value of 0.61 for cell roundness in the control cells (Figure 
3.32B). The addition of P4 , MPA and LNG to the cells resulted in a similar 
appearance of cells to untreated control (Figure 3.32A). Analysis of circularity in 
these samples further confirmed no change in roundness (Figure 3.32B). The addition 
of cyclic AMP to cells, however, caused a marked change in cellular appearance 
which was further enhanced by the addition of a progestogen (Figure 3.32A). The 
changes observed visually were further confirmed by ImageJ analysis for roundness. 
Cellular roundness after cyclic AMP treatment increased from 0.61 (control) to 
0.69(P>0.05) and was further increased to 0.71(P>0.01), 0.72(P>0.05) and 
0.73(P>0.05) when cyclic AMP was combined with MPA, P4  and LNG respectively 
(3.32D).
Despite the vast differences seen in the levels of PRL gene and protein after treatment 
with different progestogens, the changes observed in cell shape were similar between 
all 3. Although no obvious difference in cell shape was observed the marked changes 
in PRL expression is likely to cause changes in the expression of other genes.
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Figure 3.32: The effects of P4 , MPA and LNG on HESC cell roundness. Cell 
morphology can he visualised in images shown in panel A. Roundness was 
quantified using imagej in the absence (C) and presence (D) of cAMP.
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3.3.5.8 Summary of Section 3.3.5
Within this section the regulation of a subset of target genes and proteins by natural 
progesterone and the two synthetic progestins was analysed within the HESC cell 
line. In order to more clearly view this regulation four tables were made summarising 
the data (Tables 3.4A-D).
Furthermore, the data obtained in the HESC cell line was in line with findings in vivo 
in Section 3.3.1. Endometrial hyperplasia without atypia is largely self-limited with 
little apparent relationship to carcinoma (Horn et al., 2007), suggesting its regulation 
is more like that found in the normal endometrium. The HESC cell line is 
representative of primary cells of the healthy endometrium (Krikun et al., 2004) so it 
is not surprising that similar patterns in protein regulation were obtained between 
HESC cells and patient biopsies. What is of particular interest is that several of these 
proteins were differentially regulated by P4  and LNG in the HESC cell line compared 
to MPA, this suggests that differential protein regulation may also occur in vivo.
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A Gene
Regulation by Progestogensin HESC 
MPA P4 LNG
FOXOl 1.4 1.08 1.08
PR 0.81 1.5* 1.7*
LF 1.03 0.56** 0.64*
GREB1 1.00 1.01 1.3
PRL 0.94 1.09 3.83
B Protein Regulation by Progestogens in HESC
MPA P4 LNG
FOXOl 2.20 0.94 1.15
PR 1.19 1.08 1.13
LF 0.92 0 .7 5 * * 0 .8 3
GREB1 1.08 1.05 1.04
PRL 4.18* 0.95 21.18
C
Gene Regulation by Progestogens in the presence ofcAM P
cAMP MPA P4 LNG
FOXOl 6.02* 11.36* 5.96* 4.89*
PR 1.31 1.44 1.89* 1.55
LF 0.92 0 .3 4 * * 0 .4 2 * * 0 .5 *
GREB1 5.3* 3.60
*
3.39
PRL 2.4e6*** 1.4e7*** 1.4e6*** 1 le 6 * * *
D
Protein Regulation by Progestogens in the presence of cAMP
cAMP MPA P4 LNG
FOXOl 1.41** 2.26* 1.44** 1.95*
PR 1.35** 1.53** 1.47*** 1.61**
LF 0.94 0 .67* 0 .7 4 * 0 .6 9 *
GREB1 1.49** 1.44* 1.53* 1.33*
PRL 37.71** 73.42* 37.72* 23.36**
Tables 3.4 A-D: Tables summarise the regulation of target genes (A) and 
proteins (B) by progestogen treatment alone and in combination with estradiol 
(C and D) in HESC cells. Green indicates an increase in protein expression, blue 
indicates a decrease and pink indicates no change.
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3.4 C om parison of the regulation of ta rge t proteins by M PA in vivo and  in 
v itro
A s several d iffe ren ces w ere v isually  observed  b e tw een  in vivo  and in vitro  data, a 
form al ana lysis  w as used  to test fo r s ign ifican t d iffe rences be tw een  these  d ata  sets. A 
s tu d en t’s t-tes t w as ca rried  ou t be tw een  p a tie n t’s p re and post M PA  trea tm en t and 
con tro l and  M P A  trea ted  cells. In o rd er to c lea rly  v isualise  d iffe ren ces/s im ila rities  
betw een  the tw o d a ta  sets, all data  w as converted  to  fo ld  and a d irect co m p ariso n  w as 
m ade. A s id e-b y -sid e  co m p ariso n  o f  fo ld  data can  be seen in T ab le  3.5.
Protein Fold increase com pared to  untreated  p atien t [In Vivo) 
or control sam ple (In Vi tro)
In Vivo Ishikawa P Value In Vitro HESC P Value
FOXOl 1.34 1.23 0.3 1.26 2.20 0.28
PR 0.83 1.01 0.58 0.65 1.14 0 .0 3 *
LF 1.13 0.06 0 .0 1 * * 0.97 0.93 0.65
AREG 1.03 1.47 0 .0 4 * - - -
Table 3.5: The regulation of target proteins by MPA in vivo and in vitro. Green 
indicates an increase in protein expression, blue indicates a decrease and pink 
indicates no change. Differences between in vitro/in vivo data were tested by 
Student’s T-test and P values are given (*, P<0.05 **, P<0.01).
In som e in stances the reg u la tio n  o f  targe t p ro te ins by M PA  is s im ilar in vitro  as in 
vivo. H ow ever, th e re  w ere  s ign ifican t d ifferences be tw een  3 targe ts. M ost n o tab ly  is 
the LF pro te in  w as u p -reg u la ted  in vivo  and d o w n -reg u la ted  in the Ish ikaw a cell line 
(T able 3 .5). T he  d a ta  su ggests  that the cell lines m ay be poor rep resen ta tiv es o f  the in 
vivo  s ituation  su g g estin g  h y p erp la sia  cell lines w ou ld  be p re ferab le  w hen m aking  
such a com parison . E ven  though  the cell lines m ay not be rep resen ta tiv e  o f 
endom etria l h y p erp la sia , they  c learly  show  adverse  reg u la tio n  be tw een  the progestins 
and natural p ro g este ro n e  that requ ires addressing . M oreover, in instances w here data
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is similar (e.g LF in HESC) the in vitro data shows a significant difference between 
MPA and P4  which may indeed be occurring in the patient receiving therapy.
3.5 Discussion
The first line of treatment for non-atypical endometrial hyperplasia is synthetic 
progestin therapy with either MPA or LNG (Armstrong et al., 2012). However, a 
number of side-effects have been attributed to synthetic progestin use due to adverse 
gene and protein regulation by these compounds (Bafaloukos et al., 1999, Thigpen et 
al., 1999). Thus, the main aim of this chapter was to determine the regulation of a 
subset of target genes and proteins by MPA and LNG differed from that of P4. To 
determine this we identified a number of PR target genes and evaluated their 
expression in vivo in samples from endometrial hyperplasia patients to assess 
whether they were adversely expressed in this condition. Following this, endometrial 
biopsy samples were taken from patients pre and post progestin treatment. It was not 
possible to obtain samples from patients treated with LNG or P4, especially as P4 is 
not currently prescribed for this condition. Thus, samples were taken from patients 
receiving MPA treatment only. In order to compare gene and protein regulation by 
P4, MPA and LNG, several targets were also assessed in endometrial cell lines and 
this data was compared with in vivo MPA data.
IHC was used to assess four protein targets in the patient samples; these were 
FOXOl, PR, AREG and LF. The level of each of these proteins was found to be 
significantly altered in hyperplasia patients compared to control. Moreover, the 
expression of these targets significantly changed in at least one compartment of the 
endometrium when patients were subject to MPA regime.
Although Ishikawa cells are a good model of human endometrial epithelium they 
may not be fully representative of what happens in vivo in hyperplasia patients. 
Previous research has suggested that PR is a major mediator of stromal and epithelial 
crosstalk and that progesterone effects on uterine epithelium may also be mediated 
through stromal PR (Kurita et al., 1998). Since a mono-cell culture model was not 
used, cell-cell communications or interactions that can mediate progesterone action 
in endometrium would not have been detected. Nonetheless, the detailed analysis
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carried out within this study was able to reveal subtle yet important differences in 
target gene and protein regulation by the progestogens.
The regulation of LF was particularly interesting whereby MPA up-regulated LF 
protein expression in patient samples and caused no change in its expression in 
Ishikawa cells, whereas LNG and P4  both caused a significant down-regulation of the 
LF protein. This data is not the first to suggest that MPA has opposite effects to 
natural progesterone. When investigating the effect of progestins in the pathogenesis 
of endometriosis, MPA was shown to represses the expression of the chemokine 
named RANTES in endometrial stroma (Zhao et al., 2002), whereas natural 
progesterone has been reported to elevate the expression of the RANTES gene 
(Ramhorst et al., 2006). Another example of this is with intracellular adhesion 
molecule-1 and vascular cell adhesion molecule-1 where both MPA and LNG have 
been shown to increase these molecules but natural progesterone is not known to 
stimulate them (Tatsumi et al., 2002).
As well as LF, the regulation of the PR was also differentially altered by P4 and the 
synthetic progestins. P4 was seen to markedly increase PR protein compared to MPA 
and LNG (both P<0.01), whereas MPA was seen to down-regulate the PR in vivo. 
The PR is a transcription factor for a number of genes and can act in a ligand 
dependent and independent manner (Leonhardt et al., 2003a, Weigel and Zhang, 
1998) therefore even slight alterations in its regulation could have major 
consequences in vivo. Furthermore, for the treatment of diseases such as endometrial 
hyperplasia, synthetic progestins serve to antagonise estrogen-driven growth but 
these benefits are short lived as the progestins serve to down-regulate their own 
receptor, counteracting the initial effect (Satyaswaroop et al., 1992). Thus, the data 
obtained from this cell line suggests natural progesterone may cause an increase in 
PR in certain cell types. In vivo this would serve to prolong treatment effectiveness 
and ultimately improve patient outcome. Although these observations need 
validation they certainly warrant further research.
Another gene differentially regulated by the progestogens in the Ishikawa cell line 
was IGF1. IGF1, which is an androgen-regulated gene but not a target of
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progesterone (Weihua et al., 2002, Ace and Okulicz, 1995), was upregulated by LNG 
and MPA but not by P4 ( This differential regulation is likely due to the ability of 
MPA and LNG to bind the AR and activate androgen target genes. P4, which is 
unable to bind the AR, had no effect on this gene. As PR and LF are not androgen 
targets it is possible that adverse signalling through other receptors or differences in 
binding affinity were the main cause for the dissimilarities in their regulation.
Even though the Ishikawa cell line is not wholly representative of what happens in 
vivo, the differential regulation of target protein by the progestogens certainly 
highlights the importance of adverse gene regulation by the synthetic progestins.
As endometrial hyperplasia is often associated with over-exposure to E2 , target gene 
regulation was also determined in the presence of this hormone. Indeed, the addition 
of estradiol to progestogen treatment was shown to influence target regulation in 
Ishikawa cells; for example the down-regulation of LF was reduced when estradiol 
was included in the treatments. Despite this, there were no significant differences 
recorded between progesterone and the progestins in this particular set of target 
genes after combined treatment with E2 . However, studies have shown that estrogen 
can have a strong influence on a number of factors when added to progestogens in 
vivo such as decreasing glucose tolerance (Wynn et al., 1979) and elevating high- 
density lipoprotein (Bradley et al., 1978, Wynn and Niththyananthan, 1982). 
Therefore, even though no significant differences were seen in this study, the 
potential role of E2 in affecting progestogen gene regulation should not be 
overlooked.
Overall, the results obtained in the Ishikawa cell line showed that P4, MPA and LNG 
regulate selected targets in a similar manner; however, in a few instances the data 
highlighted differential target regulation by the three progestogens which could 
potentially have profound consequences in an in vivo situation.
Unlike the Ishikawa cell line, the regulation of proteins by MPA the HESC cell line 
was found to be similar to in vivo patient samples in the stromal compartment. This 
suggests HESCs may be a good model for predicting in vivo protein regulation. 
However, all synthetic progestins have been shown to bind PR with different binding
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affinities, binding affinity also differs depending on tissue type or cell-line 
highlighting the need for caution when interpreting these results (Africander et al., 
2011). Nonetheless, target regulation by MPA was determined in vivo in endometrial 
stroma and in vitro in HESC cells and the regulation in HESCs was also compared to 
LNG and P4. This was also carried out in the presence of cyclic AMP.
In both patient biopsies and HESC cells, cytosolic FOXOl protein was found to be 
up-regulated by MPA alone, however, in HESC cells, LNG or P4 alone did not alter 
FOXOl expression. Previous research, as well as data from this study, shows that 
cyclic AMP plus progestin causes cytoplasmic retention and inactivation of FOXOl 
and progestin withdrawal causes nuclear re-accumulation and activation of FOXOl 
(Labied et al., 2006). However, progestogen alone is not known to alter FOXOl 
expression (Labied et al., 2006). FOXOl is a key transcription factor with pro- 
apoptotic activity. Therefore, if MPA alone causes FOXOl up-regulation in 
cytoplasm, even in the absence of cyclic AMP, it may influence the apoptotic state of 
stromal cells. Apoptosis in a proportion of decidualised stromal cells, is a cardinal 
feature of impending menstruation (Dahmoun et al., 1999, Kokawa et al., 1996) and 
evasion of apoptosis is linked with cancer (Hanahan and Weinberg, 2011) thus 
showing the importance of FOXOl regulation in these cells. Despite some clear 
trends being observed in the regulation of FOXOl in vitro and in vivo, the 
differences seen in FOXOl regulation were not significant between the progestins.
Akin to FOXOl, P4, MPA and LNG did not differentially regulate PR, LF or GREB1 
RNA or protein in HESC cells. The extent of cellular decidualisation was also similar 
with the three treatments both alone and in combination with cyclic AMP. 
Conversely, PRL was differentially regulated by the progestogens whereby the PRL 
protein was up-regulated by MPA and LNG but not altered by P4 (Figure 3.26, 3.27). 
The addition of cyclic AMP to the HESC cell line also caused significant changes in 
PRL gene expression. When combined with MPA, cyclic AMP caused a significantly 
higher PRL gene-induction than when combined with P4 (Figure 3.26, 3.27). Cross­
talk between different progestogens and second messengers has not been investigated 
but previous research has reported that PRs found in the plasma membrane (mPRs) 
can modulate cyclic AMP levels in response to progesterone (Zhu et al., 2008, Sen
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and Hammes, 2010). Although research into synthetic progestin interaction with mPR 
has not been undertaken, such differences could certainly attribute to adverse gene 
and protein regulation such as that seen here.
There are also several other reasons that progesterone targets in the endometrium 
may be differentially regulated by the progestins. Firstly, MPA and LNG have a 
higher affinity for binding the PR than P4  which could lead to changes in rate and 
extent of up or down-regulation of target genes causing differences in gene 
concentration to be seen at 48 hours of treatment. Secondly, differences in binding 
affinities for the different PRs may have influenced gene and protein regulation. 
Humans express two ligand-regulated PR isoforms; these are PR-A and PR-B. The 
two PR isoforms have different physiological functions owing to the extra activation 
factor on the N-terminus of the PR-B. Indeed, Schoonen et al showed that the 
sytntetic progestins, LNG and gestodene, displayed different binding affinities for 
PR-A and PR-B (Schoonen et al., 1998) Considering this; it may be possible that the 
different PR isoforms mediate different physiological responses to natural 
progesterone compared to other PR agonists, such as MPA and LNG. In the Ishikawa 
cell line the level of PR-A was shown to be much lower than PR-B which may 
explain why the expression levels of PR-B regulated proteins (LF, FOXOl) were 
more inducible than the PR-A regulated protein (AREG). However, an up-regulation 
in AREG was seen after MPA treatment both in vitro (non-significant) and in vivo 
(significant) suggesting that MPA may be a stronger transactivator of the PRA. This 
is especially important as PR-A is a known suppressor of PR-B (Vegeto et al., 1993).
Alternatively, the obvious regulation of FOXOl compared to AREG may be as a 
result of the PR mechanism of action. Ligand-bound PR directly activates promoters 
containing PREs, such as those found in FOXOl (Kyo et al., 2011). FOXOl was 
similarly up-regulated in vitro with each of the progestogens and in vivo with MPA. 
This may indicate that progestins similarly control targets that are regulated through 
direct signalling mechanisms. Indeed in the breast cancer cell line, T47D, a number 
of progestins have been shown to regulate direct PR targets with a highly similar 
mechanism of action (Bray et al., 2005). However, PR ligands can also activate genes 
by tethering to other transcription factors to regulate promoters lacking PREs, such as
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that of AREG, whereby the PR binds DNA via proteins such as SP1 (Cheng et al., 
2006) and tethers SRC3 in order regulate transcription (Han et al., 2006). Moreover, 
different PR isoforms are able to recruit different transcription factors (Giangrande et 
al., 2 0 0 0 ) and if the progestins have different affinities for these isoforms it is 
certainly possible gene regulation could be altered in this way.
Furthermore, the regulation of progesterone target genes may occur in a time and 
dose dependent manner (Yie et al., 2006), therefore these factors combined with 
progestin binding affinities may have further influenced the differences seen in target 
regulation.
Overall, data from this study and others show the adverse effects of progestin 
treatments (Wynn et al., 1979, Wynn and Niththyananthan, 1982, Ottoson et al., 
1984, Gruber and Huber, 2003, Lockwood et al., 2000, Murphy et al., 1986, Ellmann 
et al., 2009). Adverse signalling and gene regulation by progestins is of great 
importance. Not only can it cause minor side effects (Whitelaw et al., 1966, Hickey 
and d’Arcangues, 2002), but it may also affect levels of genes and proteins that can 
cause more serious problems such as the adverse regulation of oncogenes. Indeed 
progestin treatment has been linked to increased incidence of breast and endometrial 
cancer (Fournier et al., 2005, Stanford et al., 1995, Seeger et al., 2003, Kelley et al., 
1976, Kaaks et al., 2002).
Despite the reasons behind the differential regulation of these targets not being fully 
understood, it is clear that some differences are present. Although, in general, the 
clinical profile of synthetic progestins is accepted by the user, the known and 
unknown risks involved in their administration are cause for concern. Thus, natural 
progesterone is considered to be a better option in hormone therapies, particularly in 
the case of endometrial hyperplasia where serious side-effects caused by synthetic 
progestins have been described (Bafaloukos et al., 1999, Thigpen et al., 1999).
Moreover, the use of a vaginally delivered natural progesterone (micronized) cream 
to treat endometrial hyperplasia has been previously explored with complete 
regression in over 90% of patients and minimal side effects (Affinito et al., 1994, 
Baker et al., 2012). Furthermore, there has been a flurry of interest in the use of
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orally delivered natural, micronised, progesterone for endometrial hyperplasia 
treatment in recent years. Micronised progesterone has been shown to be effective 
given in 14 or 21 day regimens at 400mg per day causing decreased proliferative 
activity and activation of apoptosis in the hyperplastic endometrium (Chemukha et 
al., 2013). Micronised progesterone has also been shown to increase the regression 
rate of both simple and complex hyperplasia (Marra et al., 2014, Stanosz et al., 
2014). However, research suggests that synthetic progestins have better endometrial 
control (Tasci et al., 2014) which may be due to wide inter and intra patient 
variability associated with micronized progesterone (Levine and Watson, 2000b).
Effectively overcoming the poor bioavailability of progesterone has hindered 
pharmaceutical companies in producing a main-stream drug containing the natural 
product for the treatment of endometrial hyperplasia and other diseases. The poor 
bioavailability of progesterone can be largely attributed to its first pass metabolism. 
Thus, the following chapter will investigate the reasons behind the poor 
bioavailability of orally administered progesterone in order to probe the 
pharmacokinetics leading to the poor oral bioavailability of this compound.
3.6 Summary
Altogether, the data obtained within this study has highlighted key differences in the 
regulation of target genes and proteins by MPA, LNG and P4  in endometrial cell 
lines. The regulation of proteins by MPA in the HESC cell line also matched the 
regulation of proteins in vivo suggesting that the adverse regulation of these targets is 
also occurring in endometrial hyperplasia patients. This highlights the need for 
patients to receive a natural progesterone formulation.
The data obtained in this chapter also highlighted a number of progesterone targets as 
potential marker for the presence and progression of endometrial hyperplasia.
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4. Site Dependent Metabolism of Progesterone within the Gastro-Intestinal 
Tract
4.1 Introduction
The use of a natural progesterone for the treatment of endometrial hyperplasia has 
long been desired but has never been achieved, this is largely due to its low aqueous 
solubility (8.81pg/ml) (Yalkowsky et al., 2010) and its susceptibility to first pass 
metabolism followed by rapid clearance (Yamazaki and Shimada, 1997, Sitruk-Ware 
et al., 1987). Thus, synthetic progestins have become the choice hormones for the 
treatment of hyperplasia, yet they often lead to adverse side effects including 
headache, dizziness and nausea (Berenson and Wiemann, 1993). Furthermore 
research shows that the use of natural progesterone has fewer side effects than the 
synthetic progestins, it does not cause changes in the levels of important lipids, such 
as cholesterol, and it also prevents osteoporosis (Sitruk-Ware et al., 1987, Murray, 
1998, Rosano et al., 2000).
A large body of evidence has shown that the liver is responsible for a substantial 
proportion of progesterone first pass metabolism (Penning et al., 2000, Williams et 
al., 2004, Yamazaki and Shimada, 1997, Szklarz and Halpert, 1997a, Swart et al., 
1993a, Nebert and Russell, 2002), however, there is very little information on 
progesterone metabolism in the intestine. The only data that appears to be available 
is in early studies carried out over 30 years ago by Nienstedt et al (Hariri et a l, 1969, 
Nienstedt et al, 1980). The intestine is likely to be the most significant site of drug 
biotransformation outside of the liver, which is due to the presence of metabolising 
enzymes such as Cytochrome P450s (CYPs) and aldo-keto reductases (AKRs) 
(Thelen and Dressman, 2009, Barski et al., 2008). Suggesting the intestine may play 
a substantial role in progesterone metabolism after oral delivery.
Furthermore, different regions of the intestine have different metabolising 
capabilities due to the presence of enzymes within the intestinal mucosa, pancreatic 
enzymes and enzymes secreted from bacterial microbes. The presence of microbes 
increases substantially along the GI tract; in the stomach and small intestine the 
microbial count is 1 0 2 - 1 0 4  cfu/ml, this increases significantly in the lower part of the
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S 7small intestine to 1 0  - 1 0  cfu/ml and increases further in the colon to approximately 
10n -1012 cfu/ml (Jung and Kim, 2010).
Thus the aim of this study is to obtain an understanding of the first pass metabolism 
of progesterone following its oral administration; this will be done in order to 
identify an optimal site for delivery of progesterone where degradation is less 
significant. There are a number of objectives required in order to achieve this aim.
The first objective is to compare progesterone metabolism between liver and 
intestine in order to understand how relevant the metabolism by the latter is in 
decreasing the oral bioavailability of progesterone. This will be assessed in the 
presence and absence of inhibitors of all AKR isoforms independently and together. 
Enzyme inhibitors of potential non-NADPH dependent enzymes will also be 
incubated with liver cytosol to identify the potential enzymes involved in NADPH 
independent degradation of progesterone.
The second objective is to investigate the metabolic degradation of progesterone by 
intestinal mucosal enzymes by incubating with whole intestine homogenates and 
with homogenates of different sections of the intestine of rats. In order to obtain this 
goal the stability of progesterone in these homogenates will be determined in the 
presence and absence of nicotinamide adenine dinucleotide phosphate (NADPH). 
NADPH is a cofactor that acts as a source of electrons for redox reactions of several 
enzymes implicated in progesterone metabolism including CYPs and AKRs (Lemley 
and Wilson, 2010). Therefore, by incubating progesterone with and without NADPH, 
it can be determined to what extent progesterone metabolism can be accounted to 
NADPH dependent enzymes whose concentration throughout the GI tract is well 
documented (Thelen and Dressman, 2009, Mitschke et al., 2008, Chhabra, 1979).
The final objective is to investigate the stability of progesterone to enzymes present 
in the lumen of the gastro-intestinal tract. A simulated colonic fluid produced from 
faeces of healthy adult males will be used to evaluate stability to metabolism by 
faecal bacteria. As human fluids of the small intestine are difficult to obtain, 
simulated fluids containing pancreatin will be used as an to assess the stability of 
progesterone in this region. The currently available information on progesterone
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stability to intestinal bacterial metabolism is insufficient and this work will help 
clarify the true role of gut metabolism in progesterone bioavailability.
Investigation into the metabolism of progesterone throughout the GI tract will not 
only give novel insight into the complex degradation of this hormone, but it will also 
highlight the region of the GI tract where progesterone is most stable and least 
susceptible to enzymatic degradation indicating an optimum site for oral delivery.
4.2 Materials and Methods
Materials and methods used within this chapter are described in detail in Chapter 2.2. 
In brief, the stability of progesterone was determined in rat and human liver and 
intestinal homogenates using a multiwall plate assay with manual sampling at pre­
determined time-points. Progesterone concentration was then determined using LC- 
MS/MS. This methodology will be used as well to determine the stability of 
progesterone to liver and intestinal cytosol in the presence and absence of specific 
enzyme inhibitors detailed in Table 2.9. The stability of progesterone to simulated 
human intestinal and faecal fluid was determined as described above but UV-HPLC 
was used instead of LC-MS/MS for progesterone concentration quantitation.
4.3 Results and Discussion
4.3.1 Progesterone metabolism by human and rat liver homogenates.
Rat liver homogenates, prepared as described in Methods (Section 2.2.1), were 
incubated with progesterone for two hours in the presence and absence of NAPDH to 
determine the in vitro stability of progesterone in these conditions (Figure 4.1). 
Progesterone was shown to be completely degraded below the limit of detection 
within 10 minutes of incubation in the presence of NADPH with only 8 % of parent 
remaining at 5 minutes. An early study by Wiswel and Samuels (1953) showed that 
the a,P-unsaturated ketone structure in ring A of progesterone disappears on 
incubation with rat liver tissue in vitro. Rapid A-ring reduction has also been 
reported as the main route of progesterone metabolism in other studies in the rat liver 
(Yates et al., 1958, Shirley and Cooke, 1968). These suggest that A-ring reduction
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m ay be  the rou te o f  rap id  paren t dep le tio n  ob serv ed  in rat liver h o m o g en a tes  in the 
p resen ce  N A D PH  o b serv ed  in th is study  (F igu re  4 .1). In the absence  o f  N A D P H , the 
d ep le tio n  o f  p ro g este ro n e  is s ign ifican tly  s lo w er than  in the p resence o f  N A D P H  
(PcO.OOl) w ith ov er 40%  o f  d rug  still rem ain ing  afte r tw o  hours o f  incubation  
(F igu re  4.1). T o g e th e r these  data  suggest that enzym es o f  the N A D P H  p a th w ay  p lay  
a m ajo r ro le  in the d eg rad a tio n  o f  p ro g este ro n e  in the ra t liver. A n o th er in v estig a tio n  
into th e  stab ility  o f  p ro g este ro n e  in co m m o n  lab an im al livers has been  ca rried  ou t 
p rev iously . R ao and T ay lo r (1 964) d esc ribed  the ra te  o f  deg rad atio n  o f  rad io lab e lled  
p ro g este ro n e  in h o m o g en ised  liver tissue o f  the rat, gu inea-p ig , rabb it and ham ster. 
T hey  o bserved  that p ro g este ro n e  w as rap id ly  d eg raded  in rat, rab b it and  h am ste r 
livers bu t at a s low er ra te  in the gu inea-p ig . T he  au thors also  show ed  that g en d er can  
in fluence the ra te  o f  p ro g este ro n e  m etabo lism  in these species. F o r ex am p le , their 
data  show ed  that that p ro g este ro n e  is d im in ish ed  to ap p ro x im ate ly  10% w ith in  10 
m in u tes  in the m ale rat bu t it is less rap id ly  d im in ish ed  in the fem ale  (1 5 -2 0 %  in 
lO m inutes). T he p resen t study  o n ly  included  m ale rat livers since fem ale rat livers 
w ere u navailab le , how ever, the data  ob ta ined  is in ag reem en t w ith  the p rev ious 
fin d in g  reported  by  R ao and T aylor.
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Figure 4.1: Concentration (expressed as percent of initial value) of progesterone 
as a function of time of incubation with homogenates of the rat liver in the 
presence (blue) and absence (red) of NADPH (n=3, error bars are +/- SD).
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Akin to the degradation found in rat liver homogenates, natural progesterone was 
also completely degraded in vitro in the human liver with only 7% of parent 
compound detectable after 5 minutes of incubation in the presence of NADPH, this 
reaction was again slowed significantly in the absence of the cofactor (P>0.001) 
(Figure 4.2). In fact, the rate of metabolism was found to be significantly reduced in 
the absence of NADPH at each timepoint (P<0.001). In the absence of NADPH the 
initial rate of depletion was slow with >87% of parent compound detectable at 
20minutes, the rate of metabolism then increased rapidly with over 30% of the drug 
being metabolised between 20 and 30minutes, but as described for the rat liver, 40% 
of progesterone remained after the 2 h incubation period.
It has been previously reported that a major route of NADPH dependent metabolism 
is through CYP pathways. CYP mediated oxidative metabolism of progesterone 
predominantly occurs through hydroxylation, counting for 75% of metabolites found 
after progesterone incubation with liver microsomes (Waxman, 1988). However, it 
has been previously reported that the reduction of progesterone to a 3-hydroxy-5- 
pregnane derivative occurs before hydroxylation takes place. Following this reaction 
the progesterone molecule becomes sensitive to hydroxylation at various positions 
giving rise to a large quantity of metabolites (Kremers et al., 1981) which would 
explain the vast amount of hydroxylated metabolites seen in the study by Waxman et 
al.
The susceptibility of progesterone to CYP enzymes is well documented. Known 
CYP enzymes that catalyse the metabolism of progesterone include CYP2C3, 
CYP2C5, CYP2C9, CYP2C19, CYP3A4, CYP17A1 and CYP21A2 (Williams et al., 
2004, Yamazaki and Shimada, 1997, Szklarz and Halpert, 1997a, Swart et al., 1993a, 
Nebert and Russell, 2002). In particular several studies have shown that progesterone 
is a major substrate of CYP3A4 (Yamazaki and Shimada, 1997, Szklarz and Halpert, 
1997a, Williams et al., 2004). CYP3A4 oxidizes progesterone to form 16a-, 60-, and 
2 0 -hydroxyprogesterone as major products and 2 1 -hydroxyprogesterone as a minor 
product (Yamazaki and Shimada, 1997). A noteworthy difference between rat and 
human livers is the presence of different CYP enzymes, surprisingly the CYP3A4 
enzyme is absent in the rat liver (reviewed by (Martignoni et al., 2006), yet other
189
Chapter 4 Site Dependent Metabolism of Progesterone within the Gastro-Intestinal
Tract
C Y P 3 A  enzym es are p resen t in the rat liver and  in testine  such  as C Y P 3 A 9 , 
C Y P 3 A 6 2  and C Y P3A 1 m ay p lay  a sim ila r ro le  to C Y P 3 A 4  (M atsu b ara  et al., 2004 , 
C h ib a  et al., 1997). M ore C Y P  enzym es k now n  to ca ta lyse  p ro g este ro n e  are C Y P  
2C 9 and  2C 19 w hich  are also  p resen t in the h um an  liver yet absen t in the rat liver 
(M artig n o n i et al., 2006). N one the less, no sig n ifican t d iffe rences w ere ob serv ed  in 
th e  ra te  o f  deg radation  (k) b e tw een  h u m an  and ra t liver in the p resence o r absence o f  
N A D P H  w ith in  th is study  (F igu res 4.1 and 4 .2 ). H ow ever, it is w orth  no ting  that, 
w hen  on ly  look ing  at the 20m inute  tim e-p o in t there  is a sign ifican t d iffe rence 
b e tw een  the rat and h um an  sam ples (PcO.OOl).
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Figure 4.2: Concentration (expressed as percent of initial value) of progesterone 
as function of time of incubation with human liver homogenates in the presence 
(blue) and absence (red) of NADPH (n=3, error bars are +/- SD).
A s w ell as m em bers o f  the C Y P  fam ily  o f  enzym es, A K R s have a lso  been  reported  
to  be invo lved  in N A D P H -d ep en d en t p ro g este ro n e  m etabo lism  in the liver (P enn ing  
et al., 2000) and although  th e ir ro le  in p rog este ro n e  m etabo lism  is less w ell 
d o cu m en ted  than the ro le  o f  C Y P s, it is still po ssib le  that they are re sp o n sib le  fo r 
p art o f  the deg radation  seen  in liver h o m o g en a tes  w ith in  th is study.
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Differences between rat and human liver metabolism of some steroids has been 
analysed previously. One example of a difference in the metabolising capabilities of 
the human and rat livers is in the metabolism of the estrogen receptor antagonist, 
tamoxifen, whereby the amount of its hydroxylated metabolites are much lower in 
humans (Lim et al., 1994). Reduced steroidal glucoronidation has also been reported 
in the human liver compared to rats in the metabolism of the xenoestrogen, bisphenol 
A (Elsby et al., 2001).
Despite the differences in the apparent metabolising capabilities of rat and human 
livers, this study shows that the rate in which they are both capable of metabolising 
progesterone is similar. A rate constant of 0.014mm1 was obtained for progesterone 
depletion in human liver homogenate and a similar rate of 0.013mm'1 was obtained 
in rat liver homogenate in the absence of NADPH (Table 4.2) based on 60 minutes of 
incubation. The half-life of progesterone was also similar in rat and human liver 
homogenates in both the absence and presence of NADPH. In the presence of 
NADPH the half-life of progesterone was 3.6 minutes in human liver and 3.7 
minutes in rat liver and in the absence of NADPH the half-life of progesterone was 
81 minutes in human and 77minutes in rat. Both the rate constant and half-life of 
progesterone were similar in both human and rat suggesting, unlike with other 
steroids, the rat is a good model for assessing the rate of progesterone metabolism in 
liver tissue.
4.3.2 Progesterone Stability to homogenates of the Intestinal Mucosa
4.3.2.1 Progesterone metabolism by human and rat pooled small intestinal 
homogenates.
To further investigate differences in rat and human metabolising capabilities and to 
compare the rate of progesterone depletion in liver and intestine, progesterone was 
also incubated with pooled intestinal homogenates of human and rat.
There is no previous published data reporting the rate constant or half-life of 
progesterone in intestinal homogenates of any animal species. Indeed one study has 
looked at the metabolism of progesterone placed in the intestine of anaesthetised
191
Chapter 4 Site Dependent Metabolism of Progesterone within the Gastro-Intestinal
Tract
dogs but their repo rt shed ligh t on  m etab o lite  fo rm atio n  as o pposed  to  the  stab ility  o f  
the w ho le  d rug  in these co n d itio n s  (N iensted t and H artia la , 1969). T h u s  the data  
p resen ted  herein  p rov ides novel insight into the stab ility  o f  p ro g este ro n e  in the w hole  
sm all in testine  (poo led ) as w ell as its s tab ility  in the p rox im al and  d ista l sm all 
in testin e  and the large in testine  o f  a rat m odel.
In the poo led  in testine  o f  the rat, includ ing  a co m b in a tio n  o f  duo d en u m , je ju n u m  and  
ileum , p rogeste rone w as deg raded  to 74%  in  2 hours in the p resen ce  o f  N A D P H  
(F igu re  4 .3). In teresting ly  p ro g este ro n e  co n cen tra tio n s  rem ain ed  h ig h  (9 5 % ) in the 
sam e tim e fram e in the absence o f  N A D PH  su g g estin g  that the m ajo rity  o f  
p ro g este ro n e  m etabo lism  in the in testine is carried  out by  N A D P H  d ep en d en t 
enzym es (F igure 4.3).
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Figure 4.3: Concentration (expressed as percent of initial value) of progesterone 
as a function of time of incubation with pooled rat intestinal homogenates in the 
presence (blue) and absence (red) of NADPH (n=3, error bars are +/- SD).
U nlike the rat, a d iffe ren t effect can  be seen  in the h u m an  in testinal h o m o g en ates . 
T h e  stab ility  o f  p ro g este ro n e  to h o m o g en a tes  o f  the poo led  h um an  in testine  can be 
seen in F igure 4.4. A fter 120 m inu tes o f incubation  on ly  62%  o f  p aren t d rug  
rem ain ed  de tec tab le  in sam ples co n ta in in g  N A D PH . H ow ever in the ab sen ce  o f  a c o ­
facto r p ro g este ro n e  w as still degraded  to  68% , suggesting  that n o n -C Y P  en zy m es
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play  a sign ifican t ro le  in d eg rad atio n  o f  p ro g este ro n e  in the in testine . In b o th  the 
p resen ce  and absence o f  N A D P H  the d eg rad atio n  o f  p rog este ro n e  w as g radual and 
u n lik e  the rat did not p la teau  (F ig u re  4 .4 ).
T he  s tab ility  o f  p ro g este ro n e  in the h u m an  in testine  has only  been  reported  in a 
sing le  study  by  N iensted t et al. (1980). They desc ribed  p rog este ro n e  m etab o lism  in 
in testina l tissues o f  tw o adu lt m ale sub jects  and 13 hum an  foetuses. T h e  g roup  
o b ta in ed  tw o ileum  tissue sam ples and one co lon ic  sam ple  from  the adult m ales and 
o b ta in ed  in testinal ho m o g en ates from  the foetuses. A lthough  deta iled  in fo rm atio n  is 
av a ilab le  on  m etabo lite  fo rm ation , d eg rad atio n  ra te and h alf-life  are not d isc lo sed , 
bu t from  the data  it can be deduced  that afte r 2hours o f  incubation  w ith  rad io ac tiv e  
p ro g este ro n e  betw een  38 and 48%  o f  the d rug  rem ains in the adult m ale ileum  and  in 
the on e  co lon  sam ple  p ro g este ro n e  w as deg raded  to 36 .9%  in this tim e-fram e 
(N ien sted t et al., 1980). N o data  on  p rog este ro n e  m etabo lism  in the h u m an  
d u o d en u m  and je ju n u m  is ava ilab le . It is thus d ifficu lt to determ ine to w hat ex ten t 
d iffe ren t reg ions o f  the in testine  have an effect on p rogeste rone  stability .
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Figure 4.4. Concentration (expressed as percent of initial value) of progesterone 
as a function of time of incubation with pooled human intestinal homogenates in 
the presence (blue) and absence (red) of NADPH (n=3, error bars are +/- SD).
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The half-life of progesterone in the rat pooled small intestinal homogenate was 248 
minutes compared to 171minutes in the human intestine in the presence of NADPH 
(Table 4.1). Although the half-life appears much less in humans this was not 
statistically significant (P=0.24). Instead, a significant difference was observed in the 
half-life of progesterone between human and rat small intestine in the absence of 
NADPH (Table 4.2). Progesterone half-life was 1491 minutes in the rat and 166 in 
human which was deemed significant by t-test (P<0.05) (Table 4.2).
The human intestinal homogenate was obtained from a single individual, therefore 
these results could be different if intestinal homogenates obtained from various 
individuals were to be used. Moreover, this particular patient suffered from 
peritonitis, a condition that causes inflammation of the inner wall of abdominal 
organs, including the intestines (Verger et al., 1983). Peritonitis has been shown to 
alter enzyme expression in the intestinal mucosa (Ramachandran et al., 2002) so it is 
conceivable that the attained results are not representative of human healthy male 
individuals. Further to this, differences may have been found if samples had been 
obtained from females subjects.
Although there was a significant difference between the rat and human pooled 
intestine in the absence of NADPH this may have been due to the reasons discussed 
and the remainder of the results proved similar between species. Therefore, the 
intestinal mucosa studies were subsequently carried out in rat intestine as. a 
representative model for humans. This approach has been used previously when 
analysing progesterone metabolism in liver (Rao and Taylor, 1965, Waxman et al., 
1988).
4.3.2.2 Progesterone metabolism by homogenates of the proximal small intestine 
of the male rat
There is no published data establishing the stability of progesterone in different 
regions of the small intestine in rat. When incubated with rat proximal intestine, 
approximating the duodenum and jejunum, progesterone degradation seemed 
independent of a co-factor; in fact in both samples, the percent depletion was similar 
at all time-points which also resulted in a similar half-life in presence and absence of
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NADPH (described in Table 4.1 and 4.2). The overall degradation of progesterone 
was slightly greater in the rat jejunal mucosa compared to the duodenum with 64% 
of parent drug detectable in rat duodenum after 2hours compared to 58% detectable 
in jejunum in the presence of NADPH (Figure 4.5 Panel A vs Panel B). However in 
the pooled rat sample the cofactor seemed to have a greater impact on the 
degradation of progesterone which could potentially be due to the presence of distal 
small intestinal mucosa in the pooled intestine (Figure 4.3 compared to Figure 4.5). 
Unfortunately, the ileum was not available for analysis from individual male rat 
segments.
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Figure 4.5: A and B. Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with male rat proximal small 
intestinal homogenate sections approximating the duodenum (A) jejunum (B) in 
the presence (blue) and absence (red) of NADPH (n=3, error bars are +/- SD).
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4.3.2.3 Progesterone metabolism by homogenates of the proximal and distal 
small intestine of the female rat
It has been  p rev iously  rep o rted  th a t co m p o u n d  deg rad atio n  can  d iffer betw een  m ales 
and  fem ales (B ass et al., 1985, M artignon i et al., 2006), and th is has also  been 
dem o n stra ted  in the case o f  p ro g este ro n e  in the liver o f  ra ts (R ao  and T ay lo r, 1965). 
T o  de term ine  w he ther the p rox im al in testinal m ucosa (ap p ro x im atin g  the d u odenum ) 
o f  the fem ale  rat d iffered  from  that o f  the m ale, the s tab ility  o f p rog este ro n e  to 
fem ale  p rox im al sm all in testine  w as d e term in ed  (F igure  4 .6). D ue to sam ple 
u n ava ilab ility  the je ju n a l segm ent o f  the fem ale ra t w as no t analysed . A fter 2 hours 
p ro g este ro n e  w as d eg raded  to 70%  in the absence o f  N A D PH  and to  63%  in the 
p resence o f  N A D PH  (F igure  4.6).
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Figure 4.6: Concentration (expressed as percent of initial value) of progesterone 
as a function of time of incubation with female rat proximal small intestinal 
homogenate approximating the duodenum in the presence (blue) and absence 
(red) of NADPH (n=3, error bars are +/- SD).
S im ilarly , in the m ale rat, there w as a drop  in free p rog este ro n e  to 66% in the 
absence o f  N A D PH  and 65%  in the p resence  o f  N A D P H  (F ig u re  4.5 panel A). In the 
fem ale rat, N A D PH  appeared  to cau se  som e accelera tion  in p rog este ro n e  d ep le tion
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though  there  w as no s ign ifican t d iffe ren ce  in ra te co n stan t b e tw een  sam ples 
incubated  w ith N A D P H  and those incubated  w ithou t (T ab le  4.1 and 4 .2 ). T he  
d iffe ren ce  betw een  m ale  and fem ale ra ts w as not found  to  be sign ifican t. H ow ever, 
due to the ava ilab ility  o f  sam ple  and the fact that this d rug  is in ten d ed  fo r fem ale 
co n su m p tio n  fu rth er w ork  into the stab ility  o f  p rog este ro n e  in G I m u co sa  w as carried  
out in fem ale rats.
A kin  to  the p rox im al sm all in testine , the add ition  o f  N A D P H  to  h o m o g en a te s  o f  the 
d istal sm all in testine  o f  the  fem ale rat had  no s ign ifican t effec t on  the  d eg rad atio n  o f  
p rogesterone. A fter 2 h o u rs  o f  incubation  70%  o f  free p ro g este ro n e  w as detec ted  in 
the p resence  o f  N A D P H  and 57%  w as de tec ted  in the absence (F ig u re  4 .7). T he fact 
that am oun t o f d ep le tio n  w as g rea ter in the p resence  o f  N A D P H  suggests  that the c o ­
facto r had  abso lu te ly  no  in fluence on p ro g este ro n e  s tab ility  in the d ista l sm all 
in testinal m ucosa o f  the  fem ale rat.
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Figure 4.7: Concentration (expressed as percent of initial value) of progesterone 
as a function of time of incubation with female rat distal small intestinal 
homogenate approximating the ileum in the presence (blue) and absence (red) of 
NADPH (n=3, error bars are +/- SD).
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4,3.2.4 Progesterone metabolism by female rat large intestinal homogenates
A lthough  the m ost likely  rou te  o f  m etabo lism  in the large in testine  is th rough  
bacterial en zy m es, the p resence  o f  m ucosal enzym es in th is reg io n  has also  been 
docu m en ted  (T h o m  et al., 2005). T hus the stab ility  o f  p ro g este ro n e  to  h o m o g en ates  
o f  the fem ale  ra t large in testina l m u co sa  w as determ ined . A s w ith  the d ista l sm all 
in testine , the  ad d ition  o f  N A D PH  to the h o m o g en a te  cau sed  no sign ifican t change in 
p ro g este ro n e  d ep le tio n  (F igu re  4 .8). T h e  h a lf-life  o f  p ro g este ro n e  in co lon ic  m ucosa 
w as found to  be 139 m in u tes  in the p resen ce  o f  N A D PH  and 142 m inu tes in its 
absence (T ab le  4.1 and 4 .2).
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Figure 4-8. Concentration (expressed as percent of initial value) of progesterone 
as a function of time of incubation with female rat large intestinal homogenate 
(colon) in the presence (blue) and absence (red) of NADPH (n=3, error bars are 
+/- SD).
4.3.2.5 Where is progesterone most stable?
D ata ob ta in ed  fro m  p ro g este ro n e  stab ility  assays ca rried  out in h o m o g en a tes  o f 
d iffe ren t reg io n s  o f  the rat in testinal m ucosa w ere sta tis tica lly  ana lysed  (F ig u re  4.9).
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S ince the stab ility  o f  p ro g este ro n e  w as not deem ed  sta tis tica lly  d iffe ren t b e tw een  
m ale and fem ale  rats, these sam ples w ere poo led  in o rder to u n co v e r the reg ion  o f  
least m etabo lism  o f  p rogeste rone. T he  ra te  constan t o f  p ro g este ro n e  w as found  to be 
reduced  in the rat d istal sm all in testine  (ileum ) com pared  to  o th er reg ions o f  the 
in testine in both  the p resen ce  and  absence o f  N A D PH  and in m ost cases th is 
d iffe rence w as found  to be sign ifican t. T herefo re , h om ogenates o f  the d istal sm all 
in testinal m ucosa appear to  have the low est im pact on the ra te  o f  p ro g este ro n e  
depletion .
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Figure 4.9: Rate constant (m in 1) of progesterone in homogenates of the rat 
intestine approximating the duodenum, jejunum, ileum and colon.
In o rder to  sum m arise  the data  d isp lay ed  g raph ically  th ro u g h o u t th is chap te r the rate 
constan t, h a lf-life  and percen t d rug  rem a in in g  afte r 60 m inutes are d isp layed  in tab le
4.1 and 4.2.
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Sample (+NADPH) Rate constant (min1) Half-life(minutes)
% Drug remaining 
After 60minutes
Human Liver - 3 .5 5  ± 0 . 0 3 0
Human Intestine 0 .0 0 4 3 9  ± 0 .0 0 0 9 9 1 7 1 .4 2  ± 5 .8 5 7 7 . 1 3 ± 4 . 5 1
Rat Liver - 3 .7 1  ± 0 . 0 6 0
Rat Intestine 0 .0 0 4 4 5  ± 0 . 0 0 0 6 1 2 4 8 .0 8  ± 1 8 .7 9 7 6 .6 8  ± 2 .7 6
Male Rat Proximal
small intestine 0 .0 0 2 6 9 7  ± 0 .0 0 0 3 7 1 8 4 .7 6  ± 9 .6 9 8 5 .1  ± 1 . 8 8
(Duodenum)
Male Rat Proximal
small intestine 0 .0 0 7 2 0 2  ± 0 .0 0 0 3 1 3 4 .7 8  ± 4 .0 2 6 4 .9 3  ± 1 .1 5
(Jejunum)
Female Rat Proximal
Small Intestine 0 .0 0 4 6 1 6  ± 0 0 0 5 6 1 5 3 .6 5  ± 1 1 .2 2 7 5 .8 9  ± 2 .5
(Duodenum)
Female Rat Distal 
Small Intestine (Ileum)
0 .0 0 1 8 3 2  ± 0 .0 0 0 2 7 1 4 3 .4 5  ± 1 4 .2 1 8 9 .6 1  ± 1 .4 6
Female Rat Large 
Intestine (Colon)
0 .0 0 8 1 3  ± 0 . 0 0 2 5 4 1 3 8 .6 3  ± 2 9 .7 6 7 5 . 2 9 ± 2 . 1 6
Table 4.1: The mean (± S.D) degradation rate (k min-1), half-life (tl/2 min) and 
% drug remaining after 60 minutes for progesterone after incubation with rat 
and human tissue homogenates in the presence of NADPH.
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Sam ple ( NADPH) Rate constant (m in 1) Half life(m inutes)
% Drug rem aining 
After 60m in u tes
Human Liver 0.01397 ± 0.00106 80.91 ± 1.05 43.42 ± 2.8
Human Intestine 0.00224 ± 0.00084 166.56 ±8.10 87.65 ± 4.32
Rat Liver 0.01293 ± 0.00014 77.38 1 ±.20 46.04 ± 0.4
Rat Intestine 0.00063 ± 0.00104 1491.08 ± 127.70 96.69 ± 6.2
M ale Rat Proximal
small in testine 0.0031 ±0.00053 184.54 ±13.44 83.12 ± 2.6
(Duodenum)
M ale Rat Proximal
small in testine 0.00759 ± 0.00041 132.37 ±3.71 63.47 ± 1.58
(Jejunum)
Fem ale Rat Proximal
Small Intestine 0.00246 ± 0.00172 186.71 ±21.91 87.17 ± 8.83
(Duodenum)
Fem ale Rat Distal
Small Intestine 0.00301 ± 0.00033 204.32 ±9.28 83.5 ±1.64
(Ileum)
Fem ale Rat Large 
In testine  (Colon)
0.00474 ± 0.00047 141.9573 ±15.54 73.64 ± 2.16
Table 4.2: The mean (± S.D) degradation rate (k min-1), half-life (tl/2 min) and 
% drug remaining after 60 minutes for progesterone after incubation with rat 
and human tissue homogenates in the absence of NADPH.
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4.3.3 Progesterone Metabolism in Human Liver and Intestinal Cytosol
4.3.3.1 Progesterone metabolism in liver cytosol -  NADPH dependent enzymes
To further investigate progesterone metabolism, the stability of this compound was 
determined in liver cytosol in the presence of specific enzyme inhibitors including 
AKRs inhibitors in the presence and absence of the NADPH co-factor.
Aldo-Keto Reductase Inhibitors
As discussed, enzymes of the cytochrome P450 family play a significant role in 
progesterone metabolism in the liver, particularly CYP3A4 (Yamazaki and Shimada, 
1997, Szklarz and Halpert, 1997a, Williams et al., 2004). However, the role of 
aldoketo reductases (AKRs) in progesterone metabolism is also important. AKRs are 
a superfamily of NADPH-linked oxidoreductases involved in endogenous and 
xenobiotic metabolism (Penning and Drury, 2007). Their role in progesterone 
metabolism has been investigated previously (Penning et al., 2000, Charbonneau and 
The, 2001, Chen et al., 2011) but to a lesser extent than CYP enzymes. Hence the 
role of AKRs in progesterone metabolism was investigated herein. Enzymes of the 
AKR1C family have been shown to be involved in the oxidation of progesterone 
(Penning et al., 2000) and are highly expressed in the human liver (Palackal et al., 
2002). Diazepam is a known inhibitor of all members of the AKR1C subfamily 
(Byms et al., 2011, El-Kabbani et al., 2011) and is a more potent inhibitor of the 
AKR1C1, 1C2 and 1C4 isoforms relative to AKR1C3 (Byms et al., 2011). However, 
no difference was observed in progesterone metabolism with Diazepam incubation in 
human liver cytosol compared to incubation with cytosol alone (Figure 4.10). The 
reason for no observed change is unclear; however, previous findings by Penning and 
colleges (2000) were based on incubations with recombinant human liver AKRs 
which may have yielded different results to those found within this study. The study 
by Penning and colleagues uses specific enzyme concentrations whereas the level of 
AKRs in the homogenates used in this study were not predetermined (Penning et al., 
2000).
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AKR1D1 is also known to metabolise progesterone. AKR1D1 is able to catalyse the 
conversion of progesterone to 5p-dehydroxy progesterone (Charbonneau and The, 
2001, Chen et al., 2011). Finasteride is a synthetic drug used in the treatment of 
prostate hyperplasia and is a competitive inhibitor of AKR1D1 but with low 
micromolar affinity (Drury et al., 2009). Finasteride is also a 5a-reductase inhibitor 
(Tian et al., 1994) and progesterone is a known substrate of 5a-reductase (Azzouni et 
al., 2011). When incubated with intestinal cytosol and NADPH in the presence of 
Finasteride, the rate of progesterone degradation was reduced significantly (P=0.03), 
taking more than 1 2 0  minutes to fully metabolise compared to complete metabolism 
in less than 60 minutes when incubated with cytosol alone (Figure 4.10). It is not 
clear whether the inhibition of AKR1D1 or 5a-reductase had the largest impact on 
the rate of progesterone metabolism but as finasteride is a more potent inhibitor of 
5a-reductase this is likely to have a substantial influence.
The final AKR enzyme investigated was AKR1B1. AKR1B1 has not been shown to 
be involved in the metabolism of progesterone and it is likely to play a role in the 
initiation of labour through metabolism of prostaglandins (Byms, 2011). It has been 
reported that prostaglandins are involved in progesterone production and their 
inhibition can lead to a reduction in progesterone in uterine tissue (Elvin et al., 2000, 
Speroff and Ramwell, 1970). Although, there is no evidence suggesting this kind of 
reaction is catalised in liver cytosols. To investigate the role of AKR1B1 on 
progesterone metabolism Epalrestat was incubated with progesterone in the liver 
cytosol solution. Epalrestat is an AKR inhibitor shown to inhibit AKR1B1 (Zhang et 
al., 2013, Liu et al., 2009). Like Finasteride, Epalrestat significantly reduced the rate 
of progesterone metabolism (P=0.04). Eleven percent of progesterone could still be 
detected after 60 minutes of incubation compared to complete degradation of 
progesterone by this time-point in the absence of an inhibitor, suggesting AKR IB 1 
plays a previously unreported role in progesterone metabolism.
In the presence of all three inhibitors (AKR cocktail) the rate of progesterone 
metabolism was significantly reduced with more than 32% of free progesterone still 
detectable after 1 hour and almost 1 0 % of free progesterone still detectable after 2  
hours (Figure 4.10). The decrease in metabolism caused progesterone half-life to
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increase sign ifican tly  from  11 m inu tes in the  absence o f  an in h ib ito r and to 52 
m inu tes in the p resence o f the A K R  cock ta il (P < 0 .01 ). T he d ecrease  in p ro g este ro n e  
m etabo lism  in the p resence o f  A K R  inh ib ito rs  suggests  a substan tia l ro le  o f  A K R s in 
p rog este ro n e  m etabo lism .
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Figure 4.10: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human liver cytosol and 
ImM of NADPH alone (red) or with NADPH and Epalrestat (Green), 
Finasteride (Purple), Diazepam (Light Blue) or a combination of all three (Dark 
blue) (n=3, error bars are +/- SD).
T o confirm  that the enzym e in h ib ito rs  w ere  spec ifica lly  in h ib iting  N A D P H - 
dep en d en t enzym es, p rog este ro n e  w as also  incubated  w ith all d iscu ssed  in h ib ito rs  in 
liver cy toso l in the absence o f  N A D P H  and, as expected , no ch an g e  w as o bserved  
(F igu re  4 .11).
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Figure 4.11: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human liver cytosol in the 
absence of enzyme inhibitor (red) or in the presence of Epalrestat (Green), 
Finasteride (Purple), Diazapam (Light Blue) or a combination of all three (Dark 
blue) (n=l).
4.3.3.2 Progesterone metabolism in liver cytosol -  Non-NADPH dependent 
enzymes
A s w ell as illu s tra tin g  the ro le  o f  d iffe ren t enzym es in p rogeste rone  m etabo lism , the 
w ork  carried  ou t in liver cy toso l in the p resence  and absence o f N A D PH  also  show ed  
that, w ithou t en zy m e inh ib ito rs, p ro g este ro n e  w as still dep le ted  to alm ost h a lf  its 
in itial value  in the absence o f  a co fac to r (F igu re  4 .11 , red  line). T here  is very  little  
in fo rm ation  on  p ro g este ro n e  m etab o lism  by  enzym es that do  not requ ire  N A D PH  as 
an  e lec tro n  donor; th ere fo re  som e key , n o n -N A D P H , enzym es w ere investigated  for 
th e ir po ten tia l ro le  in p ro g este ro n e  m etabo lism .
A ld eh y d e  and X an th in e  O x idase  Inh ib ito rs
A ld eh y d e  o x id ases  co n stitu te  a sm all sub -fam ily  o f  enzym e (G arattin i et al., 2009) 
and  are not k n o w n  to be invo lved  in p ro g este ro n e  m etabo lism . A s one o f  the m ost
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im portan t n o n -P 4 5 0  enzym es in drug  m etabo lism  (B eedham , 1997), the ro le  o f  
A ldehyde O x idases in p rogeste rone m etabo lism  w as assessed . H ydra lazine  and  
C h lo rp ro m azin e  are po ten t in h ib ito r o f  a ldehyde o x idase  ac tiv ity  in vitro  and in vivo  
(Johnson  et al., 1985, O bach  et al., 2004) and w ere thus incubated  w ith  p rog este ro n e  
in liver cy toso l (F igu re  4 .12). It w as con firm ed  that a ld eh y d e  ox id ases  do not affec t 
p rogeste rone  deg rad atio n  since  no changes w ere o bserved  in the rate o f  reduction  o f  
p rog este ro n e  in the p resence and absence o f  these inh ib ito rs (F ig u re  4 .12).
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Figure 4.12: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human liver cytosol in the 
absence of enzyme inhibitor (red) or in the presence of Hydralazine (Blue) or 
Chlorpromazine (Green) (n=3, error bars are +/- SD).
X anth ine ox idases are stru c tu ra lly  re la ted  to a ldehyde  o x id ases (G arattin i et al., 
2009) and  their ro le  is generally  accep ted  as a fundam en tal enzym e in purine  
ca tab o lism , yet the structu ral com plex ity , low substra te  spec ific ity  (H arrison , 2002) 
and spec ia lised  tissue d is trib u tio n  (H uh  et al., 1976) ind icate  that o th er ro les for these  
enzym es m ay yet to  be identified . X an th ine ox id ase  has been  reported  to cause
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inh ib itio n  o f  p ro g este ro n e  p ro d u c tio n  in lu teal ce lls (G atzu li et al., 1991, O ta  et al., 
2001), but no d irec t in teraction  o f  xan th in e  ox idase  and  p ro g este ro n e  has been  
reported . A llopu rino l is a co m m o n ly  ad m in is te red  d rug  k n o w n  to inh ib it x an th in e  
ox id ase  (P ach er et al., 2006 , M assey  et al., 1970). A fter, 2 hours o f  in cu b a tio n  in 
liver cy toso l in the p resence  and absence  o f  alluporino l no  d iffe ren ce  w as observ ed  
in the ra te  o f  p ro g este ro n e  deg rad atio n  (F ig u re  4 .1 3 ) su g g estin g  no d irec t in te rac tion  
betw een  x an th ine  o x id ase  and p ro g este ro n e  m etab o lism  in the  liver.
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Figure 4.13: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human liver cytosol in the 
absence of enzyme inhibitor (red) or in the presence of Allopurinol (Blue) 
(n=l).
L ike h y d ra laz in e  and  ch lo rp ro m azin e , m en ad io n e  is a lso  an a ld eh y d e  o x id ase  
in h ib ito r (O bach  et al., 2004). In add ition , m enad ione inh ib its  several enzym es 
inc lu d in g  an ilin e-p -h y d ro x y lase  ac tiv ity  and can n eg a tiv e ly  affect C Y P  red u ctase  
ac tiv ity  (F lo rean i and  C arpenedo , 1990). T h erefo re , p ro g este ro n e  w as in cu b ated  w ith  
M en ad io n e  in liver cy toso l in the p resence  and absence o f  N A D PH  (F ig u re  4 .14).
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M enad ione sig n ifican tly  inh ib ited  p ro g este ro n e  deg radation  at a s im ilar level in bo th  
the p resen ce  (P = 0 .0 5 ) and  absence o f  N A D P H  (P = 0 .002) suggesting  m enad ione  d id  
not inh ib it N A D P H -d ep en d en t enzym es. M oreover, p rev ious incubation  o f  
p rog este ro n e  w ith  the a ld eh y d e  o x idase  inh ib ito rs, h y d ra laz in e  and ch lo rp ro m azin e , 
did not affect the  ra te  o f  p ro g este ro n e  d eg rad atio n  (F igu re  4 .12). T h is  suggests 
m en ad io n e -in d u ced  a ld eh y d e  o x id ase  in h ib ition  is no t resp o n sib le  for the decrease in 
the ra te  o f  p ro g es te ro n e  m etabo lism . M enad ione is a lso  capab le  o f  inh ib iting  
N R H :qu inone o x id o red u c tase  2 (N O Q 2) (L ong  et al., 2002). N O Q 2 is a cy toso lic  
flavopro te in  that u tilises  d ih y d ro n ico tin am id e  riboside  (N R H ) as an e lec tron  do n o r 
(M egarity  et al., 2 0 1 4 ) bu t this w ould  requ ire  the p resence o f  N R H  in the liver 
cy toso l w hich  has no t been  confirm ed . T h is d ata  p resen ts  novel insight in to  
p rogeste rone m etab o lism  in the liver suggesting  a ro le  fo r not on ly  the w ell 
charac te rised  N A D P H -d ep en d en t enzym es but also  for enzym es that do  not requ ire  
N A D PH  as a co fac to r. T he p rec ise  enzym es invo lved  in the no n -N A D P H  
m etabo lism  o f  p ro g este ro n e  requ ires fu rther in vestiga tion  bu t at least w ith in  th is
♦  ■ - In h ib ito r  
—• — -Inhib itor+ N A D P H  
♦ M e n a d io n e  
——  + M e n a d io n e  +NADPH
Figure 4.14: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human liver cytosol alone 
(blue) or with Menadione (Green) or incubated with human liver cytosol plus
study their ro le h as  been  show n to be sign ifican t.
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ImM  of NADPH (Red) or with human liver cytosol plus ImM of NADPH with 
Menadione (Purple) (n=3, error bars are +/- SD).
4.3.3.3 Progesterone metabolism in intestinal cytosol
T he s tab ility  o f  p ro g este ro n e  w as also  assessed  in hum an  in testinal cy toso l in the 
p resen ce  and absence  o f  N A D PH . A fte r 2 h ours o f  incubation  free p rog este ro n e  w as 
d ep le ted  to 57%  o f  its initial value  in the p resence  o f  N A D PH  and th is w as reduced  
to 72%  in the absence o f  N A D PH  (F ig u re  4 .15). T h is  led to  a s ign ifican t d iffe ren ce  
in p ro g este ro n e  ha lf-life  (P > 0 .05 ); w h ereb y  in the p resence  o f  N A D P H  the h a lf-life  
o f  p ro g este ro n e  w as 131 m inu tes and in the absence  o f  N A D PH  this w as reduced  to  
209 m inu tes. T he o ccu rren ce  o f  N A D P H  d ep en d en t enzym es, includ ing  C Y P s and 
A K R s, is w ell d o cu m en ted  in the hum an  in testine  (T helen  and D ressm an , 2009 , 
B arski et al., 2008) w h ich  is the likely  reason  for the increase  seen  in the p resence o f  
N A D PH .
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Figure 4.15: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human intestinal cytosol 
either alone (blue) or combination with ImM of NADPH (red) (n=3, error bars 
are +/- SD).
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As the largest amount of metabolism was observed in the presence of NADPH, it 
was decided to further investigate the role of NADPH-dependent enzymes only in 
progesterone depletion in intestinal cytosol. AKRs are found throughout the human 
gastrointestinal tract at varying levels (Palackal et al., 2002), with the highest levels 
being found in the proximal regions of the small intestine. Moreover the expression 
of distinct subtypes of these enzymes differs between regions of the small and large 
intestine (Barski et al., 2008). For example, enzymes of the AKR1C family are 
involved in the oxidation of progesterone and can be found at varying levels in small 
intestine with the exception of AKR1C4 which is found almost exclusively in the 
liver (Penning et al., 2000). Progesterone was incubated with intestinal cytosol in the 
presence of diazepam, a known inhibitor of the AKR1C subfamily (Byms et al., 
2011, El-Kabbani et al., 2011) as well as a combination of diazepam and flufenamic 
acid. Flufenamic acid is also a known inhibitor of AKR 1C (Bauman et al., 2005, 
Adeniji et al., 2012).
After 2 hours of incubation in the absence of an inhibitor, free progesterone was 
reduced to 57%, however progesterone metabolism was significantly reduced to 65% 
in the presence of diazepam (P>0.01) and to 64% in the presence of AKR 1C cocktail 
(P>0.05) (Figure 4.16). The addition of the AKR1B1 inhibitor, Epalrestat also 
significantly reduced progesterone depletion to 6 8 % (P>0.01). Free progesterone was 
found to be 67% in the presence of the AKR ID 1 inhibitor Finasteride after 2 hours 
of incubation which was, again, a significant reduction compared to the minus 
inhibitor sample (P>0.01). The reduction in progesterone depletion with the addition 
of AKR inhibitors in intestinal cytosol confirms that members of this family of 
enzymes play a role in progesterone stability in the human intestine and may 
influence the overall bioavailability of progesterone after oral administration.
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Figure 4.16: Concentration (expressed as percent of initial value) of 
progesterone as a function of time of incubation with human intestinal cytosol 
alone plus ImM of NADPH in the absence of an inhibitor (red) or in the 
presence of Diazepam (Purple), Epalrestat (Green), Finasteride (Light Blue) or 
AKR1C cocktail containing Diazepam and Flufenamic acid (Dark Blue) (n=3, 
error bars are +/- SD).
4.3.4 Stability of Progesterone in Simulated Fluids of the Intestine
A s w ell as in testinal m ucosa, in testinal flu id  is also  capab le  o f  d rug  m etab o lism  due 
to the p resence  o f  bac te ria l enzym es and enzym e secretions from  the p an creas  and 
m ay im pact on drug  stab ility  and overall b ioavailab ility . P ro g estero n e , m ain ly  as 
m etabo lites , has been recovered  from  the faeces and urine o f  p rim ates a fte r oral 
ad m in is tra tio n  w ith  over 40%  o f  the to tal d rug  recovered  rep o rted ly  b e in g  found  in 
faeces (W asser et al., 1994, Z ieg ler et al., 1989) thus show ing  that a large  p o rtio n  o f 
o ra lly  ad m in is te red  p rogeste rone reaches the ileo -co lon ic  reg io n  o f  the 
g astro in testinal (G I) tract. It has been  suggested  that p rog este ro n e  is ab le to  undergo  
en tero h ep atic  c ircu la tion  (S ym onds et al., 1994), if  th is is indeed  the case  then  it m ay 
be that p ro g este ro n e  requ ires en zy m atic  m etabo lism  in o rder to  be re -ab so rb ed . T he 
availab le  in fo rm ation  on p ro g este ro n e  stab ility  to  co lon ic  bac teria l m etab o lism  is
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insufficient with the available studies providing no quantitative information but only 
highlighting the metabolites formed from such incubations. Furthermore the 
available studies were all carried out before 1980 (Schubert et al., 1964, 
Bokkenheuser et al., 1977, Eriksson and Gustafsson, 1970, Adlercreutz et al., 1979). 
Therefore, the stability of progesterone to metabolism by simulated intestinal fluids 
was assessed herein.
4.3.4.1 Solubility of Progesterone in Simulated Small Intestinal and Colonic 
Fluids
The method used to assess the stability of progesterone in simulated fluids involved 
incubating a solution of progesterone with simulated colonic fluid (SCF) and 
simulated intestinal fluid (SIF). However, seeing that progesterone is very poorly 
soluble there is a risk of precipitation on addition of the progesterone solution into 
the SIF/SCF.
Simulated fluids were prepared using a PBS phosphate saline buffer (see Materials 
and Methods Section 2.2.5), therefore the solubility of progesterone in PBS was 
determined and found to be >2pg/ml. Thus, the addition of different solvents and 
solubilisers were assessed as a means of enhancing progesterone solubility for this 
stability assay. Two solvents, DMSO and ethanol, were assessed in combination with 
the solublilisers Cremophor or Tween80. The findings suggested that the solubility 
of progesterone in PBS was enhanced most by the addition of DMSO and Tween80 
(Figure 4.17). The solubility of progesterone in this solution was approximately 
50pM.
The presence of proteins such as albumins in faeces is also likely to increase the 
solubility of progesterone. Hence the solubility of the progesterone solution was 
assessed in simulated colonic fluid (SCF) before running the experiment. It was 
observed that progesterone was soluble at a concentration of 65pM in this solution, 
thus this concentration was used for intestinal fluid stability assays. 65pM was 
deemed to be sufficient progesterone content to visualise degradation by UV-HPLC.
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Figure 4.17: Solubility (pM) of progesterone in four solutions: 1. PBS with 
l% DM SO and 1% Tween80, 2. PBS with l% Ethanol and l%Tween80, 3.PBS 
with l%DMSO and 1 % Cremophor and 4.PBS with 1% Ethanol and 
l% Crem ophor (n=3, error bars are +/- S.D.). Solubility of progesterone was 
determined as described in Section 2.2.4 (Materials and Methods).
4.3.4.2 Simulated Intestinal Fluid with Pancreatin
A s sm all in testinal flu id  is d ifficu lt to  access, sim u la ted  flu ids o f  the sm all in testine 
w ere  used  as an alternative . S im u la ted  in testinal flu id  (S IF) w as p ro d u ced  w ith 
p an c rea tin  as d esc ribed  in M ateria ls and M ethods S ection  2 .2 .5 . P an crea tin  con tains 
en zy m atic  co m p o n en ts  p roduced  b y  the exocrine  cells o f  the pancreas includ ing  
trypsin , am ylase , lipase, ribonuclease , and  p ro tease  (D esnuelle  and R o v ery , 1961). 
6 5 p M  o f  p rogeste rone , d isso lv ed  in D M S O  and T w een 8 0  w as incubated  w ith  SIF 
p lu s pancrea tin  fo r 24h (F ig 4 .18). T h ere  w as no change in p ro g este ro n e  
co n cen tra tio n  after 2 hours o f  incu b atio n  w ith  S IF  p lus pancrea tin . F u rth e r sam ples 
w ere  taken  at 6 and  24hours bu t no  s ign ifican t change in the level o f  p ro g este ro n e  
w as o bserved  (F igu re  4 .18). T he  d a ta  suggests that the enzym es p resen t in pancrea tin  
are not ab le to m etabo lise  p ro g este ro n e . H ow ever, it is qu ite  likely  that bac teria l 
en zy m es present in the sm all in testine  w ould  play  a far m ore s ig n ifican t ro le  in 
p ro g este ro n e  d eg rad atio n  in natu ra l h u m an  in testina l fluid.
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Figure 4.18: Stability of progesterone (concentration expressed as percent of 
initial value) in simulated intestinal fluid plus pancreatin measured by HPLC 
(n=3, error bars are +/- SD).
4.3.4.3 Progesterone Stability in Simulated Colonic Fluid
T o assess the stab ility  o f  p rog este ro n e  in sim u la ted  co lon ic  flu id  (faecal slu rry , SC F), 
the faeces o f  tw o hea lthy  adu lt m ales w ere o b ta ined  and a slu rry  w as p roduced  as 
desc ribed  in M ateria ls and M ethods S ection  2 .2 .5 . T here  are cu rren tly  no 
co m m erc ia lly  ava ilab le  m ix tu res o f  co lon ic  enzym es w hich  is due to the vast 
quan tity  o f  enzym es p resen t in th is flu id , som e o f  w hich  have not been  identified . 
T h erefo re , the p repara tion  o f  S C F  from  by  suspend ing  faeces in bu ffered  so lu tion  is 
the best m ethod  fo r assessing  co lo n ic  d ru g  m etabo lism .
B efore assessing  the stab ility  o f  p ro g este ro n e  to SC F , the am oun t o f  N A D PH  present 
in the S C F  w as determ ined , as the level o f  co -fac to r ava ilab le  to p rogesterone- 
m etab o lis in g  enzym es can have a sign ifican t im pact on the stab ility  o f the d rug  as 
ob serv ed  in liver ho m o g en ates ex p e rim en t described  in this ch ap te r (F igure  4 .10).
T he level o f N A D PH  w as d e term in ed  by  H PL C  by co m p arin g  s tandards o f know n  
co n cen tra tio n s o f N A D PH  to levels o f  N A D P H  found  w ith in  the SC F. T he S C F  w as 
also  sp ik ed  w ith  N A D PH  to co n firm  the peak  o bserved  at the co rrec t re ten tion  tim e
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w as indeed  N A D P H  and not co n tam in an ts  from  w ith in  the slurry. F igure  4 .19  show s 
the H P L C  ch ro m ato g ram  ob ta in ed  fo r th is experim ent.
Figure 4.19: Chromatogram showing levels of NADPH in three solutions. 
NADPH standard containing 1 2 0 |liM  NADPH in PBS (with 1% DMSO and 1% 
Tween) can be seen in red, NADPH levels in faecal slurry can be seen in green 
and faecal slurry spiked with 120pM of NADPH can be seen in pink. A blank 
sample containing buffer only (PBS plus 1% DMSO and 1% Tween) is also 
present on the chromatogram in blue with no visible peak.
U sing  the lin ear eq u a tio n  ob ta in ed  from  5 standards o f  d iffe ren t concen tra tion  o f  
N A D PH , the  final co n cen tra tio n  o f  N A D P H  in S C F  w as d e term in ed  to  be 5 0 3 .9 6 p M  
at the tim e o f  the  experim en t. T h erefo re , N A D P H  w as not added  to the  incubation  o f  
p ro g este ro n e  w ith  S C F  as su ffic ien t am oun ts o f  this co -fac to r w ere  a lready  p resen t 
(F igure 4 .19).
4.3.4.4 Stability of Progesterone to SCF
T he m e tab o lism  o f p rogeste rone by  h um an  co lon ic  bac teria  has been  investigated  
p rev io u sly  (S chubert et al., 1964, B o k k en h eu ser et ah , 1977, E riksson  and 
G u stafsso n , 1970, A d le rc reu tz  et ah, 1979). P ro g estero n e  is reduced  to  
te trah y d ro d eriv a tiv es  w hen  incubated  w ith  in testinal m icro o rg an ism s (S chubert et 
ah, 1964). In add ition  p rog este ro n e  is transfo rm ed  to p regnaned ione  w hen incubated
< NADPH in faecal slurry'spiked with 120pM NADPH (Pink)
NADPH in faecal slurry (Green)
300
100
N.ADPH standard (120pM )-------- >
(Red)
Buffer only (Blue)
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with the faecal bacteria E.Lentum and C.Paraputrificum, (Bokkenheuser et al., 
1977). Other previous studies have also described the bacterial metabolism of 
progesterone (Adlercreutz et al., 1979, Eriksson and Gustafsson, 1970). These 
studies provide a good insight into the type of metabolism that may occur in colonic 
fluid but do not provide any information on the rate of progesterone degradation or 
its half-life in such conditions. As well as progesterone there is very little 
information on MPA and no data available on LNG metabolism in the colon. There 
is, however, a great deal of information available on the metabolism of MPA and 
LNG in the liver (Thigpen et al., 1999, Pannuti et al., 1982, Eriksson and Gustafsson, 
1970, Fotherby, 1996, Humpel et al., 1978, Grimmer et al., 1986, Back et al., 1987). 
MPA, like progersterone, has low oral bioavailability which estimated to be as low 
as 15% (Fotherby, 1996, Adlercreutz et al., 1983b, Pannuti F, 1982) whereas LNG 
has a very high oral bioavailability of more than 87% (Humpel et al., 1978, Grimmer 
et al., 1986, Back et al., 1987). Due to the substantial differences seen in the oral 
bioavailability of progesterone, MPA and LNG as well as the lack of previous 
research, the stability of all three hormones was assessed in SCF.
The degradation of each hormone in SCF is represented in Figure 4.20A and an 
example chromatogram can be seen in Figure 4.20B. Progesterone was rapidly 
degraded within 2 hours of incubation whereas MPA and LNG were degraded at a 
slower rate. Within 60 minutes only 12% of progesterone remained detectable by 
HPLC whereas more than 80% of LNG and MPA could be detected at this time- 
point. Each drug was also incubated with buffer only for 24hours with >99% 
recovery confirming that the observed degradation was a result of faecal bacteria and 
enzymes (Appendix M).
LNG is derived from and structurally similar to testosterone but with the addition of 
an ethynyl group (HC=C) to significantly reduce androgenic activity (Stanczyk, 
2002). Unlike progesterone, the oral bioavailability of LNG is considered to be very 
high (>87%). However LNG has been shown to undergo extensive reduction at the 
a,P-unsaturated ketone in ring A and hydroxylation at carbons 2 and 16 (Stanczyk 
and Roy, 1990). Reduction is also likely to play a role in the degradation of LNG in
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the co lo n  seen w ith in  th is study. Indeed  en zy m es from  several bac te ria  stra in s have 
been  im p lica ted  in the o x id o -red u c tio n  o f  s tero ids (A ries and H ill, 1970).
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Figure 4.20 A: Stability of progesterone (concentration expressed as percent of 
initial value) in simulated colonic fluid measured by HPLC (n=3, error bars are 
+/- SD). B: An example chromatogram of progesterone at t-0 of study.
T he data  ob ta ined  in this study  sh o w s that LN G  is suscep tib le  to gradual d eg rad a tio n  
un d er co lon ic  cond itions ov er a p e rio d  o f  at least 6 hours, w ith a half- life o f  192 
m inu tes. S im ilar to L N G , M PA  w as d eg rad ed  g radually  in the p resence o f  co lon ic
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bacteria but had a greater half-life of 327 minutes. MPA differs from progesterone by 
the addition of a hydroxyl group which has been acetylated at carbon 17 and the 
further addition of a methyl group at carbon 6  (Stanczyk, 2002). Like LNG, MPA 
also undergoes extensive metabolism by A-ring reduction but also undergoes 
hydroxylation at carbons 6  and 2 0  and conjugation (primarily glucuronidation) with 
subsequent elimination in urine (Stanczyk, 2002).
Some studies have looked into MPA metabolism by intestinal bacteria. In particular a 
study by Martin et al (1980), revealed that MPA is readily reduced in cultures of 
human faecal bacteria and rat caecal bacteria incubated aerobically or anaerobically. 
In both the human faecal and rat caecal bacteria, MPA was metabolised mainly to 
tetrahydro-derivatives but also dihydro-derivatives and the author suggests that A- 
ring reduction in both the liver and intestine are possible fates of MPA in humans 
(Martin et al., 1980). Despite the large amount of information provided on MPA 
metabolism, the percent of free parent drug remaining after incubation has not yet 
been explored. However, due to its reported susceptibility to intestinal reduction it 
was hypothesised that MPA would be rapidly and completely reduced in simulated 
colonic fluids yet more than half of free drug remained after 6 h of incubation with 
>10% still detectable after 24hours. It has been previously suggested that the acetate 
group on carbon 17 of the MPA molecule may be involved in the reduced 
metabolism of this drug through steric hindrance, which may in part explain the 
reduced rate of MPA metabolism seen within this study (Stanczyk, 2003).
Unlike LNG and MPA, progesterone was rapidly metabolised in simulated colonic 
fluids. The rapid clearance of progesterone is in accordance with the previuos 
reports. Metabolism of progesterone by liver enzymes and intestinal bacteria after 
oral administration has been investigated in several previous studies and indeed 
many enzymes have been shown to metabolise this hormone (Williams et al., 2004, 
Yamazaki and Shimada, 1997, Szklarz and Halpert, 1997a, Swart et al., 1993b, 
Nebert and Russell, 2002). The presence of two ketone groups and a double bond on 
its molecule makes progesterone vulnerable to reduction and hydroxylation 
(Stanczyk 2003), which is the likely route of depletion in the colon as colonic
219
C hapter 4  Site D ependent M etabolism  o f Progesterone w ith in  the Gastro-lntestinal
Tract
microbiota are known to be involved in reductive and hydrolytic reactions (Sousa et 
a l, 2008b)
Based on the available data, it can be speculated that the colonic degradation of all 3 
hormones is likely to involve the ring A structure. LNG has been shown to be 
reduced at the a,p-unsaturated ketone in ring A and hydroxylation at carbons 2 and 
16. The two ketone groups and a double bond in ring A on the progesterone molecule 
allows reduction and hydroxylation reactions to occur. In addition, several studies 
have suggested MPA is highly susceptible to reduction at ring A. Yet, despite the 
reported susceptibility of all 3 drugs to metabolic degradation, there is great 
variability in their stability to colonic conditions.
4.4 Discussion
The aim of this study was to better understand the role of different regions of the 
intestines in the first pass metabolism of orally delivered progesterone, with a view 
to identifying an optimal site for the delivery of this compound. Insight into the 
intestinal metabolism should help to establish a region of the GI tract where 
progesterone is most stable and least susceptible to degradation, highlighting an 
optimal region of the intestine for targeted drug delivery. Information on 
progesterone metabolism was determined in human and rat liver and intestinal 
homogenates. Prior to this work, only a very limited amount of data was available on 
the progesterone-metabolising capabilities of the intestinal mucosa and fluids 
(Adlercreutz et al., 1979).
The data obtained within this study showed that, like many drugs, progesterone was 
rapidly degraded in liver homogenates of both human and rats in the presence of the 
electron-donor, NADPH (Figure 4.1 and 4.2) confirming previous finding that the 
liver plays a significant role in the metabolism of this drug (Rao and Taylor, 1965, 
Shirley and Cooke, 1968, Yamazaki and Shimada, 1997). However, homogenates of 
the human and rat pooled small intestine were also shown to have progesterone 
metabolising capabilities (Figure 4.3). It was found that within 60 minutes of 
incubation with intestinal homogenates, in the presence of NADPH; more than 20% 
of progesterone had been depleted. Intestinal metabolism has been shown to
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contribute significantly to the overall metabolism and bioavailability of several drugs 
(Benet et al., 1996, Gomez et al., 1995, Hebert, 1997) and the degree of metabolism 
reported in this study suggests that the intestinal mucosa can influence the overall 
bioavailability of progesterone. This novel finding suggests that targeted delivery to 
an area of reduced progesterone metabolism may enhance the oral bioavailability of 
this compound.
Furthermore, until now, no direct comparison had been made between rat and human 
liver and intestines when assessing the degradation rate and half-life of progesterone, 
yet rats are the often the animal models of choice in such stability experiments (Rao 
and Taylor, 1965).
As a result of this research it was possible to assess the suitability of rats as a model 
species for progesterone stability. When comparing the data obtained from rat and 
human liver and pooled small intestine, similar results were observed. No significant 
differences were seen in the rate of progesterone metabolism between species with 
the exception of the human and rat pooled intestine in the absence of NADPH. 
Indeed there is a possibility that this difference was due to the presence of different 
enzymes in the mucosal lining of the rat and human intestine (Mitschke et al., 2008, 
Nishimura and Naito, 2006, Paine et al., 2006). Nonetheless, similar results were 
seen in progesterone depletion within the remaining samples. Based on these 
findings the rat appeared to be a good surrogate for assessing progesterone stability 
to degradation by mucosal enzymes throughout the GI. Therefore, the remainder of 
the experiments were carried out in rat intestinal segments of the proximal and distal 
small and large intestinal mucosa.
As the samples obtained for this study were from both male and female rats, the 
effects of gender on progesterone metabolism in the rat intestine were also 
investigated. Although similarities in free progesterone recovery have been reported 
in male and female rat livers (Rao and Taylor, 1965), no work has set out to compare 
differences in progesterone stability between male and female rat intestine. However, 
gender difference in the intestinal metabolism of some compounds has been 
previously documented (Liu et al., 2010a). Due to sample availability it was not
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possible to directly compare each region of the male and female rat intestine. 
However, samples of the male and female rat proximal small intestine, 
approximating the duodenum, were obtained. With the limited data generated it was 
not possible to put forward a case for gender difference in rat intestinal metabolism. 
Therefore, gender was assumed to have only a minimal effect on this data-set but 
was still considered a potential limitation in the findings. The rat intestinal samples 
obtained for this study included male rat duodenal and jejunal intestinal homogenates 
and female rat duodenal, ileal and colonic homogenates.
At present there is very little data on progesterone stability in different sections of the 
GI tract. There is no data available whatsoever on the influence of the duodenum on 
the rate of progesterone metabolism and only a very limited amount of information 
available on progesterone metabolism in the jejunum, ileum and colon (Nienstedt 
and Hartiala, 1969, Harri et al., 1969). The rate of progesterone degradation (K) in 
rat intestinal homogenates differed significantly between certain samples with the 
highest rate of degradation being found in the jejunum. In particular the degradation 
of progesterone was most reduced in homogenates of the ileum (Figure 4.9). As 
described in Section 1.9, published data shows that the distribution of CYPs and 
AKRs varies throughout the GI tract (Thelen and Dressman, 2009, Mitschke et al., 
2008, Chhabra, 1979), with some data showing that these enzymes are lower in the 
distal parts of the small intestine (Mitschke et al., 2008). This may be the reason a 
reduced rate of progesterone depletion was seen in this area whereas the highest was 
noted following incubation with jejunal homogenates.
To further investigate the first pass metabolism of progesterone and identify enzymes 
to which progesterone is substrate, the stability of this drug was also assessed in 
human liver and intestinal cytosol in the presence of NADPH dependent and 
independent enzyme inhibitors. Studies in cytosol further confirmed the rapid liver 
degradation of progesterone compared to the intestine and the significant impact of 
NADPH on progesterone metabolism. Moreover, in intestinal cytosol, more than 
40% of progesterone was depleted in the presence of NADPH (Figure 4.15), further 
elucidating the importance of the intestine in progesterone bioavailability.
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From the literature it is already clear that progesterone is highly sensitive to 
degradation by several members of the cytochrome P450 family (Yamazaki and 
Shimada, 1997). These enzymes are expressed throughout the length of the GI tract 
at varying levels (Thom et al., 2005). Of particular interest is the elevated expression 
of CYP3A4 in the duodenum compared to the distal parts of the intestine (Thom et 
al., 2005). CYP3A4 is a potent metaboliser of progesterone which may influence 
drug stability in this region.
As well as CYPs, AKRs are also known to be involved in progesterone metabolism 
(Penning et al., 2000, Charbonneau and The, 2001, Chen et al., 2011). Different 
AKRs are expressed at varying levels along the human GI tract (Pratt-Hyatt et al., 
2013, Nishimura and Naito, 2006, Penning and Byms, 2009), yet the role of these in 
progesterone metabolism is not clear. Thus the degradation of progesterone by AKRs 
was examined within this study.
The results suggest that progesterone is susceptible to degradation by AKR1B1 
(Figure 4.16). The expression of AKR1B1 has been reported in the human small 
intestine but with no details on its expression level or location (O'connor et al., 
1999). One study has found that the levels of this enzyme are low in the jejunum and 
ileum of the mouse and is virtually absent in duodenum and colon (Pratt-Hyatt et al.,
2013). Thus the role of AKR1B1 could potentially affect progesterone stability in the 
gut but to what extent in the different regions of the human intestines is unclear.
Findings from this study also suggest that AKR1D1 is involved in progesterone 
metabolism. The precise location of this enzyme has not been studied though in 
silico research has suggested it is liver specific (Penning and Byms, 2009). 
Nonetheless, data within this study showed that the rate progesterone degradation 
decreases when this enzyme is inhibited in intestine, suggesting its presence in this 
tissue.
As well as AKRs, novel findings from this work have indicated that enzymes 
inhibited by Menadione can affect progesterone stability. Menadione is known to 
inhibit aldehyde oxidases (AOXs) which are found at their highest concentration in 
the liver but are also expressed at low levels in the small intestine and colon
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(Nishimura and Naito, 2006). However, Menadione is more likely to affect 
progesterone stability through its inhibition of NOQ2. The human tissue-specific 
expression of NOQ2 has not been determined though its expression has been 
reported in mouse colon (Long Ii and Jaiswal, 2000).
These unique findings not only help unpick the role of AKRs in progesterone 
metabolism, but also further reveal the potential of the intestines to considerably 
influence the oral bioavailability of progesterone.
The role of intestinal mucosa on progesterone metabolism is substantial; however, 
the influence of bacterial enzymes on drug metabolism must not be overlooked. 
Intestinal bacteria may indeed have an effect on progesterone stability; early studies 
have shown that some C21 steroid metabolites, found in rat and human faeces, are 
most likely the products of metabolism by intestinal bacteria (Gustafsson and 
Sjovall, 1968, Janne et al., 1971). In these studies the dampening of bacterial 
metabolism through antibiotic administration greatly modified faecal steroid 
metabolite excretion.
To determine the role of intestinal fluids on the stability of progesterone, simulated 
fluids were produced. The stability of progesterone was first determined in simulated 
fluids of the small intestine containing pancreatic enzymes. However, no 
progesterone depletion was observed within this fluid. Conversely, when incubated 
with simulated colonic fluid containing human faeces, progesterone was completely 
degraded within 120 minutes. Despite the lack of data on progesterone stability in 
real fluids of the small intestine, it is likely that any metabolism taking place here is 
attributed to the presence of bacterial enzymes. This hypothesis is based on the fact 
that the non-bacterial enzymes present in the simulated fluid had no influence on 
progesterone stability (Figure 4.19).
It is worth noting that these experiments were carried out in simulated fluids of the 
human intestine only. Rats have been shown to have higher levels of bacteria 
throughout their GI tract suggesting their colonic metabolism is higher than in 
humans (Kararli, 1995) which may make rats poor models for assessing metabolism 
of progesterone in the intestine.
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It is well established that the concentration of bacteria increases along the length of 
the GI tract (Jung and Kim, 2010, Hawksworth et al., 1971). Therefore, it is likely 
that fluids within earlier regions of the GI would have a lesser impact on steroid 
metabolism than fluids in the latter regions.
4.5 Summary
Altogether, the data obtained within this chapter has suggested that the rat is a good 
model for assessing the half-life of progesterone in homogenates of the intestine and 
liver and has provided new insight into the stability of progesterone in different 
regions of the GI tract of the rat. The susceptibility of progesterone to degradation by 
specific enzymes in the human intestine and liver has also been investigated. Novel 
findings associated with the activities of NAPDH dependent enzymes including 
CYPs, AKRs and AOXs was of particular interest and requires further research.
Finally, data from this chapter has highlighted the ileum as an optimal region of the 
intestine for the targeted delivery of progesterone. Therefore, the next chapter will 
focus on the development of oral formulations that have the potential to deliver 
progesterone specifically into the human ileum whilst increasing its solubility in the 
ileum fluids, thereby ensuring complete release and dissolution at this site. The 
ultimate goal is to enhance the oral bioavailability of progesterone as compared to 
that of immediate release formulations of these drugs.
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5. Production and Evaluation of Target Specific Delivery Formulations of  
Progesterone
5.1 Introduction
A natural progesterone oral formulation for the treatment of endometrial hyperplasia 
and other forms of long-term oral dosing is not currently available. The development 
of such a pill has been hindered by the poor digestive absorption of progesterone due 
to its low aqueous solubility (8.81 jig/ml) (Yalkowsky et al., 2010). Further to this, 
when administered orally, progesterone is highly susceptible to metabolism by 
hepatic enzymes (Yamazaki and Shimada, 1997). The combination of these factors 
means that the oral bioavailability of progesterone is extremely poor deeming it 
virtually inactive post-administration (Stanczyk, 2002). These limitations have been 
partly overcome in the form of micronized progesterone in peanut oil (Hsia et al., 
2005) which has an oral bioavailability of approximately 10% (Stanczyk, 2002) but 
with significant intra- and inter- patient variability (Levine and Watson, 2000b). 
Other formulations containing micronized progesterone have also been explored with 
a view to improve bioavailability (Maxson et al., 1990, Chandler et al., 1997, Liu et 
al., 2 0 1 0 b), yet none have resulted in a commercially available, long-term, oral 
formulation.
As an alternative to the natural drug, several synthetic progestins have been 
manufactured (Schindler et al., 2008). Although the pharmacokinetic profiles of 
these drugs are favourable they each have adverse side effects which are brought 
about through undesirable binding and adverse signalling (Schindler et al., 2003). 
Synthetic progestins are also associated with increased incidence of breast and 
endometrial cancer (Fournier et al., 2005, Stanford et al., 1995, Seeger et al., 2003, 
Kelley et al., 1976, Kaaks et al., 2002). On the other hand, research shows that the 
use of natural progesterone has fewer side effects than synthetic progestins and 
brings about benefits such as improved lipid profiles and osteoporosis prevention 
(Sitruk-Ware et al., 1987, Murray, 1998, Holtorf, 2009). Moreover, recent research 
into the use of natural progesterone for the treatment of endometrial hyperplasia has
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shown great promise (Chemukha et al., 2013, Marra et al., 2014, Stanosz et al.,
2014).
It is clear that there is a preferred clinical profile for giving natural progesterone over 
synthetic progestins (Fitzpatrick 2000, Fitzpatrick 1999, Wood 2007 Valentine 
1997). However, for such a drug to be successful there must be a viable market in 
which practitioners are keen to prescribe the drug and patients are willing to take it. 
With natural estrogen at least, a study of patients taking oral contraceptive revealed 
that >75% of women would consider switching to an oral formulation containing the 
natural compound (Genazanni 2013). It has also been reported that many women are 
opting for natural estrogen and progesterone products for hormone replacement 
therapy (Adams and Cannell, 2001, Ferguson et al., 1989, Holtorf, 2009). The 
attitude of women to taking natural hormones suggest a strong consumer market for a 
natural progesterone oral product, however, in order to produce such a product, the 
poor bioavailability of progesterone would need to be substantially improved.
As described in the previous chapter, the ileum appears to be the optimal site for 
progesterone delivery due the reduced rate of progesterone metabolism observed in 
this region. There are a number of ways in which drugs can be targeted to the ileum, 
for example, pH-sensitive or time-dependent polymer coatings can be used (Philip 
and Philip, 2010). Alternatively, a novel approach could be used whereby 
progesterone is formulated into amorphous solid dispersions (ASDs). Not only would 
this formulation travel quickly through the gut and dissolve at the ileal pH with great 
accuracy but it would also cause an increase in progesterone dissolution. Accurate 
drug release is of great importance; if progesterone is not specifically targeted and 
some of the drug reaches the colon then the bioavailability can be reduced. Indeed 
rapid progesterone metabolism by bacterial enzymes present in the human colon was 
observed within this study.
An amorphous solid dispersion (ASD) generally consists of a hydrophilic matrix and 
a hydrophobic drug whereby the drug is molecularly distributed within the inert 
matrix (Van Drooge et al., 2006). When in the amorphous state, poorly water 
soluble drugs exhibit an increase in apparent solubility and have an improved
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dissolution rate as no energy is needed to breakdown the crystal lattice during drug 
release (Vasconcelos et al., 2007, Saffoon et al., 2011).
There are several methods available for the production of ASDs; the most commonly 
used methods include hot-melt extrusion, spray-drying and emulsion solvent 
evaporation which are discussed in detail in Section 1.10.1. Emulsion solvent 
evaporation will be the technique used within this study. With this method the 
polymer and drug are both dissolved in a solvent and gradually added to a liquid 
which is immiscible with the chosen solvent and contains a stabiliser. The addition of 
the dissolved drug and polymer is carried out under propeller stirring and as the 
stirring continues the solvent is removed slowly by evaporation at room temperature 
(Section 2.3.1 Figure 2.7). Eventually, a suspension of amorphous microparticles 
containing the drug and polymer is formed and can be separated from the solution by 
filtration (Kendall et al., 2009). The use of surfactants as stabilisers in the production 
process improves drug dissolution and can reduce drug precipitation or protect a fine 
crystalline precipitate from agglomerating into larger hydrophobic particles 
(Vasconcelos et al., 2007).
The key advantage to using emulsion solvent evaporation is its simplicity. The use of 
simple, inexpensive equipment reduces the production cost at lab-scale and the 
technique usually results in high loading efficiency (>70%). However, the technique 
has some draw-backs; despite the low cost, conductivity to industrial scale up can be 
challenging, as well as this, solvent residues may be an issue if evaporation is not 
fully complete (Freitas et al., 2005, Watts et al., 1989). Nonetheless, the simplicity 
and low cost of solvent evaporation makes this technique a good basis for 
investigation into the production of progesterone ASDs.
As mentioned, ASDs contain a drug dispersed in a polymer matrix. The main roles of 
the polymer are to stabilise against crystallisation and enhance dissolution by 
preventing crystallisation of the supersaturated solution. As ASDs are 
thermodynamically unstable they can recrystallize with time, negating any increase 
in apparent solubility (Lee et al., 2014), it is therefore important that they are
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stabilised within the amorphous state. Further to improving apparent solubility, 
polymers can be designed to dissolve at a set pH for targeted delivery to the intestine.
For the production of any ASD it is important to select a suitable polymer. For the 
production of progesterone ASDs Eudragit L I00 and hypromellose acetate succinate 
(HPMCAS) were investigated. The reason for selecting Eudragit for this study is due 
to its proven effectiveness in a clinical setting, as well as the successful use of 
Eudragit for the production of ASDs within our laboratory (Kendall et al., 2006, 
Kendall et al., 2009) providing a template for the production of progesterone ASDs. 
Moreover, the use of the method described in Chapter 2.3.1 was shown to be highly 
pH responsive for targeted drug delivery using Eudragit polymers (Kendall et al., 
2009) and the patent for this method of ASD production has been licenced for use by 
Kuecept Ltd, the company sponsoring this project (Basit et al., 2013). However, 
Eudragit polymers are limited by their poor aqueous solubility (Evonik Industries 
AG) so the more soluble polymer, HPMCAS, was also investigated. HPMCAS 
polymers show enhanced solubility in water-immiscible solvents, a trait which 
allows the polymer to be used in a water-based solvent evapouration technique. This 
trait may be beneficial for the production of progesterone ASDs as progesterone is 
highly lipophilic and will not dissolve into water.
Following production, the progesterone ASD must adhere to a number of in vitro 
parameters. The microparticles should be uniform in size and ideally present a size 
below 500 pm to afford predictable and reproducible transit times through the GI 
tract. The drug contained within the microparticles should be amorphous and exhibit 
higher thermodynamic apparent solubility compared to the natural (crystalline) drug. 
High drug-loading efficiency is also important; poor loading efficiency is not only 
wasteful resulting in an expensive manufacturing process but will often result in 
excess polymer being present in the final dosage form with the potential to exceed 
the polymer’s recommended daily intake dose.
The particles being developed are targeted for delivery to the ileum, thus dissolution 
of the ASD at the ileal pH is important. In its dissolved state, natural progesterone 
readily diffuses through the gut wall (Krishna et al., 2001, Rubas et al., 1993), it is
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important to maintain the high permeability of progesterone in the new formulation 
in order to enhance bioavailability and this will be tested using a gut wall model 
(CACO-2). Finally, as shown in Chapter 3, synthetic progestins are able to adversely 
regulate target genes and proteins. The new progesterone formulation should not 
adversely regulate these targets and this will be assessed at gene and protein level.
Although previous research has looked into the production of progesterone 
microparticles (Jameela et al., 1998, Gangrade and Price, 1991, Royall et al., 2001, 
Kim et al., 2007, Hill et al., 1998, Miller et al., 2012), the use of Eudragit and 
HPMCAS polymers for oral delivery of progesterone in an amorphous dispersion has 
not been fully investigated.
Overall the aim of this chapter is to enhance the oral bioavailability of progesterone 
as compared to that of immediate release formulations by way of targeted delivery 
and enhanced apparent solubility and dissolution. To obtain this aim, progesterone 
ASDs will be produced using the solvent evaporation technique with Eudragit L I00 
or HPMCAS polymers.
5.2 Methods
The methods used within this chapter are described in detail in Chapter 2.3.1. 
Progesterone ASDs were produced using the solvent evaporation technique. The 
resulting microparticles were then subjected to a range of tests to assess their 
characteristics. The shape and size of the microparticles was determined by scanning 
electron microscopy, the crystallinity of the microparticles was assessed by x-ray 
powder diffraction and differential scanning calorimetry, whereas encapsulation 
efficiency and solubility and dissolution kinetics were evaluated by UV-HPLC. After 
assessing the characteristics of the progesterone ASDs, the signalling mechanisms of 
the progesterone ASDs were compared to non-formulated progesterone. This was 
carried out by treating endometrial cell lines with progesterone and progesterone 
ASDs and assessing changes in target gene and protein expression through RT-PCR, 
InCell Analysis, and ELISA. Changes in cell morphology were also assessed using 
light microscopy and ImageJ.
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5.3 Results and Discussion
5.3.1 Development and Characterisation of Progesterone-Loaded 
Amorphous Solid Dispersions (ASDs/Microparticles) with a 10% drug­
load
In order to improve the apparent solubility of progesterone, amorphous solid 
dispersions were produced using the solvent evaporation method with two distinct 
polymers; the methacrylic copolymer, Eudragit L I00 and a cellulose derivative, 
HPMCAS. For the preparation of progesterone microparticles with Eudragit L100, 
an oil-in-oil method was used. The internal phase consisted of drug and polymer 
dissolved in absolute ethanol and the external phase consisted of liquid paraffin, 
containing 1% (w/w) sorbitan sesquioleate as previously described (Basit et al., 
2013). For the preparation of progesterone microparticles with HPMCAS polymers 
an oil-in-water method was used. The internal phase consisted of progesterone and 
HPMCAS in ethyl acetate: dichloromethane (1:1 v/v) and the external phase 
consisted of deionised water containing 1 % (w/w) polyvinyl alcohol as a dispersing 
agent.
5.3.1.1 Properties of Progesterone-Loaded Eudragit L100 Microparticles
The particle size and morphology of the progesterone-loaded Eudragit L100 
microparticles was assessed by scanning electron microscopy (SEM). According to 
the SEM images the microparticles were highly spherical and smooth in appearance 
with no pores or perforations as seen in Figures 5.1 A-E. Additionally, by means of 
the scale bar, the size of the microparticles was estimated to be less than 40pm 
whereas unformulated progesterone has a particle size of approximately 150pm 
(Flores et al., 1994).
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Figure 5.1 A-E: SEM micrographs of progesterone loaded eudragit L100 
microparticles prepared by an O/O emulsification solvent evaporation 
technique, at different magnifications. A) lOOx, B) 500x, C) lOOOx, D) 2500x and 
E)5000x
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T o  assess the physical fo rm  o f  p ro g este ro n e-lo ad ed  eudrag it m ic ro p artic les , p o w d er 
X -ray  p o w d er d iffrac tio n  (P X R D ) w as used. T he  P X R D  pattern  fo r natu ral 
p ro g este ro n e  can  be seen in F ig u re  5.2 A , the pattern  is ch arac te rised  by  sharp  peaks 
rep resen ta tiv e  o f  c ry sta llin e  p rogeste rone . T h e  P X R D  pattern  ob ta ined  from  
p ro g este ro n e-lo ad ed  E u d rag it L I 00  m icro p artic les  w as co m p le te ly  devo id  o f  any  
d iffrac tio n  peaks as co m p ared  to  the cry sta llin e  pattern , ind icating  successfu l 
fo rm a tio n  o f  an am o rp h o u s so lid  (F igu re  5.2 B).
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Figure 5.2: Graphical Representation of the Powder X-ray diffraction 
measurement of natural progesterone powder (A) and Progesterone-Loaded 
Eudragit L I00 microparticles (B). Graph shows peak intensity (Lin Counts) vs. 
2 -theta scale.
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Determination of progesterone encapsulation within the Eudragit LI 00 
microparticles showed only 2 2 % of the total drug added was successfully loaded into 
the microparticles (This can be seen in Figure 5.13, page 245). The poor 
encapsulation efficiency was likely due to the lipophilic nature of progesterone. Oil 
was used as the internal phase allowing progesterone to partition into the oil instead 
of into the polymer. Therefore, a water-based solvent evaporation technique would 
be a more efficient method for increasing encapsulation efficiency.
In order to use a water-based method with the Eudragit L I00 polymer, a solvent 
immiscible with water, yet able to dissolve the polymer and drug, needed to be used. 
However, given the poor solubility of Eudragit L I00 (practically insoluble in ethyl 
acetate, methylene chloride, petroleum ether and water (Evonik Industries AG), a 
water immiscible solvent able to dissolve this polymer was not obtainable. Therefore, 
the more soluble polymer, HPMCAS, was utilised as an alternative. As a result of the 
poor loading efficiency (<2 2 %) no further characterisation was carried out with 
progesterone-loaded Eudragit L-100 microparticles.
5.3.1.2 Properties of Progesterone-Loaded HPMCAS Microparticles
Production of progesterone ASDs was carried out using a fine HPMCAS-HFwhich 
dissolves at pH >6 .8 . Progesterone loaded HPMCAS HF microparticles were 
produced as described in Section 5.3.1 As with the progesterone-loaded Eudragit 
L100 microparticles, the particle size and morphology was assessed by SEM as 
described in Chapter 2, Section 2.3.1.2 The SEM images of progesterone-loaded 
microparticles can be seen in Figure 5.3, the microparticles were spherical in 
appearance with no pores or perforations but the size of the microparticles was 
variable and drug could be seen on the surface which may be related to the drug 
load. Although the size of the microparticles was variable, they were estimated to be 
less than 1 0 0 pm based on the scale bar, with the majority appearing to be less than 
50pm.
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Figure 5.3: SEM images of progesterone loaded HPMC AS-HF microparticles. 
A) lOOx magnification, B) 500x magnification, C) lOOOx magnification, D) 2500x 
magnification and E) 5000x magnification
T he P X R D  pattern  o b ta ined  fo r p ro g este ro n e-lo ad ed  H P M C A S  H F m icropartic les 
con firm  that the d rug  w as p red o m in an tly  am o rp h o u s as seen  by  the absence o f  
m u ltip le  d iffraction  peaks and  p resence o f  a ch a rac te ris tic  am orphous ha lo  (F igure 
5.2A ). T o  assess w h e th e r the m icropartic les w ere  stab le  ov er a long perio d  o f  tim e 
they w ere stored  at room  tem p era tu re  in a sea led  co n ta in e r fo r 2 years then  again  
ana lysed  by  p o w d er X -ray  d iffrac tio n  (F igu re  5.4 B). T h e  d ata  ob ta in ed  show ed  
m in im al re cry sta lisa tio n  w ith in  th is tim e-sca le  su g g estin g  the  A S D s are h igh ly  
stable.
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Figure 5.4: Graphical Representation of the Powder X-ray diffraction 
measurement of Reloaded HPMCAS HF microparticles A. At time of 
production and B. 2 years post-production. Graph shows peak intensity (Lin 
Counts) vs. 2-theta scale. Data shows progesterone is in an amorphous state.
To further test the physical form of the progesterone loaded into the HPMCAS HF 
microparticles, differential scanning calorimetry (DSC) was used. The thermogram 
obtained for the natural progesterone powder can be seen in Figure 5.5 A with a 
melting endotherm of 129.88°C, whereas the melting endotherm was absent in the 
microparticles (Figure 5.5 B) further confirming their amorphous nature.
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Figure 5.5 Differential Scanning Calorimetry of natural P4 (A) and P^loaded 
HPMCAS HF microparticles. Data shows progesterone is in a crystalline state 
with a melting point of 129.35°C whereas progesterone-loaded HPMCAS 
microparticles are in an amorphous state.
E stim a tio n  o f  the p ro g este ro n e  co n ten t in the H P M C A S  H F  m icro p artic les show ed  
that d rug  load ing  e ffic ien cy  w as 89% . T hus, the en cap su la tio n  o f  p ro g este ro n e  w ith in  
th is p o ly m er w as d ram atica lly  im proved  com pared  to  the E udrag it L I 00  po lym er. 
T h is  c lea r im provem en t in d rug  lo ad in g  w as also  p roven  to be sta tis tica lly  s ig n ifican t 
by  studen ts t-test (P < 0 .001) (F igu re  5 .13).
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A s a re su lt o f  the successfu l am orphous ou tcom e and h igh  load ing  effic ien cy  w ith  
the H P M C A S  H F  po lym er, p ro g este ro n e  w as also  loaded  in to  H P M C A S  po lym ers 
that d isso lv e  at pH  >5.5 (H P M C A S  LF) and pH  > 6 .0  (H P M C A S  M F). T hese  
po ly m ers w ere used  in o rd er to fu rth e r ch arac te rise  the use o f  H P M C A S  for 
p ro g este ro n e  load ing  and  also  as con tro ls  fo r d isso lu tio n  experim en ts.
P ro g estero n e  loaded  H P M C A S -M F  and L F  m icro p artic les w ere v isua lised  by  SEM . 
F igu res 5 .6 and 5.7 show  SE M  im ages o f  p rog este ro n e  loaded  H P M C A S  M F and L F  
m icro p artic les respec tive ly . A s w ith  the p ro g este ro n e-lo ad ed  H P M C A S  H F  
m icropartic les, the p artic le  size  w as variab le  and even  though  th e  su rface  layer o f  the 
m icro p artic les  appeared  sm ooth , excess drug  o r p o ly m er frag m en ts  cou ld  be seen  on 
the su rface.
Figure 5.6 SEM micrographs of progesterone loaded HPMC AS-MF 
microparticles. A) lOOx magnification, B) 500x magnification, C) lOOOx 
magnification, D) 2500x magnification and E) 5000x magnification
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Figure 5.7 SEM micrographs of progesterone loaded HPMC AS-LF 
microparticles. A) lOOx magnification, B) 500x magnification, C) lOOOx 
magnification, D) 2500x magnification and E) 5000x magnification
T he c ry sta llin ity  o f  the p ro g este ro n e-lo ad ed  H P M C A S  M F and L F m icropartic les 
w ere once again  charac te rized  by  P X R D  and D SC . T he  P X R D  pattern  o f  the M F  
m icropartic les w as devo id  o f  any  d iffrac tio n  peaks com pared  to  the cry sta llin e  
pattern  o f  the co m m erc ia lly  ava ilab le  p ro g este ro n e  p o w d er (S igm a A ldrich), 
ind ica ting  successfu l fo rm ation  o f  am o rp h o u s p ro g este ro n e  (F igu re  5 .8A). 
F u rtherm ore , very  little  recry sta lliza tio n  had  occu rred  o v er a 2 year tim e-p erio d  
su g g estin g  the m icro p artic le  are h ig h ly  stab le  (F ig u re  5 .8B ). A s fu rth er ev id en ce  o f 
am orph ic ity , the D SC  therm o g ram  o f  the M F m icropartic les show ed  the  m elting  
en d o th erm  o f c ry sta llin e  p rog este ro n e  w as absen t (F igures 5.9).
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Figure 5.8 Powder X-ray diffraction of P4-Ioaded HPMCAS MF microparticles. A. At 
time of production and B. 2 years post-production.
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Figure 5.9 Differential Scanning Calorimetry of P^loaded HPMCAS MF 
microparticles. Data suggests microparticles are in an amorphous state.
Unlike the previous samples, progesterone microparticles with HPMCAS LF 
polymer showed some degree of crystallinity displaying two peaks. The formulation 
showed peaks at 2-theta values of 10.6° and 21.4° which corresponded with the 
peaks found in crystalline progesterone (Figure 5.10A). However, after 2 years of 
storage, here was little change in the PXRD pattern (Figure 5.10B)., suggesting that 
the microparticles were stable in this state Despite peaks being seen with PXRD, the 
melting endotherm of pure progesterone was absent from the LF microparticles on 
the DSC thermogram (Figure 5.11).
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Figure 5.10 Powder X-ray diffraction of P4-loaded HPMCAS LF microparticles. A. At 
time of production and B. 2 years post-production
Figure 5.11 Differential Scanning Calorimetry of P4-loaded HPMCAS LF 
microparticles. Data suggests microparticles are in an amorphous state.
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E stim atio n  o f  the p ro g este ro n e  con ten t in the H P M C A S  L F  m icro p artic les  show ed  a 
h igh  load ing  e ffic ien cy  o f  o v er 90%  w hereas the en cap su la tio n  o f  p ro g es te ro n e  in the 
H P M C A S  M F w as s lig h tly  low er at 70% . N one the less bo th  w ere  s ig n ifican tly  
im proved  com pared  to  E udrag it (PcO.OOl). T he  ch ro m ato g ram s ob ta in ed  fo r the 
en cap su la tio n  effic ien cy  o f  p ro g este ro n e  w ith in  each p o ly m er are show n in F igure 
5.12; th is data  is d ep ic ted  g raph ica lly  in F ig u re  5.13.
□  P4 S ta n d a rd
□  P4 HPMC-AS HF
P4 HPMC-AS LF
□  P4 HPMC-AS MF
□  P4 E u d rag it L100
Figure 5.12: HPLC chromatogram obtained to assess encapsulation efficiency of 
progesterone in different polymers. Samples were eluted isocratically using a 
mobile phase consisting of 0.1% TFA in 50:50 acetonitrile and water. The 
column used was Zorbax 150 x 4.6 mm with 3.5pM particle size at 25°C and the 
UV detector wavelength was set at 242 nm with a flow rate of lml/min. lOOul of 
sample was injected for each run.
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Figure 5.13: Encapsulation Efficiency (%) of progesterone in different 
polymers. Results represent average of 3 experimental repeats, erro r bars are 
+/- SD. Statistical analysis was performed using a Student T test (p^O.OOl***)
5.3.1.3 In Vitro drug release from progesterone-loaded HPMCAS 
microparticles.
T h e H P M C A S  po lym ers u tilised  w ith in  th is study  each  d isso lv e  at a d iffe ren t pH ; 
H P M C A S  H F  d isso lves at pH  6 .8 , H P M C A S  M F d isso lves at pH  6 and  H P M C A S  
L F  d isso lv es at pH  5.5. T h ere fo re , the re lease  p ro files o f  p ro g este ro n e  from  
H P M C A S  HF, M F and L F  w as d e term in ed  using  the m ethod d esc rib ed  in S ection  
2 .3 .1 .5  T h e  d isso lu tion  o f  p ro g este ro n e-lo ad ed  E udrag it L 100  p artic le s  w as not 
tested  due to the poor en cap su la tio n  effic iency .
R elease  o f  p rog este ro n e  into acid  m ed iu m  w as w ell con tro lled  from  each  A S D  w ith  
less than  7%  o f  the to tal d rug  co n ten t be ing  re leased  in to  the m ed ia  afte r 120 m in u tes  
at pH  1.2 (F igure  5.14). U pon  ch an g in g  the  pH  to  5.5, 6 .0  and 6.8 fo r H P M C A S  LF, 
M F  and H F  m icro p artic les re sp ec tiv e ly , rap id  re lease  o f  p ro g este ro n e  w as ach iev ed  
w ith in  30 m inu tes o f  the change  (F igu re  5 .14). F or H P M C A S  M F  and  H F  
m icro p artic les  drug  re lease  w as h igh , w ith  > 85%  o f  d rug  being  d e tec ted  a fte r 2 hours 
in  the a lka line  m edium . H ow ever, d ru g  re lease  form  H P M C A S  L F m icro p a rtic le s  
w as s ig n ifican tly  low er at on ly  59%  (P < 0 .0 0 1 ), w hich  cou ld  be re la ted  to the 
p resen ce  o f  c rysta lline  d rug  w ith in  these  m icro p artic les (F igure  5 .10). T h e  lim ited
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re lease  o f  p ro g este ro n e  from  these  m icro p a rtic le s  w as not in vestigated  fu rther and 
the rem a in in g  ch a rac te risa tio n  o f  H P M C  m icro p artic les  w as carried  ou t in H P M C A S  
M F  and H F  po lym ers.
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Figure 5.14: In Vitro release of progesterone from HPMCAS microparticles 
with time, using a pH change dissolution method (drugrpolymer ratio 1:10) 
(n=3, error bars are +/- SD). pH was maintained at 1.2 for 2hours, this was then 
increased to 5.5, 6.0 or 6 . 8  for HPMCAS LF, MF and HF polymers respectively.
5.3.1.4 In  V itro perm eability  of progesterone and progesterone loaded 
microparticles
A n u m b er o f d iffe ren t delivery  app roaches have  been  deve loped  w ith  an aim  to 
im prove the apparen t so lu b ility  o f  lipoph ilic  co m p o u n d s b u t the use o f  m any  such 
ap p ro ach es o ften  cause a red u ctio n  in perm eab ility . T he use o f su rfac tan ts , for 
ex am p le , can s ign ifican tly  d ec rease  the free  frac tio n  o f  d rug  av a ilab le  fo r in testina l 
p erm eatio n  (M iller et al., 2011). S uch  so lu b ilisa tio n  m ethods re ly  on en h an c in g  the
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equilibrium solubility of the drug but, unlike other formulations, ASDs enable an 
unstable supersaturated solution to be attained. This difference leads to an increase in 
apparent solubility without compromising intestinal permeability (Miller et al., 
2012).
To ensure the permeability of progesterone was not compromised during 
microparticle production, the permeability of natural progesterone and the 
progesterone loaded HPMCAS HF and MF microparticles was evaluated in vitro 
using the CACO-2 permeability assay as described in Section 2.3.3. Figure 5.15 
shows the percentage of progesterone recovered from the basolateral compartment of 
the CACO-2 transwell at different time-points for up to 120 minutes and no 
statistically significant differences were observed between progesterone and 
progesterone loaded microparticles. Percentage was calculated based on the 
concentration determined in the apical compartment of the transwell at 0  minutes 
(16pM). As well as calculating the appearance of progesterone in the basolateral 
compartment of the CACO-2 transwell, the percentage of progesterone in the apical 
compartment was also calculated at 1 2 0  minutes and the data obtained was consistent 
between the natural product and the ASDs (Figure 5.16). Determining progesterone 
concentration in the apical and basolateral compartment allowed quantification of 
total progesterone recovery which was found to be more than 80% with each sample. 
Any progesterone not recovered was most likely retained in the CACO-2 cells.
In line with these findings, Yu and co-workers have shown that progesterone travels 
at a higher rate from the apical to basolateral compartment of the CACO-2 
membrane than from the basolateral to apical. The groups suggested that this were 
due to the absence of P-glycoprotein driven efflux in the CACO-2 membrane (Yu et 
al., 1997). This may also explain why more than 50% of progesterone entered the 
basolateral compartment breaking the concentration gradient.
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Figure 5.15. Appearance (%) of progesterone in basolateral compartment of 
CACO-2 cell line at several time-points for up to 120 minutes (n=3). CACO-2 
cells were grown to confluency on transwell units and permeability to 
progesterone was assessed by HPLC. E rror bars not shown for clarity but are 
detailed in Appendix N.
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Figure 5.16. Percent of progesterone remaining in the apical compartment 
(dark grey) and percent appearance of progesterone in the basolateral 
compartment (light grey) of the CACO-2 transwell after 120 minutes of 
incubation (n=3, error bars are shown as standard deviation from the mean). 
Students t-test was used to assess for statistical differences between 
progesterone and progesterone loaded microparticles (P>0.05).
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Figure 5.17. Apparent permeability (PAPP) of progesterone and progesterone- 
loaded HPMCAS HF and MF microparticles across the CACO-2 cell monolayer 
(n=3, error bars are shown as standard deviation from the mean). Students t- 
test was used to assess for statistical differences between progesterone and 
progesterone loaded microparticles (P>0.05).
T o  fu rth e r investigate  the perm eab ility  o f  p rogeste rone , the data  ob ta ined  w as used  to 
ca lcu la te  the apparen t perm eab ility  (P app) as d esc rib ed  in S ection  2 .3 .3 .8 . T he P appo f 
p ro g este ro n e  and p ro g este ro n e  loaded  m icro p a rtic le s  can  been  seen in F igure  5.17 
and  w as found  to  be in line w ith  find ings repo rted  by  K rishna et a l  w ho  also  used  the 
C A C O -2  cell line to investigate  the  p erm eab ility  o f  p ro g este ro n e  (K rishna et al.,
2001). M oreover, no  sign ifican t d iffe ren ces w ere  o bserved  w hen  com paring  
p ro g este ro n e  and p ro g este ro n e-lo ad ed  m icro p artic les (P > 0.05).
5.3.1.5 A pparen t solubility of progesterone com pared  to progesterone 
loaded m icroparticles
It has been  p rev io u sly  d o cu m en ted  that am orphous so lid  d ispersions can enhance  the 
o ral b io av ailab ility  o f  poorly  w a te r so lub le  drugs th rough  enhanced  apparen t 
so lu b ility  (L eu n er and D ressn tan , 2000 , V asconcelos et al., 2007). T o  assess w h e th er 
p ro g este ro n e  m icro p a rtic le  p roduced  w ith  H P M C A S  H F  p o ly m er caused  an increase  
in apparen t so lub ility , the sh ak e-flask  m ethod  w as used  to  determ ine the apparen t
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so lu b ility  o f  p rog este ro n e  co m p ared  to  the p ro g este ro n e-lo ad ed  m icropartic les 
(S ec tio n  2 .3 .4). T he ex p erim en ts  w ere ca rried  ou t in sim u la ted  in testinal flu ids 
rep resen tin g  the fasted  and fed  state (F asS IF  and  FesS IF ). A fte r one ho u r in F asS IF  
the  apparen t so lu b ility  o f  p ro g este ro n e  w as s ig n ifican tly  increased  from  25 to 
3 0 p g /m l (F igure  5 .18B ) and th is w as m ain ta in ed  for up to 24 hours. A fte r 1 h o u r in 
F esS IF  the apparen t so lu b ility  o f  p ro g este ro n e  w as sig n ifican tly  increased  in the 
A S D  from  85 to 129pg/m l (F igu re  5 .18A ). D esp ite  the increase in p rogeste rone  
ap p aren t so lub ility  b e ing  s ign ifican t an  even  g rea ter increase  that is in line w ith  o r 
m o re  than  cu rren tly  ava ilab le  fo rm u la tio n s  w ould  have been  desirab le  to  fu rth e r 
im prove  oral b ioavailab ility .
A B
Figure 5.18: Apparent solubility of progesterone (P4) and progesterone-loaded 
HPMCAS HF microparticles (HF) in simulated intestinal fluids of the A) fasted 
and B) fed state. Apparent solubility of progesterone was determined as 
described in Section 2.3.4. The solublity of unformulated (natural) P 4 was 
determined in the presence of an equivalent amount of drug polymer. N=3, 
error bars are shown as standard deviation from the mean.
D u rin g  th is study  the apparen t so lu b ility  o f  p ro g este ro n e  w as im proved  th ro u g h  the 
p ro d u c tio n  o f  p ro g este ro n e  am o rp h o u s so lid  d isp ersio n s. P rev ious w ork  has 
su g g ested  that a lte ra tions in the physical and chem ical p ro p erties  o f  a d rug  a fte r 
fo rm u la tio n  m ay have quality  and clin ical issues (R ahm an  et al., 2014). For ex am p le , 
if  a so lid  d isp ersio n  fo rm u la tio n  is no t co rrec tly  p repared  o r p ro p erly  stored  the d rug  
m ay  beg in  to degrade, increasing  the  risk  o f  im puritie s  w hich  can  p o ten tia lly  lead  to
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unfavourable biological effects. As well as this, it is possible for excipients to 
interact either chemically or physically with the drug which can lead to alterations in 
the chemical nature of the drug and as a consequence alter there their therapeutic 
safety (Bharate et al., 2010). Although this process is unlikely to occur and any 
particulates are unlikely to reach the target cells after oral dosing it is still important 
to assess any differences in gene regulation by the formulated drug.
Therefore, the biological effect of P4  ASD, its basic signalling mechanisms and gene 
regulation was compared to the unformulated drug. Thus, the remainder of the 
chapter will assess the regulation of progesterone target genes and proteins 
comparing P4 ASD to unformulated P4. This will also further confirm the findings 
obtained in chapter 3 of this study.
5.3.2 Regulation o f Genes and Proteins by Progesterone and 
Progesterone-Loaded Microparticle
To establish whether target gene and protein regulation is affected by progesterone 
loaded ASDs, their regulation was analysed in the Ishikawa and HESC cell line after 
incubation with progesterone and progesterone-loaded HPMCAS HF microparticles. 
The target genes and proteins to be assessed are described in detail in chapter 3, the 
known progesterone-regulation of these targets will, therefore, only be discussed 
briefly within the context of this chapter. Furthermore, the data obtained within this 
section will not be critically analysed this has been done in Chapter 3. The purpose 
of this section is to compare gene and protein regulation between P4 and the P4 ASD.
5.3.2.1 FOXOl is up-regulated by P4 and P4-ASD in the Ishikawa and HESC 
cell line
Progesterone-induced FOXOl up-regulation has been well characterised, and is 
shown to occur specifically through progesterone binding to the PR-B (Kyo et al., 
2011, Wang et al., 2009). Data obtained in Section 3.3.3. confirmed that FOXOl is 
significantly up-regulated by progesterone in the Ishikawa cell line and this was 
again replicated in this chapter whereby PR RNA was induced 1.9 fold (P<0.05) with 
natural P4 treatment (Figure 5.19 Panel B). Treatment of Ishikawa cells with
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progesterone ASD also caused a statistically significant, 1.9 fold increase in FOXOl 
gene expression (Figure 5.19 Panel B). Thus both P4 and the P4 ASD regulate the 
FOXOl gene in a similar manner. This is also the case in the presence of E2 whereby 
there was a 1.6 fold increase in FOXOl gene expression after both treatments 
(Figure 5.19 Panel B). Akin to FOXOl RNA, FOXOl protein in Ishikawa cells was 
also upregulated after treatment with P4 or P4 ASD in the presence and absence of E2 . 
However, at protein level the up-regulation of FOXOl was significant after each 
treatment and in each case the up-regulation was found to be between 1.6 and 1.7 
fold (Figure 5.19C). Crucially, there was no statistical difference in FOXOl 
regulation between P4 and P4 ASD.
Since FOXOl is able to translocate in and out of the nucleus (Lengyel et al., 2007, 
Ward et al., 2008), the cellular location of this protein was also analysed after 
treatment with P4 and P4 ASD in the presence and absence of estrogen. The cellular 
location of the FOXOl protein was similar between all four treatment regimens, 
whereby FOXOl staining was much higher in the nucleus than in the cytoplasm 
(Figure 5.19D). The nuclear position of FOXOl could also be visualised in the 
InCell images (Figure 5.19A)
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Figure 5.19. FOXOl gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. A) Fluorescent images showing 
formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas-Red 
stained FOXOl protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of FOXOl normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser Workstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. D) Cell and Nuclear Intensity. Cell intensity 
accounts for the average intensity of the whole cell whereas nuclear intensity 
accounts for the intensity found above the DAPI stain only.
A negative control containing Ishikawa cells incubated with secondary antibody 
only can be seen in Figure A; InCell Analyser Data is normalised to 
background based on this negative. E rror bars represent standard deviation 
from the mean of 3 repeats. Data was analysed using a two-tailed students T-
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Test (*P<0.05, **P<0.01, ***P<0.001). All data presented in this section was 
subjected to the same analysis.
The regulation of FOXOl RNA in HESC cells was also similar between P4  and P4  
ASD whereby neither treatment alone upregulated FOXOl in the HESC cell line. 
However, when combined with cyclic AMP, FOXOl RNA was up-regulated 3-fold 
or more (Figure 5.20 B). A similar pattern was seen with FOXOl protein whereby no 
change was observed after treatment with P4  or P4  ASD alone, but after the combined 
treatment with cyclic AMP, FOXOl was significantly induced by 1.4 (P<0.01) and 
1.7 (P<0.02) fold by P4  and P4  ASD respectively (Figure 5.20 C). The induction of 
FOXOl can be visualised in the images obtained from the InCell Analyser in Figure 
5.20 A. Unlike the Ishikawa cell line, the intensity of the FOXOl protein stain 
appeared to be across the whole cell as opposed to just in the nucleus (Figure 5.20A). 
To determine whether this was true the average intensity for the whole cell was 
subtracted from the nuclear intensity. Although, there was some elevation in nuclear 
protein compared to cytoplasmic protein, this increase was small in both the control 
and progestin treatments. Moreover, the protein position was similar after P4  and P4  
ASD treatment both in the presence and absence of cyclic AMP (Figure 5.22 D).
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Figure 5.20 FOXOl gene and protein expression in the HESC cell line following 
hormone treatment for 48h. A) Fluorescent images showing formaldehyde fixed 
cells with DAPI-stained cell nucleus (blue), Texas-Red stained FOXOl protein 
(red) and fused DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data 
showing basal transcript level of FOXOl normalised to GAPDH. C) Cell 
intensity data obtained from InCell Analyser Workstation based on an average 
of 3 repeats observing at least 3 fields of view within each repeat. Data is 
represented as fold. D) Cell and Nuclear Intensity. Cell intensity accounts for 
the average intensity of the whole cell whereas nuclear intensity accounts for the 
intensity found above the DAPI stain only. A negative control containing 
Ishikawa cells incubated with secondary antibody only can be seen in Figure A; 
InCell Analyser Data is normalised to background based on this negative. E rror 
bars represent standard deviation from the mean of 3 repeats. Data was 
analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). 
All data presented in this section was subjected to the same analysis.
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5.3.2.2 P4 and P4-ASD similarly regulated the Progesterone Receptor in the 
Ishikawa and HESC cell lines.
Progesterone has been widely reported to down-regulate the PR (Graham and Clarke, 
1997b) whereas estrogen has been reported to up-regulate the PR in human 
endometrial epithelium (Hata and Kuramoto, 1992, Jamil et al., 1991). Work carried 
out in Chapter 3.3.3 contradicted the literature whereby PR was up-regulated by 4 
fold or more by progesterone in the endometrial cancer cell line. This finding was 
also significantly different to PR regulation by the progestins. In this chapter both P4  
and P4 ASD significantly upregulated PR RNA; whereby an induction of 5-fold or 
more was seen in the absence and presence of E2 (Figure 5.21 B). PR protein was 
also highly up-regulated after treatment with P4 or P4 ASD by 6.1 and 4.5 fold 
respectively. A more modest induction was seen after combined treatment of P4 or P4 
ASD with E2 whereby PR protein was upregulated by 2.6 and 2.9 fold respectively 
(Figure 5.21C).
Like FOXOl, PR is also a transcription factor able to shuttle in and out of the 
nucleus (Leonhardt et al., 2003a), therefore the cellular location of this protein was 
also analysed after treatment with P4 and P4 ASD in the presence and absence of 
estrogen.The cellular location of the PR protein also changed after P4 treatment 
whereby there was a greater difference between cell and nuclear intensity after 
treatment and this was the case with each treatment regimen (Figure 5.21 D). 
Interestingly, the loss of PR is associated with poor prognosis in endometrial cancer, 
which is, in turn, is treated with synthetic progestins which serve to down-regulate 
this hormone receptor (Janne et al., 1979). However, there was an increase in PR 
protein after P4 and P4 ASD treatment in Ishikawa cells, thus suggesting that natural 
progesterone treatment could have greater benefits in the treatments of some 
endometrial cancers, further promoting the need for a natural compound and a place 
in the market for the formulation presented herein.
Thus, in the Ishikawa cell line, P4 ASD acts in a similar manner to the natural drug, 
unlike the synthetic progestins analysed in Section 3.3.4.2.
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Figure 5.21. PR gene and protein expression in the Ishikawa cell line following 
hormone treatment for 48h. A) Fluorescent images showing formaldehyde fixed 
cells with DAPI-stained cell nucleus (blue), Texas-Red stained PR protein (red) 
and fused DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data 
showing basal transcript level of PR normalised to GAPDH. C) Cell intensity 
data obtained from InCell Analyser Workstation based on an average of 3 
repeats observing at least 3 fields of view within each repeat. Data is 
represented as fold. D) Cell and Nuclear Intensity. Cell intensity accounts for 
the average intensity of the whole cell whereas nuclear intensity accounts for the 
intensity found above the DAPI stain only. A negative control containing 
Ishikawa cells incubated with secondary antibody only can be seen in Figure A; 
InCell Analyser Data is normalised to background based on this negative. E rror 
bars represent standard deviation from the mean of 3 repeats. Data was 
analysed using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). 
All data presented in this section was subjected to the same analysis.
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Previously documented work has shown that PR regulation in stroma differs from in 
epithelial cells whereby an induction of up to 10-fold has been reported (Tseng and 
Zhu, 1997). Akin to data obtained in Section 3.3.5.2, a 1.6 fold increase was seen in 
PR RNA after treatment with P4  in HESCs and similarly, a 1.9 fold increase was 
observed after treatment with the P4 ASD in HESCs. Although there was no 
significant difference between the treatments themselves, the PR up-regulation 
instigated by P4 ASD was significant compared to control unlike the treatment by 
natural P4 (Figure 5.22 B). This induction, however, was not observed at protein level 
(Figure 5.22 A and C).
Data obtained in Chapter 3 revealed that P4  is able to significantly up-regulate PR in 
HESC cells in the presence of cyclic AMP. This observation was further confirmed 
in this chapter whereby PR RNA was up-regulated 1.9 fold and 2.3 fold after 
treatment with cyclic AMP+P4  and cyclic AMP+P4  ASD respectively (Figure 5.22 
B). When assessing the PR protein after the same treatment a smaller but significant 
increase in PR was detected whereby P4  combined with cyclic AMP upregulated PR 
by 1.5 fold (P<0.01) and P4  ASD plus cyclic AMP upregulated PR by 1.4 fold 
(P<0.01). Although PR protein increased, the intensity of PR stain in the nucleus did 
not change with any treatment suggesting that progesterone had no effect on PR 
cellular location in the HESC cells (Figure 5.22 D).
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Figure 5.22. PR gene and protein expression in the HESC cell line following 
hormone treatment for 48h. A) Fluorescent images showing PR fixed cells with 
DAPI-stained cell nucleus (blue), Texas-Red stained PR protein (red) and fused 
DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data showing basal 
transcript level of PR normalised to GAPDH. C) Cell intensity data obtained 
from InCell Analyser Workstation based on an average of 3 repeats observing 
at least 3 fields of view within each repeat. Data is represented as fold. I)) Cell 
and Nuclear Intensity. Cell intensity accounts for the average intensity of the 
whole cell whereas nuclear intensity accounts for the intensity found above the 
DAPI stain only. A negative control containing Ishikawa cells incubated with 
secondary antibody only can be seen in Figure A; InCell Analyser Data is 
normalised to background based on this negative. E rror bars represent 
standard deviation from the mean of 3 repeats. Data was analysed using a two- 
tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data presented in 
this section was subjected to the same analysis.
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5.3.2.3 Differential regulation of Lactoferrin in the Ishikawa cell line by P4 and 
P4-ASD was observed at RNA level but no difference was observed at protein 
level. There was no difference in P4 or P4 ASD-induced lactoferrin regulation in 
the HESC cell line.
Work carried out in Section 3.3.4.4 showed Lactofferin is significantly down- 
regulated in the Ishikawa cell line after progesterone treatment and this finding was 
in line with previous documentation (Kurita et al., 2000, Conneely and Jericevic,
2002). The P4  induced down-regulation of LF was again confirmed in this chapter 
whereby P4  significantly down-regulated LF RNA by 0.01 fold (P<0.001). P4  ASD 
also significantly down-regulated LF RNA in Ishikawa cells (P<0.01), however, this 
reduction was by 0.17 fold which was significantly less than the down-regulation 
recorded after treatment with unformulated P4  (P<0.05) (Figure 5.23 B). The 
combined treatment of P4  or P4  ASD with E2 also caused LF RNA to be reduced but 
there was no difference between the treatments in this instance (Figure 5.23 B). 
Furthermore, differences seen between P4  and P4  ASD at gene level were not seen at 
protein level (Figure 5.23 A and C), this may have been down to the sensitivity of the 
antibody used for the InCell analysis or possibly due to the enhanced down- 
regulation of LF gene by P4  not being great enough to cause a significant difference 
in the levels of LF protein.
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Figure 5.23. LF gene and protein expression in the Ishikawa cell line following 
hormone treatment for 48h. A) Fluorescent images showing formaldehyde fixed 
cells with DAPI-stained cell nucleus (blue), Texas-Red stained LF protein (red) 
and fused DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data 
showing basal transcript level of LF normalised to GAPDH. C) Cell intensity 
data obtained from InCell Analyser Workstation based on an average of 3 
repeats observing at least 3 fields of view within each repeat. Data is 
represented as fold. A negative control containing Ishikawa cells incubated with 
secondary antibody only can be seen in Figure A; InCell Analyser Data is 
normalised to background based on this negative. E rror bars represent 
standard deviation from the mean of 3 repeats. Data was analysed using a two- 
tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data presented in 
this section was subjected to the same analysis.
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In the HESC cell line P4  caused a significant down-regulation of LF RNA by 0.6 fold 
whereas P4  ASD caused a 0.55 fold down-regulation of LF but this was not 
significant compared to control (Figure 5.24 B). When observing the amount of LF 
protein after the same treatments it was found that both P4  and the P4  ASD 
significantly down-regulated LF at similar levels (Figure 5.24 A and C). The addition 
of cyclic AMP to P4  and P4  ASD enhanced the overall down-regulation of LF RNA 
(Figure 5.24 B) but such a drastic change was not observed with LF protein (Figure 
5.24 C). The regulation of LF by cyclic AMP has not been previously reported and 
cyclic AMP alone was shown not to influence LF in HESC cells in Chapter 3.3.5. 
Suggesting synergistic action between progesterone and cyclic-AMP in the 
regulation of this target.
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Figure 5.24: LF gene and protein expression in the HESC cell line following 
hormone treatment for 48h. A) Fluorescent images showing formaldehyde fixed 
cells with DAPI-stained cell nucleus (blue), Texas-Red stained LF protein (red) 
and fused DAPI/Texas Red image at lOx optical zoom. B) RT-PCR data 
showing basal transcript level of LF normalised to GAPDH. C) Cell intensity 
data obtained from InCell Analyser Workstation based on an average of 3 
repeats observing at least 3 fields of view within each repeat. Data is 
represented as fold. A negative control containing Ishikawa cells incubated with 
secondary antibody only can be seen in Figure A. InCell Analyser Data is 
normalised to background based on this negative. E rror bars represent 
standard deviation from the mean of 3 repeats. Data was analysed using a two- 
tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data presented in 
this section was subjected to the same analysis.
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5.3.2.4 P4 and P4-ASD do not effect AREG expression in the Ishikawa cell line.
Although a rise in AREG expression has been reported in the human endometrium 
with rising levels of P4  (Gui et al., 2008a), no significant change in AREG RNA or 
protein was observed in the Ishikawa cell line after treatment with P4 or P4 ASD in 
both the presence and absence of estrogen (Figures 5.25). This was also the case with 
progesterone and the progestins in Chapter 3.3.3. It is worth noting that Gui and 
colleagues described AREG expression in healthy endometrium whereas this study 
investigates AREG regulation by PR in an endometrial cancer cell line, therefore, 
differences observed may be attributed to healthy versus disease models.
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Figure 5.25. AREG gene and protein expression in the Ishikawa cell line 
following hormone treatment for 48h. A) Fluorescent images showing 
formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas-Red 
stained AREG protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of AREG normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser Workstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. A negative control containing Ishikawa cells 
incubated with secondary antibody only can be seen in Figure A; InCell 
Analyser Data is normalised to background based on this negative. E rro r bars 
represent standard deviation from the mean of 3 repeats. Data was analysed 
using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data 
presented in this section was subjected to the same analysis.
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5.3.2.5 GREB1 RNA and protein are significantly altered by P4 and P4-ASD in 
the presence of cyclic AMP in the HESC cell line.
Work carried out in Section 3.3.5.4 showed that GREB1 is significantly up-regulated 
by progesterone in combination with cyclic AMP. To see whether the same effect 
occurs after treatment with P4 ASD, HESC cells were incubated with P4 or P4 ASD 
in the presence and absence of cyclic AMP. In the absence of cyclic AMP no change 
was observed in GREB1 RNA or protein, however, in the presence of cyclic AMP 
GREB1 RNA was upregulated 3.2-fold by P4 and 2.5-fold by P4 ASD (Figure 5.26 
B) though this was only significant with P4 (P<0.05). At protein level a significant 
increase in GREB1 was observed (Figure 5.26 A and C) after combined treatment of 
cyclic AMP with both P4 and P4 ASD. The increase was similar with both treatments 
though in contrast to RNA it was more significant after P4 ASD (PcO.Ol) (Figure 
5.26 B). As seen in Figure 3.29, cyclic AMP alone also caused a significant 
induction of GREB1 making it unclear what influence progesterone has on this 
target. Regardless of this, both P4 and P4 ASD did not differentially regulate the 
GREB 1 gene or protein.
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Figure 5.26: GREB1 gene and protein expression in the HESC cell line 
following hormone treatment for 48h. A) Fluorescent images showing 
formaldehyde fixed cells with DAPI-stained cell nucleus (blue), Texas-Red 
stained GREB1 protein (red) and fused DAPI/Texas Red image at lOx optical 
zoom. B) RT-PCR data showing basal transcript level of GREB1 normalised to 
GAPDH. C) Cell intensity data obtained from InCell Analyser W orkstation 
based on an average of 3 repeats observing at least 3 fields of view within each 
repeat. Data is represented as fold. A negative control containing Ishikawa cells 
incubated with secondary antibody only can be seen in Figure A; InCell 
Analyser Data is normalised to background based on this negative. E rro r bars 
represent standard deviation from the mean of 3 repeats. Data was analysed 
using a two-tailed students T-Test (*P<0.05, **P<0.01, ***P<0.001). All data 
presented in this section was subjected to the same analysis.
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5.3.2.6 Decidual PRL is similarly regulated by P4 and P4 ASD in the presence 
and absence of cyclic AMP in HESC cells.
P ro g esto g en s a lone are very  w eak  inducers o f  the P R L  gene, yet, the  ro le  o f 
p ro g esto g en s in P R L  regu la tion  is im p o rtan t as they  sy n erg is tica lly  en h an ce  cA M P - 
induced  P R L  ex p ressio n  (G elle rsen  et al., 1994, T elg m an n  et al., 1997, B rosens et 
al., 1996, B rar et al., 1997, T ang  and G urp ide , 1993). T h erefo re  P R L  gene  ex p ressio n  
w as quan tified  a fte r trea tm en t w ith  P 4 o r P4 A SD  in the p resence and absence  o f  
cy c lic  A M P . A fte r p ro g esto g en  trea tm en t in the absence o f  cyc lic  A M P  no  change in 
P R L  w as ob serv ed  as expected  (F ig u re  5.27 A). H ow ever, the ad d ition  o f  cyc lic  
A M P  caused  P R L  gene ex p ressio n  to increase  by  m ore than  5700  fold  w ith  P 4 and  by 
a lm o st 40 0 0  fold w ith  P4 A S D , w hich  w as h ig h ly  s ign ifican t by  t-te s t in both 
inc idences (P < 0 .0 0 1 ) (F igure  5.27 B).
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Figure 5.27. RT-PCR data showing basal transcript level of PRL normalised to 
GAPDH in HESCs after 48h of lpM  of P4 treatment in A) the absence and B) 
presence of 5pM of cyclic AMP.
A s the  resu ltin g  P R L  p ro te in  is sec re ted  in to  su rround ing  m edia, E L IS A  w as used  for 
p ro te in  detec tion . In line w ith  fin d in g s at R N A  level, P R L  w as also  sig n ifican tly  
induced  by P4 and P4 A S D  in the p resence  o f  cyc lic  A M P  but rem ain ed  u n changed  
in its absence (F ig u re  5.28).
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Figure 5.28: Secreted PRL levels in HESC cells in response 48hours of 
treatment.
The ELISA technique was conducted to measure hormone-stimulated levels of 
secreted PRL in HESCs. Values are given as average and standard deviation. 
Student’s t-test was used to test significance. Significant changes are represented 
by * (*, P<0.05 **, P<0.01).
5.3.2.7 The HESC cell line decidualises after treatment with P4 and P4 ASD 
combined with cyclic AMP but not with P4 or P4 ASD treatment alone.
As describ ed  in C h ap te r 3, the increase  in P R L  expression  is ind icative  o f  s trom al 
dec idua lisa tion , th e re fo re  the ex ten t o f  d ec id u a lisa tio n  w as v isualised  using  light 
m icroscopy  and fu rth e r co n firm ed  by  ca lcu la tin g  the level o f  ce llu la r ro undness u sing  
Im age J w here  a v alue  o f  1 rep resen ts  a perfec t c irc le  and th is value  decreases w ith  a 
reduction  in circu larity .
A fter trea tm en t w ith  e ith er P 4  or P 4  A S D , no change in H E SC  d ec id u a lisa tio n  cou ld  
be ob serv ed  v isu a lly  and  th is w as fu rth e r co n firm ed  w ith  im age J (F ig u re  5 .29). 
H ow ever, the ad d itio n  o f  cyc lic  A M P  to  bo th  trea tm en ts caused  H E S C  ce lls  to 
d ec id u a lise  at a s im ila r level. C e llu la r d ec id u a lisa tio n  can be seen in F igu re  5 .29. A 
change in ce llu la r-ro u n d n ess , in d ica tiv e  o f  dec idua lisa tion , w as also  co n firm ed  w ith  
im age J and w as found  to  be sig n ifican t and at a sim ilar level afte r bo th  co m b in ed  
trea tm ents.
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Figure 5.29. Light microscope images and graph showing extent of HESC cell 
roundness after 48 hours of treatment. Cell roundness was calculated using 
ImageJ software.
5.4 Discussion
A t p resen t there  is no natural p ro g este ro n e  fo rm u la tio n  av a ilab le  co m m erc ia lly  fo r 
the trea tm en t o f  endom etria l h yperp lasia . P ro g este ro n e  is an ex cellen t cand ida te  for 
such  a trea tm en t as it occurs n a tu ra lly  in the body  at h igh  co n cen tra tio n s  and 
th e re fo re  does no t pose  any  to x ic ity  p ro b lem s un like  sy n th e tic  p rog este ro n e  
d eriv a tiv es  (H apgood  et al., 2004 , B irrell et al., 2007). T he  ab sen ce  o f  an oral 
p ro g este ro n e  fo rm u la tio n  is, in part, due to  its low  aqueous so lu b ility  and poor 
d isso lu tio n  k ine tics, w hich  resu lts in incom ple te  d ig estiv e  ab so rp tio n . A s w ell as this, 
w hen  ad m in is te red  o ra lly  p ro g este ro n e  is sub ject to ex ten siv e  first pass m etabo lism
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in both the liver and intestines as detailed in Chapter 4. This combination of factors 
means that progesterone is pharmaceutically inactive when delivered orally.
In order to enhance the oral bioavailability of progesterone, several delivery methods 
have been patented. For example, Maxson et al (1990) dissolved micronized 
progesterone in glycerides and polyunsaturated fatty acids and Bensins and Besse 
(2008 and 2 0 1 2 ) invented a pharmaceutical composition comprising micronized 
progesterone, soya bean lecithin and one of a number of naturally occurring oils 
(Besins and Besse, 2012, Maxson et al., 1990, Besins and Besse, 2008). The use of 
micronized progesterone in the current patents serves to enhance the dissolution rate 
of progesterone due to the smaller size particles. Yet none of these patents has 
resulted in a commercially available, long-term, oral formulation.
During this study, a unique drug delivery platform was developed for the oral 
delivery of natural progesterone. The current delivery system is a novel, patented 
technology (Basit et al., 2013) with a number of advantages. First of all, because this 
system is a multi-unit dosage form with a size below 1 mm, transit time through the 
GI tract is expected to be rapid, reliable and reproducible with minimum retention in 
gastric contents of the fed or fasted state. These parameters lead to less 
pharmacokinetic variation, which is a problem often seen with single unit dosage 
forms particularly dose of larger dimensions (Davis et al., 1986) Furthermore, 
microparticles can be tailored for rapid particle dissolution at site specific regions of 
the GI tract. The improved GI targeting results in more reproducible pharmacokinetic 
profiles compared to conventional methods (Kendall et al., 2009). As seen in Chapter 
4, the intestines can have a major influence on the degradation of progesterone and 
the rate of this depletion is reduced in the distal small intestine. Thus, the new 
formulation is designed for ileum targeting in order to evade some early first pass 
metabolism. This approach is unique and has not been previously investigated.
Another advantage of the current formulation is its potential to increase the apparent 
solubility of progesterone in the intestinal fluids. The current formulation contains 
the drug in an amorphous state stabilised by polymers allowing for supersaturated 
solutions to be attained and maintained until absorption occurs (Miller et al., 2012).
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The manufacturing process itself also has a number of benefits; the process is simple 
with no need for high temperatures which reduces the potential of thermal 
incompatibility issues between drug and polymer. There are also no post 
manufacturing processes required (e.g densification or milling) and the resulting 
formulations are homogenous products and tend to have a high drug yield (Kendall et 
al., 2009).
Initial work within this chapter focused on the Eudragit L I00 polymer; an anionic 
copolymer derived from methacrylic acid and methyl methacrylate. Eudragit was 
selected initially because of its excellent pharmaceutical profile (Sonje and Chandra, 
2013, Ammar and Khalil, 1997) and its continuous use within our laboratories. The 
microparticles produced with Eudragit L100 using an oil in oil emulsification process 
were highly satisfactory in size, shape and amorphicity. However, when this 
approach was used, the encapsulation efficiency progesterone was very low (<25 %) 
possibly due to siginificant partitioning of the drug into the external phase. This poor 
drug-loading efficiency resulted in an actual drug load of <2.5% making this oil in 
oil approach unsuitable for lipophilic drugs such as progesterone.
The system was therefore altered to use an oil in water approach which enabled the 
use of HPMCAS, a polymer that has been shown to have excellent solubility 
enhancement properties (Konno et al., 2008, Tanno et al., 2004) and shows 
resistance to to the absorption of water enhancing its long-term stability (Rumondor 
et al., 2009). At 10% theoretical drug load, an encapsulation efficiency of a least 
70%, depending on the grade of polymer used, was achieved. This is considerably 
higher than that previously achieved with the Eudragit based microparticles and 
confirms the suitability of this approach for the encapsulation of progesterone. SEM 
analysis confirmed that some of the drug was not encapsulated (Figures 5.3, 5.6 and 
5.7) yet all encapsulated drug was amorphous as confirmed by DSC and PXRD 
analysis.
Although the progesterone microparticles displayed an improvement in solubility 
compared to the non-formulated and crystalline drug (Figure 5.18), a greater 
enhancement has been achieved by Miller et al (2012). Miller and colleges showed
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that spray-dried, progesterone loaded, HPMCAS microparticles, had a four fold 
higher aqueous solubility than progesterone and that the drug remained in solution 
for at least 10 hours (Miller et al., 2012). However, Miller and colleges used a drug 
load of only 5% as opposed to the 10% drug load used in this study which may be 
the reason for the observed differences. If the issue with solubility is indeed related 
to drug load then decreasing the drug to polymer ratio is certainly possible, 
especially as HPMCAS has low toxicity and is very well tolerated meaning increased 
polymer consumption would not pose a risk to the user (FDA, 2006). Failing this, it 
may be possible to improve microparticle topography by changing the production 
technique; for example solvent extraction can produce particles with a more regular 
shape and narrower size distribution (Pavanetto et al., 1992).
In this chapter HPMCAS polymers with 3 different dissolution profiles were used for 
the production of progesterone-loaded microparticles. In the case of progesterone 
loaded HPMCAS HF and MF ASDs, microparticles were amorphous, however LF 
microparticles showed some degree of crystallinity. It is unclear why these 
differences were observed. Nonetheless, in each incidence, progesterone ASDs 
dissolved at the expected pH (Figure 5.16). Moreover, ASDs are thermodynamically 
unstable and can recrystallize with time yet progesterone loaded HPMCAS 
microparticles were stable in ambient conditions for up to 2 years. This level of 
stability has not been previously shown with the current method in published 
research or within our own laboratories promoting the present formulation as an 
excellent option for progesterone delivery.
Previous research has shown that conventional solubility-enhancing methods can 
compromise intestinal permeability (Miller et al., 2011). However, progesterone 
ASDs have been specifically shown not to alter intestinal absorbance (Miller et al., 
2012). In line with this research, the intestinal permeability of the current 
progesterone formulation did not differ from the natural compound (Figure 5.18).
As well as establishing the pharmacological characteristics of progesterone ASDs, 
the biological effects of the formulated drug compared to the natural drug were also 
assessed. It has been previously documented that polymers can interact with the APIs
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with which they are formulated (Bym et al., 2001, Bharate et al., 2010) yet the 
regulation of a subset of target genes by progesterone ASDs was similar to the 
natural drug. As well as this, protein regulation did not differ between the two 
samples nor did cell morphology. In fact both protein regulation and cell morphology 
were highly similar between the treatments. Work carried out earlier in this study 
showed that target gene and protein regulation differed substantially between natural 
and synthetic progestogens making the natural drug a preferable choice for oral 
delivery.
Although the present progesterone delivery system is not completely optimised, the 
in vitro data obtained in this study highlight the possibility of constructing 
progesterone ASDs as a viable option for improved oral bioavailability.
Despite some minor drawbacks, this study has demonstrated that amorphous solid 
dispersions are a promising option for the future delivery of progesterone. As well as 
increasing solubility and dissolution, the formulation is targeted to the ileum where 
progesterone was shown to be most stable. Furthermore, the progesterone ASDs 
performed similarly to non-formulated progesterone in vitro, this was crucial as the 
rationale behind producing a natural oral formulation is that adverse signalling is 
diminished compared to synthetic compounds. Although further optimisation 
followed by in vivo testing needs to be carried out the current formulation shows 
great promise for the future of progesterone oral delivery.
5.5 Summary
To summarise, the work carried out within this chapter has explored ASDs as a 
possibility for the oral delivery of progesterone with improved bioavailability and 
equivalent endometrial activity. The data suggests that, with some optimisation, 
ASDs containing the polymer HPMCAS are a suitable option for the production of 
progesterone microparticles. Further work to establish changes in bioavailability in 
vivo needs to be carried out to establish the full potential of progesterone ASDs for 
oral dosing, particularly for the treatment of endometrial hyperplasia.
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6. General Discussion
Hormone therapy is widely used by women of all ages for diverse reasons, ranging 
from oral contraception and ovulation stimulation to hormone replacement therapy in 
menopause, to adjuvant therapy of tumours of the breast and uterus. Progesterone is a 
steroid hormone that is produced primarily by the corpus luteum during the luteal or 
secretory phase of the reproductive cycle. This steroid hormone exerts its action in 
tissues expressing progesterone receptor, including the breast, ovaries and the uterus 
(Deligdisch, 1999). Progesterone plays an important role in controlling proliferation 
and differentiation of the human endometrium. Continuous exposure to sex steroid 
imbalances, where there is insufficient progesterone or excessive estrogen, can cause 
hyperplasia of endometrial tissue with the potential to progress to hyperplasia with 
atypia and endometrial carcinoma.
Clinically the treatment for endometrial hyperplasia varies in relation to the grade of 
the disease; treatment can be medical, with progestins in the hyperplasia without 
atypia or surgical offering patients hysterectomy in hyperplasia without atypia (Clark 
2006). However, a surgical procedure is not always feasible; younger patients often 
wish to avoid this procedure in order to preserve their fertility while many older 
patients are unsuitable for surgery because of other medical problems (Gotlieb 2003, 
Armstrong 2012). To tackle this disease non-surgically, synthetic progestin therapy 
is prescribed which involves the oral delivery of medroxyprogesteome acetate 
(MPA) or the local delivery of levonorgestrel (LNG). Although progestin treatment 
is highly effective and often leads to regression of hyperplasia (Vereide et al.,
2006),significant is the occurrence of side-effects, some of which are considered 
serious (Cummings 2002, McCann 1994).
The occurrence of hyperplasia is most common in post-menopausal women (Lacey et 
al., 2010, Rakha et al., 2012) and is strongly correlated with high levels of serum 
estradiol (Baskin et al., 2002, Mutter et al., 2007). In the normal post-menopausal 
uterus ovarian progesterone production ceases and only low levels of estradiol 
remain in circulation, causing cell proliferation and differentiation to stop, leaving 
the endometrium thin and atrophic (Figure 6.1A) (Deligdisch et al., 1978). However, 
in some women, high levels of estrogen persist after menopause leading to
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endometrial proliferation and growth through alterations in gene expression 
(Woodruff et al., 1994). An example of an adversely regulated gene is FOXOl, a 
transcription factor involved in endometrial cell cycle regulation (Takano et al.,
2007). FOXOl was found to be significantly downregulated in endometrial 
hyperplasia both with and without atypia (Section 3.3.1.2). Other such genes are also 
adversely regulated in the hyperplastic endometrium resulting in abnormal cell 
proliferation and endometrial thickening (Figure 6 . IB). In order to restore the 
atrophic endometrium, in clinical practice, patients are treated with MPA (Figure 
6 .1C). However, as well as restoring the altered expression of some genes, MPA, 
also regulates a number of other genes in a different manner to the natural 
compound. For example, in Chapter 3, MPA did not alter LF protein expression in 
vitro and up-regulated it in vivo whereas P4  caused its down-regulation, LNG also 
down-regulated this target. Malignant transformation of the human endometrium has 
been associated with the overexpression of LF RNA and protein (Walmer et al., 
1995), thus its down regulation by progesterone may be important in maintaining a 
healthy endometrium and avoid relapse, which can occur in 38-40% of MPA treated 
patients (Ushijima et al., 2005; Ushijima et al., 2007).
Expression of PR is another example of adverse MPA gene regulation. One of the 
main issues with the PR is its down-regulation by synthetic progestins in vivo as seen 
within this study and reported in the literature (Vereide 2006, Alexander 1989). As 
progestin therapy relies on the presence of the PR in order to work, the level of 
endometrial PR strongly influences clinical outcome (Ehrlich 1988). However the 
benefits of treatment are typically of short duration as the resulting drop in PR limits 
the treatment efficacy (Satyaswaroop 1992, Mortel 1990). Yet, in the Ishikawa cell 
line, the PR protein was up-regulated by both natural progesterone and the 
progesterone ASD but not altered by the synthetic progestins. Although this data is 
based on a singular cell line, the findings are still important and supportive of clinical 
use of natural progesterone. If the presence of PR is maintained with natural 
progesterone treatment, then, in theory the treatment should remain effective with 
long term use. It would be naive to assume that in vivo the levels of PR would 
change radically after natural progesterone treatment compared to synthetic but it
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In the healthy postmenopausal endometrium only low levels of circulating 
estrogen are present and progesterone is absent resulting in a thin atrophic 
endometrium. In endometrial hyperplasia an influx of estrogen stimulates genes 
involved in cell proliferation and differentiation and inhibits genes associated 
with cell senescence. Absence of progesterone to oppose the estrogenic action, 
leads to endometrial thickening and hyperplasia. MPA treatment restores the 
atrophic endometrium but also adversely regulates a number of genes, which 
can result in disease recurrence.
Unlike synthetic progestins, natural progesterone has very little side effects post­
administration (Cummings and Brizendine, 2002) and, although it’s not used in 
clinical practice, the use of locally delivered progesterone was shown to be 
successful in the treatment of women with endometrial hyperplasia (Baker 2012, 
Affinito 1994). Moreover, recent research has looked into the oral delivery of 
micronized progesterone for the treatment of endometrial hyperplasia and the 
treatment has shown some success (Baker 2012, Chemukha 2013, Marra 2014). 
However, micronized progesterone is limited by its reduced endometrial control 
(Tasci 2014) and wide inter and intra-patient variability (Levine and Watson, 2000b, 
Nahoul et al., 1987).
The main hindrance in developing a suitable natural progesterone oral formulation is 
its poor bioavailability which is due to extensive first-pass metabolism and poor 
solubility. There is a great deal of literature available on progesterone metabolism by 
the liver; however, there is limited information available on progesterone metabolism 
in the intestines. The intestines are likely to be the most significant site of drug 
biotransformation outside of the liver due to the presence of metabolising enzymes 
such as Cytochrome P450s and aldo-keto reductases (Thelen and Dressman 2009, 
Barski 2008).
Therefore, the stability of progesterone was analysed in homogenates of intestinal 
mucosa and liver of rats and humans with a view to develop the current 
understanding of progesterone first pass metabolism and to establish the role of the 
intestine in this process. As well as confirming the susceptibility of progesterone to 
liver metabolism, work carried out in Chapter 4 also showed that the intestines make
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an important contribution to progesterone depletion. Homogenates of human 
intestinal mucosa were shown to deplete progesterone by more than 20% within 60 
minutes of incubation. The importance of drug metabolism by the intestinal wall has 
been previously reported; in the case of the synthetic estrogen, ethinylestradiol, gut 
wall metabolism plays a vital role in its systemic bioavailability (Back 1982). Back 
et al reported that the gut wall is almost twice as effective as the liver in conjugating 
ethinylestradiol (Back 1982). Thus, targeted delivery may substantially improve the 
levels of systemic progesterone after oral administration. To determine an optimal 
region for progesterone delivery rat intestinal segments were used. Segments of male 
and female rat intestinal mucosa were incubated with progesterone and the stability 
of progesterone was determined therein. Based on the data obtained, it was possible 
to identify the mucosa of the distal small intestine as the region where progesterone 
is most stable and least metabolised. Furthermore, progesterone metabolism by 
colonic fluid was assessed and rapid depletion of progesterone by gut bacterial 
enzymes was observed. The level of gut bacteria is reduced in the ileum compared to 
the colon, therefore, the ileum presents not only as a region where mucosal 
metabolism is less, but also a region where bacterial metabolism is reduced 
compared to the large intestine.
This information prompted us to consider options for targeted progesterone delivery 
to the ileum with a view to enhancing its oral bioavailability as compared to that of 
current immediate release formulations. In order to achieve this, a novel approach 
was used whereby progesterone was formulated into amorphous solid dispersions 
(ASDs). ASDs pose a great opportunity for progesterone oral administration as they 
not only travel quickly through the gut and rapidly dissolve at the ileal pH with great 
accuracy but also improve drug solubility and enhance the rate of dissolution.
Previous patents have focused on immediate release formulations containing 
micronized progesterone (Besins 2012, Maxson 1990, Liu 2010, Chandler 1997). 
Micronized progesterone has a reduced particle size, which enhances the dissolution 
rate and absorption and, by virtue, improves oral bioavailability (Hargrove 1989, 
Simon 1993 Fitzpatrick 1999). However, as well as having a reduced particle size, 
the current delivery system offers a unique platform for the oral administration of
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natural progesterone by means of ileum targeting and improved solubility. As well as 
this, ASDs contain progesterone in an amorphous form, which leads to an improved 
dissolution rate as no energy is needed to break down the crystal lattice during drug 
release (Vasconcelos 2007, Saffoon 2011).
During this thesis two polymers were investigated for the production of progesterone 
ASDs. The first polymer, Eudragit L100, was used to formulate progesterone using 
an oil-in-oil method. However, with this method the encapsulation efficiency was 
poor. Therefore, an oil-in-water method was used with the polymer HPMCAS which 
drastically improved encapsulation efficiency. In their current state, the progesterone 
loaded HMPCAS microparticles are not fully optimised. At 10% drug load, excess 
crystalline drug was observed on the microparticle surface (Figure 5.3) and only 
minor improvements in solubility were obtained in relevant fluids (Figure 5.18). Yet, 
there is potential to improve the current profile of these microparticles. For example, 
a study conducted by Miller et al (2012) showed that, at a drug load of 5%, the 
solubility of progesterone was improved to more than four times that of the natural 
compound (Miller 2012). Furthermore, Miller and colleagues produced their 
progesterone microparticles using the spray-drying technique which may have 
influenced the characteristics of the resulting microparticles. Nevertheless, 
progesterone-loaded HPMCAS microparticles show excellent potential as a future 
option for the oral delivery of natural progesterone.
The rationale behind opting for a bioidentical formulation is the reduced side-effects 
which, as described in Chapter 3 of this study, come about as a result of adverse gene 
and protein regulation by synthetic progestins. Data shown in this study (Chapter 5) 
supports further refinement of progesterone ASD formulations given the similar 
regulation of progesterone targets by natural progesterone compared to the 
progesterone ASD.
6.1 Conclusions
The main aim of this study was to produce a natural progesterone formulation with 
enhanced bioavailability and equivalent endometrial activity compared to the natural
281
Chapter 6 General Discussion
drug as a proposed treatment for endometrial hyperplasia, a condition currently 
treated with synthetic progestins.
To achieve this aim, a progesterone amorphous solid dispersion was produced. The 
dispersion was shown to have both enhanced solubility and equivalent endometrial 
activity compared to the unformulated drug, although the level of increase in 
solubility did not meet expectation. However, the progesterone ASD similarly 
regulated protein targets that were differentially altered by the synthetic progestins 
MPA and LNG in endometrial cell lines, highlighting natural progesterone as a 
preferred treatment option for endometrial hyperplasia than the currently available 
synthetic counterparts.
As a consequence of the work carried out in this thesis a number of novel findings 
came to light. Firstly, when assessing the basal expression levels of a number of 
proteins in endometrial hyperplasia, changes in levels of a panel of biomarkers were 
noted, suggesting their potential as candidates for determining endometrial 
hyperplasia presence and progression. Secondly, GREB1, a gene of unknown 
function, was shown to be up-regulated by progesterone in endometrial epithelial 
cells and also shown to be a marker of cellular decidualisation; these findings have 
not been previously reported in the literature. Finally, a number of previously 
unreported enzymes were found to metabolise progesterone in human liver and 
intestinal cytosol. Of particular interest was the discovery of the Menadione-induced 
reduction in progesterone metabolism in liver. Menadione is known to inhibit 
aldehyde oxidases, NRH:quinone and oxidoreductase 2, none of which have been 
previously implicated in progesterone metabolism.
Overall, the work carried out in this thesis has obtained the following major 
outcomes.
1. This study has identified PR targets FOXOl, Amphiregulin, PR and 
Lactoferrin, as putative biomarkers for endometrial hyperplasia with a 
potential use in clinic for diagnosis and monitoring response to treatment.
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2. A differential regulation of important progesterone target genes and proteins 
and their differential control by the synthetic progestins MPA and LNG 
compared to natural progesterone is observed in human endometrium.
3. This study has provided previously unreported insight into the role of the 
intestine in progesterone metabolism with the ileum appearing to metabolise 
progesterone the least
4. The work presented herein has highlighted progesterone ASDs as an 
attractive option for the future production of a natural progesterone oral 
formulation with equivalent endometrial activity to that seen for natural 
progesterone.
6.2 Future Prospects
The data presented within this thesis presents ileum-targeted amorphous solid 
dispersions as an interesting option for the future delivery of natural progesterone. 
However, it was beyond the scope of this study to fully optimise the progesterone 
ASDs. Therefore, this study ends with the presentation of an excellent prospect for 
future development. The continuation of this work should attempt the same method 
of producing progesterone ASDs, but with a reduced drug-load to improve 
encapsulation and further enhance solubility. Alternatively, a range of techniques and 
excipients could be employed in order to find a method for producing 10% 
microparticles with improved characteristics. Further work should also include 
progesterone stability assays in intestinal segments of humans, particularly females, 
as the current work was carried out in both male and female rat models. Stability 
assays in human intestine would ensure the correct target region has been selected.
The ultimate goal for the future of this work would be to test the optimised 
progesterone amorphous solid dispersion in human volunteers with endometrial 
hyperplasia. This work would help establish whether the oral bioavailability is truly 
improved with the progesterone ASDs and whether the new formulation is sufficient 
to transform the hyperplastic endometrium.
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A: RNA Protocol for RNeasy Kit Qiagen
1. Cells grown in a monolayer (do not use more than 1 x 107 cells): Cells can be either lysed 
directly in the cell-culture vessel (up to 1 0  cm diameter) or trypsinized and collected as a cell 
pellet prior to lysis.
2. Disrupt the cells by adding Buffer RLT. For pelleted cells, loosen the cell pellet 
thoroughly by flicking the tube. Add the appropriate volume of Buffer RLT (see Table 5). 
Vortex or pipette to mix, and proceed to step 3.
3. Pipette the lysate directly into a QIAshredder spin column placed in a 2mL collection 
tube, and centrifuge for 2min at full speed. Proceed to step 4.
4. Add 1 volume of 70% ethanol to the homogenized lysate, and mix well by pipetting. Do 
not centrifuge.
5. Transfer up to 700pL of the sample, including any precipitate that may have formed, to an 
RNeasy spin column placed in a 2mL collection tube (supplied). Close the lid gently, and 
centrifuge for 15 s at 8000xg Discard the flowthrough.
6 . Add 700pL Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15s at 8000xg to wash the spin column membrane. Discard the flow-through.
7. Add 500pL Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15s at 8000xg to wash the spin column membrane. Discard the flow-through.
8 . Add 500pL Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge 
for 2 min at 8000jtg to wash the spin column membrane.
9. Optional: Place the RNeasy spin column in a new 2mL collection tube (supplied), and 
discard the old collection tube with the flow-through. Close the lid gently, and centrifuge at 
full speed for lmin.
10. Place the RNeasy spin column in a new 1.5mL collection tube (supplied). Add 30-50pL 
RNase-free water directly to the spin column membrane. Close the lid gently, and centrifuge 
for lmin at 8000xg to elute the RNA. DNase digest protocol
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B: Liver Homogenate Donor Demographics.
1 ^ 1
M 3 8 C a u c 0 N o 1 0 / 0 3 / 2 0 0 1  0 2 :5 5 I n t r a c e r e b r a lh a e m o r r h a g e H y p e r t e n s i o n N o n e
M 6 4 C a u c A Y es 0 3 / 0 9 / 2 0 0 4  0 2 :5 0 S u b a r a c h n o i dh a e m o r r h a g e N o P M H N o n e
M 3 3 ( U n k n o w n )  ( U n k n o w n ) Y es 2 1 / 1 2 / 2 0 0 5  1 6 :3 0 R o a d  T ra f f ic  A c c i d e n t N o n e N o n e
M 5 8 C a u c 0 Y es 2 4 / 0 2 / 2 0 0 6  0 0 :5 4 S u b a r a c h n o i dh a e m o r r h a g e
u n r e m a r k a b l e  
R e n a l  s t o n e s  2 0 y r s  a g o  
H e p  B s u r f a c e  a n t i g e n  n e g a t i v e
N o n e
M 2 8 C a u c A N o 1 0 / 0 2 / 2 0 0 3  1 8 :5 6
E x a c e r b a t i o n  
o f  c y s t ic  
f i b r o s i s  
R e s p  f a i l u r e  
N H B
H e p a t i t i s  B c o r e  a n t i b o d y  
p o s i t i v e  
N o n  h e a r t  b e a t i n g  d o n o r ,  7  
m i n u t e s  a r m  I s c h a e m i a .  P a t i e n t N o n e
h a d  b e e n  h y p o x i c  f o r  1 w e e k
b u t  p r i o r  t o  t h i s  - r e a s o n a b l y  
w e l l .
M 3 7 C a u c 0 Y es 2 0 / 0 3 / 2 0 0 4  1 5 :4 6 R o a d  T ra f f ic  A c c id e n t N o n e N o n e
M 5 4 C a u c A N o 0 8 / 0 7 / 2 0 0 3  0 0 :1 0 I n t a c r a n i a lH e a m o r r h a g e N o n e N o n e
M 4 1 C a u c A Y es 1 4 / 0 2 / 2 0 0 6  0 5 :5 9 S u b a r a c h n o i dh a e m o r r h a g e H y p e r t e n s i o n N o n e
M 5 3 C a u c ( U n k n o w n ) Y es 2 0 / 0 4 / 2 0 0 7  2 1 :1 5 B r a i n S t e mI n f a r c t U n r e m a r k a b l e  
R e n a l  T r a n s p l a n t  1 9 8 4 ,  F a i le d  in
N o n e
F 3 7 C a u c ( U n k n o w n ) N o 1 1 / 1 0 / 2 0 0 5  0 3 :1 0 S u b a r a c h n o i dh a e m o r r h a g e
1 9 8 9 ,  D ia ly s is  t o  p r e s e n t  
H y p e r t e n s i v e  
2  A b n o r m a l  S m e a r s  2 0 0 5
P e n ic i l l i n
F 6 3 C a u c 0 Y es 0 9 / 0 2 / 2 0 0 6  0 0 :0 4 I n t r a c e r e b r a lh a e m o r r h a g e
H y s t e r e c t o m y - 
A d e n o c a r c i n o m a  o f  C e rv ix  
M i g r a i n e
N o n e
F 3 8 C a u c A Y es 2 1 / 0 4 / 2 0 0 5  0 9 :1 5 B r a in  T u m o u r I n s u l in  D e p e n d e n t  D ia b e t i c  
S m o k e r
N o n e
319
Appendices
C: Intestinal Cytosol Donor Demographics.
Age: Race: Cause of Height: Weight: Social history: Medical history:
death:
EBV CMV Hepatitis 
B
Hepatitis
C
30M C
36M B
Head trauma; 73" 
2nd to
motorcycle
accident
CVA 70"
48M A
52F C
Anoxia; 2nd 67” 
to MI
GSWtohcad 67”
49F C
60F B
ICH 62”
CVA 72"
73 KG ETOH: 6 pk/day 
x lOyrs; 
Tobacco: lppd 
x 13 yrs; Drugs: 
Marijuanna daily 
x lOyrs 
341 LB ETOH: rarely; 
No tobacco or 
drug use.
73 KG ETOH: 2-3
beers per year; 
Tobacco: 
unknown a m t- 
quit; Drugs: 
Marijuana x 
2 yrs
60 KG No ETOH or 
drug use; 
tobacco: 1 ppd 
x 40 yrs
97 KG No ETOH,
Tobacco or drug 
use
103 KG No ETOH,
Tobacco or drug 
use
Professional tatoos, Pos Pos Neg
tennis elbow. Meds:
none
HTN x 11 yrs -  Not Pos Neg
noncompliant with reported
meds; Meds:
clonidine, hydromax,
lodrare, aldactazide,
creon. exforge, lexapro,
tramadol, labetalol,
parafon forte, legstrol
Cardiac arrest, T2D x Pos Pos Neg
15 yrs, HTN x 2 yrs, 
end stage renal disease 
x 2 yrs w/ dialysis.
Meds: unknown
20-30% mild LAD Not Pos Neg
stenosis, chronic reported
Chron’s disease, blood
hemodialated,
hysterectomy, chronic
back pain; Meds:
unknown
HTN x 6 yrs -  
compliant w/meds, bad 
surgery to correct 
scoliosis, vaccinated foi 
Hep B, osteoporosis 
High blood pressure/ 
HTN x 10 yrs-  
compliant; Meds: HTN 
meds (names unknown] 
TOXO Pos.
Pos Neg Neg
Pos Pos Neg
Neg
Neg
Neg
Neg
Neg
Neg
HIV
Neg
Neg
Neg
Neg
Neg
Neg
320
Appendices
Appendix D: FFPE samples obtained from healthy (controls), patients 
diagnosed with hyperplasia without atypia (H) and hyperplasia with atypia 
(HA) were stained with a mouse anti-PR monoclonal antibody. Progesterone 
Receptor expression was identified in glands and stroma. Representative 
images (lOx and 40x magnification) per group are shown.
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Appendices
Appendix E: FFPE samples obtained from healthy (controls), patients 
diagnosed with hyperplasia without atypia (H) and hyperplasia with atypia 
(HA) were stained with a mouse anti-FOXOl monoclonal antibody. Expression 
of FOXOl protein was identified in glands and stroma. Representative images 
(lOx and 40x magnification) per group are shown.
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Appendix F: FFPE samples obtained from healthy (controls), patients 
diagnosed with hyperplasia without atypia (H) and hyperplasia with atypia 
(HA) were stained with a mouse anti-amphiregulin monoclonal antibody. 
Expression of Amphiregulin protein was identified in glands and stroma. 
Representative images (lOx and 40x magnification) per group are shown.
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Appendix G: FFPE samples obtained from healthy (controls), patients 
diagnosed with hyperplasia without atypia (H) and hyperplasia with atypia 
(HA) were stained with a mouse anti-lactoferrin monoclonal antibody. 
Expression of Lactoferrin protein was identified in glands and stroma. 
Representative images (lOx and 40x magnification) per group are shown.
LO
CO
(UL .
Q j
X
(U
0 )4—o4->
u
CD
03
Eo
co Xo
Xo
to~o
c
m
xo
-V K * v ‘ •*
v V • • : 
;Tv* r -j  , v . c  »• • .»
Av ,*
r v : ; r
i
rtt ? •;
if % >p; m s r s m
fc a t i
~  v
- fvV
V  r-
■P*
Efe}£>*&>
/
i r ^ " !
' ~#A.
co
u
324
Appendices
Appendix H. Effect of MPA on endometrial expression of FOXOl in vivo. FFPE 
samples from patients diagnosed with Hyperplasia without atypia was 
interrogated for expression of FOXOl by IHC. Samples were collected from 
patients before and after MPA treatment (3 months). FOXOl expression was 
identified in glands and stroma using a specific anti-FOXOl antibody. 
Representative images (lOx and 40x magnification) per group are shown
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Appendix I. Effect of MPA on endometrial expression of PR in vivo. FFPE 
samples from patients diagnosed with Hyperplasia without atypia was 
interrogated for expression of PR by IHC. Samples were collected from patients 
before and after MPA treatment (3 m onths). Progesterone Receptor expression 
was identified in glands and stroma using a specific anti-PR antibody. 
Representative images (lOx and 40x magnification) per group are shown.
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Appendix J . Effect of MPA on endometrial expression of Amphiregulin in vivo. FFPE 
samples from patients diagnosed with Hyperplasia without atypia was interrogated for 
expression of amphiregulin by IHC. Samples were collected from patient before and after 
MPA treatment (3 months). Amphiregulin expression was identified in glands and stroma 
using a specific antibody. Representative images (lOx and 40x magnification) are shown.
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A ppendix K. Effect of MPA on endometrial expression of Lactoferrin in vivo. FFPE 
samples from patients diagnosed with Hyperplasia without atypia was interrogated for 
expression of Lactoferrin by IHC. Samples were collected from patients before and after 
MPA treatment (3 months) . Lactoferrin expression was identified in glands and stroma 
using a specific antibody. Representative images (lOx and 40x magnification) per group are 
shown
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L: Fluorescent images showing formaldehyde fixed cells with DAPI-stained cell 
nucleus (blue), Texas-Red stained GREB1 protein (red) and fused DAPI/Texas 
Red image at lOx optical zoom. Images obtained using the InCell Analyser
